<SEC-DOCUMENT>0001558370-24-007695.txt : 20240510
<SEC-HEADER>0001558370-24-007695.hdr.sgml : 20240510
<ACCEPTANCE-DATETIME>20240510072049
ACCESSION NUMBER:		0001558370-24-007695
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240510
DATE AS OF CHANGE:		20240510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		24932878

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20240331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.6.2.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/10/2024 11:09:06 AM -->
<!-- iXBRL Library version: 1.0.8826.24652 -->
<!-- iXBRL Service Job ID: bf8201c9-d483-4c42-ad82-00fb12808c76 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:plx="http://www.protalix.com/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" xs:nil="true" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_VNZ6Et4Ick6Ne6-sIK5IJQ"/><ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" xs:nil="true" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" name="us-gaap:CommitmentsAndContingencies" id="Hidden_LhT2Lt5jMkmZz61In1sp6Q"/><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityCentralIndexKey" id="Tc_Vav-0d4wWku23PA1jmVxsQ_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:CurrentFiscalYearEndDate" id="Tc_t9nyX3azxk6O-xhXID5apw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:DocumentFiscalYearFocus" id="Tc_3UHQ-xC0AEm85UcRdfMp8w_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:DocumentFiscalPeriodFocus" id="Tc_eNbw5zSKbEOcIHjNlcmUlg_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:AmendmentFlag" id="Tc_u8Z-mEs3QUu3xJwnpwd4fg_6_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AoDmf9T7-EW8NibIGw8Drg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EVbVs5tNjUeS5vUf2w1OtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9j4H_qwYkSWRSCNd8Y63Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cabxw3GtuEGEzA6sOUlY4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R-M5bPoxwEejTI9jPZq0pA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UkNAV_nnI06H0twkkPSRjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_It9cBFHKPk6qc9vr0qHvLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1cdccZU09U-bigfo9gAdWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0ewi0kFMXU-CRUeaAv6HHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TnKkjPS4E0-jVZHJUJNLNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kzn5qEII7EOEguLWbvYS3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OfiAuwsd7ECIG9JmRKBQ6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dSj5Bua1QkaM-W1iMSZ6WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DqFs6ZdUS0WsAvycUW3EDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kD3z0qQXkGKOLbaYW_hYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_plWIvGvIFUyhx5jpML44MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_d371MQCH-UCwEc1UyItlwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_LIKQPrFmCUCnBtrg04Oumw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z99VySZvSUmmlbiiGP0ySQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Jd_SJ9gglEK0yT37LHcRGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_AB2WjkfrfEufyvdgXghKJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_WviQItZk-02YK8HpME_Dbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_pV_QgLXkMUeQZyfrpN-Feg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TI5qIQ-W5ECjpmDAaBfbkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_9_2024_To_5_9_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nWYpdchKYEGKP3xBFvtHig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_8_2024_To_5_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_0fFQQ6KG80qYA735CyQAfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-08</xbrli:startDate><xbrli:endDate>2024-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_HNYzKmZW0EGFk6AugmfHqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_MRoG3U83PUmyx0DXg4n4TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_6VgdHCEey0ChwG_Brnl3sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">plx:BalancesWithoutAdoptionOfAsu202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_A9tFbldDhUqAI-mwDvGBqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IMPE8wN7rEeMrPPPiQiN9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_DSkPUZ0Ock24wWZtXiDMDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0aoQ1IPKS0aCMthAjitzGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ZYB0fx44FEWMgVZL0Q2ZBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_IPYo9S6V0EqfSWhkVFWAYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C3_bHbEzuEi8F1H8pW2V5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_8a1FzJd1ik67d1aQt1PHIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VN0lXe7Da0uVnHnA1AZ-Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_xjgcoWRmyUq3QXN8beg6JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_N5rxkP1HDUKEqAztKtnJ2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_5ll4IzhZsUOjqRDIs4jcmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_o-lkPPcrrEeuOZNhLH7JRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">plx:BalancesWithoutAdoptionOfAsu202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_7SgXk48cW0uKG7aq9Ekk7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_e5XT7TC3JUOFCdJknj2Kxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_h9WLivGpgEyD1m0aAK4kOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_SyXMreozU0aUnXbYdjaAlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8VAgdb4ALkmKPOJ7uu_neA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6gG79eVy60GCAQmdhRp9TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XauTFxetDUimxtIcJ0CjJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D5tn2C8Vak231ybX4CNmDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_JDUfTJTYi0qDFhD9HD0akA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_-uvexI6zj06OIfXhkzqtLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-15</xbrli:startDate><xbrli:endDate>2024-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_FTJ8oLhaw0eNY5HLHGDojQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZmijeMu1t0aGYXoOgDHBMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xX-MG2XLX0m9iz8FCKqqug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_mrSsBTSz6UuGt_rjv0O4wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_xVfX9yUYmU-4xeITZl_dtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_uKLBpQRGtUeyn34LZ3eWsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_mGOqXZx_bkyqGouEHLnUAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YaHpHVxvLEmVk7w9ELKIkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_dtTtAUZdsU-OMRlXaEJPuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_qjzJkxA5JEGDK6mwmBPwHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-29</xbrli:startDate><xbrli:endDate>2022-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_sLr8N63ht0eaToO41XlL1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E_QTB-Qpi0GslgevMAMiVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_sTcnk7rZXkKGiMsDqP-mkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_gp6Tqjm6QkeG7ShEqzvLHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lwVtQlooKUmWHx0HxMj1WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_1_2024_3BAEb2yYok6aZSbSwaULdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_9OeDCEh91kqDTYHwfDEKIg"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item__RvHgY9WKUuWNqJlDLZ_pg"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_2rgTiQvabkK-OvDBIrW98g"><xbrli:measure>plx:Y</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_33t8Gr9f0UeEkwYS_dtQJQ_17_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gosVfC_JMUCxqvplCA6nxA_8_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_5jJVSBrasUWgBK3js2CxoQ_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_sndmI7N3c0yKdEk-SeoiAw_12_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_FGp2-PEvW0uYn-0F3PL6TQ_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_KgyFIzvufEafEs9RBm3e2w_19_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:0pt;padding-top:1pt;text-align:right;border-top:3.0pt solid #000000;margin:0pt;"><b style="font-weight:bold;">ProCell Or</b></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e6901514_7a32_49b7_82f4_844da4c0bc09"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:DocumentType" id="Narr_u1zmjt72NkOFSWFXC0lABA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:DocumentQuarterlyReport" id="Narr_pkqMYV4LvUiMK2ywruW2Vg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:DocumentPeriodEndDate" id="Narr_Wm7Qppjtc0iAwPD8W4z2HQ"><b style="font-size:8pt;font-weight:bold;">March&#160;31, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:DocumentTransitionReport" id="Narr_61yhpWZDt0-xQFFu7UGQGA"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityFileNumber" id="Narr_HvUuYcXlo0e0_Xnxl8votw"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityRegistrantName" id="Narr_oJ43oTELXEGu9DK95o28Yg"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_eVkeUGuyq0qMhZy1_SLHPg_1_1"></a><a id="Tc_uCouY0Cd_k2xZbTpQc23yw_2_0"></a><a id="Tc_ApnGGq0bZ0CEw25Qs0iREw_2_1"></a><a id="Tc_h5Y08ks9ikCDOFhAw6lMhQ_4_0"></a><a id="Tc_Us555Q0mG0-dmU1ddGUDYw_5_0"></a><a id="Tc_24D1ythFZEO-p0A5WzVVKA_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityIncorporationStateCountryCode" id="Tc_mcYiAIHwmU2f0CtlnZehVA_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityTaxIdentificationNumber" id="Narr_D-jkB-mJU067DvqeU6fq8Q"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityAddressAddressLine1" id="Narr_W3gB5ik7EEKr08AsLsHwWg"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityAddressAddressLine2" id="Narr_medoSeZ2N0mJoIhJD0sLkw"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityAddressCityOrTown" id="Narr_RC3VKjTaNEe50T5kOrZiFQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityAddressStateOrProvince" id="Narr_cX1VeAtRskCznOKMuQyCRQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityAddressPostalZipCode" id="Tc_7KRsW_AfkE6FOHq6UrkWew_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:CityAreaCode" id="Narr_tZNlLA0sTkys7c4Y2JHDOA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:LocalPhoneNumber" id="Narr_IU9Isl2k3UmHGWTvkpaxcQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_sJTJxoJJNEWObTSwDEZUOA_1_0"></a><a id="Tc_xL2aEfLRUkyBQj6kohUCNA_1_2"></a><a id="Tc_eSYxXj7hQkmfnSBPzMYtWw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:Security12bTitle" id="Tc_4ZHTruih_Ue0PGeStPZXwg_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:TradingSymbol" id="Tc_hJCipwmbukC4CImqUggW1w_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:SecurityExchangeName" id="Tc_84LUMUzci0uuffsVypFufg_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityCurrentReportingStatus" id="Narr_8Xi1mwPvL0KwvvF-CjwwOw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityInteractiveDataCurrent" id="Narr_TSMOfj2jckmB5u_gmWXJsQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_F-IzMJqN80WloIbswIfd1g_1_0"></a><a id="Tc_ezWWuslgg0yNZww15Q2k0Q_1_1"></a><a id="Tc_0rx_cjlupUeZ63lbYlus6w_1_2"></a><a id="Tc_NlW0wM3TvES_z5n4cg2gww_1_3"></a><a id="Tc_175kbJYQ7UGvmSlFgnbI9A_2_1"></a><a id="Tc_Zxkr70O6ME2qoD4XzuM1BQ_2_2"></a><a id="Tc_226DNl1PDkWK3mSYEToBbw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityFilerCategory" id="Tc_aYk76m4iqUm4c3W5NyoT8A_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntitySmallBusiness" id="Tc_KtJ-2FgwBUC9F1e1Cwwkvw_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityEmergingGrowthCompany" id="Tc_ZMjoDU3B-0KFtaZfd8RUIA_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="dei:EntityShellCompany" id="Narr_MKzF4Pu-uECDaaCPU8dmVA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On May&#160;1, 2024, approximately <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_5_1_2024_3BAEb2yYok6aZSbSwaULdQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_y7N6XqdkV0-gEj4LwAK8XQ">73,316,084</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_09268429_7477_4bb6_aa1a_fafe6bdbb026"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of March&#160;31, 2024 and December&#160;31, 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity (</span><span style="font-style:normal;font-weight:normal;">Capital Deficiency) (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2024 and 2023</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d8d1b29f_6cb1_4ce7_9e08_822238398a43"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_nmahXWvhfE6QwHmXZUV-1w_1_2"></a><a id="Tc_0avbkJEBc0qa0qmIipoORw_1_5"></a><a id="Tc_n1teG13-DkuAd84i1lE8ug_3_0"></a><a id="Tc_1TzkPIGggUGNEVMTyisQSA_5_0"></a><a id="Tc_Z-oN9x4ET0uQ5cRSXQX3_w_6_0"></a><a id="Tc_MUsXdoxO7kebGZVrcHHXAg_6_2"></a><a id="Tc_EsyokvpzI0mu1oV06aW62Q_6_5"></a><a id="Tc_K98M5FqATEmNiHorrHcKEQ_7_0"></a><a id="Tc_nEtzKvUS7kSqlZQk_30BCQ_8_0"></a><a id="Tc_yRVsxtFu5UC5itQuKoUcIg_9_0"></a><a id="Tc_7x3F1rhcW0WulHQLa8ru0A_10_0"></a><a id="Tc_FndpAUEcMEivYKfb08tkOQ_11_0"></a><a id="Tc_VjgkfXsQyE2rHnyem-ZlfA_11_2"></a><a id="Tc_g2qzKk9_RkCqPL_YwNZ3rw_11_5"></a><a id="Tc_sia_dOwB3kGB02EpktliKw_13_0"></a><a id="Tc_M8E5eR0LJEmfq0ZaFa9CUg_14_0"></a><a id="Tc_EaS84vfkwk2eJB1IS2sc8Q_14_2"></a><a id="Tc_vaIhjqZzJUy4OCN85AL8WA_14_5"></a><a id="Tc_aH8gqa0oz0q0F1NkqVbtPw_15_0"></a><a id="Tc_wvw1KqhWrEqMPKEzSJlieg_16_0"></a><a id="Tc_bsJ_QV8E7kmV1jjoYpd4mA_17_0"></a><a id="Tc__4jpQ0SJ6EKdCF4S5l65VA_18_0"></a><a id="Tc_HLcB5bS9zEWHwTVT5E0pjw_18_2"></a><a id="Tc_GbrgCgEFeUKNLd1R0lZXsQ_18_5"></a><a id="Tc_pXyn-OsWakayjUkgYTJwIw_20_0"></a><a id="Tc_EjwbKIFsB0-06p9lLl-qgA_22_0"></a><a id="Tc_auKJNnx-GEGAMDu6iWg8aw_23_0"></a><a id="Tc_XTa5ABCxwkyuH6jDizevvw_24_0"></a><a id="Tc_WIPzWwT9aEm_rdtlI_ugwA_24_2"></a><a id="Tc_jVQw4kCTpEi8Vssih3V28Q_24_5"></a><a id="Tc_vVLgGjmU-kK1oSMAQLlQxQ_25_0"></a><a id="Tc_QIx5gDKQfkGtvqjavQw-9Q_26_0"></a><a id="Tc_VBncafCpGk2hNnIXNq817w_27_0"></a><a id="Tc_Xf17IhpsUkKfTLPnSxkFxA_27_6"></a><a id="Tc_DwLGqb9tUEe5sbKfbbnUdw_28_0"></a><a id="Tc_vMAsCVXchUywk_m21450CQ_29_0"></a><a id="Tc_jmZ_26MD5km9v0uqS7UFyw_29_2"></a><a id="Tc_9Xq2OEy7Mk2qJT7PDuND_Q_29_5"></a><a id="Tc_mmidIKGRUUWHeuYOkhFbJA_31_0"></a><a id="Tc_q5TL6WCMG0iAY_c-6VKRuA_32_0"></a><a id="Tc_M00nwYv2mEaz9_dxonbWUg_32_2"></a><a id="Tc_y-HBObMDNUKlmV7M2VW0Cw_32_5"></a><a id="Tc_PHh0f3UKOUiSQF35djkVdg_33_0"></a><a id="Tc_ZSlzAuBTdUq-KxU8OStWlg_34_0"></a><a id="Tc_Gfh0lGqnh0yCuhSMu_JB8w_34_2"></a><a id="Tc_L-xocrKdR020aTymqn5aow_34_5"></a><a id="Tc_6frVyIf6AEKD0fACGvCylA_35_0"></a><a id="Tc_XUhxhBerWE--DTbAUOKqtA_35_2"></a><a id="Tc_oOh-2yukPEewRsg3PKAmDQ_35_5"></a><a id="Tc_ZNVu7hKVzUW3_ei2s2qwkw_37_0"></a><a id="Tc_muZ-8oCT7U2fYCeXJnKazA_39_0"></a><a id="Tc_31dKeXon706UrzmpSzGjpA_40_0"></a><a id="Tc_CCrx6pev10uwa8ClkE5keg_40_2"></a><a id="Tc_mlyM-tFw6EyA-CGlqWs_lg_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_IM1wlSKII0e_GthT9GZI8Q_6_3">27,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_TNSTyHXgMkmVPp_PoYxOkw_6_6">23,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_NuvP-OZGDkqIl0HZL-FExQ_7_3">21,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_PSHR_Isk1Uuc-ZkIZ4Eq5A_7_6">20,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_c6rAoTWIxE2JYWJh_NjqcA_8_3">3,759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_BUhu9VC0TkCTzlHZqk7_jA_8_6">5,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_uBstFpR9Z0uzjMxrhAo5hg_9_3">812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_83OtTmURTkmdDxNXg-cbtA_9_6">1,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Dv_7qtpoqU-0_Dv6IMdYFQ_10_3">22,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_AScX3XLhf0anJ89nEFJCkQ_10_6">19,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_WFd2RQz7LEK-_YuBWqk2yQ_11_3">75,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_tNe6Xz2rkUicpFwmoFjgeA_11_6">69,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_FYVM4CTtJEiAzbyMfH-hAw_14_3">531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_T_rhDo0qBEGRXPkeW3Woug_14_6">528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_y1RhrLOyTEWhlZZ4I_YoFA_15_3">4,781</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ZjzqRYw_gUSH3vP9E0P0Cw_15_6">4,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_bbn2OSHLgkyoFdpwoIyNUA_16_3">3,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_L9k4VpAnCECSgQwO0S6X2g_16_6">3,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_mh13VWDpdUij2lBRJjRMwA_17_3">5,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_G7ytFD1ENUqSNn74H1GhMg_17_6">5,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_mmX1sMlR1kCK4Ds7ALXcwA_18_3">89,825</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_95jddbE5E0qVowujV6lwGg_18_6">84,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_JwZSbhwlPkegv9MZSx5VQA_24_3">3,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_BWTKGccTiEmawYYa_BNyew_24_6">4,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_Xc_aop2Am0SqlDQQbyHgfw_25_3">18,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_ZAR0ej6E4kasIJqRWTcxWQ_25_6">19,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_lwb-XKeQdEGzShagPcOa2Q_26_3">1,453</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_2qxN6YcMCUy63Pm4Gc4tUw_26_6">1,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_v0M7---9Ikq5U23o_WHz0w_27_3">11,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_6EAYJN0PsEaoiOmU93GdnA_28_3">20,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_-jLhO4snTEuKsdRCc1-1FA_28_6">20,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_VxgjSRwKTke1xtD9fgQ4QA_29_3">54,828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_PAhSb0VbZ0W9aazZeRh6sA_29_6">45,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_y3Pd0-IcX0i3RwIsm-FYJQ_32_3">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_hcnkpjcJCUqi8h70Uk6QBw_32_6">714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Y8n6jnxA8UmVwYa4QlyI8g_33_3">4,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_JqTexTffp0mf_I_HjRw-QA_33_6">4,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_HSwK_lyk9Ue-KnCKASUfww_34_3">5,211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_zsk0IKNEn0aXXPleFOiOWQ_34_6">5,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_hRrgdZkftkyQpbbILp0q7g_35_3">60,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_tbWo6qCRWUOp1T35OLaK9Q_35_6">50,865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Zh6S-GWk_EKA9gg4yivAHg_39_3">29,786</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Tj3ADcLYXE2KIl4GSjMs5w_39_6">33,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_A2dJ-a-OREqxJ1thL21xAw_40_3">89,825</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Mz3THUngLkSHeMTEXxNLYQ_40_6">84,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2b198d4f_b37d_41bc_bf5e_b1967b21e5eb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_56f12b7f_6569_4577_8b68_5640a4558c2e"></a><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_oIH2eW1C8E-S9AmSBfrZcA_1_2"></a><a id="Tc_3ArvOKkg_kylfFpAsIRESg_2_2"></a><a id="Tc_36sqlVGf2ka3p0823OPvCQ_2_5"></a><a id="Tc_ogQEJ2lnKkOtOJN6Y6lhtg_3_0"></a><a id="Tc_qAbg9muR80eHwm1XTUacvA_3_2"></a><a id="Tc_ejzhtxqGCUGAMg_YrAadVA_3_5"></a><a id="Tc_2ruGLioyBki3jRSY0PnRBQ_4_0"></a><a id="Tc_Dyp1Z7PUd0ufTyXJo3y5Iw_5_0"></a><a id="Tc_6KQfqsCcx0Wz8I0q465x2w_6_0"></a><a id="Tc_xdVDXK-_LUmQPw2X61_7Pg_7_0"></a><a id="Tc_xWksd0y6nkagaIsQ7Rpjfg_8_0"></a><a id="Tc_YdPYmrtQkkux7s02FxTJ-w_9_0"></a><a id="Tc_clFEEymZmEyFl0SKWvYK5w_10_0"></a><a id="Tc_rzn4PB6PR0u5F11uhU4D2A_11_0"></a><a id="Tc_SjYw2JuUK0apz8QncnxVxg_12_0"></a><a id="Tc_hD0g8sVgakm_VfBuF0vD9g_13_0"></a><a id="Tc_3eXrbbC_Lk2uUrydOw7nHQ_14_0"></a><a id="Tc_pswH_CEnN0qks6904NLFVA_15_0"></a><a id="Tc_OWk3twetZkGjih1xBcaUDA_15_2"></a><a id="Tc_Jxtr74nr40WQ4AUSfgq7zw_15_5"></a><a id="Tc_WftMwrwQGU67YwhXm6Q_uw_16_0"></a><a id="Tc__mlgzJ0qQEqU2bwE-uDQQQ_16_2"></a><a id="Tc_YLwTTrF5hkSSNlWbwyb_AA_16_5"></a><a id="Tc_MkKpNBgcYEmltZwzR5Qj-A_17_0"></a><a id="Tc_gCptjo3RuUGzpIgTKhO_pg_18_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7083359%;padding-left:0pt;padding-right:0pt;width:103.41%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_LIKQPrFmCUCnBtrg04Oumw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Zgu-IDlF2kG-Y0m9-16Pig_3_3">3,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_WviQItZk-02YK8HpME_Dbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_3UZIDFQ8w0uBBmKContwBw_3_6">5,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z99VySZvSUmmlbiiGP0ySQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_n2TSy7-S4kWvMvjScpJNRw_4_3">71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_pV_QgLXkMUeQZyfrpN-Feg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_AH0qJdhG60qUWEgkh2iqcw_4_6">4,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_8C82ueHaTkiLnC0keARKgA_5_3">3,748</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bXoy5tZx5EKnV1COCqCVmw_5_6">9,588</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD</b></p></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_PhKXsFBd00inXpNg-XWf2A_6_3">2,602</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_Zix_6bej3kWNxBynuPIFFA_6_6">3,085</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_xDvm3MVhdkyJBkrAARDWlw_7_3">2,887</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_DPuc-Jsj4UWVu3ERCCKG2A_7_6">5,847</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_db8emrSrZEyzEpW5-2uZjw_8_3">3,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_dgJDU4y2U0G0DN1yJgvpHA_8_6">3,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING LOSS</b></p></td><td style="vertical-align:bottom;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_J2pfgH8FQUGlur68quqcKw_9_3">4,856</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_259lhwI9WEOuuP16rryJog_9_6">2,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_0mCVidCqGk2DomEcm35wMA_10_3">390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_n3JIqXVBWUa9kL8MiumudQ_10_6">649</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_UpE__mwaIE-H1iQBavklFA_11_3">513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_dg5VmIVFAUuIfI0p655oXA_11_6">172</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME (EXPENSES), NET</b></p></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_qQ1DRImzdEWNQQYmofqqow_12_3">123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_f5eaL5T4kUKW_RT3EIQrFw_12_6">477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS BEFORE TAX BENEFIT (TAXES ON INCOME)</b></p></td><td style="vertical-align:bottom;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_aQlLwIKVQE6WCW1gdyO1oQ_13_3">4,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_uwQZlzTdckaJwNrq3woOPg_13_6">2,936</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAX BENEFIT (TAXES ON INCOME)</b></p></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_iAA7BDgQ_kKrCUMwf8ugiw_14_3">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_svW8kAzh3E6LVfmiQiPicQ_14_6">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_t81SvSsSVkC7WFXqoGvB3g_15_3">4,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_tUzfg4yF4EOL5IVqzkDKOg_15_6">3,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK-BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_3Cgodxnfu0eyhVrHxnihUg_16_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_3Cgodxnfu0eyhVrHxnihUg_16_3_2">0.06</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_cddVFEa1akSavlKaJoKiTw_16_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_cddVFEa1akSavlKaJoKiTw_16_6_2">0.05</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE (Basic and Diluted):</b></p></td><td style="vertical-align:bottom;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_cxsuRF854E6Ln2ZGP6l0Qg_18_3"><ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_cxsuRF854E6Ln2ZGP6l0Qg_18_3_2">73,036,569</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_xuXHGvTkQ0CnQ0nLOifbhg_18_6"><ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_xuXHGvTkQ0CnQ0nLOifbhg_18_6_2">57,480,009</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5fb4d13b_fdff_49b3_90ef_0d1a8490b266"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_M2M1uISNTU63rnOxxGVtZA_1_7"></a><a id="Tc_oZbmDQjyg0usyr9esJEuCA_2_2"></a><a id="Tc_680OE7l2R0aAzlyHHdo8Qg_2_4"></a><a id="Tc_e0Ix7dt1vUO2xrrdCP7pGg_2_7"></a><a id="Tc_IocZ5IoDwk6QEvS7JE0tkg_2_10"></a><a id="Tc_hpM1KyioYEmS0Ij2G0OdIA_3_2"></a><a id="Tc_JhuvYPrEmUyd8LGYzSZagA_3_4"></a><a id="Tc_vsDltKltoEmhKK227Wz-Qg_3_7"></a><a id="Tc_JizsVe2H6US-PoYqX6JXZw_3_10"></a><a id="Tc_xUUpp_3ZAUGxJJ1xVKlkzg_3_13"></a><a id="Tc_eaZu64qDEk2lOynJAtai5w_4_2"></a><a id="Tc_QT3JnVCXM0OLBl04HGgVQw_5_2"></a><a id="Tc_Wu8WH2wkr0y5AuV2emNU5A_5_4"></a><a id="Tc_-kGYvcrwc0CL5H1cq7VBGA_6_0"></a><a id="Tc_9dK86ntUm0-gVHDfWLZIIg_6_4"></a><a id="Tc_9AfrvWkQL02kixJevGzTqg_6_7"></a><a id="Tc_H537j9VS0Euy1wqlYplZig_6_10"></a><a id="Tc_oPNnVgD4tUWFQ6mD0eo6Lg_6_13"></a><a id="Tc_TaEUt_LV8UiSEz3PFsxKEw_7_0"></a><a id="Tc_JYbbS875uU6ueOOfq5A3Qw_8_0"></a><a id="Tc_W5TXnhzRfU-RCLurSJl9yQ_9_0"></a><a id="Tc_X5KI3upcMEWYmQlfIrJtCQ_10_0"></a><a id="Tc_FYY9j5on60OOMy5Culo4Qw_11_0"></a><a id="Tc_flN6BJIfVk64ZD_tXlNZTw_12_0"></a><a id="Tc_zXmE4HM2fUeVqy-r6cyPDA_12_4"></a><a id="Tc_EKP9yR2MXkGGdtFkwiZtkg_12_7"></a><a id="Tc_Z0RMYapXBUqFZEJI8mzQzQ_12_10"></a><a id="Tc_mhi7CapRt0-rQ21cHs_8tw_12_13"></a><a id="Tc_ntk4UAkpREiBXVN7GS3Yog_13_0"></a><a id="Tc__gMfHt6YDkOEoqiLMumnIA_13_4"></a><a id="Tc_XpY410pOwUalXPzvosWXdg_13_7"></a><a id="Tc_3vDWnmsWS0yXtKg374LXfA_13_10"></a><a id="Tc_XO_nnpUbo0KantFTCNI2Zg_13_13"></a><a id="Tc_ESoAlSfs70q9VD1bcioIZw_14_0"></a><a id="Tc_snLO36QlPkmcoucKTc8wrQ_15_0"></a><a id="Tc_OCuYxOzMmkWu8E14oe5oiw_16_0"></a><a id="Tc_aH58jwure02bTSxY-nL4EA_17_0"></a><a id="Tc_RFx1iHTRBkysGHAlIVBCPg_17_5"></a><a id="Tc_KJjnGIlumEygbdQni8OEbw_18_0"></a><a id="Tc_OIkH85oXtES-8kk2CK7tDg_19_0"></a><a id="Tc_cfjkUvowskGIlZswamWIlQ_19_4"></a><a id="Tc_AOONK-xlPEmTFv5lH0NHuA_19_7"></a><a id="Tc_nJN6ChQcc0y8n3KbPtIaIQ_19_10"></a><a id="Tc_j7khVRtTek64E-eylRLe0g_19_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DqFs6ZdUS0WsAvycUW3EDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_5jJVSBrasUWgBK3js2CxoQ_6_2">53,790,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DqFs6ZdUS0WsAvycUW3EDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_mbn-mSQPHkaRi3y9jC7Q4Q_6_5">54</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TnKkjPS4E0-jVZHJUJNLNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zl_M8p2f1UW3sBosxSltTg_6_8">379,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0ewi0kFMXU-CRUeaAv6HHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pWUjYWbjNUazUJZY6NOxbQ_6_11">389,861</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2022_N5rxkP1HDUKEqAztKtnJ2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_hCbzzHkS-EGkwl94PGxh_Q_6_14">10,640</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8VAgdb4ALkmKPOJ7uu_neA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_gosVfC_JMUCxqvplCA6nxA_8_2">8,212,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8VAgdb4ALkmKPOJ7uu_neA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_hlt6b7p3L0WovorEHYZJdQ_8_5">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D5tn2C8Vak231ybX4CNmDA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_ILGG0MszgkqueMDC21Xxmg_8_8">14,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_-aHdXdZ4-E6HQ_EwgR6Z6A_8_14">14,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D5tn2C8Vak231ybX4CNmDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_XJvBBppZHk6-ldZzhOSaow_9_8">453</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_jIDprBljmEybhdnWZpvWew_9_14">453</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D5tn2C8Vak231ybX4CNmDA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_Elct3sUldUKwJHktGkvL_A_10_8">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_OYcYSr6ng0qvSHvb8yj0VA_10_14">93</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IMPE8wN7rEeMrPPPiQiN9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sh96ksNAMUqSF_XVs6Gxxg_11_11">3,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JqFZJJQ3V0OAVBtupKcNSA_11_14">3,131</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dSj5Bua1QkaM-W1iMSZ6WQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_sndmI7N3c0yKdEk-SeoiAw_12_2">62,002,649</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dSj5Bua1QkaM-W1iMSZ6WQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3BEKlRZvtU24C-qSoaJOeQ_12_5">62</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1cdccZU09U-bigfo9gAdWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eHXZoORImU2_8-RwCEB8DA_12_8">393,938</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_It9cBFHKPk6qc9vr0qHvLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_q5EmVcWEmkaz_Au0IL77fw_12_11">392,992</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2023_xjgcoWRmyUq3QXN8beg6JA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_sJWjeqhHoUy-PbTScqIyYw_12_14">1,008</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OfiAuwsd7ECIG9JmRKBQ6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_FGp2-PEvW0uYn-0F3PL6TQ_13_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OfiAuwsd7ECIG9JmRKBQ6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kWtNcjywLkKtlit7W4-Ugw_13_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UkNAV_nnI06H0twkkPSRjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zLEuaa_wNEukyaj5mRScAg_13_8">415,045</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R-M5bPoxwEejTI9jPZq0pA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc__meieoDTgEqUtFyASW_GvA_13_11">381,549</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_f-ASgM-E60iVfUv35VWCkQ_13_14">33,569</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Initial adoption of ASU 2020-06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EVbVs5tNjUeS5vUf2w1OtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Dsy9Q92ack2IM6dWv35Xhg_15_8">393</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AoDmf9T7-EW8NibIGw8Drg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_oodz1Dz44kCSLvgyhPFooQ_15_11">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_v8PL0h3_wUiwfI-glHZlUA_15_14">169</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XauTFxetDUimxtIcJ0CjJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_TWo9GOd3zEupPau1MYg5UQ_16_8">500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_RAKUf5NY00K8g5P2rFf9kg_16_14">500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6gG79eVy60GCAQmdhRp9TQ" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_33t8Gr9f0UeEkwYS_dtQJQ_17_2">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XauTFxetDUimxtIcJ0CjJQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc__UFD_oEU7U-RdfbTAf0yKw_17_8">481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_Zzfnr6ydnkKdzs4ye8nGXQ_17_14">481</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_A9tFbldDhUqAI-mwDvGBqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_E92oGXZbzESoGLtRmB1Zbg_18_11">4,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Oi1Jkwda706wtO5o7SgRqA_18_14">4,595</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kzn5qEII7EOEguLWbvYS3g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_KgyFIzvufEafEs9RBm3e2w_19_2">73,052,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kzn5qEII7EOEguLWbvYS3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1vnPygbu-kCAzsKWsXnstA_19_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cabxw3GtuEGEzA6sOUlY4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6qcwGXz1Y0aMz9Lr1441FQ_19_8">415,633</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9j4H_qwYkSWRSCNd8Y63Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ZO6gmVxdoky-h-byrpDMNQ_19_11">385,920</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vON1sz0vKkW-QkUvL5Yr2g_19_14">29,786</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">*Represents an amount equal to less than $1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2e03645_2643_4168_926d_13e04faf108a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ZE2uJGzu80SDHqd1F1g45g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_iypOOTgJ3UGzktNVrs79iA">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of March&#160;31, 2024 and December&#160;31, 2023 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_il5Qb-4RMEmpOFawdz8cFw"><ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_7mn90FOaWk2cBFuU515ZEQ">185,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_810f0f21_2619_450f_b311_740817018bf3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_Y7SPiW-2yUikUwT_RksQrQ_1_2"></a><a id="Tc_Cdr9XQ3qIE6PjJQNhEQ1vQ_2_2"></a><a id="Tc_Dg9iCSvhwkijrVwl1Lup_Q_2_5"></a><a id="Tc_5tOyxPwJn0qVEDA1Pb-nEA_3_0"></a><a id="Tc_tPQYHayRR0eHRrqPok9ttw_4_0"></a><a id="Tc_fy1MWgoRfUaLJKFnisf_jw_4_2"></a><a id="Tc_dYrW_oyvjUy35TSPjTvkCw_4_5"></a><a id="Tc_29bK4IjJp0-YWiJs0YtM1A_5_0"></a><a id="Tc_LAlxTq4iLk-LHwNBxP2O6Q_6_0"></a><a id="Tc_A1uLEOJiikWBhd1inUzI5Q_7_0"></a><a id="Tc_dNURIiWR1k-uH3G73X9SLQ_8_0"></a><a id="Tc_JgQLMXm-mEq4cAsnIbTXKg_9_0"></a><a id="Tc_i4CZuL65ckaO_XW5ZbTpGg_10_0"></a><a id="Tc_Rcs9KMsQa0mryMHQz7wR4A_10_6"></a><a id="Tc_96HD0y7TsUGd6WFrOoj1iA_11_0"></a><a id="Tc_DG1phxyj9UWzmYeopCaUrQ_12_0"></a><a id="Tc_1DNBkV1feUCYWYR7nSxZ8g_13_0"></a><a id="Tc_GysF2uY6TkivJyt81atMVg_14_0"></a><a id="Tc_LHLngvxeyEKLABpwgKzYaA_15_0"></a><a id="Tc_GTD9IqmtHECSaJxoGAem-Q_16_0"></a><a id="Tc_fEfK8sO98E2SXxaGzfoK2g_17_0"></a><a id="Tc_uEazS_KRl0GZZuUqPfMxwA_18_0"></a><a id="Tc_ws27TScDIE-w8IkWQrzTjw_19_0"></a><a id="Tc_6BQo_tXF40CJBhIuIKcwjA_19_2"></a><a id="Tc_ZBvIN8Y0pEu2zc81Cs1QJQ_19_5"></a><a id="Tc_J-gN4ClQ6km5nZDXa-BxHw_21_0"></a><a id="Tc_WqpJwPNNrE-01tLpWKdSHQ_22_0"></a><a id="Tc_pGV8aqq7tE2cutmUTZfKzw_22_5"></a><a id="Tc_i8qKd84LPUSW91V75KP9Ng_23_0"></a><a id="Tc_zjU9twhcn02rzuO5TYsgSQ_23_2"></a><a id="Tc_RmW_nP4f40mnrgRogQ1bqw_24_0"></a><a id="Tc_0XNGrAeU8ES7IEPbZ4u_kw_25_0"></a><a id="Tc_S3Q5t5W-nUOvfwjjMgBEvw_25_2"></a><a id="Tc_jQBPLFvOWEC6NXjHofmh2A_25_5"></a><a id="Tc_hWkcxrTD70iZH8ljvQEupw_27_0"></a><a id="Tc_3pgeo_HRdECqKigKaU68jw_28_0"></a><a id="Tc_NdwJjOXLBEivTVcSA-538A_28_2"></a><a id="Tc_gl4EzRGyWUqJG8pSGjD6HA_28_3"></a><a id="Tc_HrPu8rvpQUavusIR1BmiVw_28_5"></a><a id="Tc_ZbA1ZB3OVES2kv-RAbCzzw_29_0"></a><a id="Tc_U1etNvv0Jkqd_tYwHPNshQ_29_2"></a><a id="Tc_oktgDt0ZU06XaDd8OquuZg_29_3"></a><a id="Tc_lg9P-ZLSBEW8HMYFi1e6Bw_29_5"></a><a id="Tc_wgT0gDzcfkKTRHcH2JY-DA_30_0"></a><a id="Tc_dUBduHi4tEOr09vaeE59wg_30_2"></a><a id="Tc_udjBp2CCrE-Lj8JBYtY4Lw_30_5"></a><a id="Tc_ufv7jDNQckemKfL_8muaAQ_31_0"></a><a id="Tc_J_OLBFIe_0i5eUQvyjdGtA_32_0"></a><a id="Tc_vLYNpLcyjE2mh1mZo1xCtg_33_0"></a><a id="Tc_NgUwG4zyUke9sA7HOKYCUA_33_2"></a><a id="Tc_NGyS7BVXckyYXLphpCR7QQ_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Kbt3dD9DjUWEm6hNzOe3rg_4_3">4,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_0JBkKYm1ukmiXN1YUeRZfQ_4_6">3,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_qpGTXJUqrUmKqEx-_nXpQA_6_3">981</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_b5WLcgC0hUquS8Hb9j3O-Q_6_6">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_4UWkhxHN6k2vYiW4cnVFuQ_7_3">322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc__8rSuYmTa0W0Te0ezAFaZQ_7_6">280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_431mKaB_x0q1aa8WqJzqIA_8_3">471</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_g4FNklnsI0CGPCHX_bMe3g_8_6">91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_FKL0XpItiUmMrBC7FOHlmQ_9_3">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_FezpEiTGWk2a4GEYvCx5Zg_9_6">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_cvxHyWE1RUOFUh_1-RoSvQ_10_3">138</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_AQTz4KXuL0e9QDq2HP42KQ_11_3">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_MchgnGjbTEGtLI5JBRXXag_11_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_RyGL-8MZcUmwLmtxxEewxg_12_6">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_dIRaoiEek06yobvGeGK_7A_14_3">11,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_RXzIRfmRtUqd5iHBHlX_Mg_14_6">1,388</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="white-space:pre-wrap;">Decrease  in accounts receivable-trade and other assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_uCrfEUVG4U-mB1yTi3MHug_15_3">1,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_Qb8KCYqm-UGGr1bTClG5-w_15_6">3,823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc__BS79PN88k2VCmg7e2H9xw_16_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_0q4i_DnWi0i8K3P_ZRAARg_16_6">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_kWi4o2N7uka0mJ-3AK9DuA_17_3">3,301</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_r5DNX_YNVEOIIJrCD8dLfg_17_6">3,499</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_Glv_IyOK6UGxPkdtOUo-Cg_18_3">1,414</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_6XLYoODgtEiBIkmPq-Ldag_18_6">353</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_dwfJ6FUOWkubLV0pmtC0xg_19_3">4,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_O37a9E7ozkuRL71XuaYSKg_19_6">2,998</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_ec_OMziUl0O0ly4-eiFyDw_22_6">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_4bLz4du9akmUv1EInvYs2Q_23_3">598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_8l84yOS5902XAhJYw991Zg_23_6">248</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_8cxYlPrevkGFdTfmWpvRJQ_24_3">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_Vg_HD1NjYU6GFoXV1azrjg_24_6">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_djtqz1pc3k-JQjZyYnasgQ_25_3">606</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_yKoubttZUk6gkcbNMBfWRg_25_6">4,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_GZIbB1QUvESg-C78pXfUdA_28_6">14,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_MzZt28tC40yyYQP3Vfc2wA_29_6">14,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_1wtumY9MRUio1kLzsJyfaw_30_3">7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_qgGNenJrVE6kfSfF7aQAog_30_6">42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_8hWygluGiEWNNaA1-7WtRA_31_3">3,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_r0ttSuMRdkamt5Zvdq7rvw_31_6">15,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_CxrN7swxyUC-6ZJG8XK5FQ_32_3">23,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2022_N5rxkP1HDUKEqAztKtnJ2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_D4lGaHopD0yKBB2rdV4RVQ_32_6">17,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_81U_VbGTVkm1Dkj8-B5AGA_33_3">27,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2023_xjgcoWRmyUq3QXN8beg6JA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_wisunZ8ZrEWhKquVeNvAsA_33_6">33,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_6lZjN0YG70ycZizZyrRA5g_1_2"></a><a id="Tc_keeO4PRn1kiKrtgbQ8TIKg_2_2"></a><a id="Tc_smcDwDZySkKgQ2cAYE8pcA_2_5"></a><a id="Tc__56DH321aU-LM6EVkw-T2Q_3_0"></a><a id="Tc_7UrCDqFNRkCuekEHhlTONg_4_0"></a><a id="Tc_7cMUo8SoN0OPG9-xsVSDjA_4_2"></a><a id="Tc_ylxWdS4HgE-zK1jUDK-7PQ_4_5"></a><a id="Tc_PAkU8_5dCUm8drTmV5MIHA_5_0"></a><a id="Tc_a8g-0nKxYkqTzSHsKf8S-Q_5_2"></a><a id="Tc_n2780ad350KymO90tJkuow_5_5"></a><a id="Tc_kOFypLew8ES9dLi6q1dU1g_6_0"></a><a id="Tc_Zi0clfZ8WkSfVrDRnuXSGw_7_0"></a><a id="Tc_MZRI9c9dKkiIXK17aTNtgA_7_2"></a><a id="Tc_3uWvSG7i00menwa3kylp3g_7_5"></a><a id="Tc_KttxfOGj1kWcPxjd8ltgYA_8_0"></a><a id="Tc_7W5Za_t3c0uMi8AVZvJRQQ_8_2"></a><a id="Tc_tCqxRPA5RkCGfCaCSOhoeQ_8_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_vePAnrDEKU6qe5kJxTYSKA_4_3">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_wcf61Na1-0OZDdeGA4Kf2w_4_6">326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_iF1ZbODmK0OB4LwStDZAPg_5_3">186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_JI6ePkBBGEmOOwIQvygARw_5_6">312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_MKSNtcZOeEGeSHVTnHKHcg_7_3">766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_jSNdCW1-fEKMqVWGAyhmew_7_6">1,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_jAWZ7fKOm0i8pnLvbW8hcg_8_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_fEn-qxWHAkacDmnkhkLoWg_8_6">78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_KcMrpTkVOkK29Gx7NWunbQ" continuedAt="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_HHXnuzRg_kmiAHqf_xK3lQ" continuedAt="Tb_HHXnuzRg_kmiAHqf_xK3lQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into <ix:nonFraction unitRef="Unit_Standard_agreement_9OeDCEh91kqDTYHwfDEKIg" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfGlobalLicensingAndSupplyAgreements" scale="0" id="Narr_KWvfgS48HU2Is0_6GnpeBw">two</ix:nonFraction> exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont1" continuedAt="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont2"><ix:continuation id="Tb_HHXnuzRg_kmiAHqf_xK3lQ_cont1" continuedAt="Tb_HHXnuzRg_kmiAHqf_xK3lQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase&#160;I First-in-Human clinical trial of PRX-115. This study was designed to be conducted in approximately 56 adult male and female subjects in the dose escalation phase with seven sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of March&#160;31, 2024, 56 patients have been dosed in this study. The Company has decided to expand the study by adding an eighth cohort with eight new subjects and to commence preparations for a phase&#160;II clinical trial of PRX-115.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xX-MG2XLX0m9iz8FCKqqug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_KZfqxbP3mUuBlE8y_fa21A">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xX-MG2XLX0m9iz8FCKqqug" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_5sn1yOMaAEaXvEWFrta8Aw">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TI5qIQ-W5ECjpmDAaBfbkg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_qWjJoBpzA0WcXpE1tpLn5g">13,980,060</ix:nonFraction> ATM Shares for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TI5qIQ-W5ECjpmDAaBfbkg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_TsBv-2H6lE6lA9iXcPmVAQ">20.0</ix:nonFraction>&#160;million thereby completing the ATM program under said agreement.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont2" continuedAt="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont3"><ix:continuation id="Tb_HHXnuzRg_kmiAHqf_xK3lQ_cont2" continuedAt="Tb_HHXnuzRg_kmiAHqf_xK3lQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZmijeMu1t0aGYXoOgDHBMA" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_4KQAlw7bfEG80h_XWkFT5Q">20.0</ix:nonFraction>&#160;million. As of March&#160;31, 2024, shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_FTJ8oLhaw0eNY5HLHGDojQ" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_ruSRHG2P7UO85HNunkrCGw">6.4</ix:nonFraction>&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_SyXMreozU0aUnXbYdjaAlg" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_j6l5WwADkkiJIBQ9V3cLAg"><ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_h9WLivGpgEyD1m0aAK4kOw" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_zUSxP6Kqx0qd1k9ab9hyiQ">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lwVtQlooKUmWHx0HxMj1WQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_sdszIpU1RkKgv1I3p_iYXQ">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lwVtQlooKUmWHx0HxMj1WQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_-LqULqHejkyrdikuOiJrfg">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_gp6Tqjm6QkeG7ShEqzvLHQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_5F65NZmTekWeK3EYN9s8jg">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_gp6Tqjm6QkeG7ShEqzvLHQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_WSndhCQCO0SDnV4XlK0-vw">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YaHpHVxvLEmVk7w9ELKIkg" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_SRLZAPi8xEa5omwZw9JF2Q">20.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_sTcnk7rZXkKGiMsDqP-mkA" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_5M_aZz-IAUqk-FbtFdEBRw">10.0</ix:nonFraction>&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E_QTB-Qpi0GslgevMAMiVw" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr__QGA6XI6Jky__6PjUzEJsA">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_uKLBpQRGtUeyn34LZ3eWsA" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_Ki3S3XKkHkCs6YkRd3WGwg">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_mGOqXZx_bkyqGouEHLnUAg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_IPdLQck7kk-7p_kc4RQOaw">35</ix:nonFraction>% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_mrSsBTSz6UuGt_rjv0O4wg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_Z2VIA5eUakyHt9y9v0DUQw">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_xVfX9yUYmU-4xeITZl_dtw" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_y-T-4n_31Eik_3hu00C_Bg">40</ix:nonFraction>% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;<ix:nonNumeric contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_qjzJkxA5JEGDK6mwmBPwHQ" format="ixt-sec:durwordsen" name="plx:ExtendedTermOfAgreement" id="Narr_Ud8HhkjSP0CO6Mq67dz3-Q">seven years</ix:nonNumeric>&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_sLr8N63ht0eaToO41XlL1A" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_A9XfHn2xu0CfeMkouAV3tg">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont3" continuedAt="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont4"><ix:continuation id="Tb_HHXnuzRg_kmiAHqf_xK3lQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_dtTtAUZdsU-OMRlXaEJPuw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_7vTc54V6uUqFp2TJxgLRIg">7.50</ix:nonFraction>% Senior Secured Convertible Notes due September 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_dtTtAUZdsU-OMRlXaEJPuw" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_GUwVNVOz-Uyd99pBva4lKA">7.5</ix:nonFraction>&#160;million. As of March&#160;31, 2024, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash, cash equivalents and short-term bank deposits as of March&#160;31, 2024 are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_Td19wJRaGkumCTaDxY8FmQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_yxA46jLb9UCRoGAJLFRkTQ" continuedAt="Tb_yxA46jLb9UCRoGAJLFRkTQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates loss per share by dividing the net loss by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_K8VfeUC8RU2F-5Jj44lq4A_1_0"></a><a id="Tc_0ETsrtAHN0axsGHDtXHzlQ_1_2"></a><a id="Tc_7z3MJQ19W06-L81xgrg3QQ_1_5"></a><a id="Tc_73Bh5jam8kicw6ZEZTQqdg_1_8"></a><a id="Tc_667_s_7ui0u6FzfBZkG1ag_2_0"></a><a id="Tc_wqAbTuJjvkiUy8ioTdZ20w_2_2"></a><a id="Tc_O9yyTNFAkUGAsuarGOMW2Q_2_5"></a><a id="Tc_3kJwpRpUv06VRf2OswBp3g_2_8"></a><a id="Tc_-ezYqD24x02qSz5-3fNWjw_3_0"></a><a id="Tc_Qq15L3jZzUmTrwpmJSfYnw_4_0"></a><ix:continuation id="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont4" continuedAt="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont5"><ix:continuation id="Tb_yxA46jLb9UCRoGAJLFRkTQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted loss per share does not include <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_WjpBWRASqUS_j95EpoYkTQ">36,292,208</ix:nonFraction> shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2023 because the effect would be anti-dilutive. Diluted loss per share does not include <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_RUaPiE1zgUu6n4z2Dq9b9A">31,839,345</ix:nonFraction> shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2024 because the effect would be anti-dilutive.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:DebtPolicyTextBlock" id="Tb_t26Hvol2E0K7LSOZvJe-rg" continuedAt="Tb_t26Hvol2E0K7LSOZvJe-rg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. <span style="background:#ffffff;">The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued </span>ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; (&#8220;<span style="background:#ffffff;">ASU 2020-06&#8221;). </span>ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#8212;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06<span style="background:#ffffff;"> </span>using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. <span style="background:#ffffff;">The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. </span>Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="Group_dmykjd-SY0OHCgwwZFdy5w" continuedAt="Group_dmykjd-SY0OHCgwwZFdy5w_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated January 1, 2024</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_BNU8qhR3gEml-KeKGKnI9A_2_3">20,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_e5XT7TC3JUOFCdJknj2Kxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_KA5K7vSrjUWCGirCEM_WPA_2_6">20,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_7SgXk48cW0uKG7aq9Ekk7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_0gWql53pnkOFaTQKL_Tx9A_2_9">169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_vy736Q6xxEiJAQ7Gto3aGQ_3_3">415,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_e5XT7TC3JUOFCdJknj2Kxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_Hefx7tYXdU6SzZBR5ZoBbQ_3_6">414,652</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_7SgXk48cW0uKG7aq9Ekk7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" sign="-" scale="3" id="Tc_BnrrBYiuYE-wWfDMP7cPXQ_3_9">393</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_89ysCFMOIkCV0e5N0q2QwQ_4_3">381,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_e5XT7TC3JUOFCdJknj2Kxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_9Rlml1syo02MPRSahR7_hA_4_6">381,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_7SgXk48cW0uKG7aq9Ekk7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_S4xNJ5A7Fk2097MaKFbIDw_4_9">224</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The impact of adoption of ASU 2020-06 on the condensed consolidated balance sheet as of March&#160;31, 2024 and on the Company&#8217;s condensed consolidated statement of operations for the three months ended March&#160;31, 2024 was as follows:</p><ix:continuation id="Group_dmykjd-SY0OHCgwwZFdy5w_2" continuedAt="Group_dmykjd-SY0OHCgwwZFdy5w_2_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_nPRaNSS_G0Kj1ciMyjezVQ_1_0"></a><a id="Tc_nKLVv5Cm40K70Xmc79X4DQ_1_2"></a><a id="Tc_moCwJywewUKLE83dSGc67Q_1_5"></a><a id="Tc_TWYdCKCnwEi7JP7wol44GQ_1_8"></a><a id="Tc_ncMb7RQvxEe6hC6A5G7vsQ_2_0"></a><a id="Tc_6x49raIotEibAmRlCM2M5A_2_2"></a><a id="Tc_4MFgtIV6PkCpchdukXcdsA_2_5"></a><a id="Tc__84kDWhnuEGd15wA3uMiTA_3_0"></a><a id="Tc_7L0vMrnJOkqqWmWnietu0w_4_0"></a><a id="Tc_mSPavPKE8kSDRtRdkek5Yw_5_0"></a><ix:continuation id="Tb_KcMrpTkVOkK29Gx7NWunbQ_cont5"><ix:continuation id="Tb_t26Hvol2E0K7LSOZvJe-rg_cont1"><ix:continuation id="Group_dmykjd-SY0OHCgwwZFdy5w_2_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balances without Adoption of ASU 2020-06</b></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial expense</p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_MRoG3U83PUmyx0DXg4n4TQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_0qHyZde-R0uxbxOpWLDnDQ_2_3">382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_6VgdHCEey0ChwG_Brnl3sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_iwxPMKTIBECcSoR4UClhow_2_6">444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_HNYzKmZW0EGFk6AugmfHqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" sign="-" scale="3" id="Tc_O5bEABjpbkCN0K6qpSJBAA_2_9">62</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_5ll4IzhZsUOjqRDIs4jcmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_Mr6BCJApm0-ubZ8Qp9kbDw_3_3">20,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_o-lkPPcrrEeuOZNhLH7JRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_1JqH_vbA6UCUn2NgI7m3uw_3_6">20,313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" sign="-" scale="3" id="Tc_Dvkpx9naREauxXPcKow_Wg_3_9">107</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_5ll4IzhZsUOjqRDIs4jcmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_kYAH-7WwfUiRZ7q5ZdYcIA_4_3">415,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_o-lkPPcrrEeuOZNhLH7JRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_hLlto2EyNEu-dJqbW84KVg_4_6">416,026</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_C6RVQExmn0WG8U8E2QjdFA_4_9">393</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_5ll4IzhZsUOjqRDIs4jcmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_L17Fw_G-LUKhv6sbukxmEg_5_3">385,920</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_o-lkPPcrrEeuOZNhLH7JRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_62mR3VHLMESHE21CSAta8w_5_6">386,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_g6j0up9VfUWgSdEWz8tU8g_5_9">286</ix:nonFraction>)</p></td></tr></table></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_MHYGD-XzKU-NSmqHfvyy2w" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently adopted accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures</span><span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="Tc_umOfYqSKiEuf1RBbf26Hcw_1_2"></a><a id="Tc_h4H5AtFjQ0yf2cJ3aSe2Mg_1_5"></a><a id="Tc_ZznjzB1Zn0-YzVeYpb__-Q_2_0"></a><a id="Tc_-KGlXBi4VkK4sUvHy4GXrA_2_2"></a><a id="Tc_zoZ0GE_d00aSTWiTLh_uXQ_2_5"></a><a id="Tc_PiSXgSKt60mc4iSeGmxRjA_3_0"></a><a id="Tc_7DyjTzqazEm0SDtdcqV4vQ_3_2"></a><a id="Tc_GT0WDQ7uDUKRWJ8dXl9YZQ_3_5"></a><a id="Tc_O9NZSCHvHEqVU6As_kZDWQ_4_0"></a><a id="Tc_UH6bJFUDVkanL3r78wfqzA_5_0"></a><a id="Tc_G8MOujN-kU6_AmuEUkYBQA_6_0"></a><a id="Tc_KC5LBvwhbEyjCKBxUWMrKw_6_2"></a><a id="Tc_hXp4rpsII0aksf5FUDi0KQ_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_KFRjVSJX30W0KuNKrDF2Yg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2024 and December&#160;31, 2023 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb__axIGmRC3U27lmySgT4qNg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_S1fe5tnTckCWuUwWC9_pkQ_3_3">4,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_Iqc93tVZVEWbfN6fvS4hGQ_3_6">4,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_TE03mlPn40aaej4J14JYDg_4_3">9,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_FlQUXVwI_EKsx3AO-T55cA_4_6">9,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_x05m5d0yaEWED4z2Ux7i5g_5_3">9,153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_YVQYNTbbJk-Pm_hTWeKU2g_5_6">5,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_vwlhcVoR6keBrF0SH7mfQQ_6_3">22,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Py35xvmW_kKboA2UVhzAuw_6_6">19,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_5440SXtmMEK970Ub4BVZsw_1_5"></a><a id="Tc_Cx-29_UGPES8TjpeRviqyg_2_0"></a><a id="Tc_uHk2gw1Sd0ak2v1vF5umJA_3_0"></a><a id="Tc_n46TMyFjg0-jH51sgmmc5Q_4_0"></a><a id="Tc_cPpbuLNK7UGq6YETXD5emQ_4_6"></a><a id="Tc_YESRz-zMSUiVm4S-T0vesA_5_0"></a><a id="Tc_QMI4SOL820-cXXV4u-UYDA_5_6"></a><a id="Tc_ISOMexDCI0qbgAC25FgNUw_6_0"></a><a id="Tc_-Aksbwc89k6ZyDQhlwnliA_6_6"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_iSPh-HUPD0Kt30MGSEgjQg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level&#160;3 measurement, as of March&#160;31, 2024, the fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VN0lXe7Da0uVnHnA1AZ-Ug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_JeYUDgRuDEOHWQlGT-oVyw">20.4</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VN0lXe7Da0uVnHnA1AZ-Ug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_TVsMLf4GMkqJ7bAGQAFK_A">21.2</ix:nonFraction>&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: </p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_DSkPUZ0Ock24wWZtXiDMDw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_cw5_mRCfbUqPtDbiaivazw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg" contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0aoQ1IPKS0aCMthAjitzGQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_Sn7cb6wNgkmdk7bIE_2LSg_2_5">1.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_2rgTiQvabkK-OvDBIrW98g" contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C3_bHbEzuEi8F1H8pW2V5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_Gdtp8_-9eEqJlWzPoVd57Q_3_5">0.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ZYB0fx44FEWMgVZL0Q2ZBg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_KOi7rrYeEU2c8X4tlgR1Rg_4_5">5.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_IPYo9S6V0EqfSWhkVFWAYw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_ZObkU_po3EeRK3SvzJZGxg_5_5">67.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_8a1FzJd1ik67d1aQt1PHIw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="-2" id="Tc_bLdZyA5PC0KCcJ_lHCDEgA_6_5">12.06</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_fUCTZ2X_rkCbSLfHchZQ3w_1_2"></a><a id="Tc_rtLaaOaPsEKRlvleTkrsvg_2_0"></a><a id="Tc_WhF96Nhw6kKpYhAbU-13Sw_2_2"></a><a id="Tc_TwqY7M2FdESnHtJ-8W1IZA_2_5"></a><a id="Tc_gQzrgol530iGkvGvX1lU6A_3_0"></a><a id="Tc_oPH-d7EbXU2J4cLOsFecww_3_2"></a><a id="Tc_WcIktYXQqUuOIdyd3dKVdQ_3_5"></a><a id="Tc_nN_y9wY0XkybJRAhs7_WEQ_4_0"></a><a id="Tc_ItrF41XJhUO2OFSckhQ4gw_4_2"></a><a id="Tc_FwvcFhhRVUWZ2sI5cqXxpg_4_5"></a><a id="Tc__XQCRJwp5kif_wjexKo9rg_5_0"></a><a id="Tc_yw3-osI-HkGzmg2EbfeLOg_5_2"></a><a id="Tc_QNb5v5iMr0up0wxEd8L4PA_5_5"></a><a id="Tc_ygCWz3kzl0G1caTGLNuqDg_6_0"></a><a id="Tc_er3tgR2gSUmy7yzhNWhSjQ_6_2"></a><a id="Tc_Iz8fW9Gs3EO6EBitas-1iw_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="plx:RevenueDisclosureTextBlock" id="Tb_lSrcmqQrq0GiRUA-_MUA2w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_sakxcqdf70aeqAak7aK4-Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_plWIvGvIFUyhx5jpML44MA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc__Gq1zolc7k-nJ52F8xMAjA_3_3">1,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Jd_SJ9gglEK0yT37LHcRGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_mOtx4nVL_kmuvNTBzia28Q_3_6">2,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_d371MQCH-UCwEc1UyItlwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_6k21pnh4vkSBq4ohQKbsMg_4_3">2,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_AB2WjkfrfEufyvdgXghKJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_qUxzyFCH1kapeIdi9iBxOA_4_6">2,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_LIKQPrFmCUCnBtrg04Oumw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wZwcfDYKYkamvjjWxj5H7Q_5_3">3,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_WviQItZk-02YK8HpME_Dbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_x4iU2_1b1ECRtSsslwPQbA_5_6">5,066</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z99VySZvSUmmlbiiGP0ySQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_XFL3vFQDTE6iPof8JB-CCg_6_3">71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_pV_QgLXkMUeQZyfrpN-Feg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wzW-Zk-8jU2WReG6sslejQ_6_6">4,522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_NvAm1pAhu06Il_jVJr_Ayw" continuedAt="Tb_NvAm1pAhu06Il_jVJr_Ayw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On January&#160;15, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_pRKa2jpEhU-PRc1xg4XVew">100,000</ix:nonFraction> shares of restricted Common Stock, in the aggregate, to certain of the Company&#8217;s employees under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). All such shares of restricted Common Stock vest over a <ix:nonNumeric contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_M1dunx2DMEmEDWm0QoHxrw">three-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item__RvHgY9WKUuWNqJlDLZ_pg" contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" scale="0" id="Narr_tKLs2HnYXUmlXsZjzyB0qg">12</ix:nonFraction>&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_-uvexI6zj06OIfXhkzqtLQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_lO4lYHaYkkGZRW9fQCppGA">0.2</ix:nonFraction>&#160;million.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_NvAm1pAhu06Il_jVJr_Ayw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_vJgBXQRquEOxuFKRf6Dfzw_1_2"></a><a id="Tc_1YsqSt3kGEqOJh5VNO6JUQ_2_0"></a><a id="Tc_9EW-yJcl-0eIkIdYutk24g_2_2"></a><a id="Tc_aIN0RAhKfkq5CFJElQ90yg_2_5"></a><a id="Tc_7mX9voiStk61qejkxJIyjQ_3_0"></a><a id="Tc_DbGjXO3000CH_yXccKWbIQ_3_3"></a><a id="Tc_0z9oMzoWZ0G8fgHFOhsJ7A_3_5"></a><a id="Tc_XpSkezT2L0691dv0VGz_Cg_4_0"></a><a id="Tc_UOcQI63zq0i6F0zs1CeUpw_4_2"></a><a id="Tc_y9wfRYmSF0-U2cVeofFLQw_4_6"></a><a id="Tc_lBb2DW1sS0-jYsRPfMN3cg_5_0"></a><a id="Tc_0mLPHDjVvk2tAZtR3y6eFw_5_2"></a><a id="Tc_kfaFBWr0X0Ghocp-msxksw_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_oqXjh-s2IUGim0cm9_OfKg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; TAXES ON INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_FTvazY-hhkWPmZWlCYRI_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_TQsM44O-L02cRWJLTIwZFw_3_6">195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_P506Z-QuG0CcsTusUpUcDw_4_3">138</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td></tr><tr><td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income (tax benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_m7c7tFmAO0-34pGb3dEegg_5_3">138</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_WNIczZhgrkKjv-7jmGea6g_5_6">195</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of (<ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Narr_jMe2Rts2_kGO0rw3_Jwy2A">3</ix:nonFraction>)% for the three months ended March&#160;31, 2024, compared to an effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_ZNWiBeEujEqCXnsFa0N4fw">7</ix:nonFraction>% for the three months ended March&#160;31, 2023. For the three months ended March&#160;31, 2024, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of <ix:nonFraction unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g" contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_1w9edxyUTkCdzaXHq1paaA">21</ix:nonFraction>% was the result of forecasted profits derived primarily from U.S. taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#8220;TCJA&#8221;).</p></ix:nonNumeric><a id="Tc_-akTAgYzEEuojrN_LtdKiQ_1_2"></a><a id="Tc_iB2bnCga1ES_M_lCBVfrGw_1_5"></a><a id="Tc_4t4tkn-yGU6QycOWcjo7CA_2_0"></a><a id="Tc_9yKWv8Tn40ychnhaic660A_2_2"></a><a id="Tc_nJo7qvuYcECKqx3VdR_TnQ_2_5"></a><a id="Tc_RzF1rG_30Uy6W7r1sWXJjA_3_0"></a><a id="Tc_H1R1EEd9zkmyQKpWCcWSdw_4_0"></a><a id="Tc_KX1f3EPnAEeNsdQG7SniqA_4_2"></a><a id="Tc_xPRjYVKrV0CiP7wtBt_yUg_4_5"></a><a id="Tc_VNY32sN8zE2UP6uxNtzG4g_5_0"></a><a id="Tc_kk6Nyl15BU2tmIqRtRhh7g_6_0"></a><a id="Tc_GptDVFUZ1EmpTpt-T-L8Tw_7_0"></a><a id="Tc_gi5ILCxhUUyU1JIfWVOghQ_8_0"></a><a id="Tc_JonFcktMFUuQHwXmEPKLUA_9_0"></a><a id="Tc_gPFa-fR9eESYBcuc4iL-lg_10_0"></a><a id="Tc_iufJT6ptikiujM9K1hlQ5g_11_0"></a><a id="Tc_roAUz65klUm6wiQyz72hTA_12_2"></a><a id="Tc_2yJmvn_zzU-PJalUMKaLcw_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_ETdnjbAoJ0iR1BOSTccp6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_u9A8Y1ssRkqU60eOYK3mgw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_CqocsvfE50es8RMkg7rjCA_4_3">2,502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_KlN8fkAI7EC_gQM6NSLktQ_4_6">1,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_S8Yb-_acEUChshsRXfkSug_5_3">128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_idN-hmz9h0akqY6SwLorZA_5_6">511</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_S7h8gcMmcESCGZQHqVX2wg_6_3">1,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_SmJ8ibfZFEOZcXLOtQ36HQ_6_6">1,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_j4MrUQZnMUySyuNZfAYydA_7_3">8,451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_8PuNOYIRu0CpeKFbp1i7GQ_7_6">9,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_Vv-qEBVebkWrewHO4XXnKQ_8_3">110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_vwPCtf7_9UCAqv3s2D-nsA_8_6">637</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_StgzUWuViEOmpd9Lr1OZ2A_9_3">2,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_SavOv2jmpEyvWpRqpC0diw_9_6">2,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="plx:ReserveForDeductionsFromRevenueCurrent" scale="3" id="Tc_agV9AwGlX0utifWldWmOBw_10_3">2,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="plx:ReserveForDeductionsFromRevenueCurrent" scale="3" id="Tc_87nOBkEpuEmM-BfwQkyXlg_10_6">2,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_p8b0fGRrWkWxTuA1v-jb2Q_11_3">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_J2-ZXypGh0WpMTp7qgr26w_11_6">614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_5qhWmFCbdUGuvIEVBP5Kew_12_3">18,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_evzUwC3I70S_hIliPOvpQA_12_6">19,550</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_8Vu9TIMpFUWJHfNeNxseAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On May&#160;9, 2024 the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_5_9_2024_To_5_9_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nWYpdchKYEGKP3xBFvtHig" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_cm3S0VYolkieeKzQTr4hZQ">1.1</ix:nonFraction>&#160;million from sales to Pfizer and on May&#160;8, 2024 the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="Duration_5_8_2024_To_5_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_0fFQQ6KG80qYA735CyQAfw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_51R9TnRl8EiyV6anIjfUmw">2.6</ix:nonFraction>&#160;million from sales to Brazil<span style="background:#ffffff;">.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On April&#160;1, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonFraction unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ" contextRef="Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kD3z0qQXkGKOLbaYW_hYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_H7yx1ePM4EKRcLnAsBbsuA">263,960</ix:nonFraction> shares of fully-vested restricted Common Stock, in the aggregate, to its President and Chief Executive Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA" contextRef="As_Of_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_JDUfTJTYi0qDFhD9HD0akA" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="6" id="Narr_8OG9BkLbDkaG8tGMh5CW1A">0.3</ix:nonFraction>&#160;million.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5a8e6d49_89ff_44ae_828f_82092eead918"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2023. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company, our subsidiaries or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the commercialization of Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa-iwxj), our approved product for the treatment of adult patients with Fabry disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to Elfabrio&#8217;s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possible disruption of our operations due to the war declared by Israel&#8217;s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers, and the risk that the current hostilities will result in a greater regional conflict;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the regulatory approval and commercial success of our other product and product candidates, if approved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the projected market for our products and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with global conditions and developments such as supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity or debt markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic partnerships;</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash, cash equivalents and short-term bank deposits;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Fiocruz with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug products to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In May 2024, we decided to expand our phase&#160;I First-in-Human clinical trial of PRX-115 by adding an eighth cohort with eight new patients. We also decided to commence preparations for a phase&#160;II clinical trial of PRX-115.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expression in suspension. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression, and with the recent approval of Elfabrio, we now have two commercial proteins produced through our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins. The system plays an important role in the execution of our corporate strategy as its allows us to develop and produce tailored complex recombinant therapeutic proteins and to genetically engineer and/or chemically </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:229.64pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">modify such proteins pre- and/or post-production. The engineering and modification of the therapeutic proteins have the potential to provide added clinical benefits by improving the biological characteristics (e.g., glycosylation, half-life, immunogenicity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We developed ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins which are the essential foundation of modern biotechnology. We develop new, recombinant therapeutic proteins by using the natural capability of agrobacterium to transfer a DNA fragment into the plant chromosome, allowing the genome of the plant cell to code for specific proteins of interest. The agrobacterium-mediated transformed cells are then able to produce specific proteins, which are extracted and purified and can be used as therapies to treat a variety of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology can be utilized to express complex therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines. The entire protein expression process, from initial nucleotide cloning to large-scale production of the protein product, occurs under Current Good Manufacturing Practice-, or cGMP-, compliant, controlled processes. Our plant cell culture technology uses cells, such as carrot and tobacco (BY-2) cells, which undergo advanced genetic engineering and/or chemical modifications, and are grown on an industrial scale in a disposable, flexible bioreactor system. Our system does not involve mammalian or animal-derived components or transgenic field-grown or whole plants at any point in the production process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cell growth, from initiating scale-up steps from a cell-bank through large-scale production takes place in a clean-room environment in flexible, sterile, custom-designed polyethylene bioreactors, and does not require the use of large stainless-steel bioreactors commonly used in mammalian-based systems for recombinant protein production. The ProCellEx reactors are easy to use and maintain, allow for rapid horizontal scale-up and do not involve the risk of mammalian viral contamination. Our bioreactors are well-suited for plant cell growth using a simple, inexpensive, chemically defined growth medium. The reactors, which are custom-designed and optimized for plant cell cultures, require low initial capital investment and are rapidly scalable at a low cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20240331x10q005.jpg" alt="Graphic" style="display:inline-block;height:229.64pt;width:540pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:226.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20240331x10q006.jpg" alt="Graphic" style="display:inline-block;height:226.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:540pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Products and Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20240331x10q007.jpg" alt="Graphic" style="display:inline-block;height:170.54pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:540pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Marketed Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have two commercial products, each of which is an ERT; Elelyso and Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in 23&#160;markets including the United States, Brazil, Israel and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; Recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1&#160;in 400 to 1&#160;in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.6&#160;billion in 2023, is forecasted to be approximately $1.6&#160;billion in 2024 and is forecasted to grow at a CAGR of approximately 1% from 2023-2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">The current standard of care for Gaucher disease is ERT, which is a medical treatment where recombinant enzymes are injected into patients to replace the lacking or dysfunctional enzyme. In Gaucher disease, recombinant GCD is infused to replace the mutated or deficient natural GCD enzyme. Elelyso is the only alternative ERT treatment of Gaucher disease to Sanofi Genzyme&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Takeda&#8217;s (Shire) Vpriv.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Elfabrio, our second commercial product, was approved by the EC for marketing in the EU and by the FDA for marketing in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease. According to the EMA, overall, the benefit/risk balance of Elfabrio is positive in the claimed indication (Fabry disease). The FDA publicly released the internal review documents for Elfabrio. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study, our phase&#160;I\II clinical trial of Fabry disease, with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study. The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support the non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">In August and September of 2023, Elfabrio was approved in Great Britain and Switzerland, respectively, and by the Israeli Ministry of Health in January 2024, for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">, in blood vessel walls throughout their body. The ultimate consequences of Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">&#160;deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The standard of care for Fabry disease is ERT. Currently, the ERTs for Fabry disease are agalsidase alfa, agalsidase beta, and now Elfabrio. Through an ERT, the missing &#945;-galactosidase-A is replaced with a recombinant form of the protein via intravenous, or IV, infusion once every two weeks. Fabry disease, if left untreated, will progress from a less severe condition to a more serious one. It can have a significant impact on quality of life due to presence of serious, chronic and debilitating complications, including cardiovascular and renal complications, and comorbid conditions such as pain can have a significant impact on the psychological well-being of Fabry patients and their social functioning. Fabry disease involves substantial reduction in life expectancy. Causes of death are most often cardiovascular disease and, to a lesser extent, cerebrovascular disease and renal disease. The life expectancy of Fabry patients is significantly shorter compared to the general population. Untreated male Fabry patients may experience shortened lifespans to approximately 50&#160;years, and 70&#160;years for untreated female patients with Fabry disease. This represents a 20- and 10-year reduction of their respective lifespans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes agalsidase beta, Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, agalsidase alfa, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $2.0&#160;billion in 2023 and is forecasted to grow at a CAGR of 6.8% from 2023-2029 reaching approximately $3.1&#160;billion in annual sales at the end of the decade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio Regulatory Background</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">On November&#160;9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and the submission was subsequently </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">accepted by the FDA and granted Priority Review designation. However, in April 2021, the FDA issued a complete response letter, or CRL, in response to the initial BLA. In preparation for the BLA resubmission, we and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission had the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The data package in the BLA resubmission, given the change in the regulatory landscape in the United States, included the final two-year analyses of our&#160;<i style="font-style:italic;">BALANCE&#160;</i>study, which were completed in July 2022, and long-term data from our open-label extension study of PRX-102 in adult patients treated with a 2&#160;mg/kg every four&#160;weeks dosage of PRX-102. The initial BLA included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase&#160;I/II clinical trial of PRX-102, including the related extension study, interim clinical data from our phase III BRIDGE clinical trial of PRX-102 for the treatment of Fabry disease, or the <i style="font-style:italic;">BRIDGE</i>&#160;study, and safety data from our then on-going clinical studies of PRX-102 in adult patients receiving 1&#160;mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">No concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package were raised in the CRL. The FDA noted in CRL that the FDA noted that an inspection of our manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a new drug. Due to travel restrictions during the COVID-19 pandemic, the FDA was unable to conduct the required pre-approval inspection during the review cycle. In addition to the foregoing, the FDA noted that agalsidase beta had recently been converted to full approval, a change in regulatory circumstances which had to be addressed in the resubmitted BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">On February&#160;7, 2022, the PRX-102 MAA was submitted to, and subsequently validated by, the EMA. The submission was made after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. At the meeting, we and Chiesi discussed the scope of the anticipated MAA submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of the planned MAA submission. The MAA submission included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed and ongoing clinical studies evaluating PRX-102 as a potential alternative treatment for adult patients with Fabry disease. The submission was supported by the 12-month interim data analysis generated from our <i style="font-style:italic;">BALANCE</i> study, which was released in June 2021. Data generated from the completed&#160;<i style="font-style:italic;">BRIDGE</i>&#160;study, the phase&#160;I/II clinical trial in naive or untreated patients, and from the extension studies with 1&#160;mg/kg every two weeks were also included in the submission. In addition, the MAA included data from the completed 12-month switch&#8211;over phase&#160;III BRIGHT clinical trial of PRX-102 for the treatment of Fabry disease for adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage, or the <i style="font-style:italic;">BRIGHT</i> study. As part of the EMA review process, we and Chiesi received the Day 120 list of questions in June 2022, and the full response package thereto was submitted to the EMA in September 2022 (following a 3-month clock-stop period). An essential portion of the response included the submission of the final analysis of the two-year&#160;<i style="font-style:italic;">BALANCE</i>&#160;study (the final Clinical Study Report), and an interim analysis of the long-term, open-label extension study of PRX-102 in adult patients with Fabry disease treated with the 2&#160;mg/kg every four&#160;weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;24, 2023, we, together with Chiesi, announced that the CHMP had adopted a positive opinion, recommending marketing authorization for PRX-102. The CHMP opinion was then referred for final action to the EC. <span style="background:#ffffff;">As disclosed above, Elfabrio was subsequently approved by the EC for marketing in the EU and in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our PRX-102 clinical development program was designed to show that PRX-102 has a potential clinical benefit in all adult Fabry patient populations when compared to the then marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;III clinical program included three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study the <i style="font-style:italic;">BRIGHT</i> study, all of which have been completed. In the phase&#160;III clinical program overall, two potential dosing regimens for PRX-102 were analyzed; 1&#160;mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2&#160;mg/kg every four weeks. The phase&#160;III program was preceded by the phase&#160;I/II clinical trial, a dose range finding study in ERT-na&#239;ve adult patients with Fabry disease, which was completed in 2016.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The <i style="font-style:italic;">BALANCE</i> study (PB-102-F20, NCT02795676) was a pivotal 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">administered every two weeks compared to agalsidase beta. The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study was completed in July 2022. The final analysis confirmed the positive top-line results (announced in April 2022) and favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an eGFR slope at screening worse than -2&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77&#160;patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100&#160;years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">TEAEs were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11&#160;(21.2%)&#160;patients in the PRX-102 arm experienced a total of 13&#160;events compared to six (24.0%) patients experiencing a total of 51&#160;events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients that received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in-line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial from both the PRX-102 and agalsidase beta treatment arms, 69 opted, with the advice of the treating physician, to receive PRX-102 1&#160;mg/kg every two weeks in the long-term open-label extension study which is now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> study (PB-102-F30, NCT03018730) was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of PRX-102, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa for at least two years and on a stable dose for at least six months. In the study, patients were screened and evaluated over three months while continuing agalsidase alfa treatment. The study was completed in December 2019.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea. An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial, 18 opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every two weeks in a long-term open-label extension study which is now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study (PB-102-F50, NCT03180840) was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14&#160;infusions). The study was completed in June 2020. The 2&#160;mg/kg every four weeks dosage has not been approved by the EMA, FDA or any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Enrollment in the study included 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12 months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The final results from the <i style="font-style:italic;">BRIGHT</i> study indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the applicable Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36 nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60 nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every two weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every four weeks as an effective and tolerable alternative treatment option. Additional long term data is being collected as part of the ongoing long term extension study (PB-102-F51, NCT03614234) of the 2&#160;mg/kg PRX-102 every four weeks dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients that completed the trial, 29 opted, with the advice of the treating physician, to continue receiving PRX-102 2&#160;mg/kg every four weeks in a long-term open-label extension study which is now sponsored by Chiesi. Two of such patients are being treated with 1&#160;mg/kg every two weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;I/II clinical trial of PRX-102 (NCT01678898) was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. It was completed in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We initiated the phase&#160;I\II study after PRX-102, in preclinical studies, showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of ADAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the phase&#160;I/II study, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Results show that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients who completed the trial, 10 patients opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Extension Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Overall, 126 subjects who participated in our PRX-102 clinical program initially opted, with the advice of the treating physician, to enroll in one of our long-term, open label, extension studies of PRX-102: 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60, NCT03566017) (10 subjects who completed an extension study from the phase&#160;I/II study, 18 subjects who completed the <i style="font-style:italic;">BRIDGE</i> study; 69 subjects who completed the <i style="font-style:italic;">BALANCE</i> study), and 29 subjects who completed the <i style="font-style:italic;">BRIGHT</i> study in the 2&#160;mg/kg every four weeks extension study (PB-102-F51, NCT03614234). Two of the subjects in the PB-102-F51 study are being treated with 1&#160;mg/kg every two weeks. As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the open-label extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Over time, and as Elfabrio is approved for marketing in different jurisdictions, participants switch-out of the open-label extension studies. Most of them have transferred to a commercial setting; others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Pediatric FLY Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Chiesi is sponsoring, with our collaborative efforts, a clinical trial entitled &#8220;Multi-Centre, Open-label Trial to Assess the Safety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigalsidase alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed Fabry Disease,&#8221; or the <i style="font-style:italic;">FLY</i> study (NCT06328608). The FLY study is currently in the start-up phase. The design of the study is based on the Initial Pediatric Study Plan (iPSP) agreed to with the FDA and the paediatric investigation plan (PIP) for Elfabrio, which has been accepted, as amended, by the Paediatric Committee (PDCO) of the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Japanese RISE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is currently enrolling patients in its clinical trial entitled &#8220;A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease,&#8221; or the <i style="font-style:italic;">RISE</i> study (NCT05710692). The aim of the <i style="font-style:italic;">RISE</i> study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned that a total of approximately 18-20 male and female Fabry disease patients between the ages of 13 and 60 years will be enrolled in the study which is being conducted in Japan.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization of Approved Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and development cost reimbursements of $45.0&#160;million, and is entitled to approximately $1.0&#160;billion in potential milestone payments as well as additional payments as consideration for drug product supply. The additional payments for drug product supplied are based on the average selling price of the drug product in the relevant territory multiplied by tiered payments, as detailed below. During the quarter ended June&#160;30, 2023, we received net proceeds of $20.0&#160;million representing a milestone payment earned upon the FDA&#8217;s approval of Elfabrio for adult Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments for drug product purchased from Protalix based on the average selling price of the drug product in the relevant territory multiplied by 15% to 35%, depending on the amount of annual net sales outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On July&#160;23, 2018, Protalix&#160;Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments for drug product purchased from </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix based on the average selling price of the drug product in the United States multiplied by 15% to 40%, subject to certain terms and conditions, depending on the amount of annual net sales in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On August&#160;29, 2022, we entered into the F/F Agreement and the Letter Agreement with Chiesi. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement will expire December&#160;31, 2025, unless terminated earlier in accordance with its terms and may be extended by mutual agreement in writing for an additional period of seven years. The Letter Agreement changed our obligations and those of Chiesi under the License Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the License Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of the October 2015 Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period (i.e., until October 2030).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Development Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our corporate strategy includes development of treatments for rare and orphan diseases. To execute on the strategy, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. Our current pipeline of product candidates includes PEGylated uricase for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I for the treatment of NETs and other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">PEGylated Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of patients with uncontrolled gout. The uricase enzyme converts uric acid to allantoin, which is easily eliminated through urine and does not exist naturally in humans. This recombinant enzyme, expressed via our ProCellEx system, is designed to lower uric acid levels and improve clinical manifestation of the disease while having low immunogenicity and increased half-life of the drug in the blood. Pre-clinical data demonstrates long half-life, reduced immunogenic risk and high specific activity which supports the potential of PRX-115 to be a safe and effective treatment for patients with gout. One-month multiple dosing toxicity studies in two species and 6-month multiple dosing toxicity study in one species were conducted to support single and multiple dose studies is humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PRX-115 is being analyzed for the potential treatment of uncontrolled gout in our phase&#160;I clinical trial of PRX-115 for the potential treatment of uncontrolled gout entitled &#8220;A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels&#8221; (NCT05745727), or the <i style="font-style:italic;">FIH</i> Study. The first subject was dosed in the study on March&#160;21, 2023. The study is being conducted at New </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines. The study was initially designed to include sequential dosing cohorts, each composed of eight subjects (six active and two placebo), a 3:1 ratio. Subjects in each cohort, males and females aged 18 through 65, received a single dose of PRX-115 and are analyzed for safety, pharmacokinetics (PK) and pharmacodynamics (PD) (concentrations of plasma uric acid) for 85 days. As of March&#160;31, 2024, 56&#160;subjects with no previous exposure to PEGylated uricase have been enrolled in the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After a review of initial positive top-line results from the seven cohorts, and following the review and acceptance of the safety data from cohort 7 by the safety and monitoring committee for dose escalation for the FIH Study, the Company decided to expand the study by adding an eighth cohort of eight new subjects to analyze a higher dose and its potential to result in increased exposure time. In addition to the expansion of the FIH Study, the Company also decided to commence preparations for a phase&#160;II clinical trial of PRX-115.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Key preliminary results from the FIH Study are as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Exposure to PRX-115 increased in a dose-dependent manner.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>PRX-115 rapidly reduced plasma uric acid concentrations to below 6.0&#160;mg/dL over time following a single administration. The effect of PRX-115 on plasma uric acid concentrations and the duration of response was found to be dose dependent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>PRX-115 was well-tolerated. Twenty-six percent (11/42) of the subjects treated with PRX-115 in the first seven cohorts reported study drug-related adverse events, the majority being mild to moderate and transient in nature. One subject in cohort&#160;2 experienced an anaphylactic reaction immediately following the commencement of the infusion, and the reaction was fully resolved. There were no other serious adverse events reported in the study, and no adverse events were reported in the highest doses, cohorts 6 and 7.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis, affecting an estimated 14.0&#160;million adults in the United States, 2.0&#160;million in France, 2.0&#160;million in United Kingdom, 0.7&#160;million in Italy, 1.5&#160;million in Germany, 0.7&#160;million in Spain and over 190.0 million in China. An estimated approximately 5% of the gout population is considered to have chronic refractory disease. The risk of gout increases with age, and it is thus more common in ageing populations. Gout results from sustained elevation of serum urate levels (hyperuricaemia). Urate levels may increase due to diet, genetic predisposition and environmental factors leading to the deposition of monosodium urate crystals and\or tophi in joints, tendons and other tissues, which triggers recurrent episodes of pronounced acute inflammation, known as gout flares. Gout leads to substantial morbidity, severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently in a combination known as the metabolic syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Uncontrolled gout occurs when oral gout therapies fail to lower serum uric acid (sUA) levels below the gout guideline goal of 6&#160;mg/dL at the maximum medically appropriate dosage or when gout does not improve clinically with oral urate-lowering therapies (ULTs), and may involve systemic urate deposition. Uncontrolled gout is also reported to involve urate crystal deposition and associated inflammation in joints, soft tissues, and organs, such as the heart, kidneys, and eyes. Currently available ULTs can be effective in treating gout. However, low adherence, under dosing and disease progression that cause high patient burden require new, effective and safe therapies to treat these underserved uncontrolled gout patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering uric acid treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. The FDA label of Krystexxa was amended in 2022 to include co-treatment of metrotrexate to prolong efficacy and increases tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons. We believe that new effective, safe therapies are needed to treat severe gout, chronic refractory and uncontrolled<b style="font-weight:bold;"> </b>gout, regardless of treatment history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase&#160;I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of these conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The administration of PRX-119 resulted in a decrease in circulating of DNA levels and significantly enhanced the survival of mice in both a CLP-induced sepsis model and an ARDS model. Additional preclinical development is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of March&#160;31, 2024, we hold a broad portfolio of more than 70 patents in Europe, the United States, Israel and additional countries worldwide, as well as more than 45 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Research &amp; Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Consistent with our corporate strategy, we are focusing on new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Three months ended March&#160;31, 2024 compared to the three months ended March&#160;31, 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $3.7&#160;million during the three months ended March&#160;31, 2024, a decrease of $1.4&#160;million, or 27%, compared to revenues of $5.1&#160;million for the three months ended March&#160;31, 2023. The decrease resulted primarily from a decrease of $1.1&#160;million in sales to Pfizer, and of $0.3&#160;million in sales to Brazil which decreases resulted primarily from the timing of delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We recorded revenues from license and R&amp;D services of $0.1&#160;million for the three months ended March&#160;31, 2024, a decrease of $4.4&#160;million, or 98%, compared to revenues of $4.5&#160;million for the three months ended March&#160;31, 2023. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The decrease resulted primarily from the completion of our research and development obligations with respect to Elfabrio and, as Elfabrio was approved in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the United States and the European Union in May 2023, from the completion of the regulatory processes related to the review of the BLA and the MAA for Elfabrio by the FDA and EMA, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $2.6&#160;million for the three months ended March&#160;31, 2024, a decrease of $0.5&#160;million, or 16%, from cost of goods sold of $3.1&#160;million for the three months ended March&#160;31, 2023. <span style="background:#ffffff;">The decrease in cost of goods sold was primarily the result of the decrease in sales to Pfizer and to Brazil.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">For the three months ended March&#160;31, 2024, our total research and development expenses were approximately $2.9&#160;million comprised of approximately $0.5&#160;million in subcontractor-related expenses, approximately $1.5&#160;million of salary and related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.7&#160;million of other expenses. For the three months ended March&#160;31, 2023, our total research and development expenses were approximately $5.8&#160;million comprised of approximately $3.5&#160;million of subcontractor-related expenses, approximately $1.5&#160;million of salary and related expenses, approximately $0.1&#160;million of materials-related expenses and approximately $0.7&#160;million of other expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total decrease in research and developments expenses for the three months ended March&#160;31, 2024 was $2.9&#160;million, or 50%, compared to the three months ended March&#160;31, 2023. The decrease in research and development expenses primarily resulted from the completion of our Fabry clinical program and the regulatory processes related to the BLA and MAA review of Elfabrio by the applicable regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">We expect to continue to incur significant, increasing research and development expenses as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $3.1&#160;million for the three months ended March&#160;31, 2024 and for the three months ended March 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Financial Income, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial income, net were $0.1&#160;million for the three months ended March&#160;31, 2024, compared to financial expenses, net of $0.5&#160;million for the three months ended March&#160;31, 2023. The change resulted primarily from higher interest income on bank deposits and lower notes interest expenses due to notes conversions executed in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Income taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the three months ended March&#160;31, 2024, we recorded a tax benefit of approximately $(0.1)&#160;million, compared to income taxes of $0.2&#160;million for the three months ended March&#160;31, 2023. Income taxes recorded are primarily the result of the provision for current taxes in respect of Section&#160;174 of the TCJA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash and cash equivalents balances and short term bank deposits. At March&#160;31, 2024, we had $48.5&#160;million in cash and cash equivalents and short term bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, grants funding and revenues from selling goods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December&#160;31, 2023, we raised gross proceeds equal to approximately $24.9&#160;million from the sale of 12,560,150 shares of our common stock under our ATM program. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. No sales were completed during the quarters ended September&#160;30, 2023, December&#160;31, 2023 or March&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On August&#160;25, 2021, we completed exchanges, or the Exchanges, with institutional note holders of a substantial majority of the then outstanding 7.50% Senior Secured Convertible Notes due 2021, or the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate of the 2024 Notes is 563.2216 shares of our common stock per $1,000 principal amount of 2024 Notes, which is equivalent to an initial conversion price of approximately $1.7755 per share of common stock, subject to adjustment </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes remained outstanding. On November&#160;15, 2021, all of the then outstanding 2021 Notes&#160;matured and were paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to the 2024 Indenture which was entered into between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the 2024 Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and will be guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash, cash equivalents and short term bank deposits as of March&#160;31, 2024 are sufficient to satisfy our capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash provided by operations was $4.2&#160;million for the three months ended March&#160;31, 2024. The net loss for the three months ended March&#160;31, 2024 of $4.6&#160;million was increased by a $3.3&#160;million increase in inventories, a $1.4&#160;million decrease in accounts payable and accruals and was offset by an $11.0&#160;million increase in contracts liability, a $1.7 million decrease in accounts receivable-trade and other assets and $1.0&#160;million in share-based compensation. Net cash used in investing activities for the three months ended March&#160;31, 2024 was $0.6&#160;million and consisted primarily of the purchase of property and equipment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash used in operations was $3.0&#160;million for the three months ended March&#160;31, 2023. The net loss for the three months ended March&#160;31, 2023 of $3.1&#160;million was increased by a $1.4&#160;million decrease in contracts liability and a $3.5 million increase in inventories and was partially offset by a $3.8 million decrease in accounts receivable-trade and other assets and $0.5&#160;million in share-based compensation. Net cash provided by investing activities for the three months ended March&#160;31, 2023 was $4.7&#160;million and consisted primarily of proceeds from sale of short-term deposits. Net cash provided by financing activities was $14.2&#160;million resulting primarily from the sale of common stock under our ATM program.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2024, the total principal amount of our 2024 Notes outstanding was $20.42&#160;million, and 2020 Warrants to purchase 13,439,712 shares were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Future Funding Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since our inception, we have incurred significant research and development expenditures which have not been offset by revenues. We have not generated significant revenues from sales of Elelyso, and commercial sales of Elfabrio only commenced in the middle of 2023. W<span style="background:#ffffff;">e have generated operating losses from our continuing operations since our inception although the revenues generated in the year ended December&#160;31, 2023</span><span style="font-family:'28mugxoulnobhnx';"> exceeded our expenditures for the same period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'28mugxoulnobhnx';">Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;background:#ffffff;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of March&#160;31, 2024, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As we increase our research and developments efforts with respect to our current and future product candidates, we expect to continue to incur significant expenditures. We cannot anticipate the costs or the timing of the occurrence of such costs. Although we expect the revenues generated from the sales of Elfabrio and Elelyso will increase, such revenues may not be sufficient to fund the expenditures. To the extent we need to obtain additional financing in excess of such anticipated revenues, it may be difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts, (v)&#160;payments of principal and interest on our outstanding 2024 Notes and (vi) tax payments. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s progress in commercializing Elfabrio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through sales of Elfabrio and Elelyso, corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the milestone payments that may become payable under the Chiesi Agreements. On February&#160;27, 2023, we entered into the 2023 Sales Agreement pursuant to which we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million as we had then completed the ATM program under the 2021 Sales Agreement. As of March&#160;31, 2024, shares of our common stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. We do not believe currency fluctuations have had a material effect on our results of operations during the three and nine months ended of March&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of March&#160;31, 2024 and December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1a55fd5f_af84_4d17_9756_abbcc423ce2e"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and more than 50% of our expenses and capital expenditures are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 44% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:22.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.662</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.536</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.687</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.681</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.615</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.627</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b8bdd6c7_2632_4b1c_b337_d62187b4c2b6"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended March&#160;31, 2024 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_34002b2e_cc51_47e5_9ddb_65d8c178ed4c"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are not involved in any material legal proceedings.</p><a id="_d3fce7f3_8472_4b61_ad80_c04de54331fa"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">Except as set forth below, there have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2023<span style="background:#ffffff;">.</span></p><a id="_89e630d9_70f6_4faf_a710_6abfb9e10046"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_d40b77d5_830f_4fe6_aad9_416af7f8fe58"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_78d82bf7_4545_4016_ad12_ac5463fb8736"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="_6f21ef18_45f7_4eec_94a1_4b078ea152d9"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">During the quarter ended March&#160;31, 2024, none of our directors or officers </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_7y972FXv90uovwiyV1ULdg"><span style="background:#ffffff;">adopted</span></ix:nonNumeric><span style="background:#ffffff;"> or </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_8ELvMOL1tEqSAZAuugyiFQ"><span style="background:#ffffff;">terminated</span></ix:nonNumeric><span style="background:#ffffff;"> a </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_YTtbR1awbEO8Dbp6JrZ28w"><span style="background:#ffffff;">Rule&#160;</span>10b5-1</ix:nonNumeric> <span style="background:#ffffff;">trading arrangement or&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_Q5UWPHaxukOXd9Tqsif2jw">non-Rule<span style="background:#ffffff;">&#160;</span>10b5-1</ix:nonNumeric><span style="background:#ffffff;">&#160;trading arrangement (as such terms are defined in Item 408 of Regulation&#160;</span>S-K).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c1781a98_6d77_4499_b268_22aa3aef5933"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023002102/plx-20221231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">February&#160;27, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20240331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20240331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20240331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20240331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9401a91c_df85_4b3b_b48f_919a6ce98076"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;10, 2024</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;10, 2024</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>plx-20240331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/10/2024 11:09:04 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;10, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>plx-20240331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/10/2024 11:09:05 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"> I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;10, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>plx-20240331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/10/2024 11:09:05 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;10, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>plx-20240331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/10/2024 11:09:05 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2) </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;10, 2024</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20240331x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20240331x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ',!#@# 2(  A$! Q$!_\0
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M_P"%'U*?=!_Q$7+O^?,__)?_ )(_1NBOSD_X:#^(O_0VW_YK_A1_PT'\1?\
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M+O\ GS/_ ,E_^2/T;HK\Y/\ AH/XB_\ 0VW_ .:_X4?\-!_$7_H;;_\ -?\
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M3_AH/XB_]#;?_FO^%'_#0?Q%_P"AMO\ \U_PH^I3[H/^(BY=_P ^9_\ DO\
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M@ Q3QR _W6!KYLU+PUK?AV-9=0L(A"0#YF]?3)Z^E/U#1&TR&TDU1ETLW?\
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MQ'JSQASY5OF)3QD9SSUKYG\:^$KSP-XHU#0[XJUQ9R%"Z]&'9A]17UZ/VIO
M&IV<&J7=YK%M>QP[&TZ"21$+'V5@"1SSZ?A7R/\ $#Q8WC?QAJ>M-&\2W4I9
M(WD+LJ]%!8DD\5TX=UG-^TV/DN**&0TL+2>6.//?[,F_=M]KL[_,^[/#OARP
M@\"^$9;3PAIFK2W,-LER[V\2F.,QY:4DK\V"!QWS6;;?#KPEIOQMD2TTC3E-
MSI)EGLQ;H8PWF</MQ@$^P[5Y#\1OVA[(?"/PYI?A'7;NRUZU^SI<&W#1G8L3
M!AN[C=MKDOV=_B[9>%?'>JZUXOU6ZF>ZM?*^TSEIG9MPX).3TKG5&;YI^OS/
MM*G$&6+$X;!VC+X&Y^[RQLM==[]'?N;WA/\ 9YTCQ[K'B;5=4UY-*M8]3N8X
MK&T16EVK(PSM'('H *EUK]D^ST7XA^'](;69Y](U99=LPC"RQL@!QCH1R*Z3
MX>_M$> _#F@ZU;7#WFGW<NHSW/GV<.Y[A6E+*<D<<8!'85HZ[^T9X)UKQ1X,
MU9-0FBCT\S-<QR0L63>@ Y[\C%-2KJ26MO\ @'GQP?#53"QE*4'4;3?O:ZSU
M3UVM?2WH8E]^QIH\D6L0Z=XJDEU*U7?';O$N$RN5$F#D9QUK9\,?![X>3?L_
MP7]W+;6K7MK'+=:XZ!I8I"02BDYVX;Y.,4OA_P#:)\$6/C7QEJ$VH2K:ZB(1
M;MY#'=M0@\=N:XWX=?&3P&_P0_X0KQ;]MC\O<&2W0GS1YF]2&'3G^53^_E!\
MU^G_  3:/^KV'K_N%27-&JM97C=-*-W=VYDWJM;;'BOPL\*0>./B%H6AW+LE
MO>7 20KP=H!8@?4#'XU]5>./&/PT^$WB>S\&7?@BQEL9+999IULXY" 00,@@
MLY^7DDYKY&\$>*KCP1XMTO7;9%DFL9A*$;HPZ,/Q!(KZGN/C?\'O$6OV/C+4
M[6\C\16<01$,;$CCI@':V-QYKJQ$6Y+1M>1\OPMB<-2P=6$:E.G6<EK42MR=
M4K_/33U/.O!_P0T#XV>.M:N_#%S<:1X1MRC 2Q9D5V',: GIP>2>,BMWQG^R
MS%X%FT?7M)U*34]/BO[=;FWNX0K!3(HS[CGH15GP/^U7HMKX]\0SZAIATO0=
M3V"%K.,"2,J,;GVXRS9R3U& .U3?$G]H?PI<Z?IFCZ#=ZGJ"&\@DNKV]GE8+
M$LBLW!;YCQZ5E>NIQ23MIY^MSUX4N&Y8&K6G.#JWEJKQ=[^[RQN[1?;:VYZM
M/X1T(?'"RMAHNG"W;0W<P_9(]A;S1SC&,^]?$OQ,@CMOB-XGBAC2*)-3N%2-
M%"JH$C8  Z"OJ27]HKP._P 6;76QJ,O]GQZ2]JTGD-GS#("!CZ"OE/QYJEOK
M?C?7]1M',EK=7\T\3$8)1G)!Q]#1A(RC+WET_4X^,<5@L1ATL-.,G[1OW6GI
MR+MTN??]MX8TV#1_#IM/"&EZB+A8UNI6MXE,*%,E^5^;G''O7EWC']FOPCXU
M^*6H6EC-_88BTZ&XEM=/B4(LC/(N[;T7(0<#'3/>N5^,7[1EG=^ M"LO!>OW
MEGJL#HMRUN&B)01D$9[_ #8KF_V;/C'I?@W7?$NH>+=4N9+C4(X@MQ-NF>1E
MW9R3D]Q64:51*51:;_,^EQF<9-B\71RVM&,X.S<FX\L?=>S6MV]'=FI9_LKZ
M'KWBQ],T;Q8UW96$._4[KRE(BD+$+&N#@GY7)ST&WUJG\0/V6[;3_#2:]X/U
MW^W[,3+%*A XRVTL&!YP>HK/^!7QQTOX>>)?$L.L)--HFL2E_-B7+1G+<D=2
M"&'TQ77^,OV@_!OA+P,/#7@"">59)_-=YU.Q%+[WP6Y)/(]LULW7C))7>W_!
MN?/TH<-8C SK5(Q@_>NE)\R:TARJ[NFM7Y_AUWPS_9HT'P!XKTB>_P!9@U35
M9+:1I-+NH$9'7@%E!S]TD#)'>N7\3_L^:+XMOOB!KWVJ73GTZYF\JUM8E6+"
MID#':NG@_:1^&6I:[HGB&\6[BUN&W>V+&)ML"-@MGL>5&#[FL;PM^T7X)AU3
MQS9:Q)<'2]3NWF@ECB/[V)D *\<@YS^=<[]NVY:WL_S/HY+ASV,,*I4_9N5U
M[U_L;ROJM?EMU.)U[]F&%/#'@JZT?49I]3\07,4#1SJ!'$K0O*S<<\!#6WK/
M[*/A:Q@N-.B\=01>([>'S7M[HHBDD'&1G(!..:U_&O[2/A"UTWP1+X<\ZY.B
MZBDK6<J$,(/(EB/S'JV'%0^+?BE\$?$-U>>)K[2KK6-;N(0GV257 W*#C^(
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M;J:$2),(W9/,C.5;!QD>QK[*T3]ICP1X?TY9D\0ZWJ$*0"-=,O8%D<,.G[S
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M4_V:?&_C?Q_K.N:9;V3V%Y*KQ-)=!6("*O([<@URO_#'WQ%_Y]=/_P# Q?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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MYRM^G^78OU?]:+_@_P!;]%J_Q@T/1H[.:4RR6UQIC:J9HP"(X045<\]79PH
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MZ<YKU3XRE%T*PA)P1 M<Q\'$_MKQ3XG9;1K58C'E7'))+9)J[\9[W?-80@Y
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M;^OO_P F']?E_FCT:BH[>=+J".:)MT<BAU.,9!&14E( HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y]?^/V?_KHU%"_\?L__
M %T:B@#Y_P#^"B\EK'^SE,+U&:!]5ME+(?F3B3##U(]*^,?V1O'7A[X>_:S>
M:PETMS^[ACBC829+=P>!^9K[!_X*7$#]FF3/_07M?_09*_,WX.2(-1M0V !,
M<FO+<VL9:W0]'EO@V_,^H-0TJY\ >+]0U2XN8+K[5?17D+6TQ;$+ELJ?0^U0
M>-_#=T/&UC:6<DT_]H)-<(GF'Y@22/TKG/$%U $U-879U!A)9NQ.ZNNU'7KB
M;2/!WBRQ(-S9(]I(S+E58<#(KQ)5*O[RC2W5I+\;G:DN6-276Z_R,G]HG4FL
M=8T"X"NDL-A <C^'!]*\C^+FAW=GXM\):D8_]$N=2%Q&YP H<*2.O7.:]F_:
M1T^^OKJYU9WMI+18+2)E)_>JS+N^48X'XUY)\6?$*7'PDT?5I%:>31;Z/Y,]
M"#_]<5[$;RQ4HNU]'_F>=>U",EW:,?6IY9=5\07,C<PZ@Q1?9HU&?S%2>,M5
M=?$>FM&^Z26QV>N3MSC]*R[35X-;@O9TC<MJ$+3F,@<.NW(![C%-\9:C'IWB
M+0KZ, 0VYC1HV7J"N>/PK;1\S_KL3=IQ.Q^'?Q!D\/\ A"YMP-T;:B&9 V,#
M);^E?;GP<^)MCXFUF^G%P8[%((Y(89)L .%Y7GCG%? %EIC'1]:,<*^3)>1L
MA/(QG&1^==3::GJ'A[2)H4D,<T5Y:$[#G*E]K5C4YZ=3VD.Q4%"JN67<^HO'
M6A>+[K4+JY6!C;R,6'[M>%]L$5Y3X-\;>)M-^(#QVFB-?PQEK>Z^W:9E4[AD
MR_)R/UK[;L1%?Z-9EL-NA3/Y"O/?'WQ#\#?"[5]&T_Q!>I97NL3^3:1K&6+-
MP.<=!DCFO1BG>YY^SL>(?%7Q?K&J:5$/[!@LS 3)))!8>47X/!.\\=_PJG\(
M[S2X1/?Z^T02:WW6]L_02 CG'KUKZ0\6^%K/4K&6&:(-&ZX/N*^/OB=IDF@^
M*D6VC:.".0JJ]@< #/XD5QXIS4?=W9TT(QE+WMCH?$OQ.M+UKZRTQ-L#A62<
MD+PSA<[>>1SSFO$E\2_:=6MH%DQ'?R2LS-ACC_'BJUA:76H-/ KE3<0HJ/GI
M\V,_3<PKF;>T*ZIIDJRH/LKK&5&<L6<#(_[ZKCHMK5G344;<J/K7]G+Q7'?Z
MCXNDD'F323AQ+TR@+*./PJC\2;L7NH69SD-"3^IKFOV;E2UN?$$<;.Q011EV
M8$,?F/&/K75?$BSAMKC2?+SDVN6/OFO4IN])^APU-*FIYG>R/;:/>L2 (K>>
MX '4_*%'ZD5N6T,K_#7X>S01&6:&YO<+WR9#C\R*X#XA>+Q!H[6-CNCF8+;2
MR@]?FW$?RKK_  IXV\CX>Q16S--?^&IUN2\L9$<I=G<#.>W /TKRYU$XU5'5
MI?B=\4XQAYLAT72+BY\1V=G)=VT4Y>TB$9DR<J(\CCTP:Y/]J'4V\5?&O58?
M[8M;"WL((X8$NG<?+M4Y&U2.3FN_\":I#/XLU7QCK4 DC\R']S"VS=+*B\*>
M<8!:O$M6\36?B_\ :'UR/5-#MKV.'?:M&\CA7,8PKG!ZX ]JX<-;ZDYSC9O5
MH[*LY_6/=ULCVJ"]E?389+22)#+J%TQ^TQ^8V_[9(F1R!CY?R%;WCGPT_P /
MO$FA6%I=P7Z769IA'9QJ4^]SD<BN7U)4@T7PVZ+L,IN)CVSF\G.?ZU)X9\S0
M_##ZQJ$KS3ZI_HUGO8LV%WEFYZ#@C\#7!6A7JYE!PG:$;W5M]--?(TARQPW,
M]V>=?$#QWJ-S=:<UM<@QI&]NB[%8?)'!TX[L6_2O4OCUJ=U:?"_P?Y>X7 DA
M:55'S >7@\8XYKYYUFZ,$>D&-BLL<EPRD=CB#%>B_&W6+]["S=[R9GF*JQ9O
MO+@'\LY/XUZ-#$RDJDI=5^I5>BH2I1BMG^AGZWXXEM=+^R63O#>JL5Q<-N#!
M 2H$><<G[S'_ '@/X:WO"?C^+_A+M'-["\>G3S++<VS-O_<K@%03S\QW'\!7
MD5FC.MX,Y+K$,_\  ZUX;QGU-Y^@2 JN.P! %<T<3+VD6:RP\>5QW+_BVZ:;
MQ-XGEM',5IN9K>+ ^1?.0 'UX-,T/4M39-,BENU8/)+C=$I"X P1Q4&L8.J:
MR?X60$?]_HZL:9F-]*)[22G]!3C5ES_?^9,J:M:W;\B[?7<"_LQZT7*0AY6W
M- AQG[2F3C-9/D0']G32&>[:.W?4%Q((LDG$A^[GV]:=KSF']EK5@>C7"\?6
MYS_2LVYDV_LU>'5S]Z_4_P#CLM?1-+E<G_*>/"^B_O'*10:6+&-%U&8@ECG[
M+C///\=?M%^QFL:_LO?#H1.9(QIHVL5VD_._:OQ+M$!LHO4&3I_O&OVQ_8M&
M/V6OAS_V#1_Z,>N;!M.M*RZ&^*35->I[))TK&U+[C?0ULR=*QM2^XWT->R>6
M:FD?\@V#Z'^9JY5/2/\ D&P?0_S-7* .2\4?"GPMXS\4:#XBUC2H[W6-#D,E
MA<L[ Q-UZ X;GD9!P>:ZVBBC96#=W//_ !?X,O-?^)OA34_LL=SH]G:WD%YY
MC+C]ZJA5VGE@<'H*\E3]GKQ59^(?%-G;S03>'XK.T3P]+/-R$BN?M M9>K84
MY0-C[NWJ0:^FJ*%[K373^OPOH#U5F><^']%UO7_B1%XJU32'\/V]GIC:?%:3
MW$<LTSO(K,Y\IF4(-@ R<G)R!CG-U[P!K5]XO^)-_#:HUMK7AVWT^R<RJ#),
MJSAE(SE1^\3D\<^U>L44I)27+Z_C?_,:?*[^GX6_R/ M2^&VO6^CZ1'IWAN\
MLO$\&D6MI%XATG6(X1'+&F-MU&67>BDG  ER">!5?2/@YXGT#XB^(/'4-NEQ
MKLFL0O&GVE1'>V1M88IP%+81MZLP) /R#MBOH6BKYGS.75_JT_T^XCE7*H]O
M\K'$?%'PQJ/B"RT.\TN);F]T?4X=16SDD$8N N0R!CP#AB1GC('3K7G?B?X9
M>)_%\_B+7SIG]GWFJW^D"'2I;F-I(K>TE+O)(RL4WG>_RJ3PJ\DG ][HI+W?
MOO\ E_D4]?NM_7WG+?$WPQ/XN\$:GIUF=NH%!-:/NV[9T(>,Y[?,HYKS%?A9
MXGGTSX?W%U:1-K%OJMWJNM[9U(CDFM9T.TY^8!I$7CM[5[O14VW_ *_KI]R'
M?]?QT_KU/"HOAWXHTSX<_#W36TZ>\CTB9FU;2M/O8X+B4%'";)2ZK@,REEWC
M<.YQ@XWA3X.>)]-\2>'[V31H=/M+;QA<ZS)"EXDOE6TEE+$ISG+-O< @>I/(
MYKZ.HJT[2<OZW3_0EJZY?ZV:_4\]^(/AS5CXU\)>+=)LGUAM&6ZM[C38IHXI
M)8YT4;XS(0NY61>"RY!/.1@Y36'BS3O&S^,1X8-X^HZ8MA-I5MJ$)FM621FC
M8NY1""'.X*201QOZUZO14[?UW_X<?]?U]QXG\,_A-KO@[QG87]ZD,D']BW$,
M\D,H*I<2W33>6H/S%0&QNP <=JS/"OPR\7^&M/\ !'EV$8O+"QU.QN&$T;"U
M>>3=%*P+8=!@9"Y//2O?Z*'JK>OXW_S8[ZM_UI;_ "/G?PG\+_$L7BWP'J-S
MX=GLFT:WN8=3OK[5$N9)Y7AV[HE#G$98' ^4C(&T 5M_#OX8^(/#^C_"6"^L
MTCE\/VUS'J $R-Y3.F%Q@_-^&:]MHJKZW_KK_F2E8^<K3X.>*HO(W6$8V7'B
M&0_Z1'TNW<P=_P"($?3OBME/A?XKBT'X96]I%!:ZAH?A^6QN999$=+>Y-HL:
M9&3O <=LCBO=**A:1Y?3\+_YLIN\N;U_&S_0^=M ^%?B)_$_@Z^?PW<:=_9E
MG<VVH7NI:JEU+++)%MW)AV_=EL_W3T^0 5G/\$O%OB#PUX1TRXT]-+GT;P[)
MI,DDUS&\;SHT)C(V,3Y;^4><9 /(!XKZ:HJ[O?\ KK_FQ+2W]=O\CP7XB^ _
M%GQ1M+RY;03HLUIHESIUO:SW<+O=SRE,D%&*K& G!8AB3]T8KM(?!VJI\5O#
M>MF!1IUEX>FL)I?,7*S-)$P7&<GA&Y''%>C44D[-->?XW_S8FKJW]=/\D>+?
M$SX:Z_XD\5>-;VPM$FMM3\)Q:5;,TR+ON%GE<J03P-KKR>.:UKOPOKWAGQ=H
M7B?3]);7/*T(:-=:?#<1Q2Q,'5UD0R,J$9#!N0<8(STKU.BI6EK=/UO_ /),
MJ7O-W_JW+_\ (H\,\$_"3Q!X<\7^'=0NHH7BBTK5ENVBF!6&XNKF.9(E!Y(
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MP]\1?%?[7J%UIX\--%HATZTM[FX24W$S2QREF,18"+]TH&?F.YB5&,&O\0/
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M_5_D>4:?8M C2%XY(W"8:-LC()./6DA0YF4<EK4\?5A52R<VPG;8Q4F%5;'
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MF!8 =3]![5X7X(\->(O#FE_#R230;UI[:QU:R,,EN^V&667,*R@#,:,%^\<
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M&VF5G"KGMGN1CTS6KH'CC2=?\%VOBB.[BATF:V^U-.[C9$H'S;FZ?+@@_2O
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MJBV>NZG;7'C*QOY)=6MDAD,<<,BM.UND,?DJ&V\L,G@G'%$5S-)Z:KY7Y?\
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MKB2-8D)4N< F6,9Q^-<2=)2C8WG&HHMZ&??>=<:OJK)!)(0=HVJ3GGM^5/\
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M.^%XX_$$$R,LEFMH]R6C8'&0,CZYSQ7)1O.I/U-JEH0@_(WO"MG% JV>%DD
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MHZ-T8'J#5.3<G+O?\;_YD)))1?0\]^-D$WBSX,ZPNCV\^HR7EO&]O%!"S22
MLI&$QGISC%>;:KX)U:3X>_&&)-#NVO\ 4-566T46K&6X58H-K)QE@"&P1T(-
M?1L,*6\211($C10JJHP !T I]+9NW7_-/]!W>E^AXIX;67P?XB\6V>O^&M4U
MV;6=1AO+%[;3&N8IHO*C55>4_NXC&RMQ*R>JYS7(V'AW6O#GBG0O$=WH>J/I
MNF^+=6GN5MK*2:=89X'CCE6)%+NA8@$H#C.>F2/IFBA-K7RM^7^0K:6_K9_Y
MGS/X0TS6=*UZQ\6:EX=UD:-;^(-5FEL?[/>2YB$Z*(;H0 %W VLOR*2!)G&
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M><'BO1:**38!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[I/[U?[O,IJS:\VON=CZG%Q$P)$B$#J0PJ'4;UK&SGFCMY+V6)-XMH&02/[
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M ,N>,4/2_E_]M_\ (_B$=4GW_P#M?_DOP/KEYXX_OR*O^\P%97_"5Z:?%/\
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M?18S+;V\2D*QNNK=!Q6IXZL_MGQ>U2'(7S($!8]OEK*M$^SV4;AE<BXR0.V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/KWBZ:?2[G35U#35ABGNHRJAB_W.1R17WKJ%@ V-N<U\Z_M$^$_&/B2&73M
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MP7UZ77;V]US5=4:6YAGOWE1Y!;R^9MB+%8_+8[?D"]<')JUI'C745^&WPO\
M-UNZ;5+SQ2;68/=,99U66;=$_.6  4%3[5[O#X \+V^M2:Q%X;TB+5I)1.]^
MEC$)VD (#F0+N+8)&<YY-"_#_P +IK$NK+X;TA=5EE6>2^%A$)WD7[KE]NXL
M,G!SD4[Z_-/\M/P!K3Y6_/7\3RKX?2Q:MX33Q9J_B34;3Q)<7%[;O;2:JR0O
M*ID46ZVY;8"H4$;5#_+DGK7G?POM[7Q1XCO;W7/$FHVU_'X*L+D21ZG)!+(1
M+=$S.RL&?9\O!)7Y^0>*^GD\$^'8]=GUM= TM=9N$,4VHBSC%Q(A&"K2;=Q&
M .":J77PS\(7P@%SX4T2X$ C$0ETZ%O+V;MFW*\;=[8QTW''4U/]>FC6GWW_
M *N-Z_UYI_I;^K'S)XH\4:YX@\->)1J]W<N6\,Z+<&WD<[/,:]D!D"= S*JY
M('/%:NK6W_"5>*M(75K_ %"5(/B++:0[=1GB\J,V4I"KM<8Y48QTR0.&(/TO
M>^%M%U*2XDN](L+J2XC2&9Y[9',J(VY%8D<A6)(!X!.145YX,\/ZA:7%K=:'
MIMS;7$XNIH9K.-TDF!!$C*1@N"!\QYX%5=<U_P"OB3_)6#HU_7P\OYZGD?@W
M6]8U'QWIO@.?4+QIO#-W<7^HW#3,7N;;!%HKMG+!C+NP>OD<U[K7->&?!G]A
MZYK.LW5V+_4]3**\PA$02%,B., $\#)Y)Y)/2NEI7T2Z]?475_U_6MPHHHI#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y]?\ C]G_ .NC
M44+_ ,?L_P#UT:B@#PC_ (*#:9<:K^S_ .5;1"25-6MI,LZHJ +)\Q)(Z9K\
MR_A-X?DTGXHP7$ES#<;Y=N8&W ''][N:_1;_ (*=7'V;]F8-@-G6[0;2>#\L
ME?FO\%+F:X\<Z?(S?N%D 4+]W/<BN*44\0I=3J4K47'N>R?%_P ;W'@I;JYT
M^")[]T$8VQ ELCJ['D =J\=_9\OM1U'XO6EYKDT][J%V7'G3,2 -O0'OZ5TW
M[2,^OQ^(R-.T][K35A1KAT8* >@R37/_  :CO(?'_AS4W1'2/?OBCD#&/(X#
M8/%>C"/+T\SSG)WL?1GP8TEKWP@R%B/L^I3.">V)6KW*VT[=>)(J_*RAB<>U
M>._!>Z$NCW4-I"UQYFHRHX3CR\N22?85]":;8GR(>,84"K:LP006G3BM2VM0
M&'&:FM[3&.,FM&WM\D8%"%<6WM@2.U:(M\+4EO#M SS5AHR1[50FKF=Y&?K2
M?9B>WY5>6+ Y)SFG+'AN!4W HK <<C '>I$@W'!!JX(J>L63G&,4@*?V7&?2
MHI+7 QBM3R.*8\61TH R'M,C %5+FQ)0\5OM#436H(.:0(XR\L1* ",,O>L#
M5M%2Y5BR#<!^E=_>:?N)*C!K+N+3>A!&#[TO(M'SEX[\$/%K5AJT(Y@<;PW0
MIGG\NM>(>";)H/&OQ+U=;MG6..Y46[$;5W.%W8_&OJOXQ0:O8>'C+I5@EZ&<
M)-P2Z*>Z@5\P_#7PEXK/C37]0GT:2PM&DD1UO(CY=Y"YY!^G6L[-/0#!_:8T
MY+76M&\0_8EN[C[,;<LPR!M;*_H:X[X;?$Z71EN!DZ;:P1 QQPMC8Y;"@=MN
M3^N*]2^+FI>'_$FLVFEZE=_V+':@R^8TF!*6W#: 1VV?K7DKQ^#?"::J+:X'
MB SH1]EV[A&H&200/7GVJG0=6-I;=!JHZ<KH[6/XC6GB#Q+8G5='M3<B6.$7
MEF#!(ZEPRE@ORM\S,<D9^:N]_:%L=(D\3:')J&HOISQV3>41#YB-ESG=@Y'0
M5XII9L-<\0:3>:1&\6G_ &JW58KC*E 77*D^QY!KTO\ :X5QXA\/")7D9K1E
MPHSC+G'ZC'XUY$\/*%.I!ZGK4\0I5826AS%I;Z9+9VL"^(+-Q&\\@_=.N=Y0
M=_\ KG56/2+!D-O%K%M.OFE]J(QSA<?SS^5<-K.K?8H(='00L+90K7"#+,Y^
M9CGVW;?P]ZB@OY[9XD@8)<N,0Q$X9CC->34PK;?)&[>AZ"Q*23E+8[^_TZ+3
MM"#2WJRDRJJHG!/WL*,_C7A?Q"^)-U?W4&GZ?:O9Z>)$$NPE6E(. 7[X'I7K
MBQZ=J.F?9YI&N;U'$LRR$J\4F/ER.W4G\:\FU_PS=6&L1O)&UU \JGS0/5N]
M>UA,*J"4I;GC5\0ZM^78]E^.FF&74OA@$+C9*)&5?N_\LQR/S_.MGQ)=Q6WA
MJ_8$+-_:,+1R&/>5=4)! '3IC/N:R?C?>75CXK^'L2.AB<$.C+GC<H!'N,5I
MWD O_#E\^_R7M[Y9 ^_;N.Q@/YUZF^C.+JF0>+=8T;XEVL;Z]H:6U[Y87^T]
M+<QR/CNZ$8;GUYK]6?V0K;['^S5\/X \L@CTT('F^^P#M@FOQ[2/4X;@SW'B
MHP(3D0Q-D 5^Q'[)4_VG]G#P%)]H:[W:</W[]7^=N31S/D4;C7Q-GJLG2L;4
MON-]#6S)TK&U+[C?0U!H:FD?\@V#Z'^9JY5/2/\ D&P?0_S-7* "BO./B!K_
M ,0M,^('@ZS\+Z%9ZCX8NIF76KV=\26R=BO([<]#D\<=:]'H6JN#T=BM/J5I
M:W5O;374,-S<DB&&20*\I R=H)R<#GBK->1_%R9[;XD_#Z:-MLD?]H.K8Z$6
MY(KDO GQ \6V^B_"O6]4U^?7#XHLF-[8O:PQQJPMS(&CV(&#$C!RQ!SP!TH6
MJ;[?\'_(;6J7]?UJ?0%UJ5I826\=S=0V\EP_E0K+(%,KXSM4$\G / JS7S-?
MZCK>OV_PB\8:CKLMX-5U)+TZ1Y,2Q0%H)&6.(JH?*C@[V;)!Z=*T? WQ3\8:
MT/"FNS1:M);Z[<JEQ9W<%I#I\$3[MOD2 B5G7 ^\6W<_*.U<KU3W3L2W;7RO
M^9]$45\^^&O&OBVV\%Z'XOOO$LFJ&[UN33I-*^RP+"T)NY(5P50/YBA1SNQ@
M?=SR:WASXK^,-7BTKQ$(-7,-]JAMI+">"TBTV.W,S1C9*2)3*  >2<G(VBI6
MO]>G^8WI=_UU_P CZ+JM?:E::8D;WEU#:))(L2-/($#.QPJC)Y)/ '>OGW1?
M'WB^'POX?\577B.>]^U>)9-(ETQK6!8&@-U)$#D('W@ ?,&QP,KU)H^+M0UO
MQ=X1\(^*;W79U@NO%-JO]B-!$L,2+<E552%\S>-H))8@\\"FM6O5+[[?Y@]+
M^2;^Z_\ D?3-%?.FD?%?QAJ26WB&.#5S%-J_V-M/F@M(]-6W\_RN)21+YH'.
M2<$\;>:++QWXOB\,V'BF;Q+/<;_%7]C/IIM8%@:W:[,/)";]Z@@A@V.!E3S0
ME>WG_P #_-!+W;^7_!_R9]$1S1S;O+=7VL5;:<X(Z@^]/KRC]GK39[#1_%#3
M:G=Z@'U^] 6Y$0"8E.2-B+U[YS[8K:^+4WBR"QTIO#(NC;"Y)U,Z:(3>B#RV
MV^0)E:,G?LSD'C..>0GHD^]OQ#JUVO\ @=[17SW+\5]7UG4/#_A_2]0UZ[$E
MM=SWM_8:=;IJ(>&1$$31RYC4C?\ .P4YXP!G-/T#QGXT\9^*/"VAW&LS^'!/
M;ZG]L>"&V>XG\B2)8GY$B1OA_F'(^]QTPTK[>?X7_P A-VW/H&BO!HOB-XBU
M>TTO0X]3NFU4ZC>V<MQI5M%]JN8K<@"5?,5HD ++N)4\\*!GC#\,_$'QIXOU
M7PGH4OB"YTAYM6U6PO;J"&V>XECMU4QY)C:,/DX)5<=>/02OMZ_(;TW_ *W_
M ,CZ5IB31R.Z*ZLZ'#*#DK]?2OG7Q/\ $WQ7I=U_;%AJ=]>:9;>(K;2&7R+>
M.QEB:=(9 <IYK2 LV65E7/0$"J$^OZWX&\1^,UTW4=5OI]8\60Z?F.&WD>W5
MK99"\2E%!? V+O)' )!.<I:J_P#7V?\ Y)#M:Z[?\'_(^D[[4K33(TDO+J&T
MCDD6)&GD"!G8X502>23P!WJS7S/XL\2ZYJ>EC2M72_>&P\3:,UK<ZLMO'>.K
MS D2I"=HP1PVU<@].,UV6B^//$$WB6V\%7&H-)KUIK,QN[HPH#+IP!EB;&W
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M^?X<W_R+!*[MUT_'E_\ DD?4E4[_ %FPTIH5O;ZVLVFW>6+B94+[5+-MR><
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MRL&)"X4G)R5('J0?2M*O+?A1I9^('@3P?XJ\0W4NHZV]C"\DHVI&[JS-N"*
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M9.W#?+GC%1R?![PK+IJ6;6=V=ES]L6\_M.Z^V";;LW_:O-\[.WY?O]..E'_
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M=;_BV_U7J>1^&_B!XQ_X1SPKXHO?$DE\FH^(9=(FTMK.W2 P?:I8E;<J"3S
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MZ 7D_P#\731^S]X"!S_87/\ U^3_ /Q=>B44[L+(\_7X"^!4.1H0SZ_:IO\
MXNIU^"?@Q  NC8QZ7,W_ ,77<T47861Q)^#'@XG/]D'_ ,"IO_BZ8WP3\&-U
MT;_R:F_^+KN:*+A9'"_\*1\% Y_L;G_KZF_^+KK])TJUT/3H+"RB\FU@79''
MN+;1]22:MT4@L,<55GBW U<(S3&3.:!F?#</9DKM+H3TSTI7UH+_ ,L'_,58
M>W!YP/RJNUH#V'Y4 ,_M\?\ /N_YBD_X2 ?\^[_F*4V(]!^5)]B'H/RH /\
MA(!_S[O^8H_X2 ?\^[_F*/L0]!^5'V(>@_*@ _X2 ?\ /N_YBC_A(!_S[O\
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M'Y4?8AZ#\J #_A(!_P ^[_F*/^$@'_/N_P"8H^Q#T'Y4HL0>P_*@!RZX&/\
MJ'_,5(=2:1<)&5)[D]*C6S /0?E4Z6^,<#\J ([>'!YS15Q$ [44 2T44F:
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M\T9H ;L]J4+BES1F@ QBBEHH C+XIAE'K5.:Z"CK^E4I-0"D\_I0!KF8#O\
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MU@?VFOK^E']IKZ_I0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H$X/\
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M ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_R://'^36!_::^OZ4?VFOK^E
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M_IK,HH T_P#A)=6_Z"-S_P!_31_PDNK?]!&Y_P"_IK,HH T_^$EU;_H(W/\
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M^$EU;_H(W/\ W]-'_"2ZM_T$;G_OZ:S** -/_A)=6_Z"-S_W]-'_  DNK?\
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ME&);F3.U6=4' )/+$ < ]35VZ\(ZG::=+?&.">TB($DMK=13B// W;&./QH
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M75O^@C<_]_36910!I_\ "2ZM_P!!&Y_[^FC_ (275O\ H(W/_?TUF44 :?\
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M&<Y)&<UQP\0:B$T]/MDNVP)-J,_ZK)R<?C4EEXIU73DD6WO7C620RL, _/\
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M"R+:69CBMF\Y5*JY )X)&,>]27-VM]XXU+17M;4:;]BE_<K"HPRP%PP.,@Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4?\ ",ZQ_P! J]_\!W_PK[;HH ^)/^$9UC_H%7O_ (#O_A1_PC.L?] J]_\
M =_\*^VZ* /B3_A&=8_Z!5[_ . [_P"%'_",ZQ_T"KW_ ,!W_P *^VZ* /B3
M_A&=8_Z!5[_X#O\ X4?\(SK'_0*O?_ =_P#"OMNB@#XD_P"$9UC_ *!5[_X#
MO_A1_P (SK'_ $"KW_P'?_"OMNB@#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW
M_P !W_PK[;HH ^)/^$9UC_H%7O\ X#O_ (4?\(SK'_0*O?\ P'?_  K[;HH
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M?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\ A1_PC.L?] J]_P#
M=_\ "OMNB@#S+X8V\MKX/TR*:-XI53#(ZD$?4&NQ?_5_A45S_P A&;_?_I4K
M_P"K_"@#S7XQ6<]]X4FBMH)+B4S1G9$A9L9]!7A7_",ZQ_T"KW_P'?\ PKZX
MTC_D+?\  3_*NCH ^)/^$9UC_H%7O_@._P#A1_PC.L?] J]_\!W_ ,*^VZ*
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M&=8_Z!5[_P" [_X4?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\
MA1_PC.L?] J]_P# =_\ "OMNB@#XD_X1G6/^@5>_^ [_ .%'_",ZQ_T"KW_P
M'?\ PK[;HH ^)/\ A&=8_P"@5>_^ [_X4?\ ",ZQ_P! J]_\!W_PK[;HH ^)
M/^$9UC_H%7O_ (#O_A1_PC.L?] J]_\  =_\*^VZ* /B3_A&=8_Z!5[_ . [
M_P"%'_",ZQ_T"KW_ ,!W_P *^VZ* /B3_A&=8_Z!5[_X#O\ X4?\(SK'_0*O
M?_ =_P#"OMNB@#XD_P"$9UC_ *!5[_X#O_A1_P (SK'_ $"KW_P'?_"OMNB@
M#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW_P !W_PK[;HH ^)/^$9UC_H%7O\
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MQN+&&YB)E WJP<?,,C(/&.>M:DGP?T[_ (5]H?A*&[GALM)EMY8I< NWE.&
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M_"HKG_D(S?[_ /2I7_U?X4 0:1_R%O\ @)_E71USFD?\A;_@)_E71T %%%%
M!2;JCEN8H0"[A0>Y_.N&\2_&'0O#UFETTK36K!B+G<L41P.H9R-PR,93=COB
MG9O83:1WFX4;A7S1K7[:GA^WG,>FV<U^OS!9$4D/C(&.G7&>_!'2L#3?VT'>
M]>6_TB\2+;B.UM?+/(ZDL>?;%<4L70IRY9S29UPPF(J*\*;:/K;>#TYI&D5<
M9XKQKPK^T)I6K6PU'4+^UL]- !FE2"=EMB<82639L1N>YY[5/I]SJOQ:EDU!
M/,B\,,?] *7+0"Y4$CS24.Y@W4#(&".M>A"FYQYT_=[]/D>?.IR2Y&O>[=3U
MY9%<9'(H:54ZUY=<:UJ?PALC-J[&_P##(<9O [R26*GJ7+9+)GOG(]ZLV$=U
M\5((]1N;F:T\+3J?(L8R8I;I,\2R,,,JL!D)P<$9P3@-TFES=.XO:Z\MM>QU
MNN^//#WAF6.+5=9LK":4XCBGG57D.<85<Y8_04B^,;6Y3_1;74)V/(!LI(AC
MUW2!5_6LV:7PSX'=;6SLK2'49U)BLK.)1<7&.^!R>V6/'J:CO6@$D5QXFOK6
MSB<@0V+3!8\\D[B<;STXZ<=*5D.\F;/A[Q'%KB2/')!*@<J/L\PF"X./F9>
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M!P5%7*SDK>?Y?YF:NEKY?FOT,*Q_:A@U%=:O(/#5P-(T2S2ZU&YDNE$L;MN
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MMJ7A;5#9SKI2SP7%C(!M&JWKNK#'9'5F'8,">#5)7<5WM\KJ_P" GHI/M?\
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MP5D#R%AN(*JP)."<US?P\^%=YKS2#Q)X5O;E+'PC=PV::CI\BI%<"]E,2HK
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M0,9'<4F[*_S&E=V^1Z_17A'@W]I0WOPHN_$FJZ6\U]I=OI[7BV[!%FDN0G*
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M[QSY385?3DC(KI/!G[0-CX_\4/IFB:;]JM8Y4CDE:]B2Y0-&L@E-LQ#F(A@
MXZ\X'%)>]L-^[N>L45@>.O&>G_#WPIJ/B#5'V65E'O?Y@N3G &3P,DCDUY5;
M?M5:3?AK6PT^#5]8%Y9VHM=*U2&ZB/VDN(V\Y,J"#&P93R..N:%J[('HKL]T
MHKR*_P#CO>6GA;4=93PP'.E7DNGW]K)J*HZ7*LH6./Y#YI?<,8QR<4?\-!1V
MOA/4M0U#P[=6&N6%_'I\NAM.K2[W02*0X&,>7N?/HK>E*^E_ZU_X=#MK;^M#
MUVBO#[;]I.]N8MP\$7:L=%'B!0U]'C['DAB3CAP<87OGJ*;)^UOX175$C26T
M:Q\^"VD=M1A6[#R[<%;4GS'4%URPZ<G! JK.]OZWM^>A-U:_]=_R=SW*BO.?
MAO\ &)/B3JUW!9:4([&!I4-TE]%*\;H^TI-"#OB8]0"#QUQ77^*M;N/#VBRW
MMMI[:E,C*HA$R0J,G&YG<@*HZD\G'0&ELDQ];&O17BFG?M)C6M4L]'TWPVVH
M:U<7]SIYAM]1B>!'AC$C-YP!!7:>PR",8JGK7[25WJ?@S7KWPIX<GO=5TO2[
MB\O$FE4+92(9$"D?\M?FC8X&,J.O.*3?*N;YE17,TOE^-CW>BN N?B9+I7A#
MPA=/8-JFN>(8X([>S@81*\K0^8Y+'(1  QSS^->=>)OV@_$*ZQJ-IINBQV#Z
M7I6IRWT-W*',-U;Q!TQ@?.GS*>,9#=L4Y^XVGTO^&Y,/WBBUUM^.Q]"45X1;
M_M.Q>'_#>G7'B[2!I%_>:7:WUL7NXUBN3+M7EC@0_,<G<2 ._%3V/[4%CK=Y
M9Z9HNDPZ[K4]]]A,.G:K#-;*?*,JN+A058%5(Z9!&,53BTW'M_PQ,6I)/^MK
MGN%%<3XR^(T_AK5-)T>PT276M=U&&6X2QCG6(+'& 7)=AC.2 !W)[5@3?'=8
MIKZ<^&[Y='TR[AT_4KV25 UK<2*A*>6,[PAD0,P.,YQG%2M79?UT_/3U*V5S
MU6BO%--_:,N]:;2OL/@RZFBU:[N[&PD:^C422V[NK[ACY5/EL0>?3%.M/VD3
MK"V[Z1X3O=1B_L4:W=.+E$^SQB:6)TY'S.&B; '!]J/Z_"_Y(=MU_6]OS/::
M*^>M+_:KL(AJLE_+IY6?6Y+/2!>7D>GQFV2U@F+2RR' (,V.G.0,5N-^T_H[
MZ9HM_;Z1>7MMK<;QZ9):NLJW-XDIC>U#+D!AC<&SM*@D=*=GIYV_%7_KST%_
M7W.W]>6I[317#>./B/>>$M0\,:9:^'IM7U377ECCMX[A8UA,<?F-O<CICC.*
MXNR_:;M=1U"_AM_#EW]FTK3_ .T-4N);A%^R 2R1/&%P=[!HFQC ([BD']?H
M>VT5X/XZ^/\ KND:9!:V_AHZ7KEV+2\M8[JY5TELY+F.)VR!PX,J J>F\')Q
MBK=_^U1X;LM?FTR1[)1'>C3&*ZG"UT+@_+Q;9WF,,<;_ ,<8YH_K^OGIZAY_
MUW_+7T/;:*\)TW]I6632;^\/ANYO;/2+&WO]2OA/'%LCER<I'SN8 $D9'3K7
M5>%?C7#XP\:W6AZ=I7FP6L[6\]Q]MB$\)"[@[VY(<1MT#<Y],<T[.]A7TN>F
M4444AA1110!DZY]^W^IHHUS[]O\ 4T4 +X=_X\W_ -^M6LKP[_QYO_OUJT %
M(>E+37.$8^U %2^8?99<\_*:X60B"<R9 !Z>U=J\BR(RGH1BO/?%[?V8LO.U
M.H/M7#BEHI=CHHO6W<P_'>O2:+I\MW&JR!!E@#C JAH&L_VW9)=!%3S%#*P7
MG'UKSSQ1XR?4HKG2)YC'#/P)H\;D(QTS3?#'B+2_#6BVNEV]\]RML"6>XD#/
MR23D_4UX4JBYCUHQM#S/2H=<\F[:'#?*<M*.@KI] U5;R[BA2<R[O?(%>/2^
M/K,-N$3_ &/<(Y+G!VH6.!GZFO0O 5O&;OS$YDW ,0>#_G%=="6MCGJ1]V[/
M;+8_)CN *FJGITOFA^<XQ5ROH#R0HHHH ***\Q^+>L:W;^+/A_HND:S-HL.L
MZA<V]W-;Q1/(8TM9) %\Q6 .Y!SC\^E =V>G45\MZ%\6?$_A^ST/5]?\6SW5
MA>)K<-UYEE"5@6S5C',JHJEG^3D;MISP!4%U\4?'>DZQJAL]7U#4;;2])M?$
M,ME?QVC3SP"3]_$!"@V!HLD Y;*C#&A:M?UW_P FPUM_7DOS=CZKHKR?2OB<
M;[X9>+O'<VJM;Z!^_FTNX2V$GE6\:[1($X+EG#$ GGCI7AGQ,\2>(_$%MX@\
M)ZKKNIRZ:T.DW+17HLVG_?7:(Z.(XMNP@YVL#TY)&079N2C;73\177+S=-?P
M/LNBOC?PC9ZE\/?$>K:5X9>1;G5/%-SI+7Z1V5M.L%O!&8H4?R-BYZ!2I4!<
M*HKO]*\9>--9UG3/#NL>++3P\4M;^Z?5]/>VN/-\F4*BRLRF,,JG]X%"\@_=
MH5FDUU5_PO\ D-Z-I][?C8^APZLS*&!*]0#TIU>&?"@W&G'XP:C#KTNK2?VD
MTT5P1$8V;[! ZR($7H<@#DC"KU.2?.]9^*_C70/AMX>U6T\:-K=_KWA\W\TC
M6MOBRE7R_GC54'RY8H0^[GICI0E?[D_O3?Z,/\VON:7ZGUO17S=JOC#Q9HG_
M  G7F>-KI9?"5K:7%K#=6]MG43-&)"9<1@E2Q,2^7MP5Y)-<QXT\6:[XQ\.6
MGB&^\1/9W-OXN%E%X<6&+9#Y3$)U7S#(0!)RV,,/E[TMOZ\TOU_X8.G]=KGU
M)HOAG3/#UQJD^GVHMI=3NC>W;!F;S9BJH7Y)Q\J*,# XK29U3&Y@N3@9.,GT
MKYAU;XY>)],\)> K^VU2.]U"]\+7^I7L)BC/FS1I%LD8*,@*Q?A<#@@]*T]>
MM+ZZ\2?#9;GXAW&N3MK-O<FV1+198!):2MEMJ?=8JVW*C@MRW!%\K3Y?-+\>
M7]!7NG+R;_"_ZGT;17D_Q&\1ZQ-\4-$\+6GB%O">G3:/=ZI)J*11,TLD3Q*(
M\RJ5"JKL[ 8..XKRGPYK^L^$[7Q+XFL/%#W-HWCI+26VAAA-K=12M$DDA.TM
MD[LC:X QWJ(^];S_ /DE'\RI>ZK_ -;-_D?5U%?(?COXW>+-&DTR^T7Q)?RV
M6LV6JR1&_@M%4>3 [QRPQ*I=0K(!\[,#GD9KI_&?C;Q'X?\ #EY':>,]9N]7
MTS0(]8N9?(L8HHVDR4,KM'@J2I 55!P.6)(H>BN_ZW_R"VJ7?_@+]3Z5K)U7
MPYI7B.ZTF\O;=;J;2[DW=G)O8>5+L9-PP<'Y788.1S7AW@3QQK_Q#M]1U35/
M&B^&4M9[>S731#;B*X$MLK=9%W>8[/E,-CY0-K<UQG@#Q-XT@T?2?#>AZI<1
MP6>B-J:7$UQ:0F1C/(I+F2(@Q)M&0NT_-RW2FTXO7^M+DIW7]>A]=4A( ))P
M!7REK/B_Q=KNDZ_J&JZ]!-'INL:%;KID%O:W-@QEFMB[AGC9FY<LK!N.".0"
M'>,O%GB6Y\,>,=+\0>(KQQJFBZN]D^G"TGL)EA1FQ'(J[XR$^5@^[.3@J<5,
MO=BWVO\ @D_U-(1YVEW:7WGU6K!U#*0RD9!!X(I:^6="\4ZWI?B+3O#EGJYL
M(=4O=-L9M:6UMQ<JAL6D W>7M9V90JEU; X K8\3^.?$OA6_DO'\<G6_#>DQ
MPBZOM&2RED1O-*O]J@^\<C"_NV3D'CM6CC:7+YV_K[S%2O'F\KGT=12*P901
MT(S2U!84444 0PV=O;SSS101QS3D-+(B -(0  6/?  '/85-110 4444 %%%
M% !1110!R5W\*?"U_P"(#K4^E^9>M.ETZ_:91;R3H,)*\ ?RFD&!ARI(P.>*
MZVBBCI8.MPHHHH **** "LS4O#6FZOJNF:E=VHFO=,=WM)2S Q,Z[6. <'(X
MYS6G10 4444 %%%% !1110 4444 <]<_\A&;_?\ Z5*_^K_"HKG_ )",W^__
M $J5_P#5_A0!!I'_ "%O^ G^5='7.:1_R%O^ G^5='0!'.Q2&1AU"$BOAN72
M_P#A(M?U!IY,237+LSN<_P 1SS^E?<KC((]17R)\6?!M[X%\67LUO;R_V7<N
M9XI@I*J6Y*D]CG->G@)151INS:T.3$+W4[=3SS7],CTVXD5"%P,9'05SD\0E
M VF7((.\L1^E:LT4^IW:1Q1R7DIX"YW$>_\ ^NO6_AG\ EU:6*\U]7E5L;+9
M"SJ/]\J0/UKMQLXJ'+?4Y,/=SYK:'D>A_#34_%A)9Y5A #"W*'SYU_Z9KCD>
MYP.1S7T)X)^$^@V$"V>G> '%QD>9JNKN(Y 5_B5D.1]$/3J:]:TGX:Z9I(0+
M+=S*I!"RW#$#!!QUSMX^Z21V(KKXXDB4*BJJC@!1@"OG(TZ<'S)7?<]:=2M4
MT;LNQB^'O#4.CQ[@L7G$8/E1B-%'7"J. *W::>G%*!BKO?<25E9!C-+110,*
M*** "HYX([F&2&:-98I%*O&ZAE8'J"#U%244 4=%T+3?#>G1:?I.GVNEV$6?
M+M;*!88DR<G"J !DDFK-S;QWEO+!,@DAE4HZ'HRD8(J6BAZ[@M-CS.U^#U]:
MZ=::$/%M\OA:TE5XK"*(1W&Q3N6(W ;)0'MM!(XS7)WW[*T%];6MF?$CPV-I
M<W%S$D6GQK(YFCE1C-)G,C 2MACCOD'->\44/7<:=MCR3Q%^SU9>(9;61]8N
M(3!I-GI("PJ<K;W*7 ?KU8H%QVS5C5?@7'<^.KKQAIVNSZ;K[W(N+>;[.LL<
M2F 0R1LA(WJP4'J""!7J=%.[_/\ %W9*27]=E9?@>;>%?@Q%X1\2:7K5IK$T
MMU##=17QGA#?;#/(LC-P1Y9#J,8SQQ[URZ_![6O%/B_Q]%JNHW&G>%=7U&WE
M:R2)&^VQ)&F=KYS&"R[6XR0.,=:]QHH6EO+_ #N/OYGEUM\#8]*L].?2];FL
MM7TW4KO4;2^:W615^TD^;$\>0&7!QU!X!JI;? )M(DDOM(\375AKEY'-%J6H
MM;I*;H2MN8A"0$(/W2"<#L:]<HJ;75AW_K\3PA?V68K?PQ+X?M/%5W;Z9=6]
ME%>)]E1GG>V*['#$_*#L&1S]171WOP(CO;?7](/B"ZB\*:W+<W%UH\<"9,DR
M_/B4Y(7<=X  (/?'%>J453;>_P#5[?Y(2TV_JQR_@_PSK>@D_P!K>)YM=185
MAB1K2. *%_C;&2SGN<@>U><']F.$7<)7Q$Z6D%_=Z@D:V$8FD>X$@?SI<[I,
M>:<$XZ <U[?14M<VX+W59'CVJ_LY6.I^'O#VE'6KB(:-H:Z+%,(5)<*8BLI&
M>N8A\ON>:?/\![U/&3^*K'Q9+9:U)*9G<6*O$S-;10-\A;I^ZW 9X)]J]>HJ
MFVVV_/\ %W8+161X_;?L[6^B6<EOH/B&[TG[;8FPU20PI*]XK222-("<;)"T
MTIW#(^;IQ49_9RAL8(],T?Q%=:7X;74H=5.E"W63,T>W($A((5B@)&#R2<]J
M]DHHOK?^M[_GJ)JZL_ZTM^1Y-H_P)F\*2VUSX=\3SZ5?BT>QNKAK-)1<1&>2
M9#M)PKH97 ;G@\@U;U?X,S^(/$>FZEJWB%M3ATZ[2]M5GT^$743J.$6X4*0A
M.25VY.2,XKTZBDM-OZZ_F-Z_U\CCM1\'W?CCX>2Z'XJFC%]<I^]GL5VB-PVY
M&0'/(PI^HK*NOA5JFMIIG]N^+)]3?3]1M=0A5+..&,>3GY< DY;=\S%CT& *
M]&HIIV=U_5@Z6_K4\:NOV?KT>+SK=CXK,,0U.XU>/3KO3EG@2YE"KYF/,7+(
MH(4GIN8]>E>Z^#USXJ^+EUK>HFYA@@T4V,USL6.&]O&#QK<)$';!CBDD3+?W
M\#I7MM%3;1+I_P "WY?IV&VVV^K_ ,[_ )_KW/+[?X%6=N@4:K.?^*8_X1G_
M %0_U>[=YO7[WMTI/"/P7O/ @6TT+Q7<V&D2/%-<VBVD;/)(B*K%';.P/M!(
MVGO@BO4:*J[O?^MV_P VR;*UOZV2_)(\HN?@_JMMXCE\5Q:W#J7B6RL[J#3)
M9]/CA;=*.%N)$(,JC  & !UZUTGQ$^'?_"R/#%AIMY>K;7-K=V]^'\@30O+$
M=P#Q,<.A/.TGL#VKLZ*79=OT=_S'Y_UKH>1^$_V?HO#?C*U\1RZ]+>W4-Y<7
MIB%HD,9:6!82H"GY5 4$"LX_LT_8=)UNRT?Q5=:4=;@N;74)5M4<R1RR2.-N
M2-K+YC+GG([5[;12:NK/M;Y#3L[KU^9P^L_#!-1\/^&+.UU.6QU'PX8GL=0$
M8?#)%Y9WH3AE9201D=>#7*7G[.T=X;VY?Q%<'4]3AO8=2NWME(G%S$(SM3/R
M;0J[1D\#G.<U['13E[S;?6_X[BC[EE'IM\MCR77OV>K#76T.4ZO<V]WHVF6]
MC97$<2DQR0LK)-@]3E.5Z$$UMCX9:AJ&N:#J^M^)9M4O-)O'NHT2T2&+#1F/
M8J@D@<YR6;GTKOZ*KF;=_G\WJ2HI*R]/E:QQGC7X>S>)=;TO7-,UA]#UO3XY
M8(KH0+.IBD W*4) Z@$'/!'>N;?X#EWOK9O$U[)H^IW<.H:G9R01[[JY14!<
M2#&P.8U+*%QG.,9KU>BI6FW]=?SU]2GJ>9>'/@?9^'(?"\<>J32C0;^^OH]T
M0'FFY>1BIYX"^:0#WQ7":3\ -=T3QFVEZ;KEU8^'/^$9_LV;4/(C<W#/>7$K
MQA2V48++PV".:^B**.MW_6C7ZCOOY_YW_,\=TC]G*T\*W7V[P_K<VF:E#J$E
M[:SO;+*L4<EO% \#*2-ZD0J<Y!S]*N^)O@8_C*ZT^\UGQ3J%Y?:7!_Q+IQ&D
M?V6Z+[FN0JX#-@*@!X"@CG<37JM%.[T\O\K?U]^XOZ_4\J^*'@WQ+X@\9?#F
MYT:]>T;3)KMKS4UA1UC#6Y52T989#-Q@=*CT#]G71M%?7O-U"YO8];TM=.O
MZA6=O-FE>8$="S3'C&!@5ZS12#M_6SN>/ZA^S\^NQ-+J_B>XO]3@M(;+3[K[
M*B+:Q1SQS<H#AV9X8]QR,A1@"MG2_A1J.B7-Y%I_BF>ST:]NGO;BPCLXRQD?
M_6*LC$[49LDK@GDX85Z/10]= _K]/R/(-/\ V=+'3_"_BC15UFX>/7=-@TYY
M3"H,2Q*RA@,\D[NE:,WP5.H^+M#UG4]<_M"+1+K[78H;"*.YC;RR@C^T+AC'
M@G*8YP,DXKTZBG=WN*VE@HHHI#"BBB@#)US[]O\ 4T4:Y]^W^IHH 7P[_P >
M;_[]:M97AW_CS?\ WZU: "H[@[8)#Z*3^E24R5/-B=,XW C- ',/J#*.]>&_
MM'^.M+TS1DL;V^EL)V*2[X@VXKDX&0.Y!%?0)\,(1C[0W_?/_P!>J5UX"M+W
M_7.LG^_$#6%6$JD;(UIRC"2;1\M:/<67BKP_:WVCZ5#=D *;BX5L,Z\$X/O3
M9O#^N:DQ^UV.GE>@(M@"/QKZC7X>VJ)M6;:/:,#^M(/A[; Y^T'_ +]C_&N'
MZF^K.KZPD[I'SZOA^^O/#=QHDBP0V,Z[71(A^>>N:Y<>)%TBWN_!MMKM[8ZY
MYD<$5]%;-*R\9Z 8/ _6OJ\>!8%&!/C_ +9C_&I8?!=O$VX2 MZ^6,U;PCTL
MPCB4KW1ROP/\,Z[X8TJ]@USQ-=^)I6\LI+=1HACY<D#:/<#G/W17IM4].TY=
M/\S:^_=CMC&,_P"-7*]",5!<J.*4G-\S"BBJ.IZ[INBM;+J&H6M@UU((8!<S
MK&9I#T1-Q&YO8<U1)>JI=Z38W]U:7-S9V]Q<V;M);32Q*SP,5*LR$C*DJ2"1
MV)%6ZXOXC>--3\+7?ABQTBQM+V^US438(;V9HHHL02REB55B?]5C&.] =S<3
MP=H"+ JZ'IJK 96A M(P(S+GS2O'&_)W8^]DYS6)+\+-#TK2+RW\*:1HGA2^
MGA:W6\L])A^1&/S#:NW.?0G&<$@]*P;7XROHFJ:[IGBNSM[:]TT6VS^R)7N5
MN&G)6.)055O,+#&W'?/2KS_'+P^'2U6VU.76#*\3:-':$WD950S,R9P%"D'.
M<<C'-)I->0TVF=5H'A'3/#OA*Q\-VUK&^DVEHMDMO*H96C"[<,#P<CKGKDU0
ML/A9X+TN'RK+PAH-I%\HV0:9"B_*P=> O9@&'H0#UK T+X_>$O$6CW^IV<MV
M;6RTR35YC);%6%NC.K$ \[LQMQ]*H6O[0^@SW\=HEM?7T]W/Y=E!86K22.OD
M1S$L#@ A9 >N/QJ]7)OK_P '_.Y-E%6Z?\-_P#N]0\#^'-6L+RQOO#^EWEE>
M3&YN;:XLHWCGE.,R.I7#-P/F// J&]^'GA74M)LM*N_#.CW6F6)!M;*:PB>&
MWQT\M"NU<>P%96C?%[0-<UF"PM_M:)=326]I?2P%;:ZDCSO6-_XB,-VP<'&:
MP_$'QWL?"?CO7=#U73;M=/TNSMKN34;6,RK&LK,"9.FU1M'//7IQ4KHEU_0;
MZ_UN=O=>#M)D35GMM/M+&^U.W-M<7L%NBS2+M*KN8 %@HZ GBL'P/\&O"O@G
MPE;:''HFE71^QPVE[=-I\2O?^6H :88^<\9^8G%9J_'7187O(I(KF]NH;ZZM
M5M],MWFD\N#&^1@<8 W#)&>O&:P;/]J#0[K5[@_V=?OX?72;35TU**!F*13,
MZDRK_ %V#N3R>.*(ZZKK;]6OU!^?2_YI?Y'J&I^"_#VMZE8ZAJ.@Z9?W]C_Q
MZ75U9QR2V_\ US=@2OX$5#>?#_POJ.N+K5WX;TBZUE=NW49K")[@;?NXD*[N
M.W/%<;X$^/&E^*]7UO3+R+^SKFPN[Z.%\EHYX+9U5I Q PV&!*]AWKJ=0^(^
MCZ7X-M/$MRT\=A=K$;>/RCYTC28V($Z[CD<4=%+T?W_YAU:]5]Q/IOP[\*Z/
M?2WMAX9T>QO)F=I+BVL(HY'+C#DL%!)8=<]>]1VOPS\'V-@;&V\*:';V1N!=
MFVBTZ%8S..DNT+C>.S=?>L"?XY:#;I$AL=9:^:.6>73QI[BXMXHVVO)(IQA,
M\ @G/;-5)?VBO"*WUY!";^\@LDMI+J]M[4M;PI.H:)F?/0@_ASFFO+^OZ8?U
M_7WG<^(?"6A>+H(8-=T73]:AA?S8H]0M8YUC?^\H<$ ^XI!X0T(6TEN-%TX0
M27 O'B^R1[6G!!$I&,%P0,-UX'/%>:Z!^T9I]W:QMJ>C:G;75WJ]YIEE;V]O
MYC3" DE^O'RC)ST.:N:E^T/H$.BW%[:6]XQ>UN)].ENX&AM[]H4+.D<G/.%)
MY'(!(SBELK_/]1I7=OE^G^9U?_"J/!'G33?\(=H'G3NTLLG]EP;I'92K,QV\
MDJS D]02.]6M7^'WA;Q!<6EQJGAK1]2GM(_*MY;RPBE:%.FU"RDJ/85Y_P""
M_P!H>T\0Z9)+>Z7<)J#WTEI:Z=IH-S-.J11R/)C"X"^8,D^W<XJYXE_:'\/:
M5H%U?Z7#>ZY<0Z>^H/!:6[-]G12RCSC_  996'0GY3QQ1+W=_P"M/\A1][;^
MM?\ ,[5/A_X7CU2RU-/#>D+J5E&(;6\6PB$UO&!@(C[<JN"1@$"JUU\+/!=]
M!%!<>$-!N((IFN8XY=,@94E8Y:0 K@,3R6ZFJDOQ-L-,\$:#K^I12I+JZ0"W
ML;13-++-*FX11CC<<;CVX4DXKGM/_:.\+ZKJD6FVMIK$M^S3A[<6)#0B%E65
MGR?E"EAD_E3::DT]U_3_ ,Q)IQ3Z/^D=])X2T.9+A)-&T]UN98YYU:UC(EDC
M(,;MQ\S*54J3R-HQTJM9?#_POINH7]_:>&](M;Z_5DO+J&PB26Y5OO"1@N7!
M[@YKCY?VBO"-M%!-<'4+:UNMIM+F6T98[M#*D9DC/=5+J23C"\]*?X@^/OAS
M2M'\0W%F9]2OM(NWTYK*"/+R7(B,NT?[.U22W8 ^E3)V3;_K9?Y(I)MV1U*?
M#;PC%H\^DIX6T5-*G"B6Q73H1!(%^Z&3;M..V1Q36^&7@]Y].F;PGH;3::H2
MQD.G0[K50<@1';\@'^SBO,?#?[4-G="XDUW0[[3+.VL+&\GNXXC(D G4$M+_
M '5!/!YX.2!7JGB[QMIO@RSLYKWSIY;V=;:TM;2/S)KB4@D*B]^ 3Z "KDG%
MZ]_Q(34EH;]%>;W7Q[\-6<!F>WU;;#;_ &N]7[ X:PBR1NG4X*CY3TSP">G-
M*OQ[\+/KD^G+]N:."]BT^74!;'[(LTJJT:^9G^(.N#[TMRGIN>CT5XKKW[3&
MFVM_9IIFG7-SIMQ:WMTNJ7,3QP2I;QEBT1 )=201VXY&:=HO[1EO>7&I-J>G
MMH]A::LFGBZN@P1T-LLY?@'!P2<''RX/4XI+7^O.WYC:M_7S/:**\QNOVAO"
MNGZ=->WT>IV$2VZW<*W-DRO=0,ZH)(A_$,LO'!Y'%2_\+[\.B5[1K35DU=9T
MMQI#6>+MB\9D0A,X*E 3G/8]Z!;GI-%<IK/C^UT[P$WBB..6*VV(XCO(7B=<
MN%PR8W Y/I6+HOQV\-ZYJT5C#'J$:R:A)I2WLUJ5MVND+!H@^>ORG'&/>G9W
ML'2YZ+17D?Q0^.=Q\//$FIZ8F@S7L5EH,FLFY)VHS+(J[,C.!@GG!Y(&*TK#
MX]^'KBVF%Q;ZC9ZG$ELW]F2VI%Q-Y^[RC$N?G#%' /'W3G%)>\KK^M6OS0/1
MV?\ 6B?ZH]*HKB;KXHV,O@/Q!XBT^"6271XYOM%A=J8I8Y8UW&-QSM."/7@B
ML"+]H#1YM!6Y>&:PU'[):WOV6]B=%DBF=$WQG&64,^,XX.,@9HW=O3\0>BN_
MZM_PYZK17F]S\?O"EDSO.U]%8EIHH-1:U/V:YDB5F>.-_P")L(V!QG:<9HM?
MCOH5[9VD\&FZU,]S;F]2W2Q)E6VX_?LN>$.< ]3S@<4 ]#TBBO/=0^.7AS3H
M+:\:+4IM'G:!?[7BLV-HAF($>7..I91D @$\UG>+OC_I6AZ1XBN--TW4]7ET
MJ"Y998;1C:RS0IN>/S1P,=R?0XR1BDW9-O\ JPTN9I+K^IZG17F:_'K0;2PB
MGO[?4(/*MH+C4I4M2T6GB0 CSF!^4<YXS@<G%;W@GXFZ5\0+K4H])M[YH+">
M2VDO)K?9 \B,594;/S8(JFFFT2FFKG745Y[;_&*P>&6=K.YN(YM0FL--@LD\
MZ>],61*ZKP H8,,D]O>MJ#XDZ!-X+NO%+7AATBT63[0\J%7A:,E71EZAPPQC
MUI=+CZV.HHKCO!WQ2TKQIK=]H]O::E8:G901W,UMJ-J866-\[#U.<X-='KFH
MG1]$U"_5!*;6WDG"$XW;5)QG\*4GRKF>PXKF=D7J*\-U#X\>(_#G@[0?$NL:
M'I1L];LC<VL%C?2/,C&W,ZAPT8&,#!(SBNS^&_QAT[X@QZ; ;.\TO4[S3(M3
M2WNX2BR1L!N:-C]Y0QQD@'H<<U?*TVNJ_P"#_D1=63Z/_@?YG?T445)04444
M <]<_P#(1F_W_P"E2O\ ZO\ "HKG_D(S?[_]*E?_ %?X4 0:1_R%O^ G^5='
M7.:1_P A;_@)_E71T )BJ6KZ5#K&GW%G.@>&>-HV#<\$8J]10!PFC^#[]2T<
M]EI6G+&<1SVEJAD;'\7HI_.NLTW2(=/0@&221OO22R%F;\3V]AQ5^BJ<FR%%
M+43:*"#VI:*DL0=.:6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R=<^_;_4T
M4:Y]^W^IHH 7P[_QYO\ []:M97AW_CS?_?K5H \VA^).OZI_:&IZ7X?M[OPY
M9W=Q9-,]V4N7:%F2201[-NP.C#ELX&<5EZ+^T7I&IZ-H]W<V=SIEU=VL%W-;
MW,3C$<D32;HCCYQE& )QG%7[_P !^'+'Q'+9MXQO])BU.=[P^&H]0@BAGF?.
M^15*>=\S$L45]A;)*\FGW?P"\.WD>F(]UJ0&GZ=#ID6V6/F*-'12WR<MASDC
M SCBDK\OW?D[_C8<OBTVU_-6_"_S*UU^TGX-T^Q-S>RWE@Q$+Q07D ADF256
M:-T#$ J0C=2.E/M/VDO U].4@U&66!;1;R2[6$F&-&C\P;CV.WVQGC.:L:K\
M!]$U*\MKZ+4=4T_4K6TMK.VO+9X2\*P+(JD"2)D)82L&W*1TP!BJ&M?L[>&-
M5ECN-6U76+NR@@56M[R\1TW(A7S?-9/-0XY(5U0GDKG-4[:V$NGI^)L>'?C7
MX?\ &GA?Q!J^@3?;6T:%I)[=V 8'RRZY*EAA@.OUK'T_]H71]0N-%2.WN'2[
MTZ:_NB+:8-!Y:H=J!HQYF2Y&0>WO6MHWAOP]X=T^^\-W?BV?4KS6X2@&HWL
MN&B*; (8T1$  SR$R3RQ8U'XB^&/ACQ=HFB6D^K3I;6UI)IUE-;7,69 X3)!
M*D.P\H'&,=<@BD]]/+];_C8%LK_TM/\ @E#_ (:4\'FVCF0:C+EKA98XK0NU
MOY'E>:9-I(  FC/4]:LW?[0OA.Q6!9C?K<374EJ+4VI\X,B)(Q*YZ;)8V&,D
MAAQUK!T#X.>!8[K688?%MSJEZT=S'?!KVUWPB<0+(2D<:B/_ (]4P, #+<=
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M+^[15VO&(V/*DE9(R!R5(SBO=*IJUB$[A1112*"BBB@ HHHH **** "BBB@
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M3*0P'9.U>H3?!3PI/:K'):W;W"W*W@U ZA<?;1*JE0WVC?YGW25^]T.*JI\
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MRI[T?94]Z -7^U[/_GNM']KV?_/=:ROLJ>]'V5/>@#5_M>S_ .>ZT?VO9_\
M/=:ROLJ>]'V5/>@#5_M>S_Y[K1_:]G_SW6LK[*GO1]E3WH U?[7L_P#GNM']
MKV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z -7^U[/\
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M_P#GNM']KV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z
M-7^U[/\ Y[K1_:]G_P ]UK*^RI[T?94]Z -7^U[/_GNM']KV?_/=:ROLJ>]'
MV5/>@#5_M>S_ .>ZT?VO9_\ /=:ROLJ>]'V5/>@#5_M>S_Y[K1_:]G_SW6LK
M[*GO1]E3WH U?[7L_P#GNM']KV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_
M\]UK*^RI[T?94]Z -7^U[/\ Y[K1_:]G_P ]UK*^RI[T?94]Z -7^U[/_GNM
M']KV?_/=:ROLJ>]'V5/>@#5_M>S_ .>ZT?VO9_\ /=:ROLJ>]'V5/>@#5_M>
MS_Y[K1_:]G_SW6LK[*GO1]E3WH U?[7L_P#GNM']KV?_ #W6LK[*GO1]E3WH
M U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z -7^U[/\ Y[K1_:]G_P ]UK*^RI[T
M?94]Z -7^U[/_GNM']KV?_/=:ROLJ>]'V5/>@#5_M>S_ .>ZT?VO9_\ /=:R
MOLJ>]'V5/>@#5_M>S_Y[K1_:]G_SW6LK[*GO1]E3WH U?[7L_P#GNM']KV?_
M #W6LK[*GO1]E3WH U?[7L_^>ZT?VM:'_ENM97V5/>C[*GO0!K#5;0_\MUIP
DU&V;I*IK)6U0>M31VZ#UH GN)5NI%V\JN>314L,0'%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20240331x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20240331x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '%!#@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH X[Q]\1X?!5QI>GP6$VL:YJKLEEIUNP4OM
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M-?U>\U.]UG2/!%GJ=A;)<RQQM=!K@QRF-& 8L(TX(P=W3I6:?N\[[7^5F_\
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MWC30;RS77]<TBZTZQM?L\<6FZ?Y4MR1@"29V)(8 =$P"2<CI7H]%).W]>O\
MFQ6O_7HOT1Y+XB^$_B"U^(&J>*?".IZ59S:Q!'#?6^K6C3IN0862/:1AL>N1
M[5B^./V==5^(>J6VHZSXI:2\T>QC70I((?)%K?!MSW3JN%8G:BX  "[AWKW2
MH;R\@T^TFNKJ:.WMH4,DLTK!410,EB3P !SFI^%+R_ K=^OX[?Y?U<^6?"/@
M/Q_XF\8_%32!K=E86%]=0V]_-)9.6DS$ [VY)P">1SD5Z'IW[-ME:S^-[26]
M5]#\0:)8Z+#;HA$ENMO'(@<L>"?G4C_=KV&PO[?5+.&[M)DN+:90\<L9RKJ>
MA!]*8^KV$>J1::][;IJ,L331V;2J)GC4@,X3.2H+*"<8&1ZU73D\K?<O^']!
M)Z\R]?Q3_-(\R\+?#WQ]I5G#8W?BC28K6TM6M[>6QTM?.E;;A'E,FX9''"@
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M\JIC,14^*;+M[K6H:E.9KJ]N+B4]7DD+$TW3YY&U"US(Q_>KU8^HJI5C3O\
MD(6O_75?YBM[)(Y;MO4_6OP__P @'3?^O:+_ -!%>2_M3''@[3L<?Z5_2O6O
M#_\ R =-_P"O:+_T 5Y+^U/_ ,B=IW_7U_2OBL+_ +Q'U/T+&?[K/T/ET2..
MC$?C5FTU:]L)/,MKN:!_[T;D&JE%?763/ATVMCLM*^,'C#1R/)UV[D4=$G?S
M%'X-FNXT3]J/Q!9LBZC9VM_'_$RKL?\ #'%>*T5SSP]&?Q11TPQ5>G\,V?67
MAW]I;PQJQ1+Y9]*E;_GH-R#_ ($*]+TGQ#INNPK+I]]!=HPR#$X/Z5\!5;T[
M5KW2)Q-8W4UI*#G="Y4_I7!4RV#^!V/4I9M4CI45_P #] Z*^4O!_P"TMK^B
M&.'5XTUBU& 7/R2@?4<'\OQKWCP7\7O#7CA42TOEM[QO^72ZPDF?0=F_ FO(
MK82K1U:NNZ/;H8VC7TB[/LSM:***XSO"BBB@ HHHH **** "BBB@ HHHH *J
M:MI%EKVF7.G:E:PWUA=1F*>VG0/'(A&"K \$$=JMTR>>.VA>6:18HD4L[N<*
MH'4D]A2=K:C5[Z%/4-!TW5M(DTJ]L;>ZTR1!$]I+&&B9!T4J>,<"N;@^#/@.
MVU6'4XO"&C1ZC"_FQW2V2"1'P!N!QG. !^ K&MOVB? ^IQW8T[4Y[N:*WDN;
M=3I]RB7JH#DVSM&%G'O$7X.>E<)H'[7VFWTG@DW^CWMK;^(8+R1V2SNGFC>
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M78Z1P$[8S&/FRH!^4YKZ)\0^!=#\5ZCIE_JE@+F\TUV>UF$CQM&6^\,J1D'
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M#%)\F]CRQ .,GDXKJM!^#G@[PSJ-E?Z;HR6UU9/*]L_GRL(3("'VJS$ ')X
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M#'::->&_L(A+)B"?.=X^;)//0Y%8/B#]EGX5^*K&.SU7P?:WEM'=3WRQO/,
M)IF#2OPXY8@'T],42][3^MXO]']XHKEL^W^4E^L?N/D[QYXP^)_PR^''@3PS
M-XRUWQ)JNO7,T]]J6CZBC7L0"Y6W2=R57'4_0UL6_P 5OB7KGP]\ ^&/$.N:
MIX'?5]<N=/F\2S31_;#:QHKQ%I5^7>=VTMW*FOIR+]ESX5P^#9/"B^#+$Z \
MWV@V;/(P$G]X,6W _0BM.Z^ 7P]O? 4'@J;PI8/X8@;='I^&"JW]X,#NS[YR
M:=]9-J]VOT_+;SZ@MH]+)_C?7\4_D>)?L9V3:=\1_C);-XA;Q2T>I6ZG5G*E
MI\1MRQ7@GU(KZMKCOA[\(/!WPI%\/"6A6^B+?,K7"V[.1(5&%.&)Q@>E=C3D
M[J*[)+[E8/M-]V%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **BN;F&S
MMY)[B5(((U+O+(P554=22> *^1_CM^V8L#W&A^!&65AE)=8<?+[B(=_]X_D:
MZ*-"IB)<L$<N(Q-/#1YJC/>/BK\>/"OPEM"=4O!/J#*3%I]N0TK_ %_NCW-?
M%'Q9_:G\7?$IY;6"X;1-&;(%I:,5+C_;;J?ITKR+4M4N]9O9;R^N9;NZE.YY
MIG+,Q^IJK7U&'P%*AJ]6?'8K,ZV(]V/NQ%9BQ)8DD]2:2BBO3/'"BBB@ HHH
MH *L:=_R$+7_ *ZK_,57JQIW_(0M?^NJ_P Q2>PUN?K7X?\ ^0#IO_7M%_Z
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MP6LT,.N^%929H=Q4^5)#D!T8J#\V1E>G->VT5<I.>KWNW\VK"24=MK6_%O\
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M.T8&3FNBNM N?"_C;QCX>U_X*ZI\0=;U_6HK_2M<6,16HB^0KYEX/GM]A7.
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M_$S1];\8^*/B5K%AX<U@6NJ^";9+9&T^56:3J8@I7.\=UZCTK&?X*ZCHNM_
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ML[3PCJ^E>$(+(I_:'B?PW;Z5J E# +&'A;$R8!.<#IUKZ[JI)))KJ3%MMI]
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MY+^U/_R)VG?]?7]*]:\/_P#(!TW_ *]HO_0!7DO[4_\ R)VG?]?7]*^)PO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F[
M]L?XSS>"?#2>%]*D:/4]60B:9<@Q0=" ?5NGTS7P:3DU^KGCKX;>'/B1IC6/
MB#3(KV/!"2D;98SZJXY'\O45\9_&']C/7O!_G:CX5=_$&E+\QM\ 7,0^G1Q[
MCGVKZ/+\31A#V;T?YGRF:83$5)^U6L>W8^;Z*?/!);3/%-&\4J$JR.I5E/H0
M>E,KZ ^8"BBB@04444 %%%% !1110 445-9V<^H7,=M:PR7%Q(P5(HE+,Q]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF$_4_=_7% 'T/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFR!%5Y(@SD#&X^IKB/H"CH_PZB%Q]MUF7^T+HG<(C_JT_#O79(BQJ%50JC@
M# %.HH **** "BBB@ HHHH **** "BBB@".>WBNHFBFC62-A@JPR#7)W?@V;
M3)FNM&E*=S:NWRGZ'M7844 <MHOBWS9OLEY#):W2G!208KJ 0PR.E<QX](BM
M-.E4 2?;$7=CG!5LC/X5T5J<P)]* )68(I+$ #J37G_C#XOZ=H.^WL<7]X,C
MY3\BGW-;/Q.=H_ >KLK%6\M>0<'[ZU\ST ;'B+Q;J?BBY,M]<LX_AB!PB_05
MCT44 %%%% !1110 5/87;V%[!<QG$D3AU/N#FH** /KFPO$U"QM[J,YCFC61
M?H1D5/7(?"C4O[1\#Z>2?GA!A/\ P$D#],5U] !1145S.MK;RS,"5C4L0.N
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M:W.F6F?M%P24$7^\& (_+FE*E.-[K1?\,.-:G*R35WTZ]SJJ*Y+P=\6?"/Q
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M7]$>_45Q4/QG\%W'B0:!'KT#:P;@VOV01R;_ #?[OW<?CT]ZC;XW^!5\4?\
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M/Q;\87/CR!'TV_T-(=%DN8]Z,P4^9''Z.6YQUKQ[X;> I/'UE'I]C%)!=+X
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MN&9YWTJU:1G^\6,2Y)]\UTE%).R:]/PO^=Q-7:?:_P"/+^5OQ"BBBI&%%%%
M!1110 4444 %?G_^TI<?:/C-XA;!&UT3GV11_2OT K\^?VBO^2Q^)/\ KN/_
M $$5V87XV>#G'\"/K^C/-Z***]0^0"BBB@ HHHH **** "OTH^&?_)/?#O\
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MD8/H17FFB_'/XHG4O"J26MO=S:AXMU336LH[Q"MS%%%(5B9S;@Q+&54[E!+
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MVO;\_P#(^M**\1^&O[2S>)O$%QH7C7PE=?#?5EM&U"!-4O8I89K8=7\T;0I
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MOAGPWX"OVTB+PIH6IQWPUB&=VNKN**4RPQ& H%C.[;N?>V0O"C/!]E7WTO\
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M+J%XX8E7J0ID(WGV7)KQ_P 6_M'^*9M4UFZ\,Z'+=:&/"4>M6<KRPH8V<O\
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MOB-\.=?TK5-*@T/4A#H#:5/;7%[)$/--U-*KAA&>%$@XQSDCC&:TE\5UY_\
MM]O_ &TQBO=:?:/YPO\ ^W'HG@_X\Z)XVURQTW3[6YW76G2:AYD@ $>QMK1L
M.H8&N(MOVCK[6_&WA::TTB:T\)7EAJ=S>2SRQ!E-M,(V?[V<+M)QWWC'0U'X
M?^!?BSX=:IHNKZ&VF:U?BPN+/4(KR=[9 \K[S)&0KY /&TCD=Q6;HO[.GBFS
MT#PQI]^^FW30V6L:=J1BN'C"I>3^8LL7R'<0 ,H<=>O'(]-5Y_?[UOE\.O\
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MME>>)#.J&:1=21Y+H2R0_9BGS ,6(E#;=H'!ZU,=7&/73_VS_.7];G1OI?\
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M#CS+FY<(B9(49)X&20/QKXWO+_7+7P/X\\=#Q3X@;6=(\2O%8Q'59_LL40E
M,9@W^6ZGT93CMBG?$V%_B!\+OB3XGU_Q/JEGJVG^($TZ#3$U"2.TB@CFA\N(
MVP8(QDSOWLI;D8.!BDM4OD_OY?\ Y)?CY7'I][7W7_R/M*.19HUD1@Z, RL#
MD$'H:=7SK^UO\0/$7P\^ %G=^&WG@N[N2UM)+FUE6*6*-\!BDC A&/0,1QUK
MYJM?B#\3K/X%>,[)]7U[3[6WU'3O[*U6]\1P:CJ$32R$2H]Q;X)7(! 8="1R
M*%JY)=&E^7^8KVBI/JK_ )_Y'Z)ZQK-CX>TNYU+4[N&PL+5#+/<W#A(XT'5F
M)X IVEZG::UIUKJ%A<Q7EC=1K-!<0L&21&&592.H(.<U\(>,H_$OP_G^)GA'
M4/&NN^+M.U'P6^J-_;=P)C#.5Y\O  5?]D "K/PVU+7/@OXA^%%U>>._$&IZ
M#XF\(RW-[8W4B/!8K!;HR&WB";5*J<<@DD9)--6LW_7VK_\ I+'+1)K^O@M_
MZ4?>%%?G_P""?']_9?&/0+GPY\0O$OB+1?$MA>S3V>NZY'=-%M1BI6".-1 0
M1D '-4/ACJGCKP[X)^#'Q%O/B/XFUBXUW6GTJXTB^O?-LS;F64#*D99\KG<Q
M)Z 8 JHQ<K7TU2^;;5OO1,VH)OM=_)*_Y'Z'T5\/V?BJ]\1^,O$?B[7/C3J'
M@K6M&UXV-KX;>026+0!@ CV:@-*7'&X'C->?:E\9OBIKWQWUW4-/N=:6YTSQ
M"=-M]/3Q!:VFF"U1PNQ[&4!Y'9?FWANK#'2HA[[BOYM?3;_Y)?U:]S7(I/MI
M\]?\F?HEKFO:=X9TFYU35KZ#3=.MD,DUU<R!(XU'4LQX JQ8WUOJ=E;WEI,E
MS:W$:RQ31-N61&&58'N""#7YZ?&K7+[X@:9\8-1\2?$O4?#=]HQ-E8^$([I$
MM;B(IG#0D9D+'C<O(]:]]^-.NZCX;_8A@U'2M2NM(OX="TXQWEG,T4L>5B!(
M92".*2?[MS?]W_R:_P#P!)7J*FNM_P +?YGTK17PCX6\7ZSX1\<:;8Z%\4-9
M\?6/B'PS=7VIB]OUN/[/F2'<C1E /)^;C'!JAX?O/%WA7]FGPAXIG^)/B>6[
M\:W-K8ZCJFH7IF32;?,@+P;A^[8C ,C$G(SFK<;7^2^;DX_FM^Q/,M/--_))
M/\GL?>U[?6^FVDMU=SQVUO$I:265@JJ!U))Z55ATO2KN>/4XK.TEGD4.EVL2
MEV!'!#XSTK\^?BDE^/!/Q0\$67Q)U[QOX3TG28=5BU>>_6>5)]X!MY)U'[Q&
M&3M]JK?%GQIXN\/7O@SP3X;\3>)M4T2R\/PZA;:C8>)[>QGNIW9LF:XE4K*B
M$;/+&.%Q4W6_I;[FW_Z2RG>]O)W_ /);?^E(_0^7Q%I<.N0:-)?VZ:K/$TT5
MF9!YKHO5@O4@5HU\.:I\2O'EW+H<NL:I?:9J4G@/5+FX@M+_ #&TZ)\DW[IM
MA<<$,.AZ50^$][XU\&:S\ _$-_\ $+Q'XB_X36W:&_TW4[OS;5$$0="BXSNP
M1EB2Q/>M(P;ER_+\9I?^DDM^[S)?THQ;_P#2C[RHHHK,H**** "OCC]M#2C;
M^.=)O@OR7%D%+?[2LP_EBOL>OG#]M/0S<^%M$U11_P >MPT3GV<#'\C710=J
MB/+S*'/A9>6I\@4445[!\,%%%% !1110 4444 %?I1\,_P#DGOAW_KQA_P#0
M17YKU^E'PS_Y)[X=_P"O&'_T$5P8O9'T63?'/T0[Q]_R+EY_US-)\./^1)TG
M_KB*7QZ"?#MX!_SS-)\.1CP5I(/_ #Q%><?5G2T444 ?-VN?"_5]0^+/C"X7
M0C+%JU[8SVFIN75+<PJ"7X&"<CCW%;\'A#7/"<[:JNE?VV\S7%NUJ48E \Q=
M9 ,=\\U[E10!XS'\+[ZWDE22%;AGT&XM"^PD>9)+OV ^@!*CV H^(GPMU+7Y
ML:2S6*Q6EO(!#\GF2Q2[MI('=>*]FHH \6\!_#O4(ELM1U&.\D>;5%NGM[\E
MVB1+>:-21@8)9_RVUEW_ ()\001:7X>CT6.YAT_48KPZN48M*@?=UQ]_UKWV
MB@#Y^\(^"_$&KZ/HV@W>C'0TL)GNWU$1LKN&\P!!D?>^?GZ#UJ+PK\)M?34'
MMKR:_5+&&:))9I"8I2ZD#:-HX_&OH:B@#QF'2/$GBU;XZKHRV:1:4VGQHRL3
M)*&&6&1]T\8/UJ:]\+:MHES)JMMI0U%+:<.+$H<NIBV$J,=0>:]@HH \>O=!
MUZ2^\-W5KHZ6%[++F9H ?*AC\S>R2#']W./]HU[#110!RWQ!_P"0=IW_ %_1
M_P#H+UT=I_J$^@KG/B""=/T['/\ IT?_ *"U=':_ZA/H* .;^*/_ "(6K_\
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M))&VU?NJY1AO4>C9%;T/PE\)VWBNV\1P:/';ZM;:=_9,,L,CHD=KG(B6,,$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZ_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'P!_P %(_A7K:7>F^.+:ZNKO0B%
MM;JV+EH[63^!PO0!LXSZX'>OA.OW7\3^&M.\8^'M0T35[9+S3;Z%H)X7'#*P
MP?Q]Z_'O]HKX$:G\!?'USH]R'GTN4F33[UEP)HL\9[;AT(H \LHHHH ****
M"BBB@ HHHH **** "BBB@"2VN9K.=)[>5X)D.Y)(V*LI]01TK[#_ &7/VV_&
M.G>)M%\(^)/^*BTZ]G2UBN96Q<09.!S_ !#V-?'%=U\"_P#DL7@__L)0_P#H
M5 '[8UY[\:OB=)\+?"\=_!:"[N9Y/)C#-A5..IKT*O!/VP?^1&TS_K\_]EH
M^9O&GQ#U[Q]?M=:Q?//S\D*G$:>P6N;HHH **** "BBB@ HHHH **** "BBB
M@ HHHH 5':-PR,58'(93@BOMG]FF/Q+)X&%WK]Y+/!.P-E'.,NL8[Y]#VKYV
M^ WPCE^)/B-9[J,KH=DP:X<CB0]HQ_7V^M?<5M;QVEO'!"@CBC4(B*,  =!0
M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM=?E:WYWT-6[\7Z%8:U!H]SK-A;ZM/CRK&6Y19Y,]-J$Y/X"M>O@_P <>.=
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M!+F/EH+A1B:W?'#HW4']#T/%?F#^T+^R3XK^!=]+=")]8\-,Q\G4H$SL'82
M?=/OTH \*HHHH **** "BBB@ HHHH *[KX%_\EB\'_\ 82A_]"KA:[KX%_\
M)8O!_P#V$H?_ $*@#]L:\$_;!_Y$;3/^OS_V6O>Z\$_;!_Y$;3/^OS_V6@#Y
M"HHHH **** "BBB@ HHHH ***.M !78?#7X7ZQ\3=96TTZ(I;(1]HNW'[N)?
M<]S[=:[+X1?LZZMX\EBO]5632]$R#N88DG'HH[#WK[!\->&--\(Z3#INE6J6
MEK$,!4')/J3W/O0!D_#OX;Z1\-M$2PTR+,C &>Y8?/,V.I]O;M75T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(\6\2?LUQ:WXGUC5+7Q3J&E6NL1>7?6<$*-YIQC(<\@>P_.M71/@7'H^H>
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M-K;:-'KFG/JZ\M8+=1F<?5,[OTKYE^'?BC4K+X@-X>\(>,+[QSX=FT^5GGO
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M0?!=/%]_H?VC69[-KRWTFQA>)I<J"B .S')/\6<$<XHULWV_X/\ DPZI=_\
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MGM4>F?M#Z%K.B6.IV6B^([B/4,-90)IC>;=)MW%XQGE0.I)%-73YNO\ G?\
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MTQ;&,(.IKV[P9X[T3X@:,VJ:'=M=6B2O!()89(98I%.&1XY%5T8=U8 U\X^
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MP3\%M,@L]%;5?$FFZ/#%'I*W$<?FW"Q*NSS&;8!NZG., XS7=T4-WBXK2_\
MP7_[<QK=-]/^!_D?/OPT\-Z[XFU2^N/B-\/=:_MC5XO+N[^ZNK!K&UB'(@A6
M*Z>0+GOMR3R<5Z=KGP<\'>(TF74-$CF\ZX^U.R32QLTGEB,G<K X**%*YP0.
M0:[2BAV:M8%==3RWXZ>"[?4/@S?Z-8W=EHT-JD;6YOYQ%;C8P*HSL> <8R:\
M$\=Z+XD^/7Q3U'0;C0#X7O3X(E2.*>\AE9I/M=M(N]X'<+&YB(4Y#$;C@5]A
M:E86>KV,]E?0PW5I,ICE@F4,C@]B#63X1^'OAGP##/%X<T*PT2.<AI5LH%C#
MD=,XZTE\3E+S^]Q:_7S].H[VBE'I;\&G^A\X:A\%]1\0>#]9AL_A9>:'KJZ1
M):17FJ^(Q=/)*P *P+]HD4(?5RA]JU_B?\!_$OCZ\\*V<-L+2U@\%WVCW-V9
MT"P74@MO+0@-N()B<$J", \\BOIFBFW?^O*2_P#;F):6MT_SB_\ VU?B?*EC
M\&-0U#P]+:CX6W>E:U:Z5-;+J>H^(_M*-,R;?]&C\^0;6[F01X':NGUGPI\0
M-&\*?"ZPLM,U*]TG3-+%MK>DZ)?6T%T;@0QK&2\KJC1J1)G:^<E2,BOH2BFW
M>_R_"_\ G^0DK6MTO^-O\CY$\$_!SQWX4M=(O)?"<[O9>)[O4&L8M2@FE-O,
MI"N))) &QGG<0?0&M;X<_#3QU\)-9TWQ0GA67Q!)+97VFW6DVEY;)<P;K^:X
MAE5I)%C9&63Y@'W#C@\X^I P89!!'J*6DFU:W]:<OY#?O73_ *U<OS9\S_"W
MX)^+/"OQ,T'7=3L(%@>TU":\-O.C):S7$A980,@M@'J!CWKLOA;X.U?P/\%/
M%&G:W:?8KR2ZU>[6/S$?,4LLKQME21RK XZCOBO92P! R,GH*9<6\=W!)!,B
MRPR*4='&0RD8((]*B:<H."[-?>[E1=IJ3[W_  L?(OPU\/\ BWXK_"WX;Z:?
M#!TG2M'9=0.KO=0&.Z"9V)$BN7#,<9WJH'J:ZG0OA)XO\.?"OX2S1Z,MUK_@
M^[FN+O1/M$0>9)!*I$<F[R]X#J1E@#SR*^B-'T:P\/:9;Z=IEG#86%NNR*VM
MT")&OH .E7:VE*[;CU=_F91C9)/M;Y?TSY?U/X4^.-:\:3?$S_A'A:ZC#JEM
M>0>&);N'[1+!$A1MTBN8A(0<@;\>K"LK6/AA\0_%OB+Q;XKF\'MI<K:_I6K6
M&E27ML9[N&WA:-U+)(463YOXF XQGO7UK16:]VUNEK>5K/\ ]M7XEOWKM]='
MZ:_YL^3_ !!\)/'WCO6_&7B.3PT-&N+B\TW4-/TZ\O(':?[,P9HG:-V56.,=
M2OO7<?$"+Q]\1=$TJ^/@*?3#H^O6M]#I<VI6KWMQ"J.LC':YA7!<8'FDD YP
M>*]XHIK1)+9-/YJW^2!ZMONFODTU^K/F:V\ >,K?QW9WGASPCJO@>:355N=1
MNH]9M[G2;FVW9D!A+F02,,C"QJ ?XL<U[CX7\71^/-#U6>VL+JR^SW5SI^RZ
M\O,CQ,T992C,"I(..<^H!R*ZBFJBH,*H49S@#%)J\.1[?\-_EMYCO[W/U_X?
M_/?R/F>?X&^([GX+^$["?26GU?0M5.H2Z.E\(6NH]YRBRHX"L5.0=PYQDBDU
M?X/:GJMM:7NA?#^?PW=?VY8W$O\ :.LK=7<D$0DR\F9I$4*7X"R,2#T%?3=%
M5?6_FG\U;_(FVEO)KY._^9\G>)?AO\2?%":=%JGA_5-2U6RUZ&^EU"75K9;-
MH%F5OW$0D#$A1TD4=\9.*NZW\%O%&H6VH13>'I[P:=XMNM<@BCU".!-2MIV<
M[8W64.DBAA]_8,YP2*^I**E:;?U\/_R*_$IN][_U\2_]N?X'S9+\(]2W6?B;
M0O 4FA:EI>JV]^-.O]9%S>:C&@(968R21HP#';^\(SU*UVWPET?Q1)\3/'OB
M77O#C^'+/5OL@LH9KB"65ECB"G?Y3N V??'H37KM%-.W]>G^1+5_Z]7^I\V7
M?PO\8VNK7][;:";J33/%0\0VBFZA6/4(2H5HT)?*2 9(WA5SCFO0_ASX>UZ]
M^(GB?QIK6D-X>34K>WLK73)YHI;@)%N_>2F)G0$EC@!CP!GTKU"BB+Y5;^MD
MOR0Y>\VWU_S;_-A1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBJ>KW<UCI5Y<V\4<T\43/''+((U9@,@%CPH]^U)NR
MNQI7=BY17S9=?M!^(8_$+>&]0FT&XDU/1+R^M[C09)3)9O&A(#LQ(;J,,N.E
M<)X"^/GB'PQ.E[J-[?>(99O#>GK:V-S<L4EO9[OR5=B>A)9<GK@544Y.RZ__
M &WZQL)Z*_\ 6\?_ )*Y]G45\^^*OCSXQ^'&I2Z5XCT;2;F]6&"^6YTXRB!K
M9I/+D&UF+!T..^"#48_:CN;K4O'EA::3 \^ESVUKH3.6VZC),RQC.#T$DB X
M[$T)<VW]6LOS?YB;MO\ U<^AJ*\%^&GQZ\0^.O%B64]MH-E!]JFMI])EFDAU
M&U",0'(<[9,XSA1T(J#]H/4_%3?%/X::%I>M'2=#U"YN)+U;>>>":410/(5+
MQ,IVX4X'KC.1Q2VY6]F/^;NCZ!HKY^TW]H#Q0?#>A>-+O1=/7P7K-RMO;QQO
M(;V%'R(Y9"3M(..0!D9KJO@3\1/%WQ0TZZUO6++2+#1?M%S:VT5IYAG9HI=@
M9BS%<$ \ 9R*I1>J[;_U\Q-I6\_^#_DST#1?">D^';_5;W3K)+6ZU6?[3>2*
MS$S28"[CD\< #C%:]?._A;X\?$+QC\5?&6A:;X8T5O#?AF_EM+C4)[MHI6"K
ME0 3C)[GH*YK0?VL?&5IXSUKP[XJ\/Z!;W*:)>ZOIKZ1>O<(WD(S[)6Z<@?P
M^E9\RY5+I:_R2O\ DBW%\S76]OFW;\V?5M%?*/@3]K#QWJ$G@?5/%G@S3=+\
M)^+"MO:7ME=L\RS$9!9">$/;O5?2?VF/$5AX9:RT#0UUOQ=J_BV]T;3;34+^
M:2$+$N]G=W8E5 !^52 ,\"M.5IM?U>Z5OQ1.ZO\ ULW?_P E9];45\X_LO\
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M:J^FC4;&YTNSDB &_;(KP;W9MO4;3EAV%8EU\8-5U30;)I==T#Q$PU_2K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20240331x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20240331x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %6!#@# 2(  A$! Q$!_\0
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M&1^N![T=;!YE^BBD)P"3T% "T50T;7=/\0V9NM-NX[VW#M&9(CD;AP1^%7Z
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MI72_3_@%/6]NO_!.-_9Q_P"2?3?]A*Y_]#KU*J6DZ+8:#:FVTZTALK<N9#%
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M_6B_4MOWVU_6K_(^>+;Q9JW@WP?XTTE;&Y\*W,(&H:=!*ZL\4;$!@",C /\
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MYKHI^5NHR"",UT#?&BQ:#2)8+":Y%[927TJQOEK=$'((QR<\=J3T6O\ 6_\
MDPZ_UY?YGHU%>=^#OB[_ ,)/8WM_<Z.=.TZVA:?[4M]#< J!G!53N4^Q%9A^
M+]]K,"6L>@7FC-K$,B:-J$\B,L\NPE,J.4SQC-#NM 5F>KT5XGX!TS68/%I<
M17**UR6)>WDB\J#+Y29V4"5B-N"I;G\S[93MI<76P4444AA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>>?%.39/IP]FKT.O /VJ/%E_X530I+
M%D5I2X;>H- &KI\G/%=-8N645\EP_&_Q+!]V2W_[\BKL7[0WBV'[LMM_WX%
M'U[!]VK2]!7R O[2GC%1@2VO_?A:D_X:;\9_\];3_P !UH ^O**^0_\ AIOQ
MG_SUM/\ P'6C_AIOQG_SUM/_  '6@#Z\HKY#_P"&F_&?_/6T_P# =:/^&F_&
M?_/6T_\  =: /KRBOD/_ (:;\9_\];3_ ,!UH_X:;\9_\];3_P !UH ^O**^
M0_\ AIOQG_SUM/\ P'6C_AIOQG_SUM/_  '6@#Z\HKY#_P"&F_&?_/6T_P#
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MKRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\
M/6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?
M_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBO
MD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_
M\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T
M_P# =: /KRMC3/\ CU'U-?%?_#3?C/\ YZVG_@.M6(?VJ/&\";%EL\=>;=:
M/M>BOBO_ (:N\=?\];+_ ,!EH_X:N\=?\];+_P !EH ^U**^*_\ AJ[QU_SU
MLO\ P&6C_AJ[QU_SULO_  &6@#[4HKXK_P"&KO'7_/6R_P# 9:/^&KO'7_/6
MR_\  9: /M2BOBO_ (:N\=?\];+_ ,!EH_X:N\=?\];+_P !EH ^U**^*_\
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MKRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\
M/6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?
M_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBO
MD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_
M\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T
M_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\
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MCE5+' &3@#K1INHV^KV%O>VD@FMIT$D;CNIZ4 6:*** "BBB@ HHHH ****
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M74[76].\66VCV%OICVSVRE9)@V"#&L+<,')Z].]6)_&VES_$&XFDU>&33O\
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MCQ2_\&Z]I5Q;P7NBZA:3W#;88Y[5T:0^B@CD_2FWGA#7=/OH+*ZT:_M[R?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW_OS0!^?U%?H#_PI/P)_T*NF_P#?FC_A2?@3_H5=-_[\T ?G]17Z _\ "D_
MG_0JZ;_WYH_X4GX$_P"A5TW_ +\T ?G]17Z _P#"D_ G_0JZ;_WYH_X4GX$_
MZ%73?^_- 'Y_45]UWOP<\$I<NJ^&=/ '815#_P *?\%?]"UI_P#WZH ^&J*^
MY?\ A3_@K_H6M/\ ^_5'_"G_  5_T+6G_P#?J@#X:HK[E_X4_P""O^A:T_\
M[]4?\*?\%?\ 0M:?_P!^J /AJBON7_A3_@K_ *%K3_\ OU1_PI_P5_T+6G_]
M^J /AJBON7_A3_@K_H6M/_[]4?\ "G_!7_0M:?\ ]^J /AJBON7_ (4_X*_Z
M%K3_ /OU1_PI_P %?]"UI_\ WZH ^&J*^Y?^%/\ @K_H6M/_ ._5'_"G_!7_
M $+6G_\ ?J@#X:HK[E_X4_X*_P"A:T__ +]4?\*?\%?]"UI__?J@#X:HK[E_
MX4_X*_Z%K3_^_5'_  I_P5_T+6G_ /?J@#X:HK[E_P"%/^"O^A:T_P#[]5IZ
M?\%_ TEN&;POIS')Y,5 'P/17Z _\*3\"?\ 0JZ;_P!^:/\ A2?@3_H5=-_[
M\T ?G]17Z _\*3\"?]"KIO\ WYH_X4GX$_Z%73?^_- 'Y_45^@/_  I/P)_T
M*NF_]^:/^%)^!/\ H5=-_P"_- 'Y_45^@/\ PI/P)_T*NF_]^:/^%)^!/^A5
MTW_OS0!^?U%?H#_PI/P)_P!"KIO_ 'YH_P"%)^!/^A5TW_OS0!^?U%?H#_PI
M/P)_T*NF_P#?FC_A2?@3_H5=-_[\T ?G]17Z _\ "D_ G_0JZ;_WYH_X4GX$
M_P"A5TW_ +\T ?G]17Z _P#"D_ G_0JZ;_WYH_X4GX$_Z%73?^_- 'Y_45^@
M/_"D_ G_ $*NF_\ ?FC_ (4GX$_Z%73?^_- 'Y_45^@#_!3P($8CPMIN<?\
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M?^ DO_Q-']K0?\\[K_P$E_\ B:NT4 4O[6@_YYW7_@)+_P#$T?VM!_SSNO\
MP$E_^)J[10!2_M:#_GG=?^ DO_Q-']K0?\\[K_P$E_\ B:NT4 4O[6@_YYW7
M_@)+_P#$T?VM!_SSNO\ P$E_^)J[10!2_M:#_GG=?^ DO_Q-']K0?\\[K_P$
ME_\ B:NT4 4O[6@_YYW7_@)+_P#$T?VM!_SSNO\ P$E_^)J[10!2_M:#_GG=
M?^ DO_Q-']K0?\\[K_P$E_\ B:NT4 4O[6@_YYW7_@)+_P#$T?VM!_SSNO\
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M-']K0?\ /.Z_\!)?_B:NT4 4O[6@_P">=U_X"2__ !-']K0?\\[K_P !)?\
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MBUIO@N]AM'B^U3R%!_K5C7+YV*&;@L=I( ]*ZO0]9@U_38KR!71')4I(,,C
MX*D>H(KQWP#\&+K4_ FCOKD\UCJR!LI.BW#)%O?RE.[.'5'(R.1FO8=#T:#0
M--BLK<NZ(2Q>0Y9V)R6)]232G&,;Q6]SUL!6QF(E[:M'EA))I=K_ (W]4C0H
MHHK$]L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQC]H+5[+3;
MK1UNKN&V+*Y42R!<\CUKV>OAG_@H[D:UX,Q_SPG_ /0EK6E#VDN4\?-\>\LP
M<\4H\W+;3;=V.[TWQ7HHQ_Q-K+_O^O\ C78:5XOT-=H.KV(_[>%_QK\U[7&.
M2<ULVF[UP?2NWZHOYC\QJ<?5Z:O]77_@7_ /TXL_&6@X'_$YL/\ P(3_ !K2
M3QIH P?[:L/_  (3_&OS)A)P!FK&,=3FM5@8_P QP2\2:R_YAE_X$_\ (_3'
M_A-?#_\ T&K#_P "$_QI/^$X\/?]!O3_ /P)3_&OS/Q11]1C_,9_\1*K_P#0
M*O\ P)_Y'Z8?\)QX>_Z#>G_^!*?XT?\ "<>'O^@WI_\ X$I_C7YGT4?45_,/
M_B)5?_H%7_@3_P C],/^$X\/?]!O3_\ P)3_ !H_X3CP]_T&]/\ _ E/\:_,
M^BCZBOY@_P"(E5_^@5?^!/\ R/TP_P"$X\/?]!O3_P#P)3_&C_A./#W_ $&]
M/_\  E/\:_,^BCZBOY@_XB57_P"@5?\ @3_R/TP_X3CP]_T&]/\ _ E/\:/^
M$X\/?]!O3_\ P)3_ !K\SZ*/J*_F#_B)5?\ Z!5_X$_\C],/^$X\/?\ 0;T_
M_P "4_QH_P"$X\/?]!O3_P#P)3_&OS/HH^HK^8/^(E5_^@5?^!/_ "/TP_X3
MCP]_T&]/_P# E/\ &C_A./#W_0;T_P#\"4_QK\SZ*/J*_F#_ (B57_Z!5_X$
M_P#(_3#_ (3CP]_T&]/_ / E/\:/^$X\/?\ 0;T__P "4_QK\SZ*/J*_F#_B
M)5?_ *!5_P"!/_(_3#_A./#W_0;T_P#\"4_QH_X3CP]_T&]/_P# E/\ &OS/
MHH^HK^8/^(E5_P#H%7_@3_R/TP_X3CP]_P!!O3__  )3_&KVE>.O#BR/G7-/
M''>Y3_&OS!HH^HK^8/\ B)5?_H%7_@3_ ,C]4/\ A/?#?_0>T[_P)3_&C_A/
M?#?_ $'M._\  E/\:_*^BCZBOY@_XB57_P"@5?\ @3_R/U0_X3WPW_T'M._\
M"4_QH_X3WPW_ -![3O\ P)3_ !K\KZ*/J*_F#_B)5?\ Z!5_X$_\C]4/^$]\
M-_\ 0>T[_P "4_QH_P"$]\-_]![3O_ E/\:_*^BCZBOY@_XB57_Z!5_X$_\
M(_5#_A/?#?\ T'M._P# E/\ &C_A/?#?_0>T[_P)3_&OROHH^HK^8/\ B)5?
M_H%7_@3_ ,C]4/\ A/?#?_0>T[_P)3_&C_A/?#?_ $'M._\  E/\:_*^BCZB
MOY@_XB57_P"@5?\ @3_R/U0_X3WPW_T'M._\"4_QH_X3WPW_ -![3O\ P)3_
M !K\KZ*/J*_F#_B)5?\ Z!5_X$_\C]4/^$]\-_\ 0>T[_P "4_QH_P"$]\-_
M]![3O_ E/\:_*^BCZBOY@_XB57_Z!5_X$_\ (_5#_A/?#?\ T'M._P# E/\
M&C_A/?#?_0>T[_P)3_&OROHH^HK^8/\ B)5?_H%7_@3_ ,C]4/\ A/?#?_0>
MT[_P)3_&C_A/?#?_ $'M._\  E/\:_*^BCZBOY@_XB57_P"@5?\ @3_R/U0_
MX3WPW_T'M._\"4_QH_X3WPW_ -![3O\ P)3_ !K\KZ*/J*_F#_B)5?\ Z!5_
MX$_\C]-[[QSX=:Z<C7-/(_Z^4_QJ#_A./#W_ $&]/_\  E/\:_,^BCZBOY@_
MXB57_P"@5?\ @3_R/TP_X3CP]_T&]/\ _ E/\:/^$X\/?]!O3_\ P)3_ !K\
MSZ*/J*_F#_B)5?\ Z!5_X$_\C],/^$X\/?\ 0;T__P "4_QH_P"$X\/?]!O3
M_P#P)3_&OS/HH^HK^8/^(E5_^@5?^!/_ "/TP_X3CP]_T&]/_P# E/\ &C_A
M./#W_0;T_P#\"4_QK\SZ*/J*_F#_ (B57_Z!5_X$_P#(_3#_ (3CP]_T&]/_
M / E/\:/^$X\/?\ 0;T__P "4_QK\SZ*/J*_F#_B)5?_ *!5_P"!/_(_3#_A
M./#W_0;T_P#\"4_QH_X3CP]_T&]/_P# E/\ &OS/HH^HK^8/^(E5_P#H%7_@
M3_R/TP_X3CP]_P!!O3__  )3_&C_ (3CP]_T&]/_ / E/\:_,^BCZBOY@_XB
M57_Z!5_X$_\ (_3#_A./#W_0;T__ ,"4_P :/^$X\/?]!O3_ /P)3_&OS/HH
M^HK^8/\ B)5?_H%7_@3_ ,C],/\ A./#W_0;T_\ \"4_QH_X3CP]_P!!O3__
M  )3_&OS/HH^HK^8/^(E5_\ H%7_ ($_\C],/^$X\/?]!O3_ /P)3_&M;3?'
MGAQ;8 Z[IP.3UN4_QK\N:*/J*_F#_B)5?_H%7_@3_P C]4/^$]\-_P#0>T[_
M ,"4_P :/^$]\-_]![3O_ E/\:_*^BCZBOY@_P"(E5_^@5?^!/\ R/U0_P"$
M]\-_]![3O_ E/\:/^$]\-_\ 0>T[_P "4_QK\KZ*/J*_F#_B)5?_ *!5_P"!
M/_(_5#_A/?#?_0>T[_P)3_&C_A/?#?\ T'M._P# E/\ &OROHH^HK^8/^(E5
M_P#H%7_@3_R/U0_X3WPW_P!![3O_  )3_&C_ (3WPW_T'M._\"4_QK\KZ*/J
M*_F#_B)5?_H%7_@3_P C]4/^$]\-_P#0>T[_ ,"4_P :/^$]\-_]![3O_ E/
M\:_*^BCZBOY@_P"(E5_^@5?^!/\ R/U0_P"$]\-_]![3O_ E/\:/^$]\-_\
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MEC#;HRQ/).U@,^U>B5A)6?\ 774][#5UB:2J15M_DT[-?)IH****DZ0HHHH
M**** "OAK_@HY_R&O!G_ %PG_P#0EK[EKX:_X*.?\AKP9_UPG_\ 0EKIP_\
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M%4OS[URW@;QW)X-^(-CXIEMCJ,MM.\[0&7R_,+!@?FP<?>]#32J.3UTM^/\
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MHX %4*ZX<W*N;<^%Q'LO;3]A\%W;TOIV"BBBK.<**** "BBB@ HHHH ****
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M7Z%44?7:G9!_Q#O*/YY_>O\ Y$_/7_ADCXE?] >#_P "D_QH_P"&2/B5_P!
M>#_P*3_&OT*HH^NU.R#_ (AWE'\\_O7_ ,B?GK_PR1\2O^@/!_X%)_C1_P ,
MD?$K_H#P?^!2?XU^A5%'UVIV0?\ $.\H_GG]Z_\ D3\]?^&2/B5_T!X/_ I/
M\:/^&2/B5_T!X/\ P*3_ !K]"J*/KM3L@_XAWE'\\_O7_P B?GK_ ,,D?$K_
M * \'_@4G^-'_#)'Q*_Z \'_ (%)_C7Z%44?7:G9!_Q#O*/YY_>O_D3\]?\
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MR1\2O^@/!_X%)_C1_P ,D?$K_H#P?^!2?XU^A5%'UVIV0?\ $.\H_GG]Z_\
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MKXA_] J'_P "4_QH_P"&6OB'_P! J'_P)3_&OO"BCZ[4[(/^(=Y1_//[U_\
M(GP?_P ,M?$/_H%0_P#@2G^-'_#+7Q#_ .@5#_X$I_C7WA11]=J=D'_$.\H_
MGG]Z_P#D3X/_ .&6OB'_ - J'_P)3_&C_AEKXA_] J'_ ,"4_P :^\**/KM3
ML@_XAWE'\\_O7_R)\'_\,M?$/_H%0_\ @2G^-'_#+7Q#_P"@5#_X$I_C7WA1
M1]=J=D'_ !#O*/YY_>O_ )$^#_\ AEKXA_\ 0*A_\"4_QH_X9:^(?_0*A_\
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MJ[10!2^QW/\ S_R_]^T_PH^QW/\ S_R_]^T_PJ[10!2^QW/_ #_R_P#?M/\
M"C['<_\ /_+_ -^T_P *NT4 4OL=S_S_ ,O_ '[3_"C['<_\_P#+_P!^T_PJ
M[10!2^QW/_/_ "_]^T_PH^QW/_/_ "_]^T_PJ[10!2^QW/\ S_R_]^T_PH^Q
MW/\ S_R_]^T_PJ[10!2^QW/_ #_R_P#?M/\ "C['<_\ /_+_ -^T_P *NT4
M4OL=S_S_ ,O_ '[3_"C['<_\_P#+_P!^T_PJ[10!2^QW/_/_ "_]^T_PKS/X
MPVTJRZ8'N7E)W8+*HQ^0KUFO,OC"NZXTSZ-0!PFG0L"O[P_D*Z[2H&^7]Z?R
M%<[IRC<.:ZO35  .: ->WB;_ )ZG\A5](FR/WA_(57MN5J\H [T ,\IO^>K?
MD*9]GF_Y^G_[Y7_"K&:* *_V>;_GZ?\ [Y7_  H^SS?\_3_]\K_A5BB@"O\
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M7^SS?\_3_P#?*_X4?9YO^?I_^^5_PJQ10!7^SS?\_3_]\K_A1]GF_P"?I_\
MOE?\*L44 5_L\W_/T_\ WRO^%'V>;_GZ?_OE?\*L44 5_L\W_/T__?*_X5JZ
M=:7#6P(OI%&3P$3_  JE6QIG_'J/J: &_8[G_G_E_P"_:?X4?8[G_G_E_P"_
M:?X5=HH I?8[G_G_ )?^_:?X4?8[G_G_ )?^_:?X5=HH I?8[G_G_E_[]I_A
M1]CN?^?^7_OVG^%7:* *7V.Y_P"?^7_OVG^%'V.Y_P"?^7_OVG^%7:* *7V.
MY_Y_Y?\ OVG^%'V.Y_Y_Y?\ OVG^%7:* *7V.Y_Y_P"7_OVG^%'V.Y_Y_P"7
M_OVG^%7:* *7V.Y_Y_Y?^_:?X4?8[G_G_E_[]I_A5VB@"E]CN?\ G_E_[]I_
MA1]CN?\ G_E_[]I_A5VB@"E]CN?^?^7_ +]I_A1]CN?^?^7_ +]I_A5VB@"C
M)9W.QO\ 3Y>A_P"6:?X5A?9YO^?I_P#OE?\ "NID_P!6WT-<]0!7^SS?\_3_
M /?*_P"%'V>;_GZ?_OE?\*L44 5_L\W_ #]/_P!\K_A1]GF_Y^G_ .^5_P *
ML44 5_L\W_/T_P#WRO\ A1]GF_Y^G_[Y7_"K%% %?[/-_P _3_\ ?*_X4?9Y
MO^?I_P#OE?\ "K%% %?[/-_S]/\ ]\K_ (4?9YO^?I_^^5_PJQ10!7^SS?\
M/T__ 'RO^%'V>;_GZ?\ [Y7_  JQ10!7^SS?\_3_ /?*_P"%'V>;_GZ?_OE?
M\*L44 5_L\W_ #]/_P!\K_A1]GF_Y^G_ .^5_P *L44 5_L\W_/T_P#WRO\
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MYZ9ZUS]"I4GL@EC<7'XIM'NG_#7/BC_H&Z;_ -\O_C1_PUSXH_Z!NF_]\O\
MXUX713]C3[$_7\3_ #L]T_X:Y\4?] W3?^^7_P :/^&N?%'_ $#=-_[Y?_&O
M"Z*/8T^P?7\3_.SW3_AKGQ1_T#=-_P"^7_QIC_M;^*F'RV&FJ?='/_LU>'44
M>QI]@^OXG^=GMW_#6OB[_GSTS_OT_P#\52_\-;>+O^?+2_\ OT__ ,57B%%/
MV4.POKV)_G9[?_PUMXN_Y\M,_P"_3_\ Q5(?VMO%W_/EI@_[9/\ _%5XC11[
M*GV#Z]B?YV>W?\-:^+O^?/3/^_3_ /Q536_[7_C"V+%;'2\GUB?_ .*KPNBC
MV5/L'U[$_P [/>_^&RO&?_/CI7_?I_\ XJC_ (;*\9_\^.E?]^G_ /BJ\$HI
M>QI]@^O8G^=GOG_#9?C/_GQTK_OT_P#\51_PV7XS_P"?'2O^_3__ !5>!T4>
MQI]@^O8G^=GOG_#9?C/_ )\=*_[]/_\ %4?\-E^,_P#GQTK_ +]/_P#%5X'1
M1[&GV#Z]B?YV>]_\-E>,_P#GQTK_ +]/_P#%5T/@K]K3Q)KFIO:WUEIXRF8_
M*1EY'7N:^8ZNZ+?G2]4MKH''EN"?IWI.C3:V+AC\0I)N;/LC_A?NL'_EQM?R
M;_&E_P"%]ZS_ ,^-K^3?XUY;#*)8TD0Y5@"#7.>/?%=WX6T_3Y+."&>XO+^&
MR43DA%\PXW''/%<KA!=#UXXBM)V4CW7_ (7WK/\ SXVOY-_C3A\>M7_Y\K7\
MF_QKQ.UG\11+-)>C2C&L;,HA:13NQQDMP!5FSU^W33;>74KNRM+AHE>15N%*
M#/H2>1[T>S@/ZQ6Z2/9/^%\:P/\ ERM3^!_QH_X7OK'_ #YVOY'_ !KRF?5;
M2UM5N9KN"*V.,3/(%0^G).*Q?$_C)-'TW3;RQ,-_%=ZA!9[TDRH$CA2P(ZD4
M>SAM_6HEB*[V9[B/CMJY_P"7.U_(_P"-.'QUUC_GRM?U_P :\MN+F*TB,L\J
M0QKU>1@H'XFJ[Z]IT=N;A]0M4MPVPRF90H;TSG&?:G[.!2Q-;N>MCXZ:N3_Q
MYVP_/_&E_P"%XZN?^72W_7_&O*9-8L8+1;J2\@CM3TG>50A_X%G%/BU:TDAA
MF2[@>&9@D;K(I5V/0*<\GV%3[.(+$U7U/4_^%X:O_P ^EO\ D?\ &E'QNU?_
M )]+;]:\7\8^*U\-Z!J5[!Y-Q=6<8D-NS\X)P,@<@4:+X[TO6=3NM-BN4^W6
MD:23QDC W#/!SSCOZ4E"&Q?MJUKW/6Y_C'J<TK,;:W!/IF@?%O4O^?>W_(UY
MK9ZO8ZG))]CO;>[*?>\B57V_7!XKG?%GBO4]+\4Z!HFF06DDNII<.9;MF"IY
M2J>B]<[J.2*!5JS=E(]L_P"%MZE_S[V_Y&G+\6=1/_+O;_D:\'NO'6HZ)<ZE
M8ZG:VK7UO8/?PO:LWE2*IP5.>0<D5T7ASQ/:Z]IUG*MQ;_;);=)I+:.4,R;E
M!QCKWHY(O^OZ[,'5K+=_UI_F>L#XK:D?^7>#\C3E^*NH=[>#/XUX]\/O%TOB
M_0/[0F@2W?[1+#LC)(PCE0>?I5ZU\1_;O%-YI5O&&BL84>YF/\,C\H@_X""3
M]5]:?LX@ZM5-IRV/5/\ A:FH?\^\'ZTX?%+4/^?>#]:\YMM<T^[EEC@O[6:2
M+_6)',K%/J >*E75;-DAD6[@*3G$3"08D/HO//X5/+$/;U%NST+_ (6CJ'_/
MO /SI?\ A9VH_P#/O!^M><P^(--FN4MTU&T>=\[8EG4LWT&<FIKO6K#3YHX;
MJ^MK:63[D<TJHS?0$\T<L"E6J=ST%?B=J'>W@_6G#XF:@>EO!^M<!>ZO8:8L
M;7EY;V@<X4SRJ@8^V3S6=-XXT>V\46WA]KM!J-S"9XTW#!4>^>I["CEAL/VM
M5ZW/4?\ A9>H?\^\/ZTJ_$K4#_R[P?K7 )K>GO?&R%_;->#K;B9?,'_ <YK$
M\>^.[;P9X<U2\CFM9M0M+=ITLI)@KOCVZXI.,$KL<:E63Y4SUP?$F_\ ^>$/
MZT?\+)OO^>$/ZUYY)K8MO#IU22%Y"+<3F*(;F/RYP!WKF;/QMJUOJ6B1ZS86
MUM;ZP2MNL+L986V[@) >.GITIN,4["56HUS*1[6OQ'OB/]1#^M/'Q$OC_P L
M(1^=>-67BK6O$YGGT"TLO[-AE:%;B^=@9RIP2@7H,@C)IA^(=]=:7"]AI@?4
MH=4CTV^LI6.8<D;F! Y&TA@>A!I))]/Z_IE\]7^8]I'Q"OC_ ,L8?UJW:_$[
M4(H]H@AQGWKP74OB)K%E9:GK*:7#'H>GSM"XN69+B4*0&=!TQGIGKBM'XA_$
MR'P+X8348;8WUW.%:&V'&5.,LWH #1:-KV+YZM[7/<!\4M0[P0?K3O\ A:&H
M?\\(?R->2/XK:UUS1[*ZB6.#5("T$P)_URC<R'ZJ<CZ&NE#^M/D78GVU3N=M
M_P +0U#_ )X0?D:<OQ.U$_\ +"#]:XD$'I3E./I4\B["]M4[G;#XFZA_SPA_
M(TX?$O4/^>$&/QKB@PSP33L\T<D6'MJG<[4?$F_/_+&$?@:/^%D7_P#SQA_(
MUQH?C'ZTX.,4^1=1JM4[G8K\1[\G_40_K3O^%BWW_/"']:X\&G9%+D0U5J=S
MKQ\1;\_\L(?UIW_"P[[_ )XP_K7'AMM.#^M+D17M9]SL5^(%Z1S#%G\:7_A/
MKW_GC#^M<@KY(-2K("<4<J#VT^YU:^/;TG'DP_K3_P#A.[S_ )XP_K7*J1G@
MTH?GGI2Y4"JS?4ZL>.;P]88L>V:7_A.+O_GC%^M<JK9/%2!AZFCE1:JS[G3'
MQK=LI'EQ<CWJE_PD$V>56LG=0#ZT<J'[6?<V1KTI_A6G#793U516.K8IX<?C
M19![6?<U_P"VY?[JTHUF7/*K65NR.:>IP/:G9#YYFI_;,A_@%/&JN?X5K+5^
M>*>LA!YI612J2-+^TY/[JT_^T9/[JUG!\TX.:=D-5)%_^T']!3A?-W JB'%/
MW$TK+L5S2+R7A8=!4@N&R,@5G ^E2QS8P#S0XH:D^Y>\_P!J!-GM5=7#&G@X
MZ5/*/F+ <$>E.J -Q3PYQ2L',^Y*,=Z7:*CWBGYHL%V2>4O]ZE6 $]3BF!]M
M2))S18I2);5 E[$![_RHI;8YO8OQ_E16;W-H[&M7-_$3PD?''@_4-&6?[-)<
M(/+E(R%8'(R/2NDHI#:4DT^IY#H_@;QOK?B7P_>>*9-)M[+0E?[.NG,[/.Q3
M8"^X8''I5-_@]K9^!6J^$%:S&K75P\J-YA\K!G$@RVW/W1Z5[516KJ-_UYW.
M:.&@N[_X:WY'CES\.O&6@>(M5NO#<VD/::W%;B\;459WMGC0(2BX(<8YP>*S
M/'WPF\<^*KO5+4:CIU[I5S#$(&N6=&@9 ,A44;1DC.>WI7NU%'M'=/\ K^D2
M\)3<7&[L_/[_ +^IX3XD^$GBV_UBVETF+1](;;$)-6M;B>.Y4J "2@^5SQWQ
M6;XM_9SU75O&FH7T1LM4T[4Y$DN&O+N>%XCCYL)&0'YY&<5]$44U5DFFB98.
ME)-/K;\/^'/,_CAH$DWPS M4:0Z5+;W(0<DI$P+?7Y0:JM\*M/\ &OQ$N?%&
MKV%AJVAWFFPK:K.-[!\YW8Q@#!]:]5(# @C(/8T !0 !@#L*E3:7WO[U9_D:
M2P\)RN]K)6]&VOS9YKX]^$UOXKUCPA&EA8OH&E22&YLI1A2A3"A5 P><>E9F
MD_#CQ-\/(/$^G>$%T[^S;Z/S-.:YD*26LQX8'"G<H!)'/48KUZBESNW+T&\/
M!RYUH_\ )6/&/"OP1U#X?ZUI5WHUZ+J*ZMVM]?2XF93<LV29D.#\P)/IQWKN
M-!^&VF>#]#U6QT;[3F^C8'[7=/-\VT@<L3@<]JZ^BB4Y333Z_P!?\,.GAZ=*
MW*MO^&_'KW/,],^'>JVGP1G\)NUO_:CV<D 8.?*W,3CG&<?A2:OX-\6V.A^$
M9?#]Y9C5-%A$,]E>$_9KC*!3E@,C&,@UZ;13<VVWW_X/^8OJ\+)=E;\O\CY_
M;X=SZ!_PAGAR>=+G5K[7Y-<O3 O[N,*"S[?11E0/7-?0%(54L&P-PZ''-+2E
M-R5G_7])(=*BJ3;7];_JVPHHHJ#H"BBB@ HHHH **** "BBB@ KXX_;W&=6\
M)_\ 7";_ -"%?8]?'7[>BDZMX4X_Y83?^A"NBA_$1YN8Z8:7R_,^?_AH\,.K
MSLVLR:#>&!A;70_U9?(^23@G:1Q7J5CXCT'39O#$_B632M2U6WUA)9IM-A##
M[&%(/FD !COP0.3A37A,*^@.*OPKQR#7H.">I\A"NZ:LD>U^+O&EOI<>E3V]
MSI5S=V^K-=H+-YIW\K!R6=SA5;CY /RK:/C'PCI/CK3+.SF@ET1;:XF$TBGR
MTNI\D;L<C9PN1TKP)5/'!IP0]E_(57LDT4L5).]ET_KYGT%X>\6Z/9>.? SZ
ME=Z3'%9W%Q)<26\DLXC1HV"AY7)SD]% XS1H_BZ'6?"NNVL%U:7NM_VX;AEO
MM2:T\VVQA"D@=00K<[<^^*^?]A]#^5.V-_=/Y4O8I:W_ *NG^A2QDK<MOZMR
MGIWB3QE9V7QO@U[=9WD%K<0/-)8(PBD*A0Q7<23TZYY(SWK<T'PO:CXC37\^
MH>&K[PS?71N'N=0GA=A&S%MOEL=ZMS@\?C7BNQO[I_*C8W]T_E5*%DDGMH9.
MO>3<EN[GT*][;37'AI?#.M:=I6FZ7J,IOX3>) -OFYWX)'F*4X&W/I3[J]T?
MQ=>^$+G2-1TZTL-*\17=Q<+=7*0&*%ITD1@K$$@@=@>?2OG?8W]T_E1L;^Z?
MRJ8T^5IWV-I8QR37+H_Z5NWGW/:?C7K5OKWABW^PZG;W26FL:AY\27*EMKS9
MC8+G+*1T(R*\4IVQO[I_*C8W]T_E54X*G'E1SXBL\1/G:L-HIVQO[I_*C8W]
MT_E6IS#:*=L;^Z?RHV-_=/Y4 -HIVQO[I_*D*D=C0 E%+BC% "44N*,4 )12
MXHQ0 E%+BC% "44N*,4 )12XHQ0 E/AB:>9(T&6=@H'N:;BNC\ Z9]OU^-W7
M,< \P_7M2;LKE1CS22/5=,MS96%O 6)\M I)Z]*Y'XN:4^M:3H=NEK)>1G6;
M1IDC0MB/<=Q..@QU-=KD>_Y4X$XXSCZ5Q-7M?NG]SN>["3@[I'/7?A73M&T3
M5?[,L%@FEMG0B($EN#@5QG@3PXTNO::^HZ8YCBT**/-Q =JONY7D8S[5ZL#Q
MSFER/>ERZW_KK_F6JDE%JV__  /\CQ[3X]0L_#NA6UW8306J7%UOO'L6N9+8
M;OD"Q;3P1W*D<51L]*U-H]2B$%]<VX\46,\+R69BW1_)N<(% "C'. ,=Z]P#
M'WI^[Z_E24;-/T_!I_H7[5NZY=[_ *_YG)?%BSFU'P+?V\$$ES(YCQ%$A9B-
MXSP*P/&.A36WB?2[H&>TT:.T:/-G8K<B.4D<M'M8\CN!7IF[W/Y4H;'<_E0X
M]11G**2MW_&W^1XY%X<^SZ-;SSR:S;*+^:XMIFLEG1 1C+VZI\JMU VD@^E3
M^1J<^@Z==RZ7Y=MI_B**\+VMH\3SP!2&F\CE@<MC&,X&<5ZZKYX.<_2G4TK.
MZ\OPM_D6ZC>Z[_C?_,\8\117>O7_ (\N[33KXP7&G6T<#26KH9B&;.T$9/7I
MC/M5^/0TBU[Q7%>Z??+'?V$'ER65N2[ +AMK8V[@>Q.3[UZR&('>GJV1WS]*
ME0M_7K_F/VLNW]:?Y'F/@3[5#XH6.&'[;8K:%6U";3&LIHR"-J'(4/GGD#MU
MJSXYT.?6OB1X,(^VQ6L45[YMS9LT9C)1-H+KTSC\:]"8C>:3(JK;7Z?\$7.^
M9R2.1USPA::=X:UV2T2YO=0N+-XC-/(T\SC!PH)R<9[5A6^@/IH^'C6>GO;O
M&-MTT4)!4&+D2'''/KWKTU<CI3\_7\J.77[OPO\ YB]I*UK=_P 58XOX.65S
MI_@WRKJ"6VE^V7#;)D*-@RL0<'UK%M;+4KJS^*.GV3F/6IKQWA?."5>WC\K'
MIP",^H->G[L>OY5031K=-=;58R\=S) +>4+C;*H.5+<9RN6QS_$>M)QOIY6_
M+_(I5'S.5NM_Q/+] TK?JGA]XWU9VL07N8WTU+985"89&81CS<],*3GKFG^#
M],N=/\80:I=Z3=1Z%=R2C3+9HW8V#$\LZ8^0/S]*]>S]?RIZR #'.?I0X]2N
M=M6/#=!>+6/APVE6&GW#>(6OG-K<BT;;&1<9\SSL;0  >,Y[8K1U71+VVU_Q
M5_:T^HE[Z8-9BVTQ+I)XO*5517*-Y9!!!R5'?UKU'PMX=M?"FD+86LDLD0=Y
M-TQ!;+,6/0#N:V0_H:R<;K^O+_(T]HU)M;7N>2:3I;^&=3C?Q-87VI6C:3!;
MVK/"UXT<BYWQML4X8Y7YL ''6FV>ARV7C+P[>+I-SI\3Z7<6\)E1KEH)2V4#
MN =O'KP.F:]@5LCUIX--J[OZ_C?_ #$JEOZ]/\CP32?#-Z^FZ7IDTNL?VY%=
MQO+$FGQQA"'RTGVKRR"N.VXD@XJ?Q+920^!/&FDW^CWM]XFN;FYEBEBL7E\Z
M-GS$RR!=H 3:-N<C'2O=@WH:<K\<FDXW37?_ ('^12JNZ=O/\_\ ,R9-2.@>
M#TO&MI[E[6S5_LT,9:1R$'RA0,YKC/ VM0>([^'4=<2]_MRX!6"V?3;E(K)#
M_ ':,+N]6)YKTK>/6G!L]^*M^])MF,6HQY3S31-8O/AIX4NM%FTVZN;^T,OV
M!X[:26&[!)*9:-6V'D [L5:^#%U<:L/%.LWUI+IFI7^I;Y].E5MUL$B1%4D@
M!B5 ;(X^85Z&&QWIR'DGUZ\4+1W?:WY?Y%N=U:W6YY2OB^+Q9XDO$U^TU*RT
M6QN#%;6!TJY?[4ZG_6NRQD%<_=&?<TGQ,\(^)+K0_$NHVMQ97\=W D<%M]BE
M:XCB#*=B8?&<\GY:]9W#UJ17PO!YJ.72QJJEG=(\X\917\MO\.+69HCJHU:&
M1O(0H B1.9, DD#;P>>]>J9%8KZ);3Z]#JTCO)<00F&%&QLC#'+,!C.3@ G/
M0"M5)0W7BK77S=_R7Z$/HNRM^;_4F!(IZMZU$&]32CD4Q$P-.5L'GI4*G;[B
MGA@?KZ4@)@^>!3@:@!Q4@<8Y- MB7<3WJ0,#TJL6ST-/$@'0T&BU1/DTN142
M2 ]33PPI#) 2*>C<=>:B#4N['<"@"PK@<]ZD5L\GI596)/)&*>'XZBIL+8M#
MU%"OZU")" .<TX,#W%(M7+&X^M"N3WJ+>?6FAN>M(HM"0=J>&]>*K[@#UJ17
MXYYH F#G/7BGAP3Q4 8#N*<'&>#S04KLL!L=Z>K\\FH!( /4TX./6@LL!_0U
M('%5E//!J0,/6@"P#3MQS5?<<C-/\S!Q04F60V1Q3@V/K4(?' -/5N.>M!9,
MK<YS4B2Y..U5@WI3@>*:&7@W'6G!S5))"#ZU820-19 3[Q4BMZU7SFI ?6LV
MK#NB8'-/#8J $CI3U;/4\TAERQ;=>1_C_*BFZ=_Q^1_C_*BLWN=,=D;=%07%
MS]GV_NI9<_\ /-<X^M0_VE_TZW/_ '[I%%VBJ7]I?].MS_W[H_M+_IUN?^_=
M %VBJ7]I?].MS_W[H_M+_IUN?^_= %VBJ7]I?].MS_W[H_M+_IUN?^_= %VB
MJ7]I?].MS_W[H_M+_IUN?^_= %VBJ7]I?].MS_W[H_M+_IUN?^_= %VBJ7]I
M?].MS_W[H_M+_IUN?^_= %VBJ7]I?].MS_W[H_M+_IUN?^_= %VBJ7]I?].M
MS_W[H_M+_IUN?^_= %VBJ7]I?].MS_W[H_M+_IUN?^_= %VBJ7]I?].MS_W[
MH_M+_IUN?^_= %VBJ7]I?].MS_W[H_M+_IUN?^_= %VBJ7]I?].MS_W[H_M+
M_IUN?^_= %VBJ7]I?].MS_W[H_M+_IUN?^_= %VN%^).A:?J\MDU[8VUXR!@
MIN(5?:/;(XKK?[2_Z=;G_OW7.>+KI9VM\Q31X!^^F,T":3T9Q=OX*T#</^)'
MIW_@)'_A6M!X)T _\P+3?_ 2/_"K%O(JC&UO^^:T()U'&UORIW9/)#LBI'X*
M\/''_$ATS_P#C_\ B:D'@KP\/^8#IG_@''_A6BEPN1\K?]\U)]I7^Z_Y47?<
M7LX=D9?_  A7A[_H Z9_X!Q__$U:&@:6!_R#;3_OPO\ A5K[2O\ =?\ *F?;
M/^F$W_?%*[&H16R(/[ TS_H'6G_?A?\ "C^P-,_Z!UI_WX7_  J?[9_TPF_[
MXH^V?],)O^^*=V/E78@_L#3/^@=:?]^%_P */[ TS_H'6G_?A?\ "I_MG_3"
M;_OBC[9_TPF_[XHNPY5V(/[ TS_H'6G_ 'X7_"C^P-,_Z!UI_P!^%_PJ?[9_
MTPF_[XH^V?\ 3";_ +XHNPY5V(/[ TS_ *!UI_WX7_"C^P-,_P"@=:?]^%_P
MJ?[9_P!,)O\ OBC[9_TPF_[XHNPY5V(/[ TS_H'6G_?A?\*/[ TS_H'6G_?A
M?\*G^V?],)O^^*/MG_3";_OBB[#E78@_L#3/^@=:?]^%_P *CN/"^C72;)](
ML9D_NR6R,/U%6_MG_3";_OBC[9_TPF_[XHNPY8]C+_X03PU_T+VE?^ 47_Q-
M'_"">&O^A>TK_P  HO\ XFM3[9_TPF_[XH^V?],)O^^*+ON+DAV1E_\ "">&
MO^A>TK_P"B_^)H_X07PU_P!"]I7_ (!1?_$UJ?;/^F$W_?%'VS_IA-_WQ1=]
MPY(=D9?_  @OAK_H7M*_\ HO_B:O:5X"\,O(X;P[I+#'>QB_^)J;[9_TPF_[
MXJ[I=_LD?_1[@\=HZ+ON')#L-_X5]X6_Z%K2/_ "+_XFE_X5_P"%_P#H6](_
M\ (O_B:TO[2_Z=;G_OW1_:7_ $ZW/_?NB[[AR0[(S?\ A7_A?_H6](_\ (O_
M (FC_A7_ (7_ .A;TC_P B_^)K2_M+_IUN?^_=']I?\ 3K<_]^Z+ON')#L9O
M_"O_  O_ -"WI'_@#%_\31_PK_PO_P!"WI'_ ( Q?_$UI?VE_P!.MS_W[H_M
M+_IUN?\ OW1=]PY(]C-_X0#PO_T+>D?^ ,7_ ,33X_ WAN$GR_#^EIGKMLHQ
M_P"RU?\ [2_Z=;G_ +]T?VE_TZW/_?NB[[AR1[%3_A#M _Z >F_^ D?^%+_P
MA^@_] 33O_ 2/_"K7]I?].MS_P!^Z/[2_P"G6Y_[]T78^6/8J_\ "'Z#_P!
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MM+_IUN?^_=']I?\ 3K<_]^Z+L.5=AO\ 8&F?] VT_P"_"_X4?V!IG_0.M/\
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M *!-Y_WVM,E_:8TQ5'EZ/=.V>C2JO]#1]3Q'\H?7\-_/^9[-17BG_#3=E_T
MI_\ P('_ ,36YH7QQM]>MWEBTIXRC;2K3C(_\=H>"KK>/Y"6/PTG93_!_P"1
MZ?17!_\ "TU_Z!I_[_\ _P!C3E^**M_S#3_W_P#_ +&I^J5OY?R-/KE#^;\&
M=U5_2/\ 6R?2O-_^%GK_ - X_P#?[_[&K%G\65M68_V66R,?Z_'_ ++1]4K?
MR_D'URA_-^#/5**\U_X7,G_0(/\ X$?_ &-._P"%QK_T"3_X$?\ V-'U2M_+
M^0?7*'\WX,](HKS?_A<:_P#0)/\ X$?_ &-'_"XU_P"@2?\ P(_^QI_5*_\
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MX2\?\^A_[^?_ %J/J]3L'UBGW.BHKGAXM!_Y=3_W\_\ K4O_  EH_P"?4_\
M?S_ZU'L*G8?MZ?<Z"BL'_A*A_P ^Q_[[_P#K4X>)@1_Q['_OO_ZU+V%3L'MZ
M?<W**Q/^$F'_ #[G_OO_ .M2CQ(#_P NY_[[_P#K4>QJ=@]O3[FU16,/$8)Q
M]G_\?_\ K4Y=?W'_ %'_ (__ /6I>QGV'[:'<UZ*RO[=_P"F'_CW_P!:E&N
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M=&3MI\7X7?EV\_D<+IUXJ^OP_C;U[Z[?,]0!R,TM(!@4M>4>R%%%% !1110
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M?^_/_P!E4]I\)GNF8?VFJX&?]1G_ -FH^M4?YOS#ZG7_ )?R. '6I>]>B?\
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M_P"^?_KTHT0@?ZX?]\__ %Z7MH=Q^QGV,Z/J:?6@NC%?^6H_[Y_^O2_V0?\
MGJ/^^:/;0[@J4^Q23I3AUJZNE%1_K?\ QVKEKX<-Q&'^T!><8V?_ %ZS]I#N
M:>SGV,BI1T'TK9_X18_\_(_[X_\ KTX>&2,?Z0/^^/\ Z])U(]QJG+L8HZTZ
MMD>&B/\ EX'_ 'Q_]>E_X1L_\_ _[X_^O4J<>Y2A+L8PZU+6I_PC9_Y^!_WQ
M_P#7I_\ PCY_Y[C_ +Y_^O0YQ[CY)=C*'2BM8: 0/]>/^^?_ *]']@'_ )[C
M_OG_ .O3]I'N')+L9X[5+5X:(1_RV'_?/_UZ?_9!_P">H_[YJ.>):BS.I5K0
M_L@_\]1_WS0-)(_Y:C_OFES(.5E&E7[PJ]_9)_YZC_OFE&E$'_6?^.T<R%RL
MJ5(/NBK/]F_]-/TIPL,#&_\ 2ES(KE95/2FGK5W[!_M_I2'3\_Q_I2<DQV93
MJ4=*E:PVJ3OZ#/2J7VO_ &?UJ;H=F6**K_:_]G]:/M?^S^M%T%F7:4=:J?;O
M]C]:!?@'[GZT7069=HJI_: _N'\Z/[0']P_G1=!9ENBJG]H#^X?SH_M ?W#^
M=%T%F7DZ4ZJ"ZD%'^K/YTO\ :@_YYG\Z5PLR]2K]X50_M0?\\S^=*-4 .?+/
MYTKC29IT5G?VN/\ GD?^^J/[7'_/(_\ ?526:#=*;5$ZN#_RR/\ WU2?VL/^
M>1_[ZH T!UIU9HU8#_ED?^^J7^UQ_P \C_WU0!HT5G?VN/\ GD?^^J/[7'_/
M(_\ ?5 %B?\ X^K;ZM_*BJ\=Y]JNX/DV[<]\]J* -&BH+BW:?;MGEAQ_SSQS
M]<@U#_9\G_/]<_FG_P 30!=HJE_9\G_/]<_FG_Q-']GR?\_US^:?_$T 7:*I
M?V?)_P _US^:?_$T?V?)_P _US^:?_$T 7:*I?V?)_S_ %S^:?\ Q-']GR?\
M_P!<_FG_ ,30!=HJE_9\G_/]<_FG_P 31_9\G_/]<_FG_P 30!=HJE_9\G_/
M]<_FG_Q-']GR?\_US^:?_$T 7:*I?V?)_P _US^:?_$T?V?)_P _US^:?_$T
M 7:*I?V?)_S_ %S^:?\ Q-']GR?\_P!<_FG_ ,30!=HJE_9\G_/]<_FG_P 3
M1_9\G_/]<_FG_P 30!=HJE_9\G_/]<_FG_Q-']GR?\_US^:?_$T 7:*I?V?)
M_P _US^:?_$T?V?)_P _US^:?_$T 7:*I?V?)_S_ %S^:?\ Q-']GR?\_P!<
M_FG_ ,30!=HJE_9\G_/]<_FG_P 31_9\G_/]<_FG_P 30!=HJE_9\G_/]<_F
MG_Q-']GR?\_US^:?_$T 7:S=7',=2_V?)_S_ %S^:?\ Q-4M4L71$S>7#<]R
MO_Q- %:BJ_V5_P#GYF_\=_PH^RO_ ,_,W_CO^%*PK(L457^RO_S\S?\ CO\
MA1]E?_GYF_\ '?\ "BP618HJO]E?_GYF_P#'?\*/LK_\_,W_ ([_ (4PL6**
MK_97_P"?F;_QW_"C[*__ #\S?^._X4#+%%5_LK_\_,W_ ([_ (4?97_Y^9O_
M !W_  H L457^RO_ ,_,W_CO^%'V5_\ GYF_\=_PH L457^RO_S\S?\ CO\
MA1]E?_GYF_\ '?\ "@"Q15?[*_\ S\S?^._X4?97_P"?F;_QW_"@"Q15?[*_
M_/S-_P"._P"%'V5_^?F;_P =_P * +%%5_LK_P#/S-_X[_A1]E?_ )^9O_'?
M\* +%%5_LK_\_,W_ ([_ (4?97_Y^9O_ !W_  H L5?TC_6R?2LC[*__ #\S
M?^._X5=TNR=Y'Q=SKQVV_P#Q- &]15+^SY/^?ZY_-/\ XFC^SY/^?ZY_-/\
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MKG\T_P#B:/[/D_Y_KG\T_P#B: +M%4O[/D_Y_KG\T_\ B:/[/D_Y_KG\T_\
MB: +M%4O[/D_Y_KG\T_^)H_L^3_G^N?S3_XF@"[15+^SY/\ G^N?S3_XFC^S
MY/\ G^N?S3_XF@"W)_JV^AKGJU9-/DV-_IUST/=/_B:POLK_ //S-_X[_A0!
M8HJO]E?_ )^9O_'?\*/LK_\ /S-_X[_A0!8HJO\ 97_Y^9O_ !W_  H^RO\
M\_,W_CO^% %BBJ_V5_\ GYF_\=_PH^RO_P _,W_CO^% %BBJ_P!E?_GYF_\
M'?\ "C[*_P#S\S?^._X4 6**K_97_P"?F;_QW_"C[*__ #\S?^._X4 6**K_
M &5_^?F;_P =_P */LK_ //S-_X[_A0!8HJO]E?_ )^9O_'?\*/LK_\ /S-_
MX[_A0!8HJO\ 97_Y^9O_ !W_  H^RO\ \_,W_CO^% %BBJ_V5_\ GYF_\=_P
MH^RO_P _,W_CO^% %BBJ_P!E?_GYF_\ '?\ "C[*_P#S\S?^._X4 :&G_P#'
MY'^/\J*ATNW9+^)C/*X&?E;&#P?:B@#H:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/U?[D?UK0KX\
M_P""A.HW=A8>$C:W,UL6EESY4A7/'?%7"/,[&%:K[&FYVO8^H**_,/X.Z5<?
M$+QS;Z-J.M:I;VCP33.]K<D2?)&7P"V1SCTK?B\.6?BOP%XCUOPYJ'B:TOM%
MN+:+[/J%Z)X[KSI/+"(R(A#YYQSQ6[H<KM?^F[?F>?#,.=74._7LK]NQ^CM%
M?F-??#7XDZ=(D<L=VTAN4LV2'5(Y6BF?A$D"2$QDGL^*E?X6?$R/4+FR=)TG
MM<"XWZO"$A8G 5W,NU6/92<GTH]BOYA?7Y?\^W_7R/TTHK\G-<F\2^&M5N--
MU.ZU"ROK=MDL,D[94_GS]15#_A(]6_Z"E[_X$/\ XTU0NKID/,[.SA^/_ /U
MRHK\C?\ A(]6_P"@I>_^!#_XT?\ "1ZM_P!!2]_\"'_QI_5_,7]J+^3\?^ ?
MKE17Y&_\)'JW_04O?_ A_P#&C_A(]6_Z"E[_ .!#_P"-'U?S#^U%_)^/_ /U
MRHK\D[+Q;K%C>07$>J7F^)PXS</U!SZU^I7P[\5Q^./ ^BZY$P87MLDC8[/C
M##_OH&L:E-TSMPV+6);5K6.BHHHK$[PHHHH **** "BBB@ HHHH *OZ1_K9/
MI5"K^D?ZV3Z4 :E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% &)?\ _'T]5ZL7_P#Q]/5>@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "MC3/^/4?4UCUL:9_P >H^IH MT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 V3_5M]#7/5T,G^K;Z&N>H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +&G_P#'Y'^/\J*-/_X_
M(_Q_E10!MUPWQJ\;ZC\._ASJFNZ3%:SW]ML$27JLT1)8#Y@I!QSV-=S7GWQY
M\&ZAX_\ AAJVAZ7 MS>76P+$\@0, P)Y)&.,TF3*_*[=F</H?Q5^(WA_QAX5
MT[QM:^$[G3O$3-%;OX<DN/.A<)ORZRG!&../SKOM$^.7@7Q'XOE\,:=XBMKG
M6XRR_9U5PKE>6".5".1@Y"D]#Z5YIHO[.:_#'QQI6K^#]%MCI][:FSU2"213
M+9,4P9H'<YZ]5!^E<E\,OV:O%7AOQYI*ZS'?W.CZ/>O>VU\/$/\ HI.21MM/
M+)4G.#\PSSSS73:$G]_Y_I^/R/.4J]-;7>GGT^6_X6\T>X^'_C_X \4^*G\.
M:7XC@N]65F01+%($=AU"2%0C'_=8U/I?QR\"ZUXPE\+67B*VGUR-BAMPKA2P
MZJLA78S#T!)KR;PO\+_B%H_CRWBTC3!X,\+)<.]TD.NF]LYXFR66.W=0T9)8
MG((Q^5<[X$_9H\6:!XZM(]2%_=:/I]^]];:@/$.+?))((M/+)#<\\C//-3&,
M':[Z?U_PVYK*K65^6-]>SV_KKL>Z6/Q_\ :EXQ/A:W\112:WO:,0>3*%9QU4
M2%=A/'0-4>A_M#?#WQ$^IK8^(XG&FV[W-X\L$L20QJVUBS.@&<X&,Y.1@5Y-
M+\,OBKXB\7:'>^(K6"\CTC66N5O%U('S8&R!LA&%0*,=<L:V--^ VNW?[.&J
M>#+E+?3M=GO);M 9%>.0BY\U%<KG(8  _AZ4E&/+=O\ KO\ +MY6*]I5<FDM
M/3UT_#?;6]C7\:?M/:"WPSUCQ)X&U.QUF[TV:".6&]@EC"*\BJ69&V-C!.#T
MR*[OP!\8/"GQ(N+JST+68-0O[)%-U#&CKL)[J6 #+GC*DCWKR#QQX ^(_P 3
M_!VNKJ7A'P_H>HSI:6\$%K-'+<S".978O<< 1@#A#WKT#0_A]JNG?&T^(S:1
M1:1_8,5AYJ.N?-5L[=HYP!WZ52C"S3\_R_7]1*=5M.W;H^_Z?H7O%G[0WP^\
M#ZW<Z1KGB%+#4;8H)8&MIF*[N0<JA!'J1P.^*E\4?'SP'X-O;"UU;7XX)K^W
M2[M1%!+,)HF;:K*R(0<GMG..>E>+:]9^*[_XU?%&R\+Z%INM/?V%O9S_ &ZX
M$+0*Z$;QD$,!G.WBNU^'OP7UCP=\1_"5[<I#=Z9I'A3^RI+L.N?M'F@D*I^;
M&W/..G%*$8M1<NNOX-_FDK^8.K4<I1BMG;9]TN^NC;MIL=I<_'[X?VGC >%Y
M?$UJFM>9Y)AVN8UDZ;&EV[ V>-I;.>*9XF_:$^'O@_6KO2-6\2V]MJ-JF^:%
M8I)"GME5(W<_=SGVKR*[^"?CS^R-3\ 1:7I4WAG4-8;4SXE>Y'VA$:7S,-%C
M<T@QC=FO,OB)XB?PM-\3_!$']F72:C=I.L]ZS1WC2$+B..(KF0^C X%*$5*R
MZO\ X'W;OUMYDU*U2%VU97[>OWWLMMK^1]6ZC\>_ FD^([30;O71#JMVL+0V
MYM9CN$HRAR$P 1ZGCOBF^'?V@/ 'BOQ-+X?TOQ%%=:M&'/D>1*@?8"6V.RA7
MP 3\I/ KF/ 7P[U[3/B!K'B%K:&&"[\/V=I9W$K*Q69(^05Z@ X^M<5H7PO^
M*&K>//".N>*K.&6319[R.>[_ +3$K3I+"ZK(L0PD:@E1M'S<\\"AQBKKR?ZV
M_P"#ZE*I5:3MO;H_*_7ST]#TG3OVIOA9JDJQP>+K8,T3S#SH)HAM7.1ET #<
M'Y>IXP.15V;]HSX=0>$X?$K^)H/[(FF-ND@AE,C2#JOE!=^>_P!VO*?!_P !
MO%&E>%_A)97FF6PG\/ZQ/>ZDOG1L$1G8JP.?F."O3)J:_P#@QXFM=/\ $$T7
MA:#5;^;7I=0L'AUHV$\*,N!)'(@.#Z@XJI1@FTG_ %=?G?\  F-2NU=K\'V?
MY-?B>_>$/&>B^/=$AU?0;]-0T^4D+*BLO(Z@JP!!]B*VZ\^^"6B^,-#\(&'Q
MG>&ZU!IF>*)YA/)!%_"CR@ .1ZXKT&LYI*5D=5*4I03EO]P4445!J%%%% !1
M110 4444 %?&G_!13_D'^$/^NLO\J^RZ^-/^"BG_ "#_  A_UUE_E6U+XT<.
M-_W>7]=3Y=^#'CRT^&WCRVUV]2Z>&&">,?8P#('>-E4C+*."0>M=;H7Q[%]X
M;FT_QJVI^)9K/5;75=+>:02$%)/WL,CLVX(Z<#&[!'2O*M!\/:EXHU./3M)L
MIM0OI 2EO;KN=@!DG'L*TM9^'?B;PZMNVI:)>6:7$@BB:6,A7<]%!Z9KT&E=
M-[Z?@[K\?\CYF$YQBU';6_S5G?Y'N\W[2/AJ.+4E_M'Q7J\5WK5KJ5O:7]K"
MD-A#%*7,,0%PPZ' P%!P.!7/6?QZT2XE\765W!<6FG:OJW]IV]RVCVFI2*.?
MD>"=@@.#]X-D>]>&WUC/IEY/:74307,+F.2-^JL#@@U!4*G'I_6W_P BC66)
MJMZ_UO\ _)/]#K?BCXR3QWXQNM5BDNI8&5(XWO8X(Y2JJ ,K"BHO3H!QZGK7
M)445<4HJR.:<G.3DPHHHJB HHHH *^Y/V%O'']J^#=4\-SR[IM-F\Z%2<GRW
MZ_@"/UKX;KZE_8.\-75UXPUO7!(\=G:VP@*C[LCL> ?H!FL:R3@ST,#)QKJW
M4^WJ***\T^K"BBB@ HHHH **** "BBB@ J_I'^MD^E4*OZ1_K9/I0!J4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8E__ ,?3U7JQ
M?_\ 'T]5Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V-,_X]
M1]36/6QIG_'J/J: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -D_U;?0USU=#)_JV^AKGJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"QI__'Y'^/\ *BC3_P#C\C_'^5% &W1110 4444
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R?ZMOH:YZBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L:?_P ?
*D?X_RHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>plx-20240331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/10/2024 11:09:17 AM-->
<!--Modified on: 5/10/2024 11:09:17 AM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2023" targetNamespace="http://www.protalix.com/20240331" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:plx="http://www.protalix.com/20240331" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" id="DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails">
        <link:definition>40601 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>40701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" id="DisclosureSignificantAccountingPoliciesConvertibleNotesDetails">
        <link:definition>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" id="DisclosureRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" id="DisclosureTaxesOnIncomeAdditionalInformationDetails">
        <link:definition>40602 - Disclosure - TAXES ON INCOME (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40801 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" id="DisclosureTaxesOnIncome">
        <link:definition>10601 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>10701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10801 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" id="DisclosureTaxesOnIncomeTables">
        <link:definition>30603 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>30703 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplyAndTechnologyTransferAgreementWithFiocruzMember" id="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentReceived" id="plx_MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExtendedTermOfAgreement" id="plx_ExtendedTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfGlobalLicensingAndSupplyAgreements" id="plx_NumberOfGlobalLicensingAndSupplyAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ReserveForDeductionsFromRevenueCurrent" id="plx_ReserveForDeductionsFromRevenueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FillFinishAgreementMember" id="plx_FillFinishAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BalancesWithoutAdoptionOfAsu202006Member" id="plx_BalancesWithoutAdoptionOfAsu202006Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>plx-20240331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/10/2024 11:09:17 AM-->
<!--Modified on: 5/10/2024 11:09:17 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638509361565967061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638509361565967061" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638509361565967061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638509361565967061" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638509361565967061" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638509361565967061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638509361565967061" xlink:to="plx_ShortTermBankDeposits_638509361565967061" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638509361565967061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638509361565967061" xlink:to="us-gaap_AccountsReceivableNetCurrent_638509361565967061" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638509361565967061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638509361565967061" xlink:to="us-gaap_OtherAssetsCurrent_638509361565967061" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638509361565967061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638509361565967061" xlink:to="us-gaap_InventoryNet_638509361565967061" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638509361565967061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638509361565967061" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638509361565977068" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638509361565977068" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638509361565977068" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638509361565977068" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638509361565977068" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638509361565977068" order="5" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638509361565977068" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638509361565977068" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638509361565977068" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638509361565977068" xlink:to="us-gaap_LiabilitiesNoncurrent_638509361565977068" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638509361565977068" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638509361565977068" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638509361565977068" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638509361565977068" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638509361565977068" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638509361565977068" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638509361565987065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638509361565977068" xlink:to="us-gaap_LiabilitiesCurrent_638509361565987065" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638509361565987065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638509361565987065" xlink:to="us-gaap_AccountsPayableTradeCurrent_638509361565987065" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638509361565987065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638509361565987065" xlink:to="us-gaap_AccountsPayableOtherCurrent_638509361565987065" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638509361565987065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638509361565987065" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638509361565987065" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638509361565987065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638509361565987065" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638509361565987065" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638509361565987065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638509361565987065" xlink:to="us-gaap_ConvertibleDebtCurrent_638509361565987065" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638509361565987065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638509361565987065" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638509361565997063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638509361565997063" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638509361565997063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638509361565997063" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638509361565997063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638509361565997063" xlink:to="us-gaap_OperatingIncomeLoss_638509361565997063" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638509361565997063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638509361565997063" xlink:to="us-gaap_Revenues_638509361565997063" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638509361565997063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638509361565997063" xlink:to="us-gaap_CostOfRevenue_638509361565997063" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638509361565997063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638509361565997063" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638509361565997063" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638509361566007060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638509361565997063" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638509361566007060" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638509361566007060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638509361565997063" xlink:to="us-gaap_NonoperatingIncomeExpense_638509361566007060" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638509361566007060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638509361566007060" xlink:to="us-gaap_OtherNonoperatingExpense_638509361566007060" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638509361566007060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638509361566007060" xlink:to="us-gaap_OtherNonoperatingIncome_638509361566007060" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638509361566007060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638509361566007060" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638509361566007060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638509361566007060" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638509361566007060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638509361566007060" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638509361566017063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638509361566007060" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638509361566017063" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638509361566017063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638509361566017063" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638509361566017063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638509361566017063" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638509361566017063" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638509361566017063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638509361566017063" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638509361566017063" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638509361566017063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638509361566017063" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638509361566017063" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638509361566017063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_ProfitLoss_638509361566017063" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638509361566017063" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_ShareBasedCompensation_638509361566017063" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638509361566027066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_Depreciation_638509361566027066" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638509361566027066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638509361566027066" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638509361566027066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638509361566027066" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638509361566027066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638509361566027066" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638509361566027066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638509361566027066" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638509361566027066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638509361566027066" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638509361566027066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638509361566027066" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638509361566037066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638509361566037066" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638509361566037066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_IncreaseDecreaseInInventories_638509361566037066" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638509361566037066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638509361566037066" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638509361566037066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566017063" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638509361566037066" order="13" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638509361566037066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638509361566037066" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638509361566037066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638509361566037066" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638509361566047062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638509361566047062" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638509361566047062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638509361566047062" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638509361566047062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638509361566047062" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637041422969008821" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638509361566047062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638509361566047062" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638509361566047062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_InterestPayableCurrent_638509361566047062" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638509361566047062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedVacationCurrent_638509361566047062" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638509361566057061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638509361566057061" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638509361566057061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638509361566057061" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638509361566057061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638509361566057061" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638509361566057061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_TaxesPayableCurrent_638509361566057061" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638509361566057061" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638509361566057061" order="8" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>plx-20240331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/10/2024 11:09:17 AM-->
<!--Modified on: 5/10/2024 11:09:17 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20240331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_FillFinishAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ExtendedTermOfAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePaymentReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" xlink:type="extended" xlink:title="40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_BalancesWithoutAdoptionOfAsu202006Member" xlink:label="plx_BalancesWithoutAdoptionOfAsu202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="plx_BalancesWithoutAdoptionOfAsu202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromCustomers" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>plx-20240331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/10/2024 11:09:17 AM-->
<!--Modified on: 5/10/2024 11:09:17 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Financial expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL INCOME (EXPENSES), NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE TAX BENEFIT (TAXES ON INCOME)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAX BENEFIT (TAXES ON INCOME)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total taxes on income (tax benefit)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - BASIC</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - DILUTED</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- BASIC</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- DILUTED</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">ASU 2020-06</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Adjustment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Effect of Change</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Changes in deferred tax asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (decrease) in contracts liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease in accounts receivable-trade and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase in inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Schedule of ASU 2020-06 on the condensed consolidated balance sheet</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's Disaggregation of Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental Information, Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex-US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex-US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FillFinishAgreementMember" xlink:to="plx_FillFinishAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Represents the number of global licensing and supply agreements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number Of Global Licensing And Supply Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number of global licensing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional amounts payable to cover development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExtendedTermOfAgreement" xlink:to="plx_ExtendedTermOfAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term  of agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended Term Of Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement amendment payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change in amount receivable for achievement of regulatory and commercial milestones</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional amount payable for achievement of regulatory and commercial milestones</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentReceived" xlink:to="plx_MilestonePaymentReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received upon achievement of certain milestone.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment on net sales percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expenses sharing percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_BalancesWithoutAdoptionOfAsu202006Member" xlink:label="plx_BalancesWithoutAdoptionOfAsu202006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_BalancesWithoutAdoptionOfAsu202006Member" xlink:to="plx_BalancesWithoutAdoptionOfAsu202006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_BalancesWithoutAdoptionOfAsu202006Member_lbl" xml:lang="en-US">Represents the information pertaining to balances without adoption of ASU 2020-06.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_BalancesWithoutAdoptionOfAsu202006Member_lbl" xml:lang="en-US">Balances Without Adoption of ASU 2020-06 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_BalancesWithoutAdoptionOfAsu202006Member_lbl" xml:lang="en-US">Balances without Adoption of ASU 2020-06</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Stock price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Measurement input</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt instrument carrying amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Debt instrument fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Shares of restricted Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Represents the vesting of awards in number of quarterly increments.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting, Number of Quarterly Increments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Vesting in number of quarterly increments</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReserveForDeductionsFromRevenueCurrent" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of reserve for deductions from revenue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Reserve For Deductions From Revenue Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Sales reserve</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Represents information pertaining to supply and technology transfer agreement with Fiocruz.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Brazil Agreement with Fiocruz</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Proceeds from Customers</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Total proceeds from sale of products</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>plx-20240331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/10/2024 11:09:17 AM-->
<!--Modified on: 5/10/2024 11:09:17 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureTaxesOnIncome" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureTaxesOnIncomeTables" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureTaxesOnIncomeAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20240331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638509361566417078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638509361566417078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638509361566417078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638509361566417078" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638509361566417078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638509361566417078" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638509361566417078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638509361566417078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638509361566417078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638509361566417078" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638509361566417078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638509361566417078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638509361566417078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638509361566417078" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638509361566417078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638509361566417078" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638509361566417078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638509361566417078" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638509361566427080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638509361566427080" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638509361566427080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638509361566427080" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638509361566427080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638509361566427080" order="12" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638509361566427080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638509361566427080" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638509361566427080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638509361566427080" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638509361566427080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638509361566427080" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638509361566427080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638509361566427080" order="16" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638509361566427080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638509361566427080" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638509361566427080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638509361566427080" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638509361566437077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638509361566437077" order="19" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638509361566437077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638509361566437077" order="20" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638509361566437077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638509361566437077" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638509361566437077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638509361566437077" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638509361566437077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638509361566437077" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638509361566437077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638509361566437077" order="24" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638509361566437077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638509361566437077" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638509361566437077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638509361566437077" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638509361566447073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638509361566447073" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638509361566447073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638509361566447073" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638509361566447073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638509361566447073" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638509361566447073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638509361566447073" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638509361566447073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638509361566447073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638509361566447073" xlink:to="us-gaap_AssetsCurrentAbstract_638509361566457077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638509361566457077" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638509361566457077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638509361566457077" xlink:to="plx_ShortTermBankDeposits_638509361566457077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638509361566457077" xlink:to="us-gaap_AccountsReceivableNetCurrent_638509361566457077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638509361566457077" xlink:to="us-gaap_OtherAssetsCurrent_638509361566457077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638509361566457077" xlink:to="us-gaap_InventoryNet_638509361566457077" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638509361566457077" xlink:to="us-gaap_AssetsCurrent_638509361566457077" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638509361566447073" xlink:to="us-gaap_AssetsNoncurrentAbstract_638509361566457077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638509361566457077" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638509361566457077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638509361566457077" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638509361566457077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638509361566457077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638509361566457077" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638509361566457077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638509361566467079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638509361566457077" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638509361566467079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638509361566467079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638509361566447073" xlink:to="us-gaap_Assets_638509361566467079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638509361566467079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638509361566467079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638509361566467079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638509361566467079" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638509361566467079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566467079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638509361566467079" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566467079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638509361566467079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566467079" xlink:to="us-gaap_AccountsPayableTradeCurrent_638509361566467079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638509361566467079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566467079" xlink:to="us-gaap_AccountsPayableOtherCurrent_638509361566467079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638509361566467079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566467079" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638509361566467079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638509361566467079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638509361566467079" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638509361566467079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638509361566477080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638509361566467079" xlink:to="us-gaap_ConvertibleDebtCurrent_638509361566477080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638509361566477080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638509361566467079" xlink:to="us-gaap_LiabilitiesCurrent_638509361566477080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638509361566477080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638509361566467079" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638509361566477080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638509361566477080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638509361566477080" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638509361566477080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638509361566477080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638509361566477080" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638509361566477080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638509361566477080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638509361566467079" xlink:to="us-gaap_LiabilitiesNoncurrent_638509361566477080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638509361566477080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638509361566467079" xlink:to="us-gaap_Liabilities_638509361566477080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638509361566487072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638509361566467079" xlink:to="us-gaap_CommitmentsAndContingencies_638509361566487072" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638509361566487072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638509361566467079" xlink:to="us-gaap_StockholdersEquity_638509361566487072" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638509361566487072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638509361566467079" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638509361566487072" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638509361566487072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638509361566487072" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638509361566487072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566487072" xlink:to="srt_ProductOrServiceAxis_638509361566487072" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638509361566487072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638509361566487072" xlink:to="srt_ProductsAndServicesDomain_638509361566487072" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638509361566487072" xlink:to="us-gaap_ProductMember_638509361566497083" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638509361566487072" xlink:to="us-gaap_LicenseAndServiceMember_638509361566497083" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566487072" xlink:to="us-gaap_StatementLineItems_638509361566497083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_Revenues_638509361566497083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_CostOfRevenue_638509361566497083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638509361566497083" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638509361566497083" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_OperatingIncomeLoss_638509361566497083" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_OtherNonoperatingExpense_638509361566497083" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_OtherNonoperatingIncome_638509361566497083" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638509361566497083" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_NonoperatingIncomeExpense_638509361566497083" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638509361566507074" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638509361566507074" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638509361566507074" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638509361566507074" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638509361566507074" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_NetIncomeLoss_638509361566507074" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638509361566507074" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_EarningsPerShareBasic_638509361566507074" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638509361566507074" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_EarningsPerShareDiluted_638509361566507074" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638509361566507074" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638509361566507074" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638509361566507074" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566497083" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638509361566507074" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638509361566517075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566517075" xlink:to="us-gaap_StatementEquityComponentsAxis_638509361566517075" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638509361566517075" xlink:to="us-gaap_CommonStockMember_638509361566517075" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638509361566517075" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638509361566517075" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638509361566517075" xlink:to="us-gaap_RetainedEarningsMember_638509361566517075" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638509361566517075" xlink:to="us-gaap_EquityComponentDomain_638509361566517075" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566517075" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638509361566517075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638509361566517075" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638509361566517075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638509361566517075" xlink:to="us-gaap_TypeOfAdoptionMember_638509361566517075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638509361566517075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566517075" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638509361566517075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638509361566527076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638509361566517075" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638509361566527076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638509361566527076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638509361566517075" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638509361566527076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638509361566527076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566517075" xlink:to="us-gaap_StatementLineItems_638509361566527076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638509361566527076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="us-gaap_StockholdersEquity_638509361566527076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638509361566527076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="us-gaap_SharesOutstanding_638509361566527076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638509361566527076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638509361566527076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638509361566527076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638509361566527076" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638509361566527076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638509361566527076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638509361566527076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638509361566527076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638509361566527076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638509361566537077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638509361566537077" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638509361566537077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638509361566537077" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638509361566537077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638509361566537077" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638509361566537077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638509361566537077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="us-gaap_NetIncomeLoss_638509361566537077" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638509361566537077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="us-gaap_StockholdersEquity_638509361566537077" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638509361566537077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566527076" xlink:to="us-gaap_SharesOutstanding_638509361566537077" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638509361566547073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638509361566547073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638509361566547073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_638509361566547073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638509361566547073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_ProfitLoss_638509361566547073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638509361566547073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_ShareBasedCompensation_638509361566547073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638509361566547073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_Depreciation_638509361566547073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638509361566547073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638509361566547073" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638509361566547073" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638509361566547073" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638509361566557078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638509361566557078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638509361566557078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638509361566557078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638509361566557078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638509361566557078" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638509361566557078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638509361566557078" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638509361566557078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638509361566557078" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638509361566557078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638509361566557078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638509361566557078" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638509361566557078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638509361566557078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638509361566557078" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638509361566557078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638509361566557078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638509361566557078" xlink:to="us-gaap_IncreaseDecreaseInInventories_638509361566557078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638509361566557078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638509361566557078" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638509361566557078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566567081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638509361566547073" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638509361566567081" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638509361566567081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638509361566567081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638509361566567081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638509361566567081" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638509361566567081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638509361566567081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638509361566567081" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638509361566567081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638509361566567081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638509361566567081" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638509361566567081" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638509361566567081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638509361566567081" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638509361566567081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638509361566567081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638509361566567081" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638509361566567081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638509361566567081" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638509361566567081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638509361566577076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638509361566567081" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638509361566577076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638509361566577076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638509361566577076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638509361566577076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638509361566577076" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638509361566577076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638509361566577076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6385093615665770761" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6385093615665770761" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638509361566577076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638509361566577076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638509361566577076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638509361566577076" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638509361566577076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638509361566587079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638509361566577076" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638509361566587079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638509361566587079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638509361566587079" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638509361566587079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638509361566587079" xlink:to="us-gaap_InterestPaidNet_638509361566587079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638509361566587079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638509361566587079" xlink:to="plx_InterestReceivedNet_638509361566587079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638509361566587079" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638509361566587079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638509361566597075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638509361566597075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638509361566597075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638509361566597075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_638509361566597075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_638509361566597075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638509361566597075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638509361566597075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncome" xlink:type="extended" xlink:title="10601 - Disclosure - TAXES ON INCOME">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638509361566607076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638509361566607076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="10701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638509361566607076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638509361566607076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10801 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638509361566607076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventsTextBlock_638509361566607076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638509361566617075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638509361566617075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638509361566617075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638509361566617075" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638509361566617075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638509361566617075" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638509361566617075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638509361566617075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638509361566617075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638509361566617075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638509361566617075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638509361566617075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638509361566617075" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638509361566617075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638509361566627080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_638509361566627080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638509361566627080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566627080" xlink:to="us-gaap_DebtInstrumentAxis_638509361566627080" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638509361566627080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638509361566627080" xlink:to="us-gaap_DebtInstrumentNameDomain_638509361566627080" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638509361566627080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638509361566627080" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638509361566627080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638509361566627080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566627080" xlink:to="us-gaap_StatementLineItems_638509361566627080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638509361566627080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566627080" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638509361566627080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638509361566627080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638509361566627080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" xlink:type="extended" xlink:title="30603 - Disclosure - TAXES ON INCOME (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638509361566637078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638509361566637078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="30703 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638509361566637078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638509361566637078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638509361566637078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638509361566637078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638509361566637078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566637078" xlink:to="us-gaap_TypeOfArrangementAxis_638509361566637078" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638509361566637078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638509361566637078" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638509361566637078" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638509361566637078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638509361566637078" xlink:to="plx_AmendedPfizerAgreementMember_638509361566637078" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638509361566637078" xlink:to="plx_ChiesiAgreementsMember_638509361566647078" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638509361566647078" xlink:to="plx_ChiesiUSAgreementMember_638509361566647078" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638509361566647078" xlink:to="plx_ChiesiExUSAgreementMember_638509361566647078" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638509361566647078" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638509361566647078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638509361566637078" xlink:to="plx_FillFinishAgreementMember_638509361566647078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566637078" xlink:to="dei_LegalEntityAxis_638509361566647078" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638509361566647078" xlink:to="dei_EntityDomain_638509361566647078" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638509361566647078" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638509361566647078" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566637078" xlink:to="srt_StatementGeographicalAxis_638509361566647078" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638509361566647078" xlink:to="srt_SegmentGeographicalDomain_638509361566647078" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR_638509361566647078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638509361566647078" xlink:to="country_BR_638509361566647078" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638509361566657077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566637078" xlink:to="srt_RangeAxis_638509361566657077" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638509361566657077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638509361566657077" xlink:to="srt_RangeMember_638509361566657077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638509361566657077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638509361566657077" xlink:to="srt_MinimumMember_638509361566657077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638509361566657077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638509361566657077" xlink:to="srt_MaximumMember_638509361566657077" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638509361566657077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566637078" xlink:to="us-gaap_DebtInstrumentAxis_638509361566657077" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638509361566657077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638509361566657077" xlink:to="us-gaap_DebtInstrumentNameDomain_638509361566657077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638509361566657077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638509361566657077" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638509361566657077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638509361566657077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638509361566657077" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638509361566657077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638509361566657077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566637078" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638509361566657077" order="6" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638509361566667081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638509361566657077" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638509361566667081" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638509361566667081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638509361566667081" xlink:to="plx_AtMarketEquityOfferingMember_638509361566667081" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638509361566667081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566637078" xlink:to="plx_SignificantAccountingPoliciesLineItems_638509361566667081" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_638509361566667081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_638509361566667081" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638509361566667081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638509361566667081" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638509361566667081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638509361566667081" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638509361566667081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638509361566667081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_638509361566667081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_SaleOfStockMaximumOfferingPrice_638509361566667081" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638509361566677076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638509361566677076" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638509361566677076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638509361566677076" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement_638509361566677076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_ExtendedTermOfAgreement_638509361566677076" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_638509361566677076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_AgreementAmendmentPaymentReceivable_638509361566677076" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638509361566677076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638509361566677076" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638509361566677076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638509361566677076" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638509361566677076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_MilestonePaymentReceived_638509361566677076" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_638509361566687081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_PaymentOnNetSalesPercentage_638509361566687081" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638509361566687081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638509361566687081" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638509361566687081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="us-gaap_ConvertibleDebtCurrent_638509361566687081" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638509361566687081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638509361566687081" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638509361566687081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638509361566687081" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638509361566687081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638509361566687081" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_638509361566697078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566667081" xlink:to="plx_MaintainOfMinimumCashBalance_638509361566697078" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails" xlink:type="extended" xlink:title="40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638509361566697078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="plx_SignificantAccountingPoliciesTable_638509361566697078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638509361566697078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566697078" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638509361566697078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638509361566697078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638509361566697078" xlink:to="us-gaap_TypeOfAdoptionMember_638509361566697078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638509361566697078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638509361566697078" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638509361566697078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638509361566697078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566697078" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638509361566697078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638509361566707076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638509361566697078" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638509361566707076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_638509361566707076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain_638509361566707076" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_638509361566707076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_BalancesWithoutAdoptionOfAsu202006Member" xlink:label="plx_BalancesWithoutAdoptionOfAsu202006Member_638509361566707076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain_638509361566707076" xlink:to="plx_BalancesWithoutAdoptionOfAsu202006Member_638509361566707076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638509361566707076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain_638509361566707076" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638509361566707076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638509361566707076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638509361566697078" xlink:to="plx_SignificantAccountingPoliciesLineItems_638509361566707076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638509361566707076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566707076" xlink:to="us-gaap_OtherNonoperatingExpense_638509361566707076" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638509361566707076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566707076" xlink:to="us-gaap_ConvertibleDebtCurrent_638509361566707076" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638509361566707076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566707076" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638509361566707076" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638509361566707076" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638509361566707076" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638509361566707076" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638509361566717077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638509361566717077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638509361566717077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638509361566717077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638509361566717077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638509361566717077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638509361566717077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638509361566717077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566717077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566717077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638509361566717077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566717077" xlink:to="us-gaap_DebtInstrumentAxis_638509361566717077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638509361566717077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638509361566717077" xlink:to="us-gaap_DebtInstrumentNameDomain_638509361566717077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638509361566717077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638509361566717077" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638509361566717077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638509361566717077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638509361566717077" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638509361566717077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638509361566727082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566717077" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638509361566727082" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638509361566727082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638509361566727082" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638509361566727082" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638509361566727082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638509361566727082" xlink:to="us-gaap_FairValueInputsLevel3Member_638509361566727082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638509361566847078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566717077" xlink:to="us-gaap_MeasurementInputTypeAxis_638509361566847078" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638509361566847078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638509361566847078" xlink:to="us-gaap_MeasurementInputTypeDomain_638509361566847078" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638509361566847078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638509361566847078" xlink:to="us-gaap_MeasurementInputSharePriceMember_638509361566847078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638509361566847078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638509361566847078" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638509361566847078" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638509361566847078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638509361566847078" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638509361566847078" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638509361566847078" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638509361566847078" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638509361566847078" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_638509361566857077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638509361566847078" xlink:to="plx_MeasurementInputYieldMember_638509361566857077" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638509361566857077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566717077" xlink:to="us-gaap_StatementLineItems_638509361566857077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_638509361566857077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566857077" xlink:to="us-gaap_DebtInstrumentMeasurementInput_638509361566857077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566857077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566857077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638509361566857077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566857077" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638509361566857077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638509361566857077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638509361566857077" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638509361566857077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638509361566857077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638509361566857077" xlink:to="us-gaap_FairValueInputsLevel3Member_638509361566857077" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638509361566857077" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566857077" xlink:to="us-gaap_DebtInstrumentAxis_638509361566857077" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638509361566867086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638509361566857077" xlink:to="us-gaap_DebtInstrumentNameDomain_638509361566867086" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638509361566867086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638509361566867086" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638509361566867086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638509361566867086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638509361566857077" xlink:to="us-gaap_StatementLineItems_638509361566867086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638509361566867086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566867086" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638509361566867086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638509361566867086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566867086" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638509361566867086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638509361566867086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_638509361566867086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638509361566867086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566867086" xlink:to="srt_ProductOrServiceAxis_638509361566867086" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638509361566867086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638509361566867086" xlink:to="srt_ProductsAndServicesDomain_638509361566867086" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638509361566867086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638509361566867086" xlink:to="us-gaap_ProductMember_638509361566867086" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638509361566877082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638509361566867086" xlink:to="us-gaap_LicenseAndServiceMember_638509361566877082" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638509361566877082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566867086" xlink:to="srt_StatementGeographicalAxis_638509361566877082" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638509361566877082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638509361566877082" xlink:to="srt_SegmentGeographicalDomain_638509361566877082" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638509361566877082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638509361566877082" xlink:to="plx_PfizerMember_638509361566877082" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BR" xlink:label="country_BR_638509361566877082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638509361566877082" xlink:to="country_BR_638509361566877082" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638509361566877082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638509361566867086" xlink:to="us-gaap_StatementLineItems_638509361566877082" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638509361566877082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638509361566877082" xlink:to="us-gaap_Revenues_638509361566877082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638509361566877082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_638509361566877082" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638509361566877082" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638509361566877082" xlink:to="us-gaap_PlanNameAxis_638509361566877082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638509361566877082" xlink:to="us-gaap_PlanNameDomain_638509361566887089" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638509361566887089" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638509361566887089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638509361566877082" xlink:to="us-gaap_AwardTypeAxis_638509361566887089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638509361566887089" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638509361566887089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638509361566887089" xlink:to="us-gaap_RestrictedStockMember_638509361566887089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638509361566877082" xlink:to="us-gaap_ClassOfStockLineItems_638509361566887089" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638509361566887089" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638509361566887089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638509361566887089" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638509361566887089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638509361566887089" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_638509361566887089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638509361566887089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638509361566887089" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638509361566887089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638509361566897086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638509361566897086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638509361566897086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638509361566897086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638509361566897086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638509361566897086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - TAXES ON INCOME (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638509361566897086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638509361566897086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638509361566897086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638509361566897086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638509361566897086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="plx_MilestonePaymentReceived_638509361566897086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638509361566897086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638509361566897086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638509361566907091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" xlink:to="us-gaap_InterestPayableCurrent_638509361566907091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638509361566907091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" xlink:to="us-gaap_AccruedVacationCurrent_638509361566907091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638509361566907091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638509361566907091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638509361566907091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638509361566907091" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638509361566907091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" xlink:to="us-gaap_TaxesPayableCurrent_638509361566907091" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638509361566907091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638509361566907091" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638509361566907091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638509361566907091" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638509361566907091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638509361566897086" xlink:to="us-gaap_AccountsPayableCurrent_638509361566907091" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638509361566907091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638509361566907091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638509361566907091" xlink:to="us-gaap_SubsequentEventTypeAxis_638509361566917080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638509361566917080" xlink:to="us-gaap_SubsequentEventTypeDomain_638509361566917080" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638509361566917080" xlink:to="us-gaap_SubsequentEventMember_638509361566917080" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638509361566907091" xlink:to="us-gaap_TypeOfArrangementAxis_638509361566917080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638509361566917080" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638509361566917080" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638509361566917080" xlink:to="plx_ChiesiAgreementsMember_638509361566917080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638509361566917080" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638509361566917080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638509361566907091" xlink:to="srt_TitleOfIndividualAxis_638509361566917080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638509361566917080" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638509361566917080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638509361566917080" xlink:to="srt_ChiefExecutiveOfficerMember_638509361566917080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638509361566907091" xlink:to="us-gaap_AwardTypeAxis_638509361566917080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638509361566917080" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638509361566917080" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638509361566917080" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638509361566927086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638509361566917080" xlink:to="us-gaap_RestrictedStockMember_638509361566927086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638509361566927086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638509361566907091" xlink:to="us-gaap_SubsequentEventLineItems_638509361566927086" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers_638509361566927086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638509361566927086" xlink:to="us-gaap_ProceedsFromCustomers_638509361566927086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638509361566927086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638509361566927086" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638509361566927086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20240331.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638509361566927086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638509361566927086" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_638509361566927086" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059753755712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,316,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059843897568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,209<span></span>
</td>
<td class="nump">$ 23,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">21,278<span></span>
</td>
<td class="nump">20,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">3,759<span></span>
</td>
<td class="nump">5,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">22,346<span></span>
</td>
<td class="nump">19,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">75,404<span></span>
</td>
<td class="nump">69,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,781<span></span>
</td>
<td class="nump">4,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">3,230<span></span>
</td>
<td class="nump">3,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,879<span></span>
</td>
<td class="nump">5,909<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">89,825<span></span>
</td>
<td class="nump">84,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">4,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">18,770<span></span>
</td>
<td class="nump">19,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,453<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">11,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">20,420<span></span>
</td>
<td class="nump">20,251<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">54,828<span></span>
</td>
<td class="nump">45,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,499<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">5,211<span></span>
</td>
<td class="nump">5,335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">60,039<span></span>
</td>
<td class="nump">50,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="nump">29,786<span></span>
</td>
<td class="nump">33,569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 89,825<span></span>
</td>
<td class="nump">$ 84,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059841317072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 3,748<span></span>
</td>
<td class="nump">$ 9,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">(2,602)<span></span>
</td>
<td class="num">(3,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="num">(2,887)<span></span>
</td>
<td class="num">(5,847)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(3,115)<span></span>
</td>
<td class="num">(3,115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(4,856)<span></span>
</td>
<td class="num">(2,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(390)<span></span>
</td>
<td class="num">(649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES), NET</a></td>
<td class="nump">123<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE TAX BENEFIT (TAXES ON INCOME)</a></td>
<td class="num">(4,733)<span></span>
</td>
<td class="num">(2,936)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAX BENEFIT (TAXES ON INCOME)</a></td>
<td class="nump">138<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="num">$ (4,595)<span></span>
</td>
<td class="num">$ (3,131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- BASIC</a></td>
<td class="nump">73,036,569<span></span>
</td>
<td class="nump">57,480,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- DILUTED</a></td>
<td class="nump">73,036,569<span></span>
</td>
<td class="nump">57,480,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 3,677<span></span>
</td>
<td class="nump">$ 5,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 4,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059843758032">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 379,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (389,861)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">53,790,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,212,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(392,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">62,002,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(381,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance (ASU 2020-06) at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (385,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,786<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,052,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of March&#160;31, 2024 and December&#160;31, 2023 &#8211; 185,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059844938016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059751298656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (4,595)<span></span>
</td>
<td class="num">$ (3,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">981<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net</a></td>
<td class="num">(471)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Changes in deferred tax asset</a></td>
<td class="num">(138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability</a></td>
<td class="nump">11,039<span></span>
</td>
<td class="num">(1,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in accounts receivable-trade and other assets</a></td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">3,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(3,301)<span></span>
</td>
<td class="num">(3,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="num">(1,414)<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">4,188<span></span>
</td>
<td class="num">(2,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(598)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(606)<span></span>
</td>
<td class="nump">4,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,233<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">3,575<span></span>
</td>
<td class="nump">15,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">23,634<span></span>
</td>
<td class="nump">17,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">27,209<span></span>
</td>
<td class="nump">33,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754373696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase&#160;I First-in-Human clinical trial of PRX-115. This study was designed to be conducted in approximately 56 adult male and female subjects in the dose escalation phase with seven sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of March&#160;31, 2024, 56 patients have been dosed in this study. The Company has decided to expand the study by adding an eighth cohort with eight new subjects and to commence preparations for a phase&#160;II clinical trial of PRX-115.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of March&#160;31, 2024, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due September 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of March&#160;31, 2024, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash, cash equivalents and short-term bank deposits as of March&#160;31, 2024 are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates loss per share by dividing the net loss by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted loss per share does not include 36,292,208 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2023 because the effect would be anti-dilutive. Diluted loss per share does not include 31,839,345 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2024 because the effect would be anti-dilutive.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. <span style="background:#ffffff;">The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued </span>ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; (&#8220;<span style="background:#ffffff;">ASU 2020-06&#8221;). </span>ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#8212;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06<span style="background:#ffffff;"> </span>using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. <span style="background:#ffffff;">The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. </span>Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated January 1, 2024</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 169</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 415,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 414,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 381,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 381,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 224</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The impact of adoption of ASU 2020-06 on the condensed consolidated balance sheet as of March&#160;31, 2024 and on the Company&#8217;s condensed consolidated statement of operations for the three months ended March&#160;31, 2024 was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balances without Adoption of ASU 2020-06</b></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial expense</p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (62)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (107)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 415,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 416,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 393</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 385,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 386,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (286)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently adopted accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures</span><span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059753892672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2024 and December&#160;31, 2023 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754361616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level&#160;3 measurement, as of March&#160;31, 2024, the fair value of the $20.4&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $21.2&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754351424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059753887616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On January&#160;15, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, 100,000 shares of restricted Common Stock, in the aggregate, to certain of the Company&#8217;s employees under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). All such shares of restricted Common Stock vest over a three-year period in 12&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.2&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754316752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; TAXES ON INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td></tr><tr><td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income (tax benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of (3)% for the three months ended March&#160;31, 2024, compared to an effective tax rate of 7% for the three months ended March&#160;31, 2023. For the three months ended March&#160;31, 2024, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S. taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#8220;TCJA&#8221;).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059845339440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,009</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 637</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,550</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059753884224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On May&#160;9, 2024 the Company collected approximately $1.1&#160;million from sales to Pfizer and on May&#160;8, 2024 the Company collected approximately $2.6&#160;million from sales to Brazil<span style="background:#ffffff;">.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On April&#160;1, 2024, the Company granted, with the approval of the Company&#8217;s compensation committee, 263,960 shares of fully-vested restricted Common Stock, in the aggregate, to its President and Chief Executive Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.3&#160;million.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754222576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#8217;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase&#160;I First-in-Human clinical trial of PRX-115. This study was designed to be conducted in approximately 56 adult male and female subjects in the dose escalation phase with seven sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of March&#160;31, 2024, 56 patients have been dosed in this study. The Company has decided to expand the study by adding an eighth cohort with eight new subjects and to commence preparations for a phase&#160;II clinical trial of PRX-115.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of March&#160;31, 2024, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due September 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of March&#160;31, 2024, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash, cash equivalents and short-term bank deposits as of March&#160;31, 2024 are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates loss per share by dividing the net loss by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted loss per share does not include 36,292,208 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2023 because the effect would be anti-dilutive. Diluted loss per share does not include 31,839,345 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2024 because the effect would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate. <span style="background:#ffffff;">The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued </span>ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; (&#8220;<span style="background:#ffffff;">ASU 2020-06&#8221;). </span>ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#8212;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06<span style="background:#ffffff;"> </span>using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. <span style="background:#ffffff;">The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. </span>Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated January 1, 2024</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 169</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 415,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 414,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 381,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 381,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 224</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The impact of adoption of ASU 2020-06 on the condensed consolidated balance sheet as of March&#160;31, 2024 and on the Company&#8217;s condensed consolidated statement of operations for the three months ended March&#160;31, 2024 was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balances without Adoption of ASU 2020-06</b></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial expense</p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (62)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (107)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 415,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 416,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 393</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 385,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 386,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (286)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently adopted accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures</span><span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059752316736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of ASU 2020-06 on the condensed consolidated balance sheet</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated January 1, 2024</b></p></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 169</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 415,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 414,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 381,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 381,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 224</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balances without Adoption of ASU 2020-06</b></p></td><td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial expense</p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (62)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (107)</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 415,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 416,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 393</p></td></tr><tr><td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 385,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 386,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (286)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-12<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754399376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059753887616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754389616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,266</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,066</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,522</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754354032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td></tr><tr><td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income (tax benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754426432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Supplemental Information, Balance Sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,009</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 637</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,550</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059747438848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 29, 2022</div></th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfGlobalLicensingAndSupplyAgreements', window );">Number of global licensing and supply agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,839,345<span></span>
</td>
<td class="nump">36,292,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,980,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Minimum cash balance required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative arrangement revenues and expenses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement amendment payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change in amount receivable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember', window );">Fill/Finish Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ExtendedTermOfAgreement', window );">Extended term of agreement</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExtendedTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended term  of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ExtendedTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received upon achievement of certain milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfGlobalLicensingAndSupplyAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of global licensing and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfGlobalLicensingAndSupplyAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059843611776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Financial expense</a></td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">$ 649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">20,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=plx_BalancesWithoutAdoptionOfAsu202006Member', window );">Balances without Adoption of ASU 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Financial expense</a></td>
<td class="nump">444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">20,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">416,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">386,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06 | Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Financial expense</a></td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">20,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">415,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">385,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06 | Effect of Change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Financial expense</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="num">(107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (286)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=plx_BalancesWithoutAdoptionOfAsu202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=plx_BalancesWithoutAdoptionOfAsu202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059844947232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,024<span></span>
</td>
<td class="nump">$ 4,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">9,169<span></span>
</td>
<td class="nump">9,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">9,153<span></span>
</td>
<td class="nump">5,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 22,346<span></span>
</td>
<td class="nump">$ 19,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059755569072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details) - 2024 Notes - Level 3<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="nump">1.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input | Y</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.6706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.1206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754431424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Additional Information) (Details) - Level 3 - 2024 Notes<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument carrying amount</a></td>
<td class="nump">$ 20.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Debt instrument fair value</a></td>
<td class="nump">$ 21.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059841359936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 3,748<span></span>
</td>
<td class="nump">$ 9,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,677<span></span>
</td>
<td class="nump">5,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 4,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754331296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - 2006 Employee Stock Incentive Plan - Shares of restricted Common Stock<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 15, 2024 </div>
<div>USD ($) </div>
<div>item </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted | shares</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements', window );">Vesting in number of quarterly increments | item</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the vesting of awards in number of quarterly increments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059751245584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Summary of Taxes on Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes on income</a></td>
<td class="num">$ (138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income (tax benefit)</a></td>
<td class="num">$ (138)<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059755655408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059841547936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 2,502<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">1,696<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,451<span></span>
</td>
<td class="nump">9,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">2,876<span></span>
</td>
<td class="nump">2,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReserveForDeductionsFromRevenueCurrent', window );">Sales reserve</a></td>
<td class="nump">2,861<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 18,770<span></span>
</td>
<td class="nump">$ 19,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReserveForDeductionsFromRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of reserve for deductions from revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReserveForDeductionsFromRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059857628544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>May 09, 2024</div></th>
<th class="th"><div>May 08, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chief Executive Officer | Shares of restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Brazil Agreement with Fiocruz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059754391584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (4,595)<span></span>
</td>
<td class="num">$ (3,131)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140059755771472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M/S@ULGA?',&?X@P.],7MEO@;DN0&\/]S'&=OC;R#ZBO.Z#]02P,$%     @
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M3T"K:89I'TA(.X\9=S69)?ZC."?)"0[E)+75GZ%J&WG9WA0-J%T-BC8'17-
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MI12 WQ\Y3UZ_R 6*OW<8_PM02P,$%     @ ECJJ6 O7_'BZ'P  S5\  !@
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M:ZTS>N*WJH%5LA6;@/;4U[^=_PC5H/G(GM0D[]E(]M)[\;Z?7E0=.&S\2F2
M\Y(2QI'$DB8+, _%7%4K6 P\S*+01I$P7\/HC9//87*!4LQDP7G"H <RNQ+<
M\&IQ^'61H%W9)/4:K+.47TV2:0/RPL+@3_"#!-T$9VZ2<]  4#-_CA\BEMA5
M@.8< +?EPK6<50TZ%N0X;$67SF>)I 2BK2 "OQ$HPPF0*P/=S+QS6_GC%ZWC
M;QWO;,-"QP216[NT!E32DW8/#"G0#K&9>=>L8(-?X'1PN-O7Y;L/M[%IMXNL
M0??\&=L502K<D<ST(WR_%FP,<?;EII25P4 "]JGJ#>Q.4$Q@#D4ARN4F%X\*
M%!8.$\ZO1IM,<UT5WS8KF7R6H&^I)%O-X =8?_7Y?C])<P$V*A<S"2!KP5[Q
MG[RP.;P%'@*KR)0BL8J,(/B@3(#(.A1@U*)@TV$VJQ+0/LG/%L7L;^<-ZN\!
M+*K!JZ-3\CM)C)0%66.8- 5R",^8ND%;%)NSR-6 @0*VHV$BDP9"B-^:I6YR
M$AOPO6G:5"R&O?M"[J[D:E:) L"+SM5<5FS5%KD&[-'DNI#ELH)MF&3OP^W;
MCR"AN:Q D<"\IY6:P3;)4,(*((A&D0DFIX]/T[Z9>3*PCM2Q9+P$7'!*:3>#
M>P-;B)XZSP=>.BKY@#%B+<4*#QJ=DK<;EFL0M\C'>DM_D6N"?/( N P2")[5
M_41RDBN0<-8TC_E8PZQO78&Y*W2=S)#3JA:S7.*FT7V@PX7=-7!8SK8PS3-P
M<G-5'U3*?$62O/@#)^?B05<T"[("G_:G2CJ-ILJ:J&"@.C:IBR$E^5^4,CR.
M-3H=X)&Q9SD#^AAED@5 <6W CH)@ K21 ;D$)<7%+Y<@?(H<TZ>TUG#8R9C,
M_OBT@^@'O9"X/QX 4-$B%BS'E:?567DD\8Y)/'<DQD2UP*3]ZNKQX,M=>-S;
MU+*I3$.@7EM 9 >@)5J [!/*+"*.64#.DHH@@8PGJ'93&Q1EBW:_%"0W=S7#
ML&W$SLPD!OZ]@:V@NP3NG77CH?\,/_J8,>!!H+TE1%M.=7O#H2"QQ?9N._:<
M3&$S^QWG9*^T1/6ZN;D)QHQP-&@O&K4-BB$!:80*I* M%6C[Z9;H#[PR.QR)
M$8/1*P:G *^E-7E/T*"" 0$&@5DH186FR!K<@943A,R5!*-8<0!A=WIQ_O[\
MX^45[X1%_^+SS6]O[3=T6/;+M^_N^<MG20+CEV^^X3J@O*5&-Z9P2]HP^%Y0
M+NW53LR!BTY:O\UU4_&/0X@&$9,K/%LF^+N80V:DMBD\YXQ ')@[]L"MD00.
MPF&HDOR:VA$C\Z*'\:HU.(&<R>^AR?Z*N! G#&![@^<A"W!:N8WH@5]%0X9Y
M9@TJX@B4G]O/_SH8CR80?I%W!B0,U(\=?C4E&'I=F:4JG6+CQC%ORMB@AP<D
M\V Y3) -5CHG.6#E"[T&GC,(EI43^*VY #=7&D(!.%Y21_C+2 26B)V&ATSD
MM#V:4QA>SH$,U)S?&W W@-#(=PW"D3A-RBJQ3N:T'#%S]PZ'R1T  ,</-Q:/
MPFV;]"&R'*!$=4TPBB*N>$$@F*,P.!0#E+$N &AO^YS=SO I>T!G ?:LF85
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M!%0V@-974IJ=81/4K\SX-U!+ P04    " "6.JI8_YVXTD8%  "]#   &
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;+57;6_;-A#^*P>U*UK \(N<I(63
M&$A:%PO0I%G2=-A'BCI;7"A2):DXWJ_?'?42M[6##<.^Q"1U]]S=<R]D3M;6
MW?L",<!CJ8T_38H0JMEHY&6!I?!#6Z&A+TOK2A%HZU8C7SD4>50J]2@=CX]&
MI5 FF9_$LVLW/[%UT,K@M0-?EZ5PFW/4=GV:3)+NX$:MBL 'H_E))59XB^&N
MNG:T&_4HN2K1>&4-.%R>)F>3V?D!RT>!KPK7?FL-'$EF[3UO+O+39,P.H489
M&$'0SP.^1ZT9B-SXUF(FO4E6W%YWZ!]C[!1+)CR^M_IWE8?B-'F70(Y+4>MP
M8]>_8AO/(>-)JWW\"^M&-ITF(&L?;-DJDP>E,LVO>&QYV%)X-]ZCD+8*:?2[
M,12]_"""F)\XNP;'TH3&BQAJU";GE.&DW 9'7Q7IA?G'LXL;^'KVZ6X!EXNS
MV[N;Q>7BZLO)*! V2XQDBW/>X*1[<*9P:4TH/"Q,COGW^B/RJ7<L[1P[3Y\%
MO!1N"-/) -)Q>O ,WK0/=!KQIO\YT ;G8#<.-\G,5T+B:4)=X-$]8#)_]6)R
M-#Y^QLN#WLN#Y]#_A9?/XUQ]_K* *;QZ\2Z=3(YA-RQ\*1#>V[(29@.Y\E);
MCQZ60CEX$+I&*%'XVB$U8:!SZV"IC#!2"0W">Z1#87+02F1*JZ#0#^'CD[;R
ML6%RH.X+9*IR2B*M1*!6K74.&5)?2Z2VS&'I;!FEO- (=DG(C8T!D-U*J!R"
MA>"$\4MT('JKFP$HP]+6Y>CTII$13=-G&-:(ACK&W=.$JX0+2BH*F%T/T=Y6
MC)"+@,-(BY#2UB8HLP(?*$CA<D!:95I1LY'R-DV%0B><+#9-<!2G=43'7R1G
M,RX14L-(56VV#I2I:O*C9HHHMM:1;6!E..;"(4+FK""J\0&U'\"Z4+( 0=(Y
M>NE4ALPF3=@9?&(1F,S@M]H&.HZL>WA=&Y'_20,%\S>1L#@.6V)\XSCC4>#H
MO8H.[R8H%D*;?EI]EWVF;B<Q*S+F(UQ!<Y*8[%C:<.BMSRTCPW:?SN#S$UMM
M'+VC?6FU-!H;X%L3LOTQO %D=0!IG;.9=8)ELDU7%!23Z$Q.9W"W(T5L+Z9I
M75 Q4;"!:]21S6T0+GCQ()1FU7_$!25L-Q73GHH+0RD.Z&CV<S$^ 0XB0M>^
M=: <<,'Q-Q%K/Z LC/I6=Z31K:%*DHEZ% TWV8Y0J4K9UH^2NRHW%B<"/@:N
MC<IV=4,0TM*]3?WH(?81.FZ]#4B'N0K@E+_G(E1LD"K)^UA=9.8IOI\(I*]L
M[6D$*>.#JYOAI(S4-=T\C,I2_!9@OJ2H5"#95KFC2W';U4+3N" OJ<\ERSB(
M(["-BPQ+X=R&85J/SKN:$WV>MKIC0+&PH4M.<W]W-7GZ.8Z7Z7AX0%1K'5\G
MJY7#%7<7%8/A$44CMF3J?G ]CO2WQV2(,L"3B=UC.W!%M>]C#5:5LY1K0J/X
M7J:38=K9:4C=]H/"-5%Q3<Y3,4:UV!ZJK'2,BRVP!YDRMF3B2YNC;J#Z*4QY
M+BMK.(V,%$WDW\__"T,R"&?LGI!%FV"KJ0O8!%6(*+G4R1=L&VX6K[#Q]/A_
M^]VBKCNZ#5;>M[?5Z[O;#V_V*A.S1_UF\5C14Y-G.77K7A5*>MIO;K@/ECS>
M>2CMU3D<3H[@%_AJM0@-V?LDC]X.QRSZAT*Z7_>ZG392[7[7NV6T]:0LT:WB
MP[EMYN9UV9_V;_.SYDGZ)-X\[*D=5M2J='<M274\?'N8T "(C^5F$VP5'ZB9
M#?3<C<N"_K] QP+T?6DI/>V&#?3_L<S_!E!+ P04    " "6.JI8LM><[+D"
M  "P!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RM5<MNVS 0_)6%
M4@0M8%@OO^ 7$"<NVD-2PT[2,R.M)"(4J9)TG.3K2U*V*C>)#T4O(G>Y,YH1
MR=5T)^2C*A U/)>,JYE7:%V-?5\E!99$=46%W*QD0I9$FU#FOJHDDM2!2N9'
M03#P2T*Y-Y^ZW$K.IV*K&>6XDJ"V94GDRP*9V,V\T#LDUC0OM$WX\VE%<MR@
MOJM6TD1^PY+2$KFB@H/$;.9=A.-%S]:[@GN*.]6:@W7R(,2C#;ZG,R^P@I!A
MHBT#,<,37B)CELC(^+7G])I76F![?F#_ZKP;+P]$X:5@/VFJBYDW\B#%C&R9
M7HO=-]S[Z5N^1##EGK"K:\/8@V2KM"CW8*.@I+P>R?/^.[0 H^ #0+0'1$YW
M_2*G\HIH,I]*L0-IJPV;G3BK#FW$46XW9:.E6:4&I^?KY?WRYFZYF?K:L-F<
MG^R1BQH9?8",X5IP72A8\A338[QO5#12HH.41722\)K(+L1A!Z(@ZIW@BQMK
ML>.+_\%:C>R]C[078:PJDN#,,R==H7Q";WY^%@Z"R0E=O497[Q3[25VGD3<_
M;I?0@_.S412&$S@0N4003^"V0,@$,Q>-\APT>6"XOVWT%15HLWPIRHKP%T<Q
MG"A(J2)Y+C$G[I*(S-RT)^1;5..&]G^/MX5$/#H]8/8^*=SF_UW\&>ZZFRZD
MQA:1"B@W-L16$9ZJ+^ZDV$?\!K;*C&79A)\@[(31L!5'G6@P> -;2/)*V5%9
MOQ\<Q:,@>.M(:,*:+P>9%"68SL/L-N1"I*K%$'<&P[:0?B=X1\CZB(O1Q/1!
M!.,:UN>DK"978(^E2;>IAV$KZ'7Z4?31'KQWC/U6%RE1YJY7*DC$ENNZH339
MIAU?U%WH3WG=R\UVYI0K8)@9:- =]CV0=7^L RTJUY,>A#8=SDT+\TM!:0O,
M>B:$/@3V!<U/:OX;4$L#!!0    ( )8ZJEB.&T1F#@,  -@&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;*55:V_3,!3]*U<9FD JS:/M-M:'U)4A
M!MI#:X'/7G*;6'/LS';:]=]S[:2EB*T@\25^W7/NN7Z<C-9*/YH"T<)S*:09
M!X6UU7D8FK3 DIFNJE#2RE+IDED:ZCPTE4:6>5 IPB2*3L*2<1E,1G[N3D]&
MJK:"2[S38.JR9'IS@4*MQT$<;"?N>5Y8-Q%.1A7+<8[V6W6G:13N6#)>HC1<
M2="X' ?3^/RB[^)]P'>.:[/7!U?)@U*/;G"5C8/("4*!J74,C)H5SE (1T0R
MGEK.8)?2 ??[6_9/OG:JY8$9G"GQ@V>V& =G 62X9+6P]VK]&=MZ!HXO5<+X
M+ZR;V/A# &EMK"I;,"DHN6Q:]MSNPQ[@+'H%D+2 Q.MN$GF5'YEEDY%6:] N
MFMA<QY?JT22.2W<H<ZMIE1/.3N:+V]E76-Q/;^;3V>+J]F8^"BWQNM4P;3DN
M&H[D%8X>7"MI"P.7,L/L=WQ(>G:BDJVHB^0@X3737>C%'4BBI'^ K[<KLN?Y
M>O]59,/1?YG#/8YS4[$4QP'=?H-ZA<'D^"@^B88'%/9W"ON'V/]1X6&.F]O%
M)0S@^.@LB>,A_$D)MQ*^,%G3XX-XT.QN!VR!,%-EQ>0&<LVDQ:Q#E] 6?H55
ME58K)D M]R-]DM.A@93&]$29?V(T*+FUB!V(HZ@311&8@M%N.30U5O.4Z!U)
M2>%SJ]+'#G#99,ISC3FS!+8*4M26+.6UM%A60FV0F&NZ<_K%F"EY!]U'8#*#
M>TK.7&IG5G#9HAL%<"53E,X<X$XPV0%F@+78MX[8,2;1T"WZ;CQ\UX6I$.1D
M:?'W"F%%\Z!6)).14(WX?H-,0X6:J\R5'R> 3S5M,GVT12TV-)MJ)!'DN+#8
M.R&BXJ6OQ"E;,JZ!3J?&[4;M:3 ^N6IV-R.,B_$G[#;XH3W;9T]'&=]$W80<
M1@@ZR:ZO.>J]>+7#/;<I4>?>4]U-J*5MC&<WN[/M:>-6O\(;SZ>'GG-I0."2
MH%'W=!" ;GRT&5A5>>]Z4):<T'<+^O6@=@&TOE3*;@<NP>YG-OD)4$L#!!0
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MC\HJT'DFI=ENK(/N/\3T/U!+ P04    " "6.JI8=)6@L1P#   G"   &0
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M[/?>#V,P%:/K=>BB%6+]Y@&-TTYK5G,?!C'6A%U:E=WW@,ONV++46%)D/1<
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MRQ+ /,G/!L7L;V<-ZN\!+*K!JZ-3\CM)C)0%66.8- 5R",^8ND%;%)NSR-6
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M\9FM;&5-W.)H>8RI&Y+!(E0T71.%0$]")>J>N6Q](^84ADEY'LJ3BDP:'!4
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ME!PD.1N> %R]EP4&?O=H!"4V!A; H)H4"S",Y(.ZEV7-,2_6$;N5U&-^TN/
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M    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;*54;6_:,!#^*Z>LJJBTD9!
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M$33H?J2)HIJ9TQA&5J[/%]+0U'#;G,8T*AM YYF49FO8!.W@CW\!4$L#!!0
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M&!)SD1@_?;47LDZ,R?AT:S>$G-,'84IBC%%[26NDS\R73^MC^\Y=AWYPWZQ
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MH_QPBU& D^P!?G]-^?M3GF0)JFWFV7]02P,$%     @ ECJJ6.EO;ZF% @
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M:)O[F(3!:!+[QPL<4<\1_1='SKB"(Q,-7D*(+B",1^$_"/[9]=N71&=XH"U
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M2[!0D.*L^(;/91 U@.!I!E@EP-H%'-K!+@&V,EHH4[9&D,.@1\D:4%DMV.1
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M W$I%2]JL8Z@H*QZDVV=ASV!]FD7^+7 ?RGHOR$(:D%@0:O(+-:4*!*%@F]
MF-7:S31L;JQ:TU!FON),"3U+M4Y%\\L?5S.XNX7KV\G=S15T9M7G!)["G&Q1
M@L[U-8MY@5WH3%$1FLLNG,+C; J=DRZ< &4PSW@I"4MDZ"H=E+%VXSJ <16
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M%5-)H#J'-KIV,RN^5X-KVL3'MEVG8NN<V78IRP!)_'(*KM.8..BTZ^MZQN@
MKUOA=4_BS3!5:2NO!1M9US)I7%_4,T8'9+[W]U7RSAV+ KA\-7<+_%Z30I4.
M4A4;14$)</OSX367.:PGTF(4^^$1W+U'U#]W1,X_!E9FOWG===KM^N:TF76C
MR*MQNWMU@"["U)/Y3'*!*"R5SKMJJ[#YKJ[9=20K3&GPQ*0J-$QSI6I!X-I
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M0-H \SX70A\G=H/A\Y/^ 5!+ P04    " "6.JI8O6/OHD@#  #0%   #0
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M,=M31M17FPW2@N_8"_O3\%Y,2!:^8UML,_)>,,@4OF-5O$N ^_@"2!V!:W5
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MU)L%Z,VH-PO0FU%O%J WH]XL0&]&O5F WHQZLP"]&?5F 7H;U-L(T-N@WD:
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MLR]02P$"% ,4    " "6.JI8!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )8ZJEA_7A;J[P   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( )8ZJEB97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ ECJJ6#%_8E?J!0  XQ\  !@
M         ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( )8ZJEA#Y7R+CP4  &H7   8              " @2X.  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "6.JI8W-';X\,$  #1$0
M&               @('S$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ ECJJ6'$R<9OE!@  KC   !@              ("![!@  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( )8ZJE@2,BP/@P(
M $D&   8              " @0<@  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " "6.JI8WLF;>*4'  #[(   &               @('
M(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ECJJ6 O7
M_'BZ'P  S5\  !@              ("!FRH  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( )8ZJECSS ')IP(  '$&   8
M  " @8M*  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "6
M.JI8_YVXTD8%  "]#   &               @(%H30  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ ECJJ6++7G.RY @  L 8  !D
M         ("!Y%(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " "6.JI8CAM$9@X#  #8!@  &0              @('450  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( )8ZJE@#Z5]#8P,  $\(
M   9              " @1E9  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ ECJJ6'25H+$< P  )P@  !D              ("!LUP
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "6.JI8DR0@
MF0$#  #2!@  &0              @($&8   >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( )8ZJEBRN][.""   ,9A   9
M  " @3YC  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MECJJ6&N6,F-3 P  P @  !D              ("!?8,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " "6.JI8W:8XCH\"   ?!@  &0
M            @($'AP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( )8ZJEC*N)W&< (  /P%   9              " @<V)  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ECJJ6)_N!HNJ @
M<@8  !D              ("!=(P  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " "6.JI8W:RX<8$"   $!@  &0              @(%5
MCP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( )8ZJEBK
M;E[B+0,  -X'   9              " @0V2  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ ECJJ6"K6"U& #0  ?+0  !D
M     ("!<94  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )8ZJEBS =;7[ (  )T*   9              "
M@7BP  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ ECJJ
M6%KG3I.H @  &P8  !D              ("!F[,  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " "6.JI8YE*?VI0"  !3!P  &0
M        @(%ZM@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( )8ZJE@]AO;2<P(  )<&   9              " @46Y  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ECJJ6*):;>Y4 P  :0H
M !D              ("![[L  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " "6.JI8KY)]OF\#   G$   &0              @(%ZOP
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( )8ZJECB%[U[
M2 (  *$%   9              " @2##  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ ECJJ6";:+PY$ @  B@8  !D
M ("!G\4  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "6
M.JI8O6/OHD@#  #0%   #0              @ $:R   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( )8ZJEB7BKL<P    !,"   +              "  8W+
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )8ZJEC<513B< ,  !L7   /
M          "  7;,  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "6.JI8
MC-]?K6X!  #=%   &@              @ $3T   >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "6.JI8!E="=X\!  !P%0  $P
M        @ &YT0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     *@ J %T+
(  !YTP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>74</ContextCount>
  <ElementCount>167</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30603 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncome</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30703 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesDetails</Role>
      <ShortName>REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenuesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40601 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails</Role>
      <ShortName>TAXES ON INCOME (Summary of Taxes on Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40602 - Disclosure - TAXES ON INCOME (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails</Role>
      <ShortName>TAXES ON INCOME (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40801 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="plx-20240331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  plx-20240331x10q.htm 9</Log>
    <Log type="Warning">[dq-0712-Presentation-Base-Set-Order] Role '40801 - Disclosure - SUBSEQUENT EVENTS (Details)', a level 4, Detail role, appears before '995410 - Disclosure - Pay vs Performance Disclosure', a level 1, Note role. https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd 30, plx-20240331.xsd 111</Log>
  </Logs>
  <InputFiles>
    <File>plx-20240331.xsd</File>
    <File>plx-20240331_cal.xml</File>
    <File>plx-20240331_def.xml</File>
    <File>plx-20240331_lab.xml</File>
    <File>plx-20240331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="plx-20240331x10q.htm">plx-20240331x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20240331x10q005.jpg</File>
    <File>plx-20240331x10q006.jpg</File>
    <File>plx-20240331x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="250">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "plx-20240331x10q.htm": {
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "plx-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "plx-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20240331x10q.htm"
     ]
    }
   },
   "keyStandard": 139,
   "keyCustom": 28,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 19,
   "memberCustom": 14,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 74,
   "entityCount": 1,
   "segmentCount": 33,
   "elementCount": 356,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 250,
    "http://xbrl.sec.gov/dei/2023": 30,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DqFs6ZdUS0WsAvycUW3EDw",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DqFs6ZdUS0WsAvycUW3EDw",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "longName": "10201 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "longName": "10401 - Disclosure - REVENUES",
     "shortName": "REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "plx:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "plx:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "longName": "10501 - Disclosure - STOCK TRANSACTIONS",
     "shortName": "STOCK TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncome",
     "longName": "10601 - Disclosure - TAXES ON INCOME",
     "shortName": "TAXES ON INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "longName": "10701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "longName": "10801 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables",
     "longName": "30103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_DSkPUZ0Ock24wWZtXiDMDw",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_DSkPUZ0Ock24wWZtXiDMDw",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "shortName": "REVENUES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables",
     "longName": "30603 - Disclosure - TAXES ON INCOME (Tables)",
     "shortName": "TAXES ON INCOME (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "longName": "30703 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_9OeDCEh91kqDTYHwfDEKIg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_9OeDCEh91kqDTYHwfDEKIg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
     "longName": "40102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Convertible notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:OtherNonoperatingExpense",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w",
      "name": "us-gaap:AdditionalPaidInCapitalCommonStock",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "us-gaap:DebtPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "longName": "40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "shortName": "FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0aoQ1IPKS0aCMthAjitzGQ",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0aoQ1IPKS0aCMthAjitzGQ",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "shortName": "FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VN0lXe7Da0uVnHnA1AZ-Ug",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VN0lXe7Da0uVnHnA1AZ-Ug",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.protalix.com/role/DisclosureRevenuesDetails",
     "longName": "40401 - Disclosure - REVENUES (Details)",
     "shortName": "REVENUES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_plWIvGvIFUyhx5jpML44MA",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "longName": "40501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
     "longName": "40601 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)",
     "shortName": "TAXES ON INCOME (Summary of Taxes on Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
     "longName": "40602 - Disclosure - TAXES ON INCOME (Additional Information) (Details)",
     "shortName": "TAXES ON INCOME (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
     "longName": "40701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "longName": "40801 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kD3z0qQXkGKOLbaYW_hYg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kD3z0qQXkGKOLbaYW_hYg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20240331x10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts payable and accruals - other",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r534"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r12"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r510"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r40"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Additional amount payable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs",
        "terseLabel": "Additional amounts payable to cover development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r424",
      "r637",
      "r638",
      "r639",
      "r685",
      "r707"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r132",
      "r133",
      "r134",
      "r135",
      "r144",
      "r174",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r277",
      "r278",
      "r279",
      "r290",
      "r291",
      "r292",
      "r293",
      "r302",
      "r303",
      "r304",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r355",
      "r356",
      "r359",
      "r360",
      "r361",
      "r362",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r381",
      "r382",
      "r383",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r250"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r556",
      "r567",
      "r577",
      "r602"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r559",
      "r570",
      "r580",
      "r605"
     ]
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "AgreementAmendmentPaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement amendment payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r571",
      "r581",
      "r598",
      "r606",
      "r610",
      "r618"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "plx_AmendedPfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "AmendedPfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r357",
      "r521",
      "r522",
      "r632"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r103",
      "r125",
      "r156",
      "r162",
      "r166",
      "r176",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r307",
      "r311",
      "r343",
      "r387",
      "r452",
      "r534",
      "r547",
      "r648",
      "r649",
      "r694"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r109",
      "r125",
      "r176",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r307",
      "r311",
      "r343",
      "r534",
      "r648",
      "r649",
      "r694"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AtMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "AtMarketEquityOfferingMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "country_BR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "BR",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil"
       }
      }
     },
     "auth_ref": []
    },
    "plx_BalancesWithoutAdoptionOfAsu202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "BalancesWithoutAdoptionOfAsu202006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to balances without adoption of ASU 2020-06.",
        "label": "Balances Without Adoption of ASU 2020-06 [Member]",
        "terseLabel": "Balances without Adoption of ASU 2020-06"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r102",
      "r508"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r71",
      "r123"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r71"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Change in amount receivable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "plx_ChiesiAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ChiesiAgreementsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiExUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ChiesiExUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex-US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ChiesiUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex-US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r155",
      "r220",
      "r221",
      "r222",
      "r224",
      "r227",
      "r232",
      "r234",
      "r417",
      "r418",
      "r419",
      "r420",
      "r523",
      "r624",
      "r633"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative arrangement revenues and expenses sharing percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r45",
      "r388",
      "r438"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r541",
      "r542",
      "r543",
      "r544",
      "r637",
      "r638",
      "r685",
      "r705",
      "r707"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r439"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Current",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Convertible notes",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Debt instrument fair value",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ConvertibleNotesDue2021And2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r125",
      "r176",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r343",
      "r648"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r628",
      "r640",
      "r643",
      "r644",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r692"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment",
        "verboseLabel": "Effect of Change"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r131",
      "r138",
      "r144",
      "r180",
      "r186",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r316",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r328",
      "r331",
      "r333",
      "r334",
      "r368"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r131",
      "r138",
      "r144",
      "r180",
      "r186",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r316",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r328",
      "r331",
      "r333",
      "r334",
      "r368"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r131",
      "r138",
      "r144",
      "r180",
      "r186",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r316",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r328",
      "r331",
      "r333",
      "r334",
      "r368"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current taxes on income",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r289",
      "r297",
      "r636"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50",
      "r51",
      "r86",
      "r87",
      "r127",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r358",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r634"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Debt instrument carrying amount",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r87",
      "r218"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r203"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Measurement input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r127",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r358",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r634"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible notes",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Changes in deferred tax asset",
        "verboseLabel": "Deferred taxes on income",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r83",
      "r92",
      "r296",
      "r297",
      "r636"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r239",
      "r240",
      "r241",
      "r451",
      "r528",
      "r703"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's Disaggregation of Revenues",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - BASIC",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r145",
      "r147",
      "r149",
      "r150",
      "r151",
      "r153",
      "r334",
      "r335",
      "r384",
      "r395",
      "r514"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - DILUTED",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r147",
      "r149",
      "r150",
      "r151",
      "r153",
      "r334",
      "r335",
      "r384",
      "r395",
      "r514"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r285",
      "r298"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "EmployeeStockIncentivePlan2006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r96",
      "r112",
      "r113",
      "r114",
      "r128",
      "r129",
      "r130",
      "r133",
      "r141",
      "r143",
      "r154",
      "r180",
      "r186",
      "r235",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r333",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r370",
      "r406",
      "r407",
      "r408",
      "r424",
      "r478"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r556",
      "r567",
      "r577",
      "r602"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r553",
      "r564",
      "r574",
      "r599"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "plx_ExtendedTermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ExtendedTermOfAgreement",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended term  of agreement.",
        "label": "Extended Term Of Agreement",
        "terseLabel": "Extended term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r338",
      "r374",
      "r375",
      "r376",
      "r519",
      "r520",
      "r526",
      "r527",
      "r528"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r338",
      "r376",
      "r519",
      "r520",
      "r526",
      "r527",
      "r528"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r374",
      "r375",
      "r376",
      "r519",
      "r520",
      "r526",
      "r527",
      "r528"
     ]
    },
    "plx_FillFinishAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "FillFinishAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fill/Finish Agreement [Member]",
        "label": "Fill/Finish Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r460",
      "r545",
      "r689",
      "r690",
      "r706"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r581",
      "r606"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r581",
      "r606"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r581",
      "r606"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r581",
      "r606"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r581",
      "r606"
     ]
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "LOSS BEFORE TAX BENEFIT (TAXES ON INCOME)",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r64",
      "r89",
      "r156",
      "r161",
      "r165",
      "r167",
      "r385",
      "r392",
      "r516"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r281",
      "r286",
      "r287",
      "r288",
      "r294",
      "r299",
      "r300",
      "r301",
      "r422"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAX BENEFIT (TAXES ON INCOME)",
        "totalLabel": "Total taxes on income (tax benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r93",
      "r142",
      "r143",
      "r159",
      "r284",
      "r295",
      "r396"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease in accounts receivable-trade and other assets",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Increase (decrease) in contracts liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r631"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r571",
      "r581",
      "r598",
      "r606",
      "r610",
      "r618"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r552",
      "r622"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r552",
      "r622"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r552",
      "r622"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r121",
      "r122"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "verboseLabel": "Interest Payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "plx_InterestReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "InterestReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r511"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r509",
      "r534"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r513"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r512"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r125",
      "r176",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r308",
      "r311",
      "r312",
      "r343",
      "r437",
      "r515",
      "r547",
      "r648",
      "r694",
      "r695"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r88",
      "r390",
      "r534",
      "r635",
      "r642",
      "r688"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r101",
      "r125",
      "r176",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r308",
      "r311",
      "r312",
      "r343",
      "r534",
      "r648",
      "r694",
      "r695"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r48",
      "r49",
      "r52",
      "r125",
      "r176",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r308",
      "r311",
      "r312",
      "r343",
      "r648",
      "r694",
      "r695"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and R&amp;D Services",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "plx_MaintainOfMinimumCashBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "MaintainOfMinimumCashBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance",
        "terseLabel": "Minimum cash balance required"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r249",
      "r378",
      "r403",
      "r429",
      "r430",
      "r483",
      "r485",
      "r487",
      "r488",
      "r490",
      "r504",
      "r505",
      "r517",
      "r523",
      "r529",
      "r536",
      "r650",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price.",
        "terseLabel": "Stock price",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "plx_MeasurementInputYieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "MeasurementInputYieldMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "auth_ref": []
    },
    "plx_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "MilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment received upon achievement of certain milestone.",
        "label": "Milestone Payment Received",
        "terseLabel": "Amount of milestone payment received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r249",
      "r378",
      "r403",
      "r429",
      "r430",
      "r483",
      "r485",
      "r487",
      "r488",
      "r490",
      "r504",
      "r505",
      "r517",
      "r523",
      "r529",
      "r536",
      "r650",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "NatureOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS FOR THE PERIOD",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r73",
      "r90",
      "r99",
      "r110",
      "r111",
      "r114",
      "r125",
      "r132",
      "r136",
      "r137",
      "r138",
      "r139",
      "r142",
      "r143",
      "r148",
      "r156",
      "r161",
      "r165",
      "r167",
      "r176",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r335",
      "r343",
      "r394",
      "r461",
      "r476",
      "r477",
      "r516",
      "r545",
      "r648"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "New accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r560",
      "r571",
      "r581",
      "r598",
      "r606"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL INCOME (EXPENSES), NET",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "plx_NumberOfGlobalLicensingAndSupplyAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "NumberOfGlobalLicensingAndSupplyAgreements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of global licensing and supply agreements.",
        "label": "Number Of Global Licensing And Supply Agreements",
        "terseLabel": "Number of global licensing and supply agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r161",
      "r165",
      "r167",
      "r516"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r534"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES",
        "terseLabel": "Financial expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r558",
      "r569",
      "r579",
      "r604"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r561",
      "r572",
      "r582",
      "r607"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r561",
      "r572",
      "r582",
      "r607"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "plx_PaymentOnNetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "PaymentOnNetSalesPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage",
        "terseLabel": "Payment on net sales percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r630"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement",
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r53",
      "r81"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "plx_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678"
     ]
    },
    "us-gaap_ProceedsFromCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromCustomers",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Customers",
        "verboseLabel": "Total proceeds from sale of products",
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r380",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r506",
      "r524",
      "r535",
      "r627",
      "r646",
      "r647",
      "r651",
      "r704"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r380",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r506",
      "r524",
      "r535",
      "r627",
      "r646",
      "r647",
      "r651",
      "r704"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r110",
      "r111",
      "r119",
      "r125",
      "r132",
      "r142",
      "r143",
      "r156",
      "r161",
      "r165",
      "r167",
      "r176",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r306",
      "r309",
      "r310",
      "r335",
      "r343",
      "r385",
      "r393",
      "r423",
      "r461",
      "r476",
      "r477",
      "r516",
      "r531",
      "r532",
      "r546",
      "r629",
      "r648"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r386",
      "r391",
      "r534"
     ]
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r242",
      "r249",
      "r273",
      "r274",
      "r275",
      "r377",
      "r378",
      "r403",
      "r429",
      "r430",
      "r483",
      "r485",
      "r487",
      "r488",
      "r490",
      "r504",
      "r505",
      "r517",
      "r523",
      "r529",
      "r536",
      "r539",
      "r645",
      "r650",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r242",
      "r249",
      "r273",
      "r274",
      "r275",
      "r377",
      "r378",
      "r403",
      "r429",
      "r430",
      "r483",
      "r485",
      "r487",
      "r488",
      "r490",
      "r504",
      "r505",
      "r517",
      "r523",
      "r529",
      "r536",
      "r539",
      "r645",
      "r650",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r553",
      "r564",
      "r574",
      "r599"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r280",
      "r702"
     ]
    },
    "plx_ReserveForDeductionsFromRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ReserveForDeductionsFromRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of reserve for deductions from revenue.",
        "label": "Reserve For Deductions From Revenue Current",
        "verboseLabel": "Sales reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r554",
      "r565",
      "r575",
      "r600"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r555",
      "r566",
      "r576",
      "r601"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r562",
      "r573",
      "r583",
      "r608"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock",
        "terseLabel": "Shares of restricted Common Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r80",
      "r389",
      "r410",
      "r415",
      "r421",
      "r440",
      "r534"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r128",
      "r129",
      "r130",
      "r133",
      "r141",
      "r143",
      "r180",
      "r186",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r316",
      "r319",
      "r320",
      "r323",
      "r333",
      "r406",
      "r408",
      "r424",
      "r707"
     ]
    },
    "plx_RevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "RevenueDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r125",
      "r157",
      "r158",
      "r160",
      "r163",
      "r164",
      "r168",
      "r169",
      "r171",
      "r176",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r343",
      "r385",
      "r648"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r533"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "SaleOfStockMaximumOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r61",
      "r62",
      "r63"
     ]
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Schedule of ASU 2020-06 on the condensed consolidated balance sheet",
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r30",
      "r31"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r78",
      "r79",
      "r80",
      "r104",
      "r105",
      "r106",
      "r155",
      "r220",
      "r221",
      "r222",
      "r224",
      "r227",
      "r232",
      "r234",
      "r417",
      "r418",
      "r419",
      "r420",
      "r523",
      "r624",
      "r633"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r426",
      "r427",
      "r428",
      "r484",
      "r486",
      "r489",
      "r491",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r507",
      "r525",
      "r539",
      "r651",
      "r704"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the vesting of awards in number of quarterly increments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting, Number of Quarterly Increments",
        "terseLabel": "Vesting in number of quarterly increments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Number of shares granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShortTermBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "ShortTermBankDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r20",
      "r96",
      "r112",
      "r113",
      "r114",
      "r128",
      "r129",
      "r130",
      "r133",
      "r141",
      "r143",
      "r154",
      "r180",
      "r186",
      "r235",
      "r277",
      "r278",
      "r279",
      "r292",
      "r293",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r323",
      "r333",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r370",
      "r406",
      "r407",
      "r408",
      "r424",
      "r478"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r426",
      "r427",
      "r428",
      "r484",
      "r486",
      "r489",
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r507",
      "r525",
      "r539",
      "r651",
      "r704"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r154",
      "r380",
      "r416",
      "r425",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r540"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r154",
      "r380",
      "r416",
      "r425",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r478",
      "r540"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r557",
      "r568",
      "r578",
      "r603"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r55",
      "r80",
      "r417",
      "r478",
      "r492"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance cost",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r55",
      "r80",
      "r424",
      "r478",
      "r492",
      "r546"
     ]
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r75",
      "r441",
      "r458",
      "r479",
      "r480",
      "r534",
      "r547",
      "r635",
      "r642",
      "r688",
      "r707"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r124",
      "r219",
      "r221",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r233",
      "r235",
      "r324",
      "r481",
      "r482",
      "r493"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r372"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r372"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r372"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r372"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r372"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r373"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "SupplementalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Supplemental Information, Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "SupplyAndTechnologyTransferAgreementWithFiocruzMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to supply and technology transfer agreement with Fiocruz.",
        "label": "Brazil Agreement with Fiocruz"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r641",
      "r693"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Adoption [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r132",
      "r133",
      "r134",
      "r135",
      "r144",
      "r174",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r277",
      "r278",
      "r279",
      "r290",
      "r291",
      "r292",
      "r293",
      "r302",
      "r303",
      "r304",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r355",
      "r356",
      "r359",
      "r360",
      "r361",
      "r362",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r381",
      "r382",
      "r383",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20240331",
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- DILUTED",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r151"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- BASIC",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r151"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-12"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-13"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001558370-24-007695-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-007695-xbrl.zip
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M]K>!TA)GF<'N?:5TG([=Z)S;0C@'(93?$[LI@9WNDJW=7NBKY"NK05\YJOT
M+]GK@M.L]^Z:X"_7]0AW*6L2[WM?UW5*IWF( Y&97'LY93]4$/B>ZRK;G5$G
M1^K>JYF.V?A,[YS8'<"IN]"W,[*'?WNXDBF^#)KBX7V_WY%'>&N#OXQ6NUOK
MUMNUSLO)7K#1K=[@3MYW:'SRFF.X[3&0/3:\%D%QLE&GL]FOI)7J2O672VLW
M9\2OB\6KJ_+Q^_EF;0];XBBW\AL<$O/IU]M3D!#L_;OAU="P>Y?#*.EM>.*,
M49L"I(9S(C=D^@V94DB)=B@D<<;X3 %2PYV1P1"X$J5)!NGB4H/WYQZ 546<
M&AXN< $,Z I9RK2^3IU-4I50'G[O8>BN@%=XO,-O_G-O<DA-,(N@<,=2,D+M
M(=$??K_AWKU8QHR4QDXA*3-"<5J$B=L!#]-SW7AGB\)4=;R06]_E*4?W-MOH
MSJJ6,2/D[0E8?:M>6$CC<V$M>_CS@#C^_?]02P,$%     @ ECJJ6!J\3!O9
M'@  Z<$! !0   !P;'@M,C R-# S,S%?9&5F+GAM;.U=ZW/B.+;_OE7W?_#-
M_7!W/Y!'IWMVNFM[M@@A/=0FD 72L_NIR[$%:,=8C&PG8?[ZE6S #_0R?DCT
M4%/5$^!(.K_ST./H2/K;W]^6GO4"< "1__GLZOSRS *^@USHSS^?1>&L\^/9
MWW_ZGS_][7\[G7_=C.\M%SG1$OBAY6!@A\"U7F&XL*9HM;)]ZP%@##W/NL'0
MG0/+NKH\_^'\W?D'J]/Y*:[BQ@Y($>1;<5WOSJ^V/_0VM2'_D_7AXNKRXMWE
MN_?6U=6GRX^?KOYJ=1^VA ^$M1F44GK0__43_>>9M&@1C'[P^6P1AJM/%Q>O
MKZ_G;\_8.T=X3DI?7E]L"<\2RD]O <Q1OUYO::\N_O5P/W$68&EWH!^$MN^D
MI6@UK')7'S]^O(A_W9&2YMUP1YOEYL-%\B,A#>"G(&[J'CEV&"M("L'B4M!/
MG2U9AW[5N7K7N;XZ?PO<+5][""1R(K]" ?U.0C_]R;(2G6#D@3&86;$X/H7K
M%?A\%L#ERJ.5QM\M,)A]/EMY;QVJV<OKA,/_FX3$0*CE]9#O I_8$?DC0!YT
MJ>'L?@U&L]$*X%A<P9E%FWL:#W(\KC *;0^^G3MH>4$)+@ZK^Z)55+V%[<]!
M,/ G(7)^72#/)4[;_RV"X;IGKR!!= MFT('$>]?UXR[7>AV2N86!XZ$@PN#.
MAOBK[47@ =CT,V5I:C][0%F_:G75R_4$SGW24SFV'W8=!T5^2+K41R);(J3@
M%H0V] [@7ZW6%I$0@R&C1PB)"(<H; H9MY7F+8UV]F[D@=%L]VLW"*+E*NX%
M#H9;H:GF,7==%](V;6_@SQ!>QCU>K5#%+=2+< Q>@!]5,,V]"FKV+]JE3K'M
M![93S:CX-=7,<?0<@-\BHL?^"QT?#F>85U&&7QL[6Y8W?Q9; ,'2/@<11BOZ
MOWBB<P$",+O8T%^\0C)<=7P;8_0*\)D4.FM"XV&\JX\VV-E\(#*Z^K%S==5Y
METBIV!9#\N75:ONNC=VN[_:B($3+[AL,;M'2AL1E9G;DA4$)8U.N*R^? RR(
MP@NVT]N9'3S'@HR"SMRV5W3>?GT!2'OT&UIE0'F^COD%P%WN6]->%8DR".U%
M_RTD\Q<Z/O1]LCY)YFCW, C+V-).U] /+URXW.G;]KS#C"8SGZ<S[@\QN+BV
MZDR1OREDY'?<1'$ULLBHNU:&8WMKAM]-U36P&]?468+E\Z%]!IO7?+W5&5T0
MGK 3/8/.3@PULLNL/<,T,1#HP\3=_%\W;5"^JKIM%@&@="YP=]_"D#:0%K<R
MY:VD.[,>8@D');FML3,6\O[QX\?+2ZMCI363#]O*+5*[E51OT?JWD'8M4$1;
M3!YR<@UZ-%J \,%],?TF[8HW7WQ+UXJ>'9 583S7H+QMV_'L9^!]/I/2?[LJ
M2$*IQ$7[B+-LW.9ZK +4?4(N1C9I#EQJHEV<ATD<?EOM#*-E.5DC&1-10)I
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M=8U[Y,]#M=PB%BG74GC$!D 4N@2;6!EF?>X@D392X:%U5V SG74$/K.:1X@
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M3HV57STPP;0M[Z1M9IA[_V<#YO4"&]G*-,]S,_W'XR94<0/1= &PO0)1")V
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MTW.HI^=03\^A?G_/H5:^Z^/T/*K^GO*/_#PJ<#<3XXIOI.[5H[OK;/JAU#W
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M^IX>U1,,=ZJ%S=C1TC4$JDK)(&/(3*N#?9Z%8V7).@P:0,NY E/#:I@-4O3
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M@"8Y.)+YG\$^O-'B32-'D*X+M462)74I\SULE3ZGJ?QXJQD*8CQI($HMK-3
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MWGV/-/^=.0PY.LGP"[,[DFZ@EDG:R;$O43_K147.0!?'>^X=WYN%$V?GITX
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MOYFA_/;7/^3?L/] 492__C]02P,$%     @ ECJJ6"0(\>96+@  D^4" !0
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M?,+648!31$E'/A4#OPOPA&A.@?PP2>O +A2.<4BT03#S-.UVMVKN!EUU&R/
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M(QV7OYRA%G1\FO.$W4=)33-<?.@RZNF[7 ;LI+U[ZXWG1@>Z\@[-7'FTHH(
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MHX<FIFT$E@+],[^0C0^X<AC2(;ZWRMC_<AAQD-G"!4O1DB_\H!.651+DKSO
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M_+*O U/;5)!2B/QM22-T@TUJA-+TB491B-?CKRO B%S/,$0LM1\@M9T:;O9
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M3U%?-GOC"C$<4JRJR( <CF1:4]-RFDXK\BA)$"3)#M,$&&WVQM>_:*LRZ!A
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MK8]NR!O5L#),((^M;J_D-4^#']@G@ 86X\4),^>^#1&@Y"F8"7\/,$55(2)
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M.N2&#9VO<)VVG=!W&GAK]P=DH?5%(P?RR#MNV):Y0HTO=-@T;!:SX5 <M*9
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M@=[$U5!Q6#/S?)X\]?AHIS%YTFF8+809C N@C=(H(9I,=G>TQ 6Q,]ALW[0
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M2B)<RZXG P(>X1__,O1#-$R_A1TW%U7[(\I/37AUC-\D6CITY(:>V^9$1RB
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M1(,B"E3*HS\U$%Z$@8^\B?2E)"!;!6T@01NKY"E$&SVA?_8*RV1R/N_GY&A
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M6&,D1> OJ"_Z*/!54>#VK[!]56WPXRC0&0]R::8R?6I'LQFMUV'XK3X= PJ
M2GCL$O2+QG\!G^ ;M]<DEW+\VVO^-91/<")>>^6W)3&N<GWMM+!X\1J*.#47
M6V8NA.1 H3[M;YY4WAACW9'4D8_2QU7D?6^CCQ_?\AK;%PD[?P@^GJ/&IJA9
M0]/LM^7H6!:&E7)RU&V, 36B</LU%@KZY>>_H/_Q8*WVR(""1B:9@I\W]%7S
MAOPD.3])SB?V>[_==N/$[KN2[NBZ6R9?82LI_[J;GXKR.8K K:>B^/?B?"ZY
MO@;A<XGO,;@QC\'A!3K),"Q>%4@&NZ#-9AIL@R;(%.0SZ90Y013<@C H=JPC
M/VOIWDVI<\::[LDQ'/ )]AL3[.WGSGRQ2(8W7R;O2)CJ*$7D2Q/$RZG*[_W\
M,,G4VTNN.0ZD8O%Y;]06V4&05'IFP@_!D%_L^4LY.5[+EQE)*J89/TO&CW+[
M63*74V9\3OBVG.#G>UQ?2WHAWR/CRKY7\SW*V[X9C)NI,+W9/-5KH<Y("*ZP
MNI3X#'7IJP#'/;EOZ+=C0EPFPZ5:5#5#<;U4CJUD.:K!MCC*_KE)52L4"1NQ
ME;3] U=OYSMLB:NTFN<,%=TE+7SA6RC?Q.MSM.X[3R?F1B,DF-41MQ9(A_0&
M;Z*J"B(#_H.[R$LL%%33:"##U"7!1"+\@57%PP\\(_.JH%AP*FG)F&L&KV0Q
MBL_Q-_#OL%!)M9#HE,W7U%?3E)F5:<V>$N5&6](8N;0U"IL1OQJ$:$A3COE7
MW'QP^5(>NL\'E\LJG[<-+HMQMH+4@M[AHO*H.<K$^#JKC0%<()OY.)79OSEW
MSY[ =ZBV%:Y%Y2NI!L<V.?S#Y^BQM[9!M^,?^1IWJF\RD^F+M73[(XE2P[NG
MB<?-1!TYXY5=MCP[58IATMV,%2LK<=U*A6>90*QK-EA8;@AZS$=B$;\MG(\?
M7R?'ZXLY2:^.'SIMFDVKW!!E?F9&^DMQ$=.7*U@N.%HC#XG@10#$=[3>L*,U
MR9;82HH#3^N+BBC%MJ@DE\U7*I"4CT?6N$:^FO;]K%_7%?*=:GY=7,RPQJ Z
M&C#!G6")Q+AHH!YN]>E%RXH9+-.9+(*KZPB6$W(BM=8K,6.UWK13@6B_D(WW
MBI%,?1 *@IX9##U$0^&+*9H^$'Q5(+A]Q^AG T%P4(GH:[G&Y-+M(K=@MV;1
M5 O!*VF8)X @'5:R?$Z;I^E-,9D,ZF(GW.@0( "%,?; ,(R?R/C-W)?O51@Y
M_/E%5,5;VZS;<44<8FL(8ZNH64,%W80@^<RLQRLL_0;DRM[QV95CA6QAV%NW
MF_V68&TGA?ZZ<SOZ99QI#SK#;*LCSYBT/(T'DA$VRPY"I E!,/80I!.^(]-'
MCVMEBGYO] @-UM.QH'4;LTU[$:KW*O$A&D<+MZ.4KB3#4OOQOLYU)\6%U4&5
M)6L0],!*:2CT0(>.ZPKZ7LQ3>NK?)H^)_/SS?#XQS\#=N)T%"%=GWCGS2\_S
MVC/SH(" B1_IS\\>IO0>';TU010O"-H,3W #5X]4S<0SX77\L4I)^-%CG5>H
M.:^3Y@YP-1H# EX=E/;%/Q&3G,?<Z-Y>PH,-$W] JD@_[K3Y2Q_(>RE:E);_
M_@_^Q_V>H"!>!XZ>/*.V$+S$X6>:_N^+ /C1T>&W1#SS)/_^'^]T]Z 2$#1%
MTW^Y8L>SCHE]P$&",F,4&.J(EP/\"+_J%Z^L^(WAK"L>?PR&73_+KYWH@I53
MD<=X_+^I_8^P_J/-F_'K@&>+'$RS2_'9WW(_(J+*_0SZ"6*H_:4CA3>E)8)G
M'SR5G(.IS2]W",^X)43ON86G)CK(NO]J55,GT0E^QH"/99KRCY>CG(\P3P%6
M K>D0'2JT)77H4#^/51XN*>G-NL\>W"$!F]09JU1;;&E?(]*YJNM'-=@:UR[
ME4\U'VS'7[Z2>CPCJ__N[%+52IJK-+DTA7]J5DOY--O"OS1;^/_*Q-/@NB%(
M_:A/PF(\L9_MQ^8CUA(5A=<-Z)5C3C3+P(J7\=>G"H0]B?]LJ[PE8N5%/.<,
M#A>=<E,?_[*I ["88?ZA@C<NGGFB.P["43Y"AT:)P1 /'81#\?" 1PP:Q!*A
MH" (H6"$C_ZP&9IWM<VHTI]6Z*=LC-X(?6G;W^@--C*&=('G(V6$JN%:0V5D
MJ:B;XV$]WLH7QX/@\4AC)J17Z?ZF*1?']:# /G'QN<#BD9'G(P>1:#H7"C)\
M.U J1[F.O JT@G6LJ]//1\;:>BJ]R%0:<LI",I>;**UJ93P(GQ@IE-M:O*E5
MZ&HMFPBLC4XS/67QR*-Y;I1U5VR&<V,NL"TRTW:Z&(C5ZGCDT3QKK-R.#R)B
MJCV+BWIKUHF4\SEV$#E^.Q\?!VBUN'Z2%ZUM,V<41_%FH(Y''KU=#<;B-"^&
M(G1Q,ZLF:+,@6]H*CSQZNUS-;.8EM(ISS818DJ(+1FPSXT'T^.U]B1:443_>
ME9NCCIYNJ%:OF5T-8L<CR_U&/B$DQ*(LY7M%)L:W*N:8Q2./YAFRNLMF-B;1
M--:.5GQ(WBCST!B//)IGT337HVIVRLA=H;:>BG'%'#^Q@_B),^I&^OS # FT
M59;B;*>_+#3J=3SRZ.UF:K%NU-@(/O?L*,6GFM6)AF"D^W:BX^\T#=O0%0"W
MY@;ZY?[@9<(HYBM'VP"Q)=CBSE6DB!K 6Z;F?F K >23 U7!8P\Y8X[%OJF[
M$W->R-A<_S[G>8QYC+P:)_#(8L_S-?S,D:*M7,1P?P^ L??+UJM6>)_>5&D<
M("(O=H?R0ZP[6R;Z#/WF94OPT.#Z+2W:^?</'6W!5U->_'.YSKDPC^&P?RXW
M>"[T&P6I_8/Q@<P_%Q_(;OU<$H^Q5VN-^^=R+7YYM?:=?RQ_="R_F?/SIMER
MM4V(_\8F7%2N7G4'CGR4O[DEV*:&#__W1^3'1[<G_)@(7S55,OX>Y^/[<\9:
M$QTAJHS_,#$HCK07/U-&V!O(=K^$Y(/*S8%*_*T->(T%7(?Y\W^/^& ''\&/
MP@>#U>/H5X*/,J\+$WN[0HP3F((\M[-EE?J$XQ).\+K7$3Z'<$*^\+F$\+FU
MW*C7**/9KM5*)(3,-IZH?"53;9395KY:@<IR^4J':[9( Z)*^F0[(JI2A2(>
MG6JI W_81Z#/UZ<H>(/W JZ0K J.'G\;Z&N5][BM??"YPN>*Y][&;[\-1 OY
M*KMP3V:OVX7(PDHF;Y#<P+FNS?%T-Q2OBA1:6-(<,F;OP4:Y2<(.'WG!ON*U
M%/I$A83O=@?ELRMYS2635[CU'*FB9%HZ@HJ/EJXC,6F9%<U\0F:-E\03MT^6
MJ,:J>IHKMJ,+%)$+Z]93LPC9<R&H57Z1FR<^[W]9WG=4F&LO\Z98_])%N#[,
M^BMA%&4J/!.@J_VTB+)LN#@*KC#KP[VSX*4NG=TIY]^Y"\G1[9P2O^J84J#<
M&D6X Q0]"__"&P8R#4H;FKRD(A%N 2"G#!O0(Z7B.6C/'J!(/-G!<S6!\NWA
MU^SAJP/K9^F.-[CTFY(IEU4G&["^ZJAM(!8@H>H 0EYUJS)F-'V')"7 @9(#
M YL38D;*,/UA-3TKTM5DN+1JFND^6QL/(D3#C%]0P_1QY-OBR(NNM*NO_*9@
MY+*JZ7EAI)"/HIJ<3&:Y6;6ZRM>7FS';@.M3H*TRQWT'?$_D_7HBZ=\->*;S
MS52IVFPWN%TG+><"[7UD5-RL\/AF:W[KXLH5FME<*RKYS4[^ZM1^ML*D;UU:
MN (-'^9Y^5ZD._<BY2&+#1DF-><ET3?7?'/-=_M\!;>/R]80+JB@4PTWRL5F
MQ13Z5<1E43/7::FY8DZ TA#05S+JNW)\;/!=.5_2E?,V-$R;%3'590(CKEA>
M=+I9=C.9(:A$ Y75'^A8W'?0?"$'S7-%4$<"DI;H?,K@79Z@GQWB9X;=B$XW
M5]8[T&XXS/D"<+/=?FQ4K,YH*3Y72\MA-S[!.EV<]& ,^?E?/H?[^5\WJ)F]
MG\%'G!I8K+LY5N:%]$R5)W))ZP*#8\WL@FK97?*W7T;\Q#S]F7V] N>B9,P5
M?@.<[Q3+?/<>*)** DY=G?<2./W^D[G]XN=1O_BY?0Y?N/BY7[S\>':5:HMK
MVC-I5:D72ID[M\O9DJ>H^940]WD%\3\M:&_7*(9=8)KY;"6?R:?82HM-I:KM
M"MRNK^%-2.6Y)M3?#KLED&WMJF+-\'*$<QB"AXZY)&](1G54PVH@W@[R/%85
MFWA_I!'6V%23Q5+%@BKGXQJ6$8*$C!:>0%+1!-G1$(>#HE#6YRVY4Y6+P41V
M':MT+758M[5:4AZ=-5\9-X!AS \*8<USCJ=FZA8Z&PH<T>CSX][# AR,39V,
M_7\!RG-,U/Z<*/>@"%5<Z(! /Z_P<!^C.G*2W+"8)F>P.3Z!7*ZG6MO&>"#/
M)#:W& W6Q9!RX@1.CWOA!-Y7*7LG6WX\]S[:_!"*/M?@_W[%-"#\B>7"*\9!
M_%(6P0NTLE,/]U*%2"[[W?SC*8/G=N:712HF'N633)0]3T7"MD32-1.?[)I*
M2AI64O$Q(@N?M_% Y57AD?H)9(0$0$AE0ZTD<T))ID$9UM"01(G7,=P\$&T5
M%+T@_4_*UG#);\P_?Y%KQ?"%U00_9Q/05G#OY/#;NQF43/&1?&$_I\?.LRD<
MO*SI>8[[Q@>B4P\E;3[AL2X@D-5@9=E6O?% ;'D+%FC5FDJ>)2+\7(U<>R8O
MQP,Q4H""+6T)3X,6H2/\\1 T;Q.^Y.X27)\VD:0:U)#W/-*S"4SL'X-<LL9S
M-'E] VM+(47AUO]C6/-C/3KVB(W< PV<B"N77)XS(^9#DGP3"X.*;<W_=6=$
MH?4<BPP#YF]L#&PG4#^=7=O-P-VR1ZJE46!</'AG3TUX.&=!P$\96?CPW)W"
MZS17&H74[6:&\,Y@,T,@9HBS,[#'/[E&R_CK'XI31OQ0E[0++?;G'(TM51KS
M"J8#N*W$X_?]1>XRP4I,K'6;9&;X"'G14B"AQ91 ';1)F0?\'4GZ#*\)T]%8
MQ5J! 8,S>-9XP9)![D !67 *IC[C8@L!>A\KEH W\/>7D>4M 6^].]_'W;8_
M8+Z3A,G!L6+%&L'E0<K4*'S"M48OP-!!2K1T,$N!5[T<@6W,,:8+H(4A0BK%
MSS&!+<$,Q9/#L"(C<E=,L@D?_&GX;TTP3!U<X"RH,(#U=_PW37V@LK 8*JE+
MD"O^0#7Q K9(5V"+X;^\H?-(P13YC!#!,,8XB1].5IR:8"J3\#'M6%RBFH_S
M1_9Q1^;VD!T0N9OY+G9W]^^<RO@K&/Q\L5B%L U_F# QVPPX+>]4D4N0U$K3
M%1%+7D3]U( !\9?P;B=U?BLI?\'7:B,\7'?@W,4 \ID',U5R&]#^%GPI@\U;
M_O_^5S#$_(/_#<;^T:BJL>(54:-2NK7=/2@C:0+^W?LD#, SUX=A/U#"'Y8E
M53),S%3X+SG$*_@0?WJ@W#-0R^V!R5TDYDJ;V/"FX W"LJK,JV-+4B>:0;C%
MYA_)X9_=4JYP@'BJ<%"2:=H\IF""T_FQRURFS@LRD2>Z"'OA("RLRLNEF,O&
M@-_(8?'GI O[Z\*"08A;MWU)^*'Z'"C  0/CD0(+00=MQQ6?GJEB_55UIT8$
M(TQ91:L'"EM.6& 3_H?9B)9@4MC>$(D;"B:+V9A, >^VB-&-J+]D)CO,@0GA
M_R:8@BE+G2$3/QF)=O<II,\(TJ(1F#&"78#$X$?(Q).45$&Q8,9XHU0LO/=K
M:>T7C;\LN>'IE:0H&!I%V#(*[#UJC-4JD-#P6*S^!]S?/8_R[@0X"42R>+@H
M"[NQ$Y,4%G FN.MMW83+;G90@;7QW>W8!SC"%8)YX+D13IQI(F__$8YY G\P
M9CP>,=.P0F,IX  DN&=*0TVT52F-,GD9[YNXQ!_#WN-EP@8J,$E56Q)CE=+F
M<TTW(8XA'2T%& *S#%8 %$VW78V8;O:K,)$P435%&\-7/X<_JIBM^8UMM$4>
M* B3/),.*6 96UUQH85+>;1(%=NX D%$(#@3PZ2XET7PI/).%K&6.<$+=XZ(
MG<\5ASIW3RZS[(%<<.'>9A_/7!/>N9(&:AE-LP556K?PJ\29#6N'S\^DV=^9
M.D8S. W!H$HV\)^<=+)T>M+ J9BVX*./JSB/5!*8QIX6)A_\I26R!:9C:\_&
M?\MC"K!L0]2_%4(R5A4T ].H38"[LRPCC =8%S(H%G,=9NW=B98]^^*\"D]<
M4;25LQ49--0M4)-AV_%ZM+DKDGG*=MD0XI= ER#'0!1SC ?B3G;OE1+^@! .
M#GJXL<G/GA!1TE,.:-M7X9TUX/G5;.RSH2UGS4"5P4<$7]^I&KERS2NSG)>L
M,+_O#MIY(R8-]UR&VAK4&=X&8'CZ9#-'NH$I -8IF:"KV3$[XV]>Y>>3C<*O
M)0P2$ _ 5 =R@#R+LU7QAD<5MTVY#5'$_Z($A<>XJ/!#A'74L2WNN_:+C;]K
M> _Q5A'XALE*!'BQ<!5Y3+>N36-@S=6&*V,SFV-SEA#1T8QM16)D 2<'\$LU
MK*Z (-RMA#) C73T10%/AUAGAFD!_GDAU"/>,"CB;0<P)#"*B1 ^-2::I1"R
MP4J%(%BZ388GUT6T530;ZKR*33%-D4;$88.)::QH6*FR%$U%\PG62C%S_"S7
MLA5,H0I6VRFPH@1=&N)E$G#&;\"$Z 8Z8 ]@-%FWO7EHOW6$)^>V]8=WP>5,
M9S&PMD>J"MJ!HCSLJ$-'2PECKHGX&1PT",(=>*AN8 B\,"?L%+R!1 ]XH "B
M-2S-W3\1.E&D&='/O1:LS6&./)_Q&PA,854?[[1DNY? 3, G D(>K\XB02H;
M8.PY#[%@'4EF0)<,V:L[@R :\4M-)T]YV99Q<&J/4H? =$$!Q;RL@1//,ZF0
M@9?_SO0!'BMLY% 'B2I*I[A)@I$7Z=93;C5*<T5P'+[<PSP\Z,JQ0K8P[*W;
MS7Y+L+:30G_=67FS!O*5S$':0,!  J0.0$L+S(('?DEKA@FV.LHJVI!7;*F"
M>0(<QQ86+1O6G>J^73EMNRHKO*X/BMWE:-P,QW/M8-Z@!]&L.D?)U8]_,>X?
M91- !1$%L[O-2OAMCO5" !C0@KR0VFV.<0C$'FL.\X)*5053&X)E0MR\1/XR
ML6<^H@,E=H??ISU,6)D\.$N,WMQNPJZXA7G:&T/M=N; SO1:*LY'W#K0;NZ'
M[^3:W-(-B[B)-$<1=KX TF",\8>8,*IGVQQKST8+4 Z) ,/P:ID&P(EC2AW8
MUJ?,0<=DA5TL6(JCP8#R@K<P_MS-=IE-.;4C#_:7,(S.D6"Z&/JJV7W2G7!!
M)/!HJ@?"F\@]:SB%>=LJ")1-=$)U^?Q>?!%K#>,UB#$2W2?F&FB(!)(/0.]0
M/3L NX<=?+O6"AB_!EX2,8&(']\6<F]-1-K+#6AD8: YKX,$<N2LZQ<"Z^R9
M/X@HI&R)K:0X>SDVMR4;^736^820AO-A-M>R/WS?O+#@4S9;QX,XUT"%@4P&
MK$;:QMX8'YMJ_'I=Z837!X\'C#1+MT<\4GD5K$$2X;/G__X- ]?FV@0$ ]>I
MHY=@@K1WS"$'1UZ"5PJKB7.BXD@O.'\];_[;^VH3*P6*O9J79N<, 8L!'KVW
M^C9P6DC%FHSB>+'L,!)\/'2DK.LK<SQ\CQ1+5+;ROL0\XYHWQAPR3'1C(LU=
MN(%]P.J\:FN-)[:$, C&,V-//C8*N,2%Y;^JK? YV#82TEW&.'K6(V5'/PXB
M=2=^O_G$D9B?..(GCOB)(]\N<00#E8/ MB[S:MJ%&\S_C>2+X,OO>#UAX#?2
M"X*7XD^OG971M1EEXF\3/1#_O^V+P*+$:S:^'&02I1$6-Z!)32UL<(J2[51X
MV$MB5[,2=7Y%C<CKB.1\69(]4DUMME.SW>^"W'7%&U&-/"HKUJ=,DSA2B)_7
M^T(\8=OWBW';P#/[1/LU66(/;:MWQP\/O0@@V+&V;@WW,0S7-X$WK8(/9K:S
MT&P'*>@6X-.1B#)W-(\5"22??MS.U1J,D4?1V+H6'<^CXT8E6A0K"$@!GPU^
M NNZ#O$J)E@D/E!#RR135AP]C"=:F(),<(H1Y0;;-?C,\(-W/KM&:>>R^[PS
M*K/LZ>W@RF0[7/^GO2?VE@0QCX#\)^,.[.,X^3M#S9#-( ?1>Z2($$X8(T*.
M'L/M81]1:O!$HT18<08V3&D!SR<.0\#,L&+.DPC23IG\O"T#0IE;0VPE*^ 0
M)55);7681'_ 1>NXS$1-L$ZX&$XF"02DU7KZ%WX$:/, !D"UL2C#1!EBR>!A
M^\>YCKTYO$BS##P12^67O*009<&U-'CPDMD.&GCB?M.(FPSR^'8LZ25MS *.
MN]NE:_#Y $(1.\9&-DOA];V/4$00/R,U7(D= NX.D[=M*013)8Y;$ERS$V=4
MB(L=[ KF$IOM]U  ?B\#G'Z2,7&-!TV%]:&%!=8CT BX9P,@+\#V $\+L0A_
M-LG_U9) '($,S?Q-!_\Z<.SQIH9?MIN<LZ4[O_C_2"?T-*A[+ F8#AR#%%L$
M_[HO)#&N9[;KX22"]%^V4?K<JTJ^^LRU^I$Y0$!3(N0AS2!FL0ME(E6<:Y@Z
M=V8VQ'%=JN55+,'!92-2Q"3'Q^24X(6LG6RF0?W$IX"?".C@>J=YG1I)BAMG
M@N_]19$(#4.'79LWIZW $-Y3"5GG<U(A*04$*HV]>/S=E8N22/S$X-S#:('Q
M%D*LF/C!ZZR#>2HHO#3S.'N(_P'3GQM)%FU;%?ZJ0$ <[X+(FSQ\]O)#;:2X
M0DS?4:-LUD>812WBA-L[,$@($(TEP:.N."DK8%0?!#9(8B:VV^RS=!P0CB0>
M2MHN/+MQ70.GT]B(WB1@WISAMT)V,-CUF(8P[9AVU.,1O'IH;AXYX [BG4Z*
MQ;/<+ZSTV[Z@?7K)L<MNGYH";&#K/=Y<-V_" O&&[?,'/M^O[\W&(R0XE^80
M#L,+@V+JJDDB[ 03()8_T_ 1VDO:S_H7F;7'3CC#O'?9H9X[8K81'CY.%R5&
MC@3W@LQ3]W'<2S^22G+1AI""_ ]F_H G,_=$WBXVB)B_'#N7"'@F<MK'CA^.
MCU( $>#D%R+Q(#>29$<0Y,+JN0#"]J=EH]R:R-Z_B,.88?X!?7H"I,M#9N%,
MPXJ]A+_E)!4",I#4$DOUB)JQ9IG_ ,T>VVMG/ ?ZFL<0/#R&Q&\<PW[KO0<R
M(0'K=&7O7SQ.YJ&&"/ *TSTVGFUABME6'<.?)EA9"D"X=!=\E'101G8A]0K7
M,@+$%B8)!DYRS2EWTVX'":7O7%*73SXA96EAA9[4 %?5>@Z-3N[5LPT"DX*(
M 4N%%#8)<B2A'0.QJ4Z[?9TZMP0<P11Q$V0I%4&^%\ C5A!A)T$O,DPT!ZMK
M84F..F,7Z7?RAMRT#-M:QI"/T9U('#M$0;*F[ Y.K@H"R5&F<2)QZS!92(#T
M%-,Q5K'F!XN'S =[JIC?A+UI#)JS0,+\GYPXM/-7!QEO/@[6*HV=)4NT5U$S
MWN>'IS+P7<S! 3NAX]#A#NMU8!!V"Y^VK?605WB89&C?T<3[ZUB=<$QKHKGA
MC8Q$'5M[QBNVZCQ"Y,==",&9*,R:W.QPN(I,U"9, U(=\+\+ZS!0(F@3K"$9
M3NH/Z 1DY:#QDWX/NU?\-*2U?6KV%$C8!9)$AMI?)P("(7N#PP\P^YUA,.&7
MR,[^]6RPNRO'J;I@O8@.C*SG;JS(WD*L[=M.91("A;E.G,78"[:G#WTH=DL@
M#W"BG;;E8 >S=GD=S\)RKQSFI]&L)_YJF^B'VM7SX"M+\G6<%#:J"BXNDLBV
M"[MZ0ZW$XF_R"DFO>AY])IN8>TP]VF_O8@A9V2U _B\_F_^#9_#X0)5*J8=G
M^:8[+C'(@_GQ\[=")I?G-<2L(?E-D'N%#K/F@JY3J.:)A1-'E)OT";^<6L?A
M-I'G.RDH!H(<F=%S]R'$-S5K;'LSR!P?* -KS,AP$1#HAOCZL PF;D(*U'=$
M_>?UK(XT)+L@4A+"?MZ F0V*F=R$+M'17+?6X2N12&MQ,JDC-@A"3@<S<.[P
M#7;W5#:PWNJH"9-AUY(QF"OK 6O:!\]A\#<W[NF7B9=ML.X%RME@K]2C9PEI
M&\^DBHN%-7XM+>2-;D)D.\@$:KQ>U4EL7>S EM20WH2EGDX)Z8\6ZV$M-&M;
M286+;P8C/LBP/_ZE'VF:.4X*F6.UF>S;89: ?1;D[?OT  PO#B#PXS$X38A1
M[/  MB5L5X8UAS-_X]1^NY3'-0XL$'EG]0_/N\L\EBO6S'U7#79E=TY1SSE%
M#)795,L\R_&])=?-Z"8?9U<__@WB@SHZ)B>&+BD*233ULGNK3!%B,#[#2>H!
MS[2U"Q,#6KP&%@X*V?@C[K^WL+#AC>G/_L.Q= L=HHR!35W(T8#L&'C=.RG,
M086G_"@Z7*%LDEYL!+61%*SPO%__K7HQ9R"Z5CZRR-<#W0B7FLYG:99/CH;R
M'Z $>77>,"PDV@=2 Q^,:%,$/F?RI].Y8XONM* EYUN6[@J].<>8\Y(:&?_X
MEPD]).+T QT])D-J3VVV@Y0<Q5C7#*+ "N3. (0N#O2K<T/!+9S2NZ#!/:2:
MLS404X,#@933ZL@#\"<!HF4DEX%@+JIP485-2#VA-NNP]7<!!+G1,=P0?5/9
M1QS@]-PT&CMX8_"2N,_X>]PE=WCCER<_N?D$C[B?X.$G>/@)'GZ"QYL)'L'?
M2O (?2C!X\0[7AD=NEB"QZ'Q>QC#=N+ZH?-:P*'7+>"=-?BV#7KTI,.)PHV(
MW[ ]/9K,]<T:;-3$SJ:\]&?2%)4MQJ3Y[%-/JX[3N629_32[)ERLL\HJ-AQQ
MV3@]&?2Z<J85>9?:\JJ;:^\K\-JF5]1"GU\+.</)95J%N%::\"L:59XBN5(N
MF]:F]4\[.=UJ-G+98"W6KL8CN8JERGHJBRW2Z&/X#7U31S-P@>\3+6R?*S'8
M]EE"IWCX@L9J?(]U;3('XH)U\.3TW9!=OOR)6Q*O5#=Q1N_OZNQ=)LZ?9KQ(
MR@=:<PQ.*OC"-W:80=O=]K!WE%SYP'.\#+4R](!)#."BSHY<6YLY)A16UR&Q
M >:T(U5[ZFUCMRQ6%>W/N+7G4X=VFYM>64?:MDWS;;4W?!*G/*M\S)O2MC>I
MHJE8@83J!IBB\"\"Q#O(3;>:O7MVK57XX"0Y3Z-*I+MBT[(L%?+)>J(3$DKL
M^,>_EW),A6!CXV??V$FB6Y*6V?F8VZ29&<VSQ;!<75US8[?MYKH6+2[6]$)D
MY 0_3$PV$B!\Y 3"OX$<&#7P9JI.:M=.)4!K)%CN92/"MWLC]?#*R!Y>3K/T
MPRD&D\B]0<E4G(2D?5J8PYC&I27^!S@1$T?S.7$HJXY95S2MV)YU<VLZMRY/
MF>[') :[VP1V!M%3 Q,#D$!+2T'^4GJ?(9+2#,]U1"]E&**QS<_;3$,NCI=,
M/C0?2$^]ERCCB!!.9?\=9*8(\&(WS.3T.? /[]3A.6>7T716P.]?DM=61XU=
M'!L@9Y<E5):P3#8U%9T^U4!IT2XM<F@J;W11DJVJ5-!'&$A#;ZMT#V[H=*=9
MDT\\\?3#RC[4S)W*[C ?J?9S%O]=_CZF"QY+9*(574[6?D B'%'(>!YM+::S
M:%U&V5ASPBVVRU+N>NP=R40CE?ZLA>0N*H:XITK"B$_'[_-(:DZABF-^!A7^
M).O_#J/[!WI6EN\V57&2JJ>J=#.M=L(]I4@'EBOH+/8Y++\K<W=X%WI"+CS8
M%?9W^:KD\@!/]H DIQX1V.Y^MV0>(,.1ZK!7X)\I&7;E$]>-ODM)\EZ$WE<-
M.71+[*;+'R^4@FQMY1)RZHUZJ>\EX/V&./3[Q.?FN<YZ6>)F'3FV2G"E8OX#
M@1&@WQT%'BB=2#Q)C\U&J<_6I/B:XR/:;-5?)0J9X/N<"I]B8'K+)C&A4YDD
M3C(23PVA/@=0$@1-C0E"AW?UCZL2>)]"[G[8 ]U\CI/T"QQ'PA%$_#F7(@XR
M-N"5*N+U )F'P,\AB?QQ]W!XDFB7<X$:5Q>"U,B "1W&\S^B1QDM095C>K\G
M%[-2V4@O:H&9_#&'U]XD@]V%']YG$D7* [Z_#>39]D(.9(9F1N22#8R7S-N2
MT>,*\![0$.$)VV>&5-%U6Q@(\MAV@7/\*8FWDRJBSMT$.]'J8H"R/S*,*.<Y
M/VY0;R4#];E$9PUEC)9EMBQU/F;AIL@>Y%5;).X/[3Q2<5#/LM%>/EJ0-X-!
MM#9M;[F"P;[+O,$FMF4?!+GT!DF[P)S >Q[)>"PA=K=OW%Q)Q\CM'1BYCQ2K
M*+OKC.\7M*[CSE)MXA$/<P0/1*T[(PF2YE0GB0_._O [Y"K+'CY4--9,4E))
M0#K)D\5 :XWP'MEI(&X^,CY:O!F73%8]<@<>Q!A()<)#W^ >39^K(=)A O!^
M18B4A7&OX[FJ ;E0X5S\$A"IK'B@??">%[E%3$!?=C8,D:LA]N59#_Z30HI8
M6@@D"?7P96XR,8F$N',_^7![ YS"%+:ZXR0>D])EHE,MG:#*T28<E%(^>#&I
M)21Y:TWL7*L\*;*)2*SF(,!R]!"'Y.$FX9)(1*3KDLTGEF)*]@M [Y)(A&I'
MU';R+RD%)AX]Q.-'.K(KCUQ'A.[)_.:V=OT<I6%;3B_<NSU0*T:U"T2^$Y;Q
MN:+!N-5O96LY8<8MAI5\>1;5"E9D_)*BM_=)8&#V_&;HYJ !KR=(#+]!@5=L
M*3GH^R?(;15+R7F]D37;:*.&PJ5^"'4-]O>SF0"Z'4%;52O()$&"&H8M1"IK
M[L X$/0F.DJA9JA7E'-RRH@^R0TQU,VN('\I<H3%_TV]OSC89;?>-E+/L/6S
M;'71ZZ\'0WFSR&H6ERNI;?8#B60?VOI\32S5!3DFRX'8?" +X4:]RF-U)W1J
MZQW6_FV^Y^W2FH3K7,ZW$?#(<#OD6G(3PW[\9W/AWD> *6'_R[EX\ 09Z$TC
MV6INHVTK:P[TZ9*NAE>?10;]8"?/1E";ES<Y,[%)+.ETN[ZZ @>^?]L_Q'_'
MV[[NC'J)3?MIU@Z$URC?ZBL#T7RU!N 9MWT3: 7"*C;F.4D>A"863:<&20Q\
MX6,E]./<]UD5W0Z-:-8:6X;IZ)8)MZC"R_DH5 9K07]GH&S5Y(4<E,S?F1/)
M)^1.KEMIXO07G_]Q']0%I8Q<Y]E=_W'K(AYHPCLEV*FLN%/<\!>>Z80O^D!?
MB(]YM/H1[,#(W@&\XTM\K@<^\X/U$_ST^K,\RM7!96;R*[F;XRV4L"NSLK]>
M]G#H,CB\CVM.H+[KPZM.B#>6\N+6>&N/>^ZBVQ?W][7>W%*7/-@XI*K?B6<Y
MU0>\.P4))XJR+]<F$1T8'Q5T<%*H-#:-]L55G#25"(0C%2C@8-_D)Q. ZNQ8
M025V'RGO3@Y\=Y('64Z',W U9F(E0GK3T*G(YE1CF%DFN ]W&JUM^JL'CG*2
M#8X?;\_S/1V6XH,@J"_!(&#I_I>WL1)8T>;$YVBYF&X+\IJ-%+ALNAB=K6;)
MV@J\WL]+I(J6?J)$*N<LN86W ;_9?;8'$-MB/#>1I\T:G:I&RXMH3-R& O4?
M_]J7\C;X!(SG)>KL_;#FF*B=;5SI4.9%]6SG'*H9.)?C)'U7^](N:&)7T(&C
M^1QP;$I -G!/:N=^/G Y'W4EV7<"V?5CP%]P6DR\0(S'I4Y/%88]Q. A,E?P
MEA/-@<B[/$4&O45 ($,=9F%?;G.FY7%HY'<59J$J:N1D\R'[2\\S%%W'Z/L6
M\Z[IL<XCGT_SX0UW+4F VC?V(/V8R%VK77UH;X$)P:D%N5=OG[]O5Y7FA:*L
MI#X$2:/SMB>%FX*'0G0OFG:(#G/;5XG8=?-0G3XOGE7@96*5?.S<U(:&0P?E
M)3PM/3Q2Z.4==/?F64K&WH^B Q=;R/%^D',BA:(DMUKU10T[T"0CCET7<GX3
MD30H(2Q".)CQ9H> +HD^:]"55S&GS9U3=GW6.IF9W14VB^!.QGP"\I8\S+F^
M/D@VWH&[SM;:^WCD&R_I\4HT-#%IQ+>T:ICI*27FP$(/OM>UNJ?5)?+,H^$<
M#[>> Y,9D%1KWT-Z58EE$[U13@VN+3HU0F59L]A.R 3KG7Y!BT7.\QV)KFR<
M*DE.313"[409<%KCK$A7$R_5GR =(+/=@^TN!> 6,\@?7,+[G'K&5:]?E2$%
MPYA7<['=FL\P[=9>>VNY''U:JW5VYX5T;*=)$-F;-UKW/%*>CD+VO7W'&4G4
MF;<:_YAVA-=S9=W8=\I40-?!&NK.36D#5H#(ZYW/<^?/-FRMEG^I>\[$@7'[
M?C6@GJN>D8^?;\DC5=%,V Y0SD7O)4?XSJZ<SO,./7@"IGW=WBZ7Z*B.CG[Z
MA:Y6)?RK5?[5*O]JE7^UZLVK5:'?NEH5_M#5JHM=EO(87X[1\ Z9Y@I04A#.
M+<OR6LWW6VB0YUEI$CKQ& =ZTTZ^:[O>R:0=P4%%'1A/]%D %=MD<)K.8!.,
MU+0D';OV3W#\&:*D(P'D/4\*8-I&*B0Y:#-)P.:5!EW9L/H(C1:TW6_D83,H
MVP35F?:1R[V]XI15.; BX6I;CI_QQ#VC:[IDD$09IUPC<EM:[BNL:!9XL53*
M%C_[(HQ9?HNU+U.7YKO(J;T1/.GF8RM O&EB26A Y$&0EG;'Q(-IXW_&"%+-
M[#F1P+GMIB+&*ZE]C'4C71/@IIWG<?8T);PY<[>^E]W,2;0,NY*.#0T&I6@"
M61@/^0;/E^>L:F?\/UL59! 1)QX/-:?(L-/G[$R-7*&C5-+/AI3*?'W1K.G8
MIG ]S]:7%-Z8(&/G4'"?CK^>0]LAF!]0-9$JH2&/K0-;<Y3@]@)$>(C'P%'O
M\<.>'R42++O:)3_$Y&B"_:/PNMW5"VN7H//;$W(.0W42]AP*XS$G8,SUCC30
MGHPH31_SJF.*&[L*2&03H022HM@6-/Z:I.\A<7>VQ.$*SW*/^9$J:SK2=D5"
MW=/'S+&?X&Y7'CP-67=+%M'(H: 9WB!L^V(%%9C.+BEJIZ&,"1*1G!';7P@E
M8#'T8!78]C<YM<6(?K:KNPWU;7>Y)O;WL*&FZ8;7)9O'9LB#?4;0)E'=;Z9C
MI;M;Z?:1S9/DS'V%1ZAV9O?OLL/NWG)GHN6ZXW12>4MW&GR1Z:ICS:Z\92\%
MQH!SPZZP:[Q4!<[%J8<#F(-:8%">C[BGGV=('+T)#$Q^+HFD]*BF+-W.2DY*
MZJZAFT#:H8F2H5MS<V?CN-DG+TSL&8 >.-J-X]I>2+'A%%SC)F22>;)4Q.?A
M!TC+L5,JD(T9]AM(4HS#^.3M^SY'.XC7\,&:TMBUI=S>8@I<QO24CMV=_GX%
M[G5/XD]UJF+L"]CMM]UPW21.&S,)+U(P/=1(U@OD0OHU@O][":WNG!-_Z< ]
M$_D4R>H](' Y"&ZKX+UN@+G'TKUVL.V;P$0'[.N*6<C:I$8623=R=GA75-9#
M;78N#-X#J#]WLK/3J9*#)U*C3FX>I@37.#ZW^^VEB[5I-#3S4$W1.G!_-<%+
M4X,BSAD,=GNW4Q.IDJ8W ?B1B,T<TMJ;7'C#"TU;")[M.,E$LV6R[;YHM /5
M<D/I\5RA9AU$<\._4>WE<)YYI_%M ^^O7<+K+<]8;-D2(N%.U&HO,O-@J[ >
MEQKY\8]_8X^14ZXQ>YV4LU#*LU**+)702!/-3;)6<IOZ^1W]L#W2=04=&Y0N
M-P3C,VN\QNBE:L.)NOY_F*P?*,=T//*T[1/D2):^&^ZST>[@'8Z?($C^]\_>
M@?#KOT;D?_@U[EN\:(S/G2>HX D$ M3PI$>P"R<@QDFN!81K)]205W9_,2FH
M46]^VM7P:U+P^_/R8?OP?]61DZ.2PMN6M'?M9%9LMKWJ5#K5;:"]$1.)>7+)
MAY4B2^CU#^[[/R.G9Q1SFD8(G4G[D!8X<4DRT(Y6'ETZ\J(Q]%K%1^!T"B.E
M"/&2'VQZ 3)>XC6KSLU# TI@VDGS6 V5H;PLV,HDZ_#T6HBQ9%A0[U5R$KT-
M+'B,T>8DM#JI^$X#;N*D=NF4<7NI85J;>(K"B[;TY<U79">9A40*A;U4YND=
MP>'3UTE2=#56448!FFMN.Y'Z8M!!,G31/,3%)/15J(Z@QSG$T-5Q#9MSPL;^
MMX5?E51(*2S'Y&^)3&)5:/!9&9-@BT^OG^*96?T'J;\ZQX_%7(2PZ6^W/G7)
M@I@T 1)6FQOHE_O#WH$(W]#Q?Z+[%=OI$8H25R3Q!-K>GK^]@PCG8<IW/"_$
M"6-J\U.EH3V%HP^>=S&GU:%/.'Y< OO'OT/GQ$W1NZB;F1XA#)*: 7H,!A\@
MM?V,_X8#^YN<\Z7*X@0/U30()!"F!)%BN4XTHO]#I(C\9&"R%8EQ?9+;#O4F
M3Y3#+HKKE"%^%H*'7I(Z"6WAOX#$%LD0FUL@'0&_9J[L-<'#1J-NOYPLR^YZ
M7!/\(-U7I)EGHIZ<GD=HV',0-ME0HD;4::?&OC<6ZTT& C14B8:QD_78/(6W
M.XDHT#WCY.X06YW8:DY_<-(,W.VT_$!>R(M3RW"Z2O\D8MQV7L.E!&PCPH:H
M/.C ?^TRU?$$]B6[[6LP(Q[;V[L7[R/*3E<-)YKN;I"=+6.X=(B?MS\WM^WD
M(U6U#0>2//7:<PCBPCZZDY)(WP*1M(M?HN>3V;5U)ED^<]MZ<Y],HNR0R'+)
MXIZ'7&"@#Y*^T^U["$OC12>#;6JISU+8/(]^XX$.M;,V0340R?."%DR8()QP
M*1TH[O8*MLDI*7HR2ROT (EF^X8V!]EHA*T>FX[[L&F[C=PF'IQ[QXITH#>,
MY[58]Q_O>\RW)ONN*G#JKOYIW_S#1WYZCOOL'4S8Y [.3MJ[&W=:RILV(<%V
MDI?KWA"K"I=5@$9!?R9+L6\*/K,ZO: #TMGI]WYPJ0*^\_;1O?M,]CJ)MX_H
MA342SFE []93?DD5V:S9<'1:&B;:J8:690NE3$-NU8]C&Z?'N1W^?,7E-<T
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M- \DD M/X$V-ID#2E[L!([Y@R\MAY%&]E9.C8_FFX[_H@\.C%:]X28;9)K3
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M:6W$MY!L7]OI_)!0:\:>*E?Q3+(PBHCIY(U4+O1*.01(!E\S@GF_N^\&723
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M(KI'X_&TR/@LV$[ "SVMG3A=R79,Q_1#@F9XK=E&)+^HY)V@<C7M=5*Q\NV
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M!UN&PG;+?H(@P7>M/[E-N'"48%#&%-C7<!F.@>A;*LAEQ$1UT!1$$;P09).
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MX2O_]9=[=[CB$OU33\J]Q+PR&(V54;)7RG<CU\T!ZS&+\-%[*@ \-@CF)\J
MTPPHO-.FR3]A$VW, 27F^*OX1P<T7HXIED] 71W].,]+/IA1\I4L$"_YZ[X;
M,0<MM3Z3>J-RL#K+793,3CIU-CU\#[@RO@4BGH^5C79[E[W\LY-74X7P96K2
MB=S&,P<S/HJ*/4EU@VF2GUYIG>>:<:O$D[S%O!B*;::0?;]XRSF@\L??#4SS
M[F.!"980?%,?\QQ-^1YQA'\0E/_6^W):N_ MXBN>=3,!/=H=M!Y:Q=JE/,Y/
M>Y72S3AA7#GQLX'C>P#U2 '42 G9DEAV [0)'_/A_D+L/\5BA7SG9G#[<"W6
M(P\7*_GRL<\W=((1S](I5]6D:=Z3?#LBI^YBMC9HA!L(,PZ63CP4_EYAEO>)
MR']_LU#*K8%Y-2C?OH,7^L7B**>EA4X]2^#[;,)I+?D+!U+.IL:;3 UZ@[.4
M]'RX4NW>2#<3MV)^VF]VAJ/;0B=S/S^<E?%0[8W:W8D1S9-&.=J</5\]%)\0
M,Q>LC$0R).[1S#@M*?>/;8K3#YK<JT13OJF_>(Z5?(^8P)<P37X\=9QC)=_8
M@,&IKW])50<?("6%"\]72E@=)9)*6*K;X=IEZ8 F2^]:>5ADXK6L6,[*5UWM
M,IO+#Q V#O-/(GLU64Y>(*Y;,?L"M=U=:+,*V(K@,*<*9;N^CH_/_*OLL(>^
MV&]G6P^1NZXYRO::U_U+>?A0CR*:960=I]&TKR6I*M6L?+FAS332&IG6;"N:
M96=82"<JPWEB5)[<#S.]=C <;<[AR8TQ6_/I??(F4E#R3?W2O@JF.N'20X8E
MD:T^.:@_FP-#BT=%M3B:%6=W8:V=V(J0:=0N@THRW[MK1ZYB\G75*A!Y/H<G
M-][>D4LC^_ZN/FT[U9*R4*)*^5;AM\AKJ)N5[B(]OQ?O1HO>52,SM)+=3GXK
MZF;)-@NQ\-W5L%V-5 M->32LQP9S>'+C[87Y3"X,AXW;=N<A8I7B\O3N:<(C
MNZM/=N_JV<;5?!(?J?WN_)$\E8VT.=B&S[F81X.&50I>CHK/XT$DW^N3ZRH^
MN?'V>J47G\75&U-T)N+\*:^DKF.U#//XUL8<9#O/T=&S)A;#LM0J7E><:6ZP
M#<F3F%%[T(@,FNWQ(KEX'E8ZP^8C=@78>'OI.=7OI(M6-%]-Y"]46[*"877.
MA/<^,3]!J?UNH#[V(]1LHH]H35,>3^OF5"RJC78FV+UI9R)[0Q]98?:7ZTC\
M6J=/_^\O/_QG;!7^LY&_S5?:^:97;')B\-];5W, @;J!S[8R[ZVS6L7XX6 N
MSAC&I(!XVR"J%-5R<:W0XC3Z@LFHSOKM7]R>D6US*[/ IDET#B] [EC2Z$F>
M*OVD*)%I1AHEI7(L6#]#[IP6Y$XB'(KL[*APKO(^5O5]ZHQ6<8+G$@XESZ@(
MIW@NT;,@.\F#.0NRTSR7LR [T7,Y'\QI'DPDE#XKF!,\EW H%C^?R][.Y9UY
M"Z\ZE#\!IVJWQ?,I>#+[AZ62#0UWY/_]$?_C@QL19:SY?9!W6K3[S U\,;2$
MO(ZM%6Y66@U\*L+7:PKGZ+D1J_N\L5\'ZF^[6_K_&-@B+GB/S&R[-NK7?]75
M;<*_?V,G$E6&K]NA9DA0,)9J6JQCB>%8DJY8?_[W/^I9+F_*Y<A'Y7(X#K,Z
M.JE\,B+:IPG=,Y&X ;5XXIL12?2LF<^:^6B:^;3R.VM]>,S\-(EY8JL[?/8J
M"]N=V#;\ZS,6%CT6^>XE+_>M[;E>29FP3+M;,PW%D>VJV23F3)57*W7XESR]
M%1^'*=@T";5(C 'L[Q /P4N.9?S('Y]HG=*L."L5VHOA4_QQ<G,=B]VLX*$$
MH^](A^69&LO>65$O[[5;G(:?#4U.CH+Z53Q22#W=9!XQ$2[ZQ]_A0#B2W$_>
MZUED?&N1<;25G93(B/I%1G3/(N-*Z3:OTH.!EB^+BU8T>7TI-XI[$1GCJOT4
MTV^ONZ.Q,ZNT+IY5*9+"/-<$&-F!2&)/J?+ITU-")R%#:(CUM&3(H9"E3N"R
MX<*4GE7M*P0>3E8!?GEM]UKJT3=4;?NTAFD';G/1O6ATE6@R?%//7@;;V7E>
M#K<7)5N;[T6I)4:1\$0?QF:CYL4T9@SKY9YU@^43451J\;BX/SOXS/-?D.</
MLXR3XOE]FK,^GL]<1#J/H[[9SSO]Q4P9W V&Y:N]\/RT_?2\*&0OPR-I0DJ*
MFE8OGJH9X'EJR*;$/?'\@6/'IVNU?DG!]RV"ORW#EC2OB$CHF\98L(BF8472
MP# 4ZT<$>8YU+_)";&3UJBTZ>1(4P\&ZHP/<M1TYDGSTI9^4HOUGQO5UJ5RO
MF85QMIW5+VQS(,:JSGB^#_TY?YC+_=Q]^7XDC6>/CYVGQ_AELMZ-H\T<#222
M/S1V?!8KIQ)M/OK23TJL_#/[O3-3ZR7[8104(_?EU.7D)M_-]0;[$"M/,;4=
MZ89[X7RV83<M2YO7ZCW$$@"S/!X0S_'E<WSYT\3MUPLX-U:,=@V85K>( *)!
M:/P?:3SY*P>&/.7ES[/AO\=1_U/->FQ=<BCK_-CK/"F=^5Y3_)KQ8T97^+=<
M>SZGT[>+YL.LV1Z/M9ZJ%FOBHEG?A_:\*UQ'9X5ZKI5/J#6CG[JZ"&:SB*\#
M1GDR_ .BV&<A<0!;^]CK/"DA\5[#^B4A,;GMU@?7=Z.;-JD_+/KFI!(LD+V8
MV//G3A!,^=1C.])ID&("C&Q"H;7 Q(X%XI$]=;PZ1[Y/+?+]SXWG?8%![@0$
MDPW-,'__;R0<B4?2_C&\(590#%_'#SL)W,B=2][7(L_@E_\4_'+/L&M-VY!'
M0^!-8EKYJ0.S04C?77B#E5EF')YDAHZ8*&G=Q]LKLYM9S)D.4T$C*!E[QW-=
M?"R\=W3")7(>/YI=M3N5:BLOQ 47C;#9JF;+0JN1J30SV5:I6MDS+B%2@\N4
M55VXDG1',A>L]"H<#PAXF@$_<I\P,"4@ R4@S%5[2+^1)A/3F$D:HO=MP_B3
MX=]@%3"$/_C'6+5M0@)OM5UXX_/[4C_1FY/BA3A=R'KC0G9BDX?ZR^9+W"/+
MY3]<,R4SAX$W.E TB&4#G</B*&&NX3_7-$FO /EZ.:KY\40S%H30ATLZ%C(A
M;#4\%A'%!/_U1:FHWS^54C?M\F1<R6E&.I_)K%SYERJ%=U@^M+GYA60A$/9R
M5S,F',J YA]<+):/U*0%!=C&U3+^6B)'6U4X*K,UE/3J!(>PBGBN5DFO =D8
MRGHKT8ID@A77*$N1QTE^V [6&G+X:1"[NR7S/_X.BV) W))3(+"C8ZB.[MXB
M>8SAM.FV!5@Y+- 0AU\$LK -00;+0U+UEPB*\)VW@&1 =FQ])@.+Q"IV&CZ"
METOX:CP8P3TW-@/!.SD!CRX@2)8@\=_^PH%QQ(CX%WY)_PS_]6=(R&B:8#GR
M\/45"C/X7$ ,#D$2WBA03YMT?;0:M(C\6W%,A!.QB/YIQ$K_<PMK O.1T6/8
M1X8W8<71GR*YF_PXG^N,Q;IQ^60"&=J(81!<$,E<MV>$"1T$B>V-0@=LW'&W
MVYA=#N[3G7+;Z52F5UKN^J$[&?P4D8,0P)]R@G *,*]JOPZJQ2:F!E)(9ICU
MUE8Q8Y>OK<BE?G_7'FMWUL/C\P)D_@#!ZC<D#%-49.J ]IFZP\,QN^.'A)9/
M=>%TQE00(&/W)=449HCZ[\H9'PM;E'<-)IP4^ T^0U4?RJ<>5WI/=#AXX[\^
MV0]GG1..245!9T:>2HGG1S%1+?7OAJ/GJ7V]&M:+[YN(J$K*P0Y[_1D\>DGX
MZ$6KQK3[2^E^-"H^-#KI?CT[F10SV-_Z)8(!TTF#?X6V^T(4(<B'@R1K(%+0
M_1VNF=)1-*CV 82TJSX:WA*.K@,:_<\*;I-WI17DWB0/7?D6PO&B(M1-'Y @
M@X62^O"NWY(VEQ:6B\6;"D5B;ECLMQ?^PJ4+\5 J]6]A^2=NP,;N(4BP;X]6
M0(#9KU9A@/EGKV!3\8.PC<G^3F'-5([Z+'I) %T#?/J_8*YO];TH (B.W*&M
M5&3SC_[XFV)+HU#)&A1 V?+\+NDSS?T-C^,5TJHUJJW,=>E.N"A56Y?Y1J:6
M;[=*V2;'_RE5LJ$CS@Z=I2:;2:LJ9*N57+[2S.?PKV;UNI3+M. ?A5(E4\F6
M,M?@3,$'-_E*J_F)<WX5NX"Z5&R^O]JZY"A@2RA_^CCV)=&RRB?;&  D%?=T
MF3.UTROFWNX>@SG)R.&".?]96[NO1\+L:G!Q5V],G7SUR2F4&_U$KO^\M3-'
M^-Z:-NWHJ)B?5J^&\=M*-7'5KF_KS)'.=X*+*UD+BJ0T*BGWCCV*Q ;;.G-(
MI8K8R S+_=$TGBU<Y;5Z6EP,MG7F2([OTC-#;=JC1'A*'D=/5Z7%8WU;9XY<
MK_AX5XV"S,Y>=A=WLESN]$IU5KJ\^J3XG#9NGHW.@UA,]0>7A>K0NDIFMG7F
MN)LT1^2Y%;D6$^FP,A-OB\_=[&!;9XYV5:Z7$M'GJ:@F"N*S%<Z2]F1K9XY%
M>MYOW(^;!3'8CLBWQ.@7KNMSEF:^^J1VT8OD.F&K*08?[ZU&K7]3B<I;.W.(
MX^O:9>[Q=C:*V)D'NQ%=)$AAOJTSQZ@O%2XZIG@G%H>&/ F.K:>1-?=UYMAS
M^ I,)V-,6M+3KHB5,;U[' :M2*E=5,>B/$Z#85<>'"@&%7E'#"KAQ:!:F;M\
M4ZA6!)#VU9O\G@-0+T6%/ZO#A"T]H8.NHU< QW7(MA)->4@41R/5/D[*T&G8
MI>^13?X)C6%R07325^T7FDT46C/I^3XX'(XZM?%#1\O>-TK=S+G9Q."TFDW\
M4%SCW=K_"$#&X1\*F'MB!Q$.11/G@SB%@XB$8C\4V_O$3@)DTYDE3N$@SK+I
M5 X"9-/Y)#[Q)-Z;\G]0M(*7EWQ ^/K=YN$G(^"^YG8?$*\^DF:UA:<+>?O:
M9FT!J%_=IP\0_\D@BM/8[I8+! ]!_-<!(,3WS!OO$@?_--/]4T"B4[&]"XM_
MPA$W6_HS?"I<^&Y[]2<2Q-<6H2\03/2?R]%CUE#"F%G'- EF9JR&>C]-*AY[
M?<?(Y4<?Z:36O3)L%I;1,U48YI)H,X)+PR$EW0INCOL>D_HS@BTG5FH=7=[8
M?NZ>_O%W\%-M\U.CN!_$:9]20,?<^9.F_@/7RW725M&(11\68K5=C=P817M>
MBW\<\(WKN1<N$+<4P[7JUDTL5@U>BQ&YT;FZ;I7F#X4YPS,.I^,[2N%./920
M(WT"FZ'L3>?_#+%S/&-V?S+HN*W"7A-(*(1^';:T_Z5DA0]*(9?U7A9#L&X8
M<XL\JL7%Q$.P[A3%K&RU'*L]:<NY.8.B#4=3&_+HSV_@Q_Y4=OZ*QOL)[.')
M6/)?, [ L#_7+ +A%WP@])AP^B2!<HX)G!06W=[,B!-<Z[<V+3Y@4HR3<M(N
MC#-5,1B-38J]J)(G@P%#ZMRO27&6 *?#%0<,9AQ]K3\EVO'V,$>G4I*?'X8#
M<U1^G 63C^,BD1(#!JOYAC"'B_.R;Q"4#_+LWM/N_26R0PE+Y@4@="+3HG@T
MGDQ>__I6Y3)Q3-(=M!Y:Q=JE/,Y/>Y72S3AA7#GQ'<73'](ND7?04]Y=DT=8
M#5A7EM44 9=6)X3-QMK4-\&(K][T\89$&K85Z8Z*5=&<1[M7\T4D\\??T4UE
M\V^<'BU+H,7IPICE+S!X@=7[. ZU@6 9$@UL&2\?Q+[/X=V,O;=SV++]#Y6.
M>D'RSF-^FKW3K8(D5F+]^1]_;V)ROW/WHR&A\,[3HM7A*BS()+I,P,NPYX3H
MVT$K-D\2L2GP44SN8"/W">@6\&$0K\*Q#7-QL",_ NLU"$Q(!@'(ZL'M EM\
MTUW[RL/;:2$\3Q/E:=%NC;+*LW1W.0U/) E8,;()!_EO82Y9;IF_H]FXJ;
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M>F\XX-T8CH;>C,2="D/3C#E(*4%9)0[)1QR&8PI]CT#D%0(QEP1B> 0"/L>
MH*_&'/75WULV&+J4!>D . L8DF8G45]GYY-N(Q[=L EV,I4U1T&P.,TB<W@?
M8>X83+L  @E[FW(VVKDQ83%8IV^ '^-<,[H._@K0_L0P;72JWCE8F0+FXG07
M(-H$HN,4W;ZT;QTGRB(@T9#0Q%IN[O*I.O-$6#A#MR6P*!1OT2^<84"82!B9
M<C3)!.>/G@F<VX3(U#O$)8-%H[-=!@\+=GBPH&O KWJ.!2^QK)5&2/R0]$'
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M$,P2%H ^B"\\IPM@O,DLBKT<"&0"W0R4',LQ\1E#EFFBADQU@:,O)83"WQD
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MMEM;H3'7EL)N$"R:BN&-@=L<Y<V-."[%:N["2I9C@/</#'!0P242S9ZB19C
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M/-]R3QCL[OQWD;G.5+)Y;%?$)K2D!#]STK#2&H=^8'"P"VP&&F2"K6,NEAB
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M$I.:>/'EM^-8[C"[3W1;6+$KD1>8EW6818FIN$+1[WK3>N^UC/F9*J%E:8*
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M&-QD6 WBS_%8*& S")^=)>=T$^37SPHF5!&:&&4'>#*X]U;ZWLCS<W-OL2
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M96/I;85@@^ZO(<7+WJDX3$TH'U3]65O:O35+'KQMBL)I1L($:IN8G$#H1N
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MNES=K:(-6^X(&A7%G^F+G5:GMPVR_XM0P/35GN=L>5[+ZZB/]-OB"]LM82!
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MDOA;%""? ;G"1<%?9/Q MQ9\];XJSSE]&;QCEFRQ-H:L4]I+IBM3!@0%A<U
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M#N  XF%8N^X[N^\^09H#XU-9N "K'3(!,ZX<=W8.WQ[1;RR6:[.@VBSA!5.
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MZH^%V[C,PP=.3E=S;N '(>QVLX-AU!(4HVM7+;M7K_IZ5WUEL+3=<OOU3FS
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MO^TKM<I_:YD;OG))KO@;K3;C6PM=FL1"VEP"?!*1(?K0CCX%4903*(N&PT:
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M(?V[Y32%]SE.PU.@21<6&,)%)],]1"\_$AYFBIQ[CWY(UR25/'%&S>5@^&P
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ME?%SG6RMC)_M;&ME?&_*^&CWUUH9;X8RMN96J65-I7?L7R1Q,K]T]B[R,,[
M5SV:G(5S7ZGQ6AW6ZK!6AS_ ;&MU>&_J<'?G7:T.GXDZW/5GD^6,PKCOHOCK
MV,_"6CG6RK%6CK5RK)7C'93CV[W]6CD^$^7X-IQ&<53KQEHWUKJQUHV;,MNG
MJQO?[;RI=>,ST8WO_'$XRVJ]6.O%6B_6>G$39ON4]&+/THN?#O<V7R_VGK%>
M7#&WN^C%3VF8B8/Z_"*JZ]G_#=&.ZYGL9FC']<QU4[3CFF:[(=JQ]^2U8[?6
MC)NA&7<__K%WZ'S:^67/.?APO'>XLWM\\,>>\W;G>,?9/WBWYVQ-H?<D9[()
M4TT"["0PQOCB-P$4N.Y1AXTCC)_M5JT,:V58*\/G/-N-4X;W FDY26;PUW^^
M&+ZX?@F Y6I-HMN5\Y7_*$Z8/B=YZER@>;OA&M3CK,=9CW-3QFEQ[+E#*0(C
MI/YZU<3?7#$71K4GJ.)5__W>C_U3HJ(%"PXZDC(G2<4/\T489Q3F6,S\&'_K
MIREP@<#',[#SSL^BR9D31&DX0<8P\9%0@8@DU"+,[4M"8$; 29@GR"L63:*%
MGX>M@NB5-)S?OX"6J8NK =.]_U-4<6[T!WLW/S)/@'BT4Q./TD;4Q*,KB4=]
M)PK^^>)DU&V[_LB=G 338>^D.^Z,3\;=X?1DY([\_B0<#=N#_@MZ*WWCZ."7
M#SO'GP_WCDYZ@^Z@/>*_KLET-%7 V'HEK^ XF07BCWJ8__UR?)^RWI3LGO >
MB@+FDX'E *V?:?C74HA=DL02T$%(WE1LB7BQ8FUB5 =WU.F:Y X-?LAIE.5
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MC)8_A IWJFR+$L1XPSE.0S];IF&*'SL*)VF8^^GE&HP./1AX\\YDDBSC7.S
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M*WSC=$$J)I+QM7SF8I*R3_ZZ$(MYM:3O36JYQ0LI7:;"?;^))OA"R>5(WF$
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M><:9F9H9G*S6G#-F.ZU];W[8;,>5DQ#9[\OV8.;I((FC+]G[*96JA^%^-,
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M+>F/0;V5=6T5&7)P=YOLEY(*_5XS4.$U\%2!T""1J\QJ# Y2H+C,:*:_^KG
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MKIRM!(Z"%]@X4X%HQO/R7';DZ+H[]>K^;*.45]X1PU:0S$YCBK0;,6E+X4]
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MM% WAV:,RK_5V 5GWF:E\CGZO6&PW]=4H/7\),_\'1T/]0 ]Y5UM:)ST:]U
M_HMO!T\7'ZE<,8B*E)5M>OV6;8CWZ?G*"LM=P9F^^:FTJ^!H+,]S(XKQ%2&G
MM0K;O"!>YI2/'XY:D7L.:7U34!\;M[WYJ6'R#QDHRX7Y3_,=@ @R/X#Q?:8W
M/ 7"V'DT"?!:*+WT],*5/.@ OC_>TI*8T9HIPN2@U07#LYY/N$='YY'/S0UZ
M.3S[=\!*GB'DFB\3)_L*G'Q;ZB&&UN]KTV,^B#8F]B5D"WO8[,7,/R-)_S%.
M'0Q'<98]QO+.^)E#7[/'#X=?O&H8F?P3W97K\M6H554/+9H7?>\=_5UE=>0;
MVN(8SZ'T ZLF?:^JG'U6R.Q6NXUWU=UBLV8*?E=NG<5[&;,A?[2EGOZUJ$MB
M%]JE_A PQ?Q]'CO':N&*+P<:T+N(\Q.Y Y"UJOR\_TJ= >F&F9\9L^UTCMP2
M!ZI VA]#%%#S^?M"69'Q]IO';GE[VA#KX?&;5U=]/WE&Y,JPL=9MT6+4WE9;
M/U;B.Q!X-OH5&6^Z/+\Y>3B<3H'8E%W[288OK'/\7J.7"MP\2D3K!P0+G1RC
M:PS\$CNGXO:-3ZNU,6=EBT9^ JC ]$:31\]M=96&"=)#^B0VV[UG'6/(=_#%
M>'A=3802_ZX]UL^_<9@56.H:63JV\HZJH')J;20X'M58-XM]_*&P_+VI_JZN
M#_?3(AIHWK;U7H!$&D+UFB.Y5;R\QL1$;*43A_NA=S_7D> = $*V"CUZA,$*
M8%3KW'R)^TLTA(;<[$?@%SQ?/U*,#7LQ=^@G&A9(+3W>:.X1O@/@0B%.M&?B
M>3^4B:JD :\I1Q@^M!4:5OY"_W-9@*_-%V?U+'&E30SK965 USHNJ4=?XYRM
M3(G(JNI83+&F'1C()*V[OW^[\IB\]TWEI]W,02S5:Z5;;%RE;4;L:;ZORLM;
M/(F9=.#R93*WW2S,::#%W^L!=MAGPC4A/!4F0NB25U>L+FPH]X[@W'V2]A I
M[35-_93PMTI/^.'6_&Q.M63XN=%,T#:"N']V"SA9ZV@Q?RT*\7"[J)Z^ ZS_
M1DR(-)GD'>?*".1CT7\4\--XS16FK5C2)*_YA<> _: Z4$UF'_SW1?=/B@PV
M.AMDKV?R"=SN1K7NM7W^&;YZWA'=;<UMM"+0LCH<>$["?"6XEX4_!>7A#\,4
MSHCN^K+G\-!K7\>>BM9RO>^;;E_W)_'E2K.S93XF"=D.S*A(U?C_C/8/4M5>
M9B(_OG7@,QLYUEF1TB./6%)YCM A:5P*CVU2^ES%-YV;S<@7!9:?%A=.[@T4
M1N@$A,E:5=/8KUG8/O>$)9AYQS3>[I;J(KT_.?L0'7^\S6W5M5YC?C8W/_)P
MB3EJ=$)&EO?$]2E/7AVQH4_#LW^XYH<'NV^JBTM_^D)%IZYN!'[(ZF9LR3%/
M>+0%KKTSXYX1"4?=MN5^1_KI)2\H\4Y)#U2.^A5;$HH!A%Q=7?$E1Q"M.% 0
M!+ZF=B-6.HM$A#N<7G,)E0I]J)"P9)/4NN[90(_5^_0^*TQ)%ZA>#SRA\ZO"
MYH7"!U!\JJL-;4X%.^0[2_2MO]$R= K00K/GDQX1J^1#=.8.TY;I/B^Y (]<
M'ZWH^K.M;$6>DD6TLZ"GQ79<J@8KWZ)+D!^5?"T</D<Y/VL@AU6\8L<])OU;
M_=.F8M-OU!2T.W4KMR:ISQWO=%S3XZ>%ZBM8(^8C/5&-='1R]U=G5+#?2%#D
M?[ AA"^#&\9N'1,T!?5>CL320O)Z3S#1("GK<__-BL!"0O<R1W-;5EA=2LL@
M&\^S)2_XGT)4Q2 7[M)V8=MR^QT@_?+9V37TUG^+#RW>38%IZ:3+S;'RW,5[
M.!O?XC@W'AZS!1LNR#RAQ!BN>9^.A5]0ZR6*U3B5+^XV+\U-1VQDSKI+JP=\
MHGMG)NVKWS*AX_ ?=5RR$!Z(0$]=G<EP"X0'O)B28[B1G3)6S_W/.+:#\?NI
M(_/@-4VM+ON4YBI<H333=>=#EY#858V07*XI/Y75ZSD1&_=K52<:DSVAM^F1
M JD.'"DU+T==1]HZ6'R2!S;;X_*ATBI#5XO \;2JID!HYJV&+"9D=<0 @^@R
MXYNTSS-PH'6$'HK\+8Y[R1'GKM4N_)RXR9 Z>"A!0Y)&4NWSVHATW]@Z^6H(
MY"KN>P.%K1[R&R=83X6VX,NA%N'ST97"!"7Z*T3%A [L;!G+$(@XNV#B0HVM
MBK6L'-'^!2T5"KVYC79Y?"S_@CO]Z:+(DE'("25.30N P;-RC.A&"!T85G<'
M>.CM21X]1,RHWK?Z;>)7O??&XK-*XL_CGRSX-61YEK=_[D+W,,LW?X\J F?3
M[@!L6X&/;@30O&9\**8"M]6Y_2Q%6%.X3GO[S---E7\0S\-(^6Q% P:RE)B@
M.ASC0%(L#2:D^PK892!0.2GI!W1P8_KQ<&!)1^JS2\A) &VU0_Z]\;C:PUH4
MF6_QW&>5.WI@\3/-G,L:+=G5.W_^Q6'&.T $^>E1U)Q&*)8G^@W&TLGV&55S
M6/CJI;VC9=H[=UB36#2=A<413K]]',_BBU(CI?0I%/SR=U9K4UL@/7#\<OXU
M1G^-"PT,J<[K]J+S.K?,&6GXZ5MF5^;!^WN0:G$PW&DQ;>Q"0R,!QW ,I=K;
MSH)"?',?BI45:3IU(ATL'&1'"+8Z28EP"HD)RAE?*F5;X X01%W91;6TW0&J
MX)L]=;"S^9MX/$ST"I#*3ZNNM<GAX7:MD4VZE$=;Y85SR^+8RP\)6E&5G[CP
M(KYH+-)433(3V)6AC;M]YH(4<RQ7=RHYTX=-*D?8/U#3#J[2)_93;D]KJX^(
M;OTGYYG-L+.IF\2U90HYNCTL.UH_ULF>[RG80:/+Q?:>ZEF/&@W_N192="#W
M!M<S9UM0[6VK>=0V9EQ3IVD(&2BA#<+(3YR\E_<#HZF%/!LW>4)G$P$-FRS/
M]':9D=$BT/@.</RAS'=D^0HF< =@C7^,TNC2> )QZ\4R3O/GAZY%OY]).\C_
M3AFVMKLIF<1!D 1X+(X3)VU5@CKJY@M4CUXE&K&*\),5G=J5R"!+85IZ9_+I
M9LZ*4=AL3D';4P\T"\7F^S0L@XYKM@)840%EI7ZVJ*.(3T'&[VO'ZXEIBX1>
M\/#^-JXS=W1U90M0PJ7LVUDFEE$#E]SP1#KDA_GC[UX9SPH5$+Y+.RFTIKUL
MMS;#]T&T:*GN']\!C&%7X7KWGKW2#V&+RNK5ESKZRE^"VJ]9M$D_&2FW\\HL
M=*.]F%=CVGXBV6.9XTKX5D[SV5?EW59JU!AHX@!+ 5W,9(/X+=/??(C]YYW0
M7/PJP#[M_KUG%*1W/HNZ=?E1HJI[?,1C6GE*3><*/1OHPF NSFON'-H;\>PK
M#-GK,/4SOO2N.\"3SA((-YLUW6 QI&%=KYG)U2_MZ#RV&I%\W;/B-E;O&_N,
M"^QMC/*BGQ%=N@-$@<_D'&<"*"&PCZV3#Z\>ION$QD=!SXQCS?S5@<\/]+8"
MKV2DCPN?TVI77!CC118'=F6B>Q26-:*0?:>!7:\_-65^=(\]S*;WY!E]<]39
M[X)L3\E/FC!&H%4"0MI;E_)"G,ZLAWW@G7< "K";R9CE*CCV%3#4@X2]H:1"
MR<U-=+CF:\9G-I)O6SG+FO4[1OI!'M$@6C_@-#M,"UQH(V2P!,PL+.QEQ7D]
MJL&]$,<S75JNOHS P"^Y,$]F)D$(#:P"DW7Y]A(+"M8SHM/3K!B%987-U&$<
M'I,O]N+ TCB_T,9\\_L&Y/ BCV\&4QNAXJ/V2]"+;7&1I(7MKR()FXQ[R W>
M.Z01&'H=6+V!N:9HJRMSMX'G2DM_VXU-;9S5Y#O(6<(OF1ZYH+Q =1,!K#L-
MXU"DG9%>AGG)GY,7XB0/'XAS<?W;"*2TOO%!-4!+%-;@Y-$&2QT0N\D^,=O7
M)%*F1R^4-%\I2?3Z4VLM&/=Z$2O(J(BH720I/"[9)=%Q&,JJOL&':[.FZ#;;
M8HQOXBG0 MW+Y'[ZUV8_/4KB242,GD]!^0X=G^JX"*LR%'WO,2"$N_^PWI3^
MGDK368W&[<CEP^0X\/5DDIWS-M Q+N7AM2(2I4T7U/[%E"ERUP"RJ9]' MV_
MM"T \ D>I"4C-$!]=X!-$23B:@>K%'[S%@.$0A Z4ZRQVDLS?B\]BE2=K8A_
MKR[A*ZP<=A[/\Q)01OJB0DP1[GN;="0'.?_:PSU*7B/[X'PG0R(_\5GP/977
M+B7Y<9G30SNYMIM?')_=.&'MJ5O [K!5IV.E*$S>:AB\$MS\>-RXCZ4!%7J>
M*!(O]#5=Z#;OR[HDRZ7# ,U:F5T P:SCJ2DY?/7QM(.?/+A(R9*JNA#L/+]@
M/)!!;]5=:E,;1B-DS?6"<&MQNWCQGAW%[@#GF^S06V^.*S;Q[K2KT*J@$OD*
M]72C;&?6A1&:KM:O)#T!HD4*S\2]G-__Z51XIDVCI? ,\+\Y<,:J_UO*H,8"
MK>]A-U8!X'=V!\![7A=W?>Z4]-*@5*J^@?3L3;9*3*TS7H#-C<3O*0?'_6>&
M\TLF1:B>V?3)VF!2S]0.;=D^\&D>ELBP)%;G' SVY) '4\%?69KX_78[>0(T
MNNE$Y7WC/^7S56R<.!H9CO4BYXT(37"D#Q\XZ#?/[$J=?8DT@1EGC2P%:YAJ
MV&,2UWS; HXQQLCBE+0 $[=^9_%!B4'NC[$_74Y%MX%XAY_09.&LJ.'AQ/JK
M/VA:8#M3(W-$YL4->^YS-/N#&3Z\C#B _%/0PXTD,)DJ@A-U$T#?$JP7IWRS
MG$$&W./YM[LF*7BHY:6G"O:PKE6/,:-(W$&X_;XMX1751Q_6/'M11IE3E#0B
M8V/XW"&'S#[1S':=QOY(#@\RPIDQ:U/U'#+^G(T+-QG9IKJ^+Q7;>[#95$P;
M6..A_.G:2OUQ,A[ PA_/^U]ZF$<@)82KETJ,PR^R,,A"\1-N3$R\(P_29QW!
M_1NV[:TR_\CJ*EMZ5_R<+BR1_R=>VV_D'"NOWD_G[6=^/7$;S).5?M9B.B8[
MZ5?&I9-(0C/&C:-T0MTPJ0<EU0&I&OUFM.F=S0M(W5F-],9'+-()98\N5/IQ
M=XRP+R=Y@:O&77P]Z7R%IG%6-$MQ/\ZOL*EVQQXZ''5-=(IW@# /L.^B\,<:
M WGVQ#<NCH7'W9_8R?P[9B-AN5=3QG'2BE:)+&#;^1^?N5QELW6-HXF-59=)
M=JFV>0_^-< TV[+2'OK[Z&L4[\'__F)\F?QE4*K14A;'CVR#Q]O0L/;%LC&S
MNXW/L2V6OMYWD/*AV+;%Y_'/BN#N=OZ])1Q,@7^QR6Z:@.QHO'B>M5L+F."A
M2[]]D/$2?W-;$\;-A;'1F^,X??@CK969.(! QXRR_&^65\XO\_BCXCO M#^X
M.4E;K39-;>&JI=M,5(-F&PC^^VN@4FM"_77_':!2_\\=@"GM!A-:8NRZ:VEI
MI41#A/OT]1D-?IO\BGKK"7+92(:5PR9IE5"29M $"YQLA:U;1SZ Q-GTV'(C
MEP0M982MJ'<.1KS_UIM7D]ZN][=*>[DYN)!,ITV*T']Z^$+RN;RT.;K7%4FY
MUEY10'L'\(2Z6F<H UV876X)=DP7?%I?KK/7'R-?9')X:#M3"[[J1QQB=?-*
M#)6AYN[ON/=*,@ !,:JE3F5L,OIX/#R['F/CAW< 2W^+I05(1M2^7@:COLP+
MR8[^R3:*_HM<C]E,MVSC0*,3I[D4W@"FZ:IO//09OPSUZ7\) 7,\VEF;Q;5M
M#^;W6[&BVYI8XE.)BGL39=[MY^ZWX]@:XQCG'."([W('0%3!5SU. WC15=6K
M$0>?IYB-QU/WUVW#F&S"AY7WC9-/1>.KMP6J]MR,.CT<G"0)._D9?IB/R8<,
M5B =HTO]^#&1YQGY04>5-X+LR[9ZRY'L7TKUI_ZMHZH>RS#+ZG,4Q34-2NA$
M^>2$U5?N!%#-U@%)BT5EN6?7J&<<'4"\)Y1$[0;;'4\(M)9:B\_GN^C$^^A;
MT&Z5O17+@R+'?\<<<TWH%X,!JT'7Y61L;0X0GZXM[=GG44BJ3-VT645-262+
M*O-0YC"F?JW"%+06$\"<]Z$.%D9+7CR=JI$C*,'=M"_^R>7(<*6P?")@PA>&
M36Q_SNWQ-&06F:< @A!M]?IH!-?3*^<R FP%55R\.PPBEBQISQ;N<QK("/ZU
MZ].E8"[%GU&2C%?X*%?WBTMBO\[@9@O4MS>=#M@%!]B(>1T\UC^?&'$#R'[,
M1_E';J&KG]5I(\K=$NAT[HUNH>A@1!G-EU0)J#'B<-M=\UN)?*ZIV/68!-IC
M."UI>XB!3VC(A==QY0Y0KOU\*,_$H]<WL#]:@,S4]HIUYZJ\IX)I*VE-DN![
M-PV1Y-Y@-36:YN%.8>Z]!MM^A:@+F*3R/,>2H,P5OTK_8@^Z WSH52?O7=WU
MK7":7J9\Y&NG?@O:\%;,^S+.IFPFR>;\W6:>C24YWDA9<].2(:U>QM] 5Y5+
MK,OS;Z]*J&Y-A_W]J0<K+FJ<!\6<'0,D[X$^@F=TXH\4H^V-EP5BX%YQ:2E>
M+VG'WT32ED$92J=N8\)B=8/W?+YS89R!!"!4>9]:P_D[YM6$.\!Z'^S]2*#I
M!\Y3IZN_3K$,\M?""U7.9FO\P(,:T61OM\V ,3/J;YXMVDHW^$8UZ*=OF/<7
M21]Q'*X2H*V!D[_,[E-'!.XF3S[.".I?.3NCP-*?RDCY5NM],7A.I57KDN8*
M/"H -0361/3O-Z'VL)WP:ZT]M'KGVSF%W-5XN0-0_1V@YM?\]2L_:>8S$N8K
M>GTJ/*"#@'P!Y8W$52[\OX4)^\')FGJ!QF5YL]5_F9G_[Z6_SB1P@YY@_ X@
MK/_B :T32[!-?AID/4TG8F(!WVU?>GIFJUT:PY7O]P:-^':C7VH*Z@Y<;?HP
M6V.L\?OEHRU2P3&Y;]8_U]J(0AM:0I;E1]I?^)G? 4+!:]6/;/D*<MXN&S>^
M&H'P^\%K2KE;_NQ+]VUIQ50;U:\%1NVL'D6VTZ*^^=BV.I@H6[92[%,U:G^D
M1'I1(1?[Y4V.^C1PS"!'?>U,]7%+@;_:LTKGAWSIGC8<R]BQ?5F,6R&\TJ<O
MAECW2;4A0F0TRFV$^]?HL_8BG?@LM/7FV.IM/AO2D*4:IC0$[I05YJ;[ YG2
M;A5GFSUOO.#;OKDY:-QNGX9:SF3+*H.%7:U@(Z1DD!]IJU>O0N&-*JJXS9\D
M+6>-1.Y\UUU(X9EP!;76=(S'-KC33V!UT<X4O!I)9QUQ,\*MHEB8+N5=5_O+
M*C0HCH,(E\41MVKUJU!/KKL?QXJ#5?<JK(M>/G]AWNROW9'HOM5"14>EU9"R
M8"J!Z[&_@HX>2 2^DAQX#] HLGM8^K;5O:7Z>SJLQLI>(+L?[,Q)S_DYNSQW
MZY_3 ((9=;V>EK[N0*"'QNO)=$S]8;0D6TC-I2GT_IHQ)4.S+U_(,_BGZ3%]
MMGNU$.HPL<H0$[B:'EJ(6OH%N\)O'RL=M5\P5F#:B1KXO6X?)2_ K2X\2D;I
M]!Z%;<N_D4#%B$OI%=E2-L #77SY<D),S)!]4Z,3K2[W*W $?7_YW)AM-NZH
M:!].HG@=" )K=#*MY,JA-G*9I';W/)64")SFWW4/+6:;RS4=F-P>]9,1&4/"
MNZ4^2A6UK8.77(+7:%/Z\@67%_)2R#3!_7["JP)/;+O\S=859^<U:M##F75I
M7@FTCE5\3#/D5A\9FDB]'#2566(LOK0<>!3-^IFN.-AU=QM!PS(8^PH>]JGB
MTH=E/BD3[FERU_L48$VDA,91V<\K64N^66P'N<PNP;-N*;&!@84E,:<O>>OV
MZF:@= BM](':[^_%%E3"I#4O)/0DF,)J=-;@X1X\%2_<_9T4IQ\C(L'\U[>A
M7CP);#CTOMC]U4=FN(P+GS#M&87@BA\W@JB)_R2RF;3Y>%>X+2L:DJ#@7+['
M*=9<XQ)<&+3\,$B_#HZ[)[9,BJ4P(J$ZE*X@(Z?/&F@-IB,<]@))QS@+[0UB
M46<EBZ?-("X'^:%!>";\D@WI7ATI1XGPD' _ /;0^?\[_3/"\&2T<I3ZR!S!
MN,W\U(_;(W52*4+DI$RF:]'![VQI,COAJY<,DVQ%S^G1 [#S#1"C99>I, ,]
MBX\T6SMZ0NEK@Y3^81$@IWN9S'X5-9H;^*NZ<YG$9-NK1'_J1K/=\<=YX]<U
MGN#19/\Y\3CU+I>0%@;+(F^.S?1EAP!]B@GQC>5%?R!9SQ5]CYS$?RZ%_D7Q
M61O43EFFB:6)-*7P2+W$^4ZZ0F5R:\?'M48=YG&@2$\B;?JKK3530$[B4XYA
MCM0AS2Y/*EH__$B@71(BKV/\B.M7W<39BXWFXPNE9W'C#GC-#U[;^ZP@<%:K
M'X*E3-.[7*@B79PXPFK+1CS;W[PADA%_\SC;K[PWP>)LH,R8\]YP&]WRB\\N
MSZ;? ;[ZZI;$WTB6@IT*D'N>PKOE]&*1KP2.;P]E6V9-8;UY))V%R$4[Y&&L
M)2^ZKM/AZ&;[#\'+)I-R*EH:+IO.@8-,- E]=_-97Q-JNCUYC;)Y2C3RW_0J
MF,+I\R<FVG1[B":[]O"KE5];28^@@<%R!+,B>4\Q7_PU%)KJ59W(3.=;T\7^
MO7,577_U5GDE5;+?14D#CE*[ W00%&%!T; ;BIEJ+#_&9ZB/B0&%:HWR/OO+
MWEB?*_FL3]?SH+_J8,%\?+8AXQYP,F<KQ#)*]CS%,V.X#0_ROU,!/(!O#LRH
M5^))(-'=F:#N0?9Q)R-?,*/10#='RT&8H>4PSPM<P0*\ZWX Z1FH,Y=Q%M1S
M!WB\@1U&/Z$SK1^6BFC])9:6QC]N_B?VP5?-5RQ"A]J RT@1V9S6.X!Q@.H1
M2'#GUB<0Q.G+E]>[3*+T\Z_9+O(\VI)O!H8,G@==HE(6]%V5M8BK%,4=*&O*
M,=?=F1SU.;U8F#D8;RT,EJ22PEON0RG;SY:)6O[:CC?K[CM&V #]N6@4[418
MGUV\NU"=_C([F79@->HD_OUF.R.&N9?IZ7BKI$>Y0*3[7PO4FBW<:DJDM)H]
M2C?M[?@@0Z*R^>-*N!@E9&,J+1UVA@Y,NL9>.&!!)?^\+IC5]I9$QUN%G9S$
M2BJ,##DZ;CLS-?-!%_X!]5FH_OZ)&P6,=R&F#*K_(0I+];W+ZN3A)V$R>.C
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MKU>IFZ-KD[$Y,N=,35S1<'WR<-@N^B+%[?(IN$?NN:%)585W!'M$AJIR#-F
M5)[=U6C7OZ=(B9X,S1^?$&-W  K'XG!#-'L82Z"GOM<U%RT;JJI92\NQ[ZG/
MKCL0_X;-,Y.DO<2IB)8KD\*17SSH>W<2]4X2N+==>B?!=HF[2?4[4CHCXWMP
MQ['Y?-XG(1)_#I2TX6?4E#KKIS^J*V6C^.MF.-=*&/7S]5Z?L+IDOE[H-)-!
MG*9R+$JB WLN=2XZHI=B71C];4%4*<Q$^3=FEJ?HLPB):)VR6]^#A+^5R^1V
M0N7*#:[VOMY?&G03.R1IS6-N7[J'I4G[$N-_A<[ ,W@R],U9T4')>Q^K6;%3
M[<*])_-BA8[B<:%O!9E739@ZNX2:_I:7U4WL VN+2UP"5WW_%KY[U^#$]X!?
MN,_[HBKJ_.W$?,S-D'UP4_5<FC@3S?1&0A+=RE=C^) IWJHYQ%4.]%SP2N\T
M,*C$G&ZYUSH3LQ98LY=6J_BCN<X!<[C6!ER["+?\/>Z1XZ]:>#)$$I1>?9CX
MB$BV-MG,>.W U$'&T*)OT9IJLJM/?$/EQ!J_37B]/V+3@:Y;]43X<9),93F$
MMR(X4 @\HKT1ZLT?_B5>.#\C%%7=?Q47OZXF6=*H\^RW\5QM1,JOIR_4&\]8
M6V'&4QZJ8_%+7 WUD_F-8?3KFXLF7:"ACY>1)#=\<7FA/D>= @0[2"P,[^S?
M"0_2I-N93TLXF>8Q,?-;ETNZ>A15UWS/<CVBAU%]]0;S](]A491%S^?%CP*,
MVQV*A:5%7 56WW.59QQEG[3+3(XA_5AK%N<[SI%JOR.LOQ!V>:PPK>B+.JVT
M&<WB-<V!A=Z/$1'[IGCR3S3B.GJ1*M.R-H_%P/3.L1*JH-_=,F]92H=?#<;^
M!5SII_N7C\Y20U(/C%YKD1[__1+6NGN27Y/DNA,XL/>3:%GOO=3!988<&\9C
MS44VAB3?E'>B;A[AZ'+<C<5O YX'_6IJ0:6'4.R?2%=FO6>UB&%AWD"DV&;6
M75%'M<IZ<>RCN]*3O$>K!^4W#O<PB$E0@WH!?CQXI2*64[>AN[8G"K[WK*3Z
MK415#&O!F5V\\1QH"LM0J5IQ%N7B6;\8__W0?41/U3AB)&8@486JYZ/$AIS&
M,50-^*&EL5UEI+#\PW/V/^A&Y6_8[\ <K7IT7/UCA&M5D<OQB%/?29R>?4P
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M&\.59BM%5:!QG'&3J^PV=X E %J9I)Q'N,>G:YN.;^1ZT/II%XY J<EM+OD
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MWJDPELC27S9]O]O]N6MN0 68>+TY82-^7'\+M \5&WNR]%1](E=XJL@[*?#
MUIOIFSEVD&O3M_I 6^3:VWTK[HL'0<.3$2<8/;X7#\4ASZ ,V],AW]6B!+]8
MU^4T,.RVT/&@VB.:]DOZ<":$/$<QP+3 9K!*OI.E;2NLHT.P=61L#=P+Y;?O
MK9J]F5A4<%V9.I-U6F/ND?PQ^=<6@9>Q7Y0IJ0)\H0,+,A-8>7JU'%4_L,F1
MZ:MYN%C;N6/*3B\*"O,RBGZ9Y&OC^&4O/O5[ @_9RKHR\AS&AJ?%0/1:"SOF
M<R59C':?]Q]CRD-Q63@S27S!LK9_?)F::3DJ*W9BB"7$5WO?2XM+10U GU7X
MG&3%6IU;L5!EZ@$CC';\I%<AZ^B'%&R\:6";"XZ"3RX)0G)-8Y2#BB=E0!V[
MM&\L-[%'1'.]#Z"Y5"J ""GKO&:W^/=72AW"O,Y*#2P2@!7]L!N!J9_P)-EW
M !8AD4>T)HP_4"J'/B<@58A>W](+W2]O,L]2?)@\KG)&H'.O^*FS]5/!3 2A
M-UI5=@ZB/9M8@9<KF6\G7JQ+Z__8,?O5&(63&$.T>4;[Y,\6H\],!30BK0A$
MO/.H8/N)\3P9)TT?E:@,CDEZG'O\@4+:2T7,PN>@;7 KK$G+[IDSGEOS0L3&
M125[6,8Q5T_@HP6(MF_&VU:4&>6W]]F7+[?G9*Z_-*I46S2@;J]5'B?2+#U_
M@'.[]E'PU,0-I ]I46B8/K",,KA@C]*-D D"\6/N ,KI;RS&#XI2D=X3F884
M3!;*M,$ARPS,71'[4TPE=3?XC<G7/'JU0H\*ZI[KSCBW!KL<G4&S+KC^7"H#
MORB.5;^_9RRK^1,9.<'(IE<FWT;=^H81MJ4)X^^4M!R>;LW;5*9X?YH22=Y,
MG=CLDN"7XYPK&G89(4P3MY1\B#=$D;C/#8K$LOR:SGH;/&NBS$LR$92U1=_Q
MI1^N;7L^^V>) \VX; C=-_R"6W5N&G('>%O%UL^D&]^G1=S'$2=+/T!$*@PC
MNO=\7Q'IEC*RQF=-V_WO$XZE@>%T2P7%D'RD-'TRD8:+T[-R*:%<PIN*'8'@
M9=+3(T+Y-3)*^@A'C[PG U1?R 3[&G$$STRPHB?67TG3O=9N)5X[0HL-U[S9
M$N5_<G]#=3\DE4;HHPKZ??KJT7MF]Z1R!UB[5P=2QG]78HM202[KR8-0U_K]
M'<.]TIJCS.),FX^8RB.W=5PV\>'YFC&'D:@3A]<.-5]?C<[U 8]"3.\ /;2/
M<SEA7SIAQ@3L/CE]C<0+*@Y/@"<S&EBI&?3E_3IMRTYN$D\;F5>Z-WR70P,H
M(!H]3(SCZ=I?VP9AB^R)9WS/%_,ZWY-A2(QN:P/ZBS'Z75+N@AD/1B>Z>9BT
MM #]ZWF3OP+H,24C4Z<#L-\#X0/LGL?G07> N(-;?^ZM@QSQ*Z[@?*ZDDS^!
M3X!][3E23@__J1F_@TQL76U\7#RS'AYW;R? !O#!3VDKW@^>@Q;$7"+,@9=T
M4D-?-Y8I.JX5X-@049,H$]DC1A;UP(-R_5&E=;-P& <$KE.*CA$;MIAVR+KU
MO:3@%&SX. #,3''"4+K"#F ?8%M8@P&EV_,96.EB^J3' (T%9P%QV>DB0Q!<
M-OI2C[0D?K]"4WH>C@U;7C>=])M4\U1ZH!?]H0C=S$;0R4SZH!L+?+Z.G1O2
M^-6*'9GP(\1T-9B;[Q*Q8.O&XG&9"61D""1;(DA]+UUU23SUF!A1]LJDI_%>
MOR[-JTN2ZP2V(5JUMCZI9UE6M=..#J\"/<5>G _V!LQB!P@GL,-PTM2P63KM
M!V2.1G#:5G\O2GBD$Q+P[EJS-K??9@?T^PY0,[?XGPH#5_)M2MX5A3X_N5';
M.R=3V'N"*I7_IT'(6,B]TD'U4'P<\<M[LSCQGFK^RH5?9C9]/(V_Q.\\!0[/
M_ &<P)ENGDT&L&!.NN1XVN#3?-5^XH*92\2V#;TO9;,#PX0D=LPB%9[Q40;M
M'GHK]0K@!7:!T,(=(-NI*B>1BL &T9Y?&>2LG*^HW7[2N_I8G)B0]2R'7M Y
M;,4]1YV'EZHZ>!48L)L99*Z/I#H."95]Z4EH9,?MV&Q/S0\MT/@EZW1\0Y8N
MQWF(&@L.8+.5:H\NO1<_537W+G9?3(T7G_/XX>=B0*4#U60639@$WIL1LYE6
M\O*155"L&E.XYT5S6C68+]%83\@DWQCY=0*=AA-R+/7$GV>^*H 68W5BXF_F
MP,G5GO1&N.&"\/CQ9Z3,OA4-LR#MBK[&.W<S3]CBT!U@(&0)ZW5S!QB^K-KK
M-FJ(MD5+]T!+%HS-=@*>PV;K+G*%\FR5]QUF7W];=_[$_B%.B+ :A%$K6+"%
MD^T7MJEE%A=MVNE_/3O9,F<CZW;6VL]OEO7J;O:*="B 31^$3I,/<)#7_M+N
M+G[-QO9W0R^J5!, P.EX$+L^M)&^D'1CW[[JH8$X@:]Z7>1)0H0UIEMEP2LD
M.CKC]>&_44?GJ7$_[3+M)T<>'@M]WU).5?V0)<^/"?'' J.?B3*'8SFG/XT;
M#7UHFYJ]Z#%J.ZM39"W1" :KZ+&Q,._"!$=)7X$8(=4E-C_WX&?0Y76,C>X=
MH#H95':B$=+* 35=A&@C+='T"QB?/YO2WP]/&_>A!T.O)[[/:CVYUO3L?"#&
M]N]QSQ.<>NL?N^W,&!"JBM;=7_$//>UPYK=S(XMT_0:^?\I/*HDJEX4%M3L?
M:<ZM2S(K:JFU+%X%5)]Q\-@>RQF@XH//!F545R.KZAC-]Q,ANR>:?&5&28.X
MAJJ_K=>)B!/'K%B<(="L99(].GN?U+D)#^KZ>DP(?K$YK"Y)2:P IRA.%"_'
MU=43=^%<]-3C&1\=N A."L(JD%P/ELS> >+%[P#L8Z*8LL^>?F]60.3\>1[E
M-E>BI[7+1D8=4Q^"5MSC/A/B91>0'Y?RBEO@1IU4C!&#C>YM?HX=0F&:[[1E
MC-%H5]!8Q6Z'76S/B57F6%%Q.T0<*$&0F/"HNF [7R!-Y=SK1N<6"'TX,V4Z
M!?(!GV'KX;E^7R:A GPBQG-3IF'K&BW"QG92>#];TD:&[;.0E(__+]K>*BJN
M)_H:; *!$#2XDP0+'CPX! OIH,$]P0*-NS0T$MPA2-#@$"P$FL;=W5T;"TZC
M#33-\%LS_^]E9AYFK?D>ZN6^W%NGSMEGGUNUZXP6\)DFTU+O8J:O@R4+O*+T
M$,5=+7+:$Q;"5[J-^5%CAU.VG^Q)PHO2N8A8EH\W@C*OZ#G_T; KK7C23M_,
M*9^J%A?OK;X@_N:I<]:S.=2T<&7P]T=@]B8)C.[54W_S#BP=J@GH78M<9WQ=
M'/P9%(^7TJ_N=I2>#_ZG)J(PB9^KQ_FM67N*CIV#>-T%XV<->;\E;\-3V U6
MR\'-&F+G ; 5E]GZ @DTG$2!-C*B1AAN9Y]9S@TGJCC\*V%NYF90IG,P42K9
MTOT")T_J8B2_S#+5&;^D]U6:<0NW.]+L4O%=_A"[O6'VZSM1@^KN8J9+%_E!
MK<8D)PS%>$ZPY/< &-T=8V []<@M44 T>C6+>]*E9\?8D']7G.-E-]1AT/)U
MH2HS^X(+B.Q"QN4=7*=;QW#1?IA#+_CE+G9\P4XJ:HZ"U"T["!C9<T3'ZH/K
M+-_]HX+Z*2FP55WN"QY.'3T ,%%Q.92=-%FCA8@G<'N*?<6F4^.8K.;$Q6K^
MP=<YX(\?M@,YD^FVHF<%QY>1G)UHUJ1N ];BWY5E&YR<ONZ1/;MWX@H.!URD
MQ$1)Y_1W!8O%;)G1NE/)(Z V I0(W/CSG9+FY&9]\QLF;XD^68[8R(T/A-AJ
M^$0&;"<KG@^ 8/07(H\QV , ]%_W"XD]-/6<X+_96_/*&!&#T\HL2QN&Y()"
M)%?"N\2%<]HT?B/AJ\4P3S9.P_2VD"J)5_@XJG6(UUYY*C23H_))0/3TG^EA
MV3H%@3SRZ%(7/.D?HOVC!'ZT=#;X()HW\NKDVHH AJ L73:/-4\T9$=>.U$M
M[P' >V8Z$\>#'"JT;=SM\F.EJMUCG<;.+P8*561:J?':(6K6>?RU.W;_D.^>
M(SEU3$/2AU_\\S372.I=<_@P.],\&W4T*-]NSN)A<;P'6VQ-R$OT\#QOVZ1\
M -3%+K+<V\WM>S,>T;L[FN=["?N64;N_84(H! N5\WE7/@ @Q\4(!B1=IBXU
M7!K/UO_-K"+,)G>M**[$J^M#4^2D+_OK'TK/R5-V/NC+*19LG@0X_<J&GMSV
M!A8?P(=M*4K=N(XUSPAN[I<'LBHE>U6^:88U55U7/0 *'@!G3"EM[FT75><2
M3-T&[JLQO-TMK"==BRE5WG"KE2(5FZ_G7?QI[[D<.8+B#\W43C[&NN *Q53\
M\X%]EQ#?S&(S&(>JD:T=&#"_U0=^,;NV$2\LB<FU5I?W<M*C?A[<%*1&?A%"
M+MQLY%L&3E!>_&B<A?:!))S35V:4(^44$5J4#'2SE<?N8[@&AGI*EL5#;VTV
M:[^MLE-KA:>12,^2C]EE<YIW".N:8#7:@)4V*@QUH3,2DL4&2QV@0F4/N3Z*
M!>X"P O*8=>?'FQL7&^=+UC(\Y/_"X7U!\#/=!UECP= (%II!/)"0KK<^,"$
M&08[19=FK)C+M,)>Z$LDA'^MCQJY&2=[^M9%Q E#4K2,)B=,R/.T$KH.G1"B
M0$B>A#\ :KDO+6M<;:MI"Y,=5$:%V3_TKH3 $ $%NA,_U+,J#AY]\=&&G A:
M770+9"1'Q%;J^<P#8.,IXKU"[LI]JR.#G!\Q4.?<Y(4G[GEJ=/)SJF,Z,YJ+
MM9AT271AWC]/'8\:6V*;]![H_79RL[]=DDRTI[UJI>ZKNN@D6(#J4Q\6<LX/
M/3PI$!?@ \">=J;N=@WAB!JCF*OZK(EP# .;6F_X60K22^U#ZAPFMF)W]!G>
MEKEPU]T<U08U\(7NOGPQXNJQ2C!3A?I<8/L F->-MZ%<Y4_2"AH%?:59)/I[
M>%X8Q]BX]CJURRRFZR7?Z]:8O/1KXSFU<[4+G-^PRYK'=)7N!=*; 'M6'21]
M6_R^2%\<-7*W9+C07"&H8DGBC5#$WGLRD'F(M<6 2QZS 2'87PSK7G#WA>#9
M-NK\=-X4K4HZ$N8E_"+FPY8MR\C1%#Q'ETE'%WC)3<[WN#;*D#UI5"2M9UO6
M X#VT8A*@W4,^ A6V(8CYK>K=)WB8EL#C]1R&QB_L0'PN:RXTO>;!8]DNYC*
M@M)=G&##VZN?$/@]6U>*CW3HI3'_ILRDXZNV.]4<EGKCV0JJNHB?,CFN\:XO
M+&]<,S>E%2943<YL+O\#$<?;E6*K'$<DXQ;X"OS"\TKZN\>9E__-D;T@<,E8
M$4]/ A8NF1?'';%(7/,$\%7*=ASI#O'>J/#B5RA?\0*J3EJ2+A\TXJ?,I?OW
MOH]71.N!0IB\Q3$#_] O1]\5*KB#R(]JZ\Y_I5!KY>>[F?D$:VTM9S:M(=IN
MXA.5%2XDKC<M2+UJUD?_-$HVWT:GIB!:FM7?CS '_$WXWNOC&JV;8=N*.U.
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M2[=7X#Q[>NT[_VM;!E;NN<-?<7=;FEZ,2FX3NW\3GDNDV[=S0/@^(:VMF!\
MWV.WK>8IR*(<Q+8(04L_,KJG0,/G9JG5Z>_H=543_0S^O2_ZI,SV#+</;Q;:
M+.FSZ!A^<<0QN&?Y9^9H!ZPX.*C_?HMT/O1(^UB(N@ 9?37Q+G1"T_$'WYI
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M.^4N#KAX -#(.!YNJM3],6B)Y!N,I> 534[S6U66L&J16R]>,#5$E+<RGCT
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M_QTH29 FX"0P4%4"G30)"ZB[&Y-LG8X9+2P934RT:#Q_LEDJR7F5<:5HY;@
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M+FJ;9QQ&\<W56$$^Z^F:CY6*= _L%LWHSEK[:,6VRC8))(,QL-<@JZ*UL.K
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MKL//Q]CCZOHQ-RJF[%"?K&IY/VUNM9J/(H\;,H=MX<WAL%;8, A-ZV[ .A\
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M/;W4_72LD[(3PW5#A61=AND%KML_PZ&%)JOE*EK/.KXIY[[/G^]]OLWF^#T
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M^E_G/F$BP+TBR\64VJ.-&@/NWZMK0I]Y<V+"F*B8\@&D1_3JVPKPC2@:M0?
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MH8@*BC'0=;M\D!Y)/DZ[0F3=4JL;'^HDXQGF/P'XN"/SOP'X/QILK^,''.B
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MTGD/6$_6Z6I&-\F/K[QU M)7$$[IP?,MYVQJO%FMWAW2\' =QZ3'K+0VGA@
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MKT],MXF:J*UKKSCLN&K]IW7+(R \R!TZU;<\=$<Q;R P;Y!'EK1DN#I63*N
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M^U73).N4@!Y9KVC-I>S.E%L/YUU?XB2[4:Z?;!NU\?001'\OS,\0N&=7D9Z
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M@)T2GSR-\1.\8K+',Q M E"DQ]$#\2=,;P53M_$DC^W?2X AI-V3<'A/[=+
ML%_=H^_*&551DGS&)GY<S/6K)%M-36JT)J]^TOW K*[$A[6SC!1VK^C8" OH
M6*V9FPE%[&UJN?7_(!\=&)0"#'RO^E)W8DVQY;<S [\QI=MDC@]RY^95DC[9
ML;%)XS=\+-N(*R.[<W0-B.J@M$>1%RYU54BDR:553J9'@E\+SPUQ3)>XU<JD
M9N<,='CJ,>T-^1&Z+_"B/)1X)["24.&>A/;(@*G1 L#3RE=)PK _C_@5_.Z
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M=Z:<CE(A3)9QH/?!K?;%GNTDF&CO55(*ZJL*]4 :_5%GN[HTANQGE=LA"$&
M6"D7JPD'FF&IT1>FH%K"FU\.9@Z@IY],G&X%"A'-_XX<^WG/\NONG4> 4%^Z
M:I1U9^9&?"&F $HEL>5;Y20V3]CX*"/Q#@'+![O/"O9W--GK%5_ -EVZ%L/V
M=<O[<":7.=< %M-UR#7 H4U/!6-0Y%,-0@KMOP*3'(B*6!N&CQ8+76IUWO[N
MQ3$O_\Z5" CS5YXAWS$\,A_IJA;0J6!CT)T/^C+ES>G,$SXR_UGE)X@;VPA
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MM-SZSKXT6JGS_\!O$.DVG>WA2J(D1SI<3B3T;V&\<0J+5Q<3E=7DUX#^K&M
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MMDX=Y<9]1L!JM0RKH=5I=]#^9J6!*;L<.C</==:5&1\AJ3']^C7[V7GHVB;
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M@7WTR FHO .^<>YN2F*86.7P!AT^C:^C/),-\^I,SM1]LI.<-7UX[RS#Q9,
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M7:AD_[;F6[DY/!;L/> '^=* 22Q^9/W)W5-T1ZA4X5^-6O^]>,W)G!%FWS\
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M\M2$8WD+CXB%8'1UL>'0\Q#HQ:E9'HRM?(5#+\^E"N+.J<%PZN[6D!RAHXN
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MA5P,C=KJP[ -H.WM2AJ#D4$K0FFC\DG*AN_84EM&]9J:B/;VD-ETM,BYM0<
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MN<U>8&L<WQXM'MT#SRU?S[&TF-2,M9:<U5URU%N0/<Y,$_R@_=&:P3ZH\?Y
MK(N2.6'.]<SI%OQ3HMI27T0-5/E+B#/;F#:VL=$_/8)#X"PR@IW!(V>@!>R0
M]>28R7XK\6-B:^&G-R@\__$^<"RY#,'QA2ACW%(U;T(E7^KBKV$2GD=E*3@(
MKS2#/*V#0!A,J]F@#78Y;SIEV;[CW<$H>*1E43\=1.T#'JIP++@=UXL2 EH\
M*M^RU57*W,)>@-Y_5O0R:\SLYJ486!W'>9NUW>3ZH3G;-]V#MF!A[Z[P*V>4
M,ID%+B\WD\^)><[ T:O"/5\7G\ ?^QF^&E=?(%^K;,PEB?UYRBHVP:,)9( /
MJ0M77R=YZ%7E\P]>4,];D OTIU1AFQMFV&*<MQ/6Y@KLZ68*%;3# -M;;9?W
MH%\#T?(B9,ND370DS;]!M4SIC:9W,62B<%[&2>6)\[L)IA?!HD,[I'[Z#0A)
MV!-)4AK0 G>3<E)%%G,_YS;T;,5>4??)#:IJ-0ECG!+LQ&BC_H)2>=?_\1<
M &#US&49[2+33)9Q47?66;F6')O5<5Q).SH&>ZE!,T1;]%LR9<31ZJ5@2M\@
M]%S$FH7A7(2@ RIT1(_MS2W?@Z:=SI]VL8%D:&BNVZ@\?JKH2KWK]-O^AX09
M7=,S]H+/V/[@?CS\<YU92>PRD[TI1\*]K(FLC4-$+!W[,MR^9^.WQ _IG$##
M8AU9;Z>.!P#QAM,#( S]L@496+'GIXULTT9PY^94*-;%!SXY9$LUVM1^&_MH
ME#W-G5$](JH_P%!CXR0<_@5NUZMU"'Z>!S$#.FE!I]1?E-DV)[-$A"04X0='
M!BLI"!Z!+^=0 _]<NWOHZ.%EL@D>2;7J_2MQNVC7ES/<*%_>DKGV6B;E AL'
MC#2Q(;.2Y;O*ROL?@I9$R*@-\RGOI4<J1V!!,>XC<)7WGQJV7-NEN](,]9C/
M'BBQS=7PN&MN":6Z2>FI*VI1%^DI 3.-S7[R7RF=YTWB=3^W:]X) =E!EL^2
M=PF#ZK<M9ZOS7@&=UBQCK$XC%\^  >NTKEJ$]G-JG/U8:'7W!:[JMAIRYT_W
M>(Y WI_PSG0P2KRV_31]Y:HFMMQBI +XJ;?S7?<;1J)8@<QSD5<[/S8:@P44
M'+?\+6_G>7^/*K"?_3/)^=?90=X1+P9*$T'7!*=%-Y0X^385B'D/ML\S9I#Z
M\-7O,"I;O=G[OEU?3=P+UTH0!%,[YI*!>'8TLKHW-"8'LYP8[,Y?NK2[<C43
M0 L#XJX<.<@R@F&KX&EH]1QH<F43J*>R?D1NAK!,.*P^]#:8W6H,FU*=6?-W
MY2&CB*%($C&O5QY38CYZAQ4^V>J&"X&NT*(T_)[YN_?\,#)9B12S;+Q)4Z[,
M/:QK'F^H]LUE.=6*1MDTC8#M9\6[%_B "H>XO!F]5NF#J[-1><7&#FK\\R8]
MCJP@X3?/L)>1F!X#>I\>!T<*E8Z@JM$@"<Q9-&@'-$&V6Q G^W\MHOU_(_^K
M!;B =UX+?3Z42?:31N/O?)X3K#KQ]@L;M&9&"@6:SO+!U9Q>#NX_Y6C38J)!
M'%GR\W9K40/OE"=1;RJD"[V$SM0G38RTG# 5-SZ\X;M[QX\US.KY2;FX>4R#
MI;)V.6YGADV]@:_(=I* &U\_J+$[3YNO3_;,P:%\X$/W'TL53'ZY=VY\CS >
M )\V0Y%SHR:E76ZT*\ H-*A.DVA]\GAL?7M%+TRD53'Q[=OAX>/1]$WQF"Y)
M!JR4V:!72+T:H%V_.%EUA;UO.6UC\5:59^' CDEE:SV9]F&AJ$=,ITY;_E"%
MZO'X[0H:9UG>A1-\X':P&?AYJIJDCNQWV$AM"L56L'3N3$H%,KRGB:JCZ5N9
MF8E2F1D_A<N6MO$(4662>.H3%&=?D,9I6E]6%K(5UT5:V<WMN'VCYDT%QY"_
MTT[_ ^"CT7=^S*W*FH_FA:*; OJ\N$%X".&T=3>"Y?O<78>KS,]C$_LB&6"N
M)PT"I+A8'OV%.!(O7@A,3] 'S$U]R(TSV NDNX7WQWI4T!(6A9D.RJ4Y;!V?
M=6'5 '^NT@1SFC,I7SLKF ^P85(*G9_TTT?0<2'\XH+>!!;)E<"O!@83(W_'
M-/CCY^8G&7D96X@AL==Q.TQNN3EPFU'\KE1J+@)JK9"$2@A[I]NMNB<':JW^
M'0[6,:60"+7)/+WZA 7YZ<Y:="R*$Z'IHKO]RJXNXV4F5>3]F9D*[_&$H5,_
MD_5PJH'R($TZDRC8N\)QEE$BDD1'.?^_-N+\_R[_]WHF23[;!\")0;7MKEK3
M#&RYFN-?;[1QYB(,/T%DJ!H+G81M#^$9K]<--5KZ0_8H=\7GY!4 'IF6."BV
M0&LW.^$,$UP0A$()SO)80#+7)N*U<YCE9Z_TH[A*D9\/@"=FQ16CUGXR\_/9
MWJV)(X+S5CMCK.J_1  >K,?IRQ.*8VN;+\OT <\!KP'%_WX=CC,&F8;07%FK
M'H_^D?=VYC*\:KDZ53C393O>T^-\9!#>?G==LQPGGO_L?"4A%CQ>LHNPUQU]
MV7CJ="0]?.E\PNL2)KP9IJLXB^-$0\K\"B,R@/0]$MP5H)3(7?UCQN6OQ_+F
MN4D22PJ\87VR1!,C_ZJ+B2$)CU40N!..9K/8DQ:8"!+ [O_!;!)5=045=XM]
MZ=<Y54B6_%K_^^"RO:UZE,NB30!5N3]BIS_9S<L'+S>]U"%C#GIU4F'F,"=B
M\ !H_EJ@Q);.\'I+4;WH-6U:8T#$"K;D*ZF* 9;JA47NX64\V7UR>A>BBG2\
MJT2TW1)+R+5\7$4>H)T2+Z8!6M\!@4K[?6UJS?FEJ,/IFF+#R<!3%1 UN#GE
MMW*[]P# ,@%9RB ?LT5WO@)F]F5E-)3O%<JY/=M-K3+46;=K;K%D4)WL8I?P
M. =43*!Z<D8FFY_"' CHDS$)B$V1KG GTSO1XR.J8.'MY>5?0\SOF3)LTXBC
M#.]V7SP2)[28(N@:?PH_>.$H?.NTH/(T(1[(\S%I/DMHGEJ0,8Q/'_#H74K<
M9E#@G>ANZ\"G2Q?BGHELSOBR64[@B5L-W>R\Y&;*K.C0>PI&K2>%C5*\6Z4H
M>M@I46<F&@;NW0KRV1BGZUD/%NB>$\]-=BCKJMB;:KS*^RC>(TE,3J>GZ,HO
M7$^#ZGW=U;U!FKGZ (CI%)T5NE<\4&VO?PN9;,2-@DP7-^<N9=$J>E/H\:S^
M2MGP72>O7\6F&X-A![%SE4"=U%KHC-=:G%J$GL(W5<AOZUEYV[$W ?B/-733
MKH).WZ;B4/E,:VR-XOJ+)_:&V'C^FE).;NS?LO-EIDGRF(HS*2ZY17.,''^T
M> !$KQZCSWL:99),9F&^MQUIX^]M)[2\F^2.5SDK'0C-.#J9*>!CH)G#O;R.
M-'.<2#0[$-IC(33;2&NM4]MQ6K@O[E/\R\6-?^A#FO%;1+WR>>TSRD]!Y8LJ
MS@GK';[GJ]'AO*7-61I,>-*GZQ*QA.ZS!ZZRVC\QMCAJ<-3MP$+I&^"P+-_&
M?"<3WQ1K+)>:/NS<_#F_!JX/%-T%@W6?AB<KV %K*C]'/#3W9'Q\_V(DW'=?
MVO\AKUX2?19\")P8&;L.4&]&Y@L'\LP79F9&:C2:JB8W$7(#.SB!BJ2Q6 #3
M8FN1OA,*$R-@U#'VA-T4BH&;NY$E=UD_3R=E-<Z8CO5<^1/V%ZO7G^MP4BSZ
M?-8T^.^ZJ]<6XM^SILX6C.9CE?%%+B0D$ X4>WD%O3A-'/WEI6;MQ8D5R6K8
M^;WX=PP&98[?^H=\P//L9!+[HB/HY2TH3\['P=)+8EVK;P#I$5BPM*P ^"V$
MRUG"+Y['QY/*QZS2YOMZGYFBWQ-':(?*L)^>=AF8M* ,359HF/&1LE@><^!E
M;,VE((5,MWRH"\YW86SN3L<IIV2>:T8NK!V'(HA5H%-!;TJK[],[>OUTWIJG
M.<=XEG*\08G3157F12Y323.9^]U))FJX82._:+!B=1,P""_]>0 8"&]0G"2<
MOW7.AEU6@+8[USH@1\B%6Y06&>(O ;(DWAVNDR^SAT<FHJ[%;8\X^O=%&E/>
M?XXEVROZ,]J"KZW(-T9Q-'3B)LVX'T*&I%^KMF7(BFH()HTL\K04X*<L9?\;
M"U\H8]>[OY$NK+9LO\]M)PC9M9NJR64_IMNG!AU1ASXGDC[:%KT^TEA88)3%
M$9JV!!+(3[<ST4>Y.D>T"NHPJV"DU(?RU4:/K;X!1(UYBD^:*(X'@EM<0U&J
M"T[7%Z*<)Y1!;Z (S6^KO]%4&@%.U-6ZYN\6S*0J37L1!1P+-Q7#AS8[UU4D
M/"'.J^X!H"/*#7,_#81MHX-=_OQ>)V5C4W,+).MI2=9>ME]6+$.Z/LY@GU&A
M#P <<#DD_02H:1KH+0PM6,=)G[WWX0SU#?J)%5I*L,U?JS^<T?7SHCP?R;=Z
M9\YK/)4_28;+;;',J39HG:5 I$25+OMZA0=#,H%X.4]+YB_2WBI=IPV"@0]&
MK$<$"6)R.::V$"\R>P/8<Z][^1?FN:_R_CHN53=-D7O135J"1\NCLQ#GR HJ
MD:.G&S!2TU^M/K#HP]*&"5X?M5A>KAH*%9;V([J^!/5BS-#%.KW[X_0#0QBF
M)&-@N7"^"R_WB?KVFBUDNH;!?O/55IU<DO"QV>-^$2L[T=)=$":*>JVOQ5Q&
M#6BP/N;T%*,UO>%YC87"5A)_[_<D)<?,IAP8M7&(>**4S\GM$AHG=07EC;!$
MJ5A-'UW4P[-W Q)A?[!_/:9PK9D4B5,DMI7#& O1=TV(</=&<2,6^CS?Y#N*
M/P!03'4.K4>=):=/"K)6#A,=*<-'.957"['%NA]UWG-.'G?B(N7.-*15O/OM
M:J,F<;VNOBGV-GU6 =PM'KD32 5N9UB&+>,W3WHO\;LP:%B7#OC@M1-I,7$4
M_^1\+>:6[6X])SI.49EF5JT4V!8@](-OR<L?U(72PD&4]KO1.-;SQ+I4[KUN
M&R]:5B@WWB,WV-<U_;-AW]31;V.A:$2ZV);IN,,$.1WH/2%'IO4&Y$5YRQ>9
M.))!R:=& BN4O+R(B[S\':C8<BGY/546]97>"LT_ 'JDD"RH[8SAVW6']W&+
MBUH5YBH<1;I<*2Z^G^N_?-0MHDGP,.21?H)471-M: W38YX4&FWZ(:DGD^7U
M$A*W]LWH[-WW0-V]CSM(^(I/I]7Q X  *1.,5OJL=*<*[#'X+00C-C*RS\B2
MCBTVV?<3%GDQ(M2[-1]1QUS)4;'Q'KY%W630!GZ.TD?0GO1F3O@,7BQ1C3F5
MKS;4-3<T)ZW;S[&*6;<L?OA:2QV'K5O8TN>C=6K=-5ZT#_^P>X"?5V'<5[ID
MVL/97XUE%:'PK,<50[(&3ZL4Q7:ZG TNJ<-K'#%7$ECLHX$VJ&#Q-_>TRHWI
M4&R> ?8=_BZK(_[5.1JVFO,7F^F^_I_%6'DM.SK9]R=[NH.O\R*%O5G1>NBY
MBW+S)UK=GSCVF*C*'@#>_R33*G'5Y80D'P#UH'37W_^[\C[_C_D@ ^AU/LJ^
M=/^@Y0?*/A^KKME4>_ !P"X9;J!9[-QAJZ,]1)3;J*MFPWR9CT=P9*IU<PS)
M@U^!SI><N. E@9/!Z5*[F(9W%N/HP&KZ_ZKG/"P_49K76_XD!&H\? #LM$[<
M@^T> %*S]9W#N1?_:?"?!O^'&U3;@[9:9PW_*I/K2SL 3GBZTP^ D8^E('O3
MC9>R*ZK#IC8;U49QV!0'LL\JMX<G"8?$RA/\+;M+8@&/BCCP[3&%)4W-8OD&
MY./:?:C=Q;X05"MQ6:7ILT#E#V3)-2OM9;9:)T%.)J!QGZK^1JT M__C%^0_
M#?[3X'_68#8:;5K]\1_='4?@[\>U,RX$**B)^[1+=E&%$XN+=L#TQ$+^9?[3
M8Q;3<G(WCI;-"=V>%S0ZLO0/\_\%4$L#!!0    ( )8ZJECP=JSR:'D! 'J)
M 0 7    <&QX+3(P,C0P,S,Q>#$P<3 P-BYJ<&?4N7<XF^'[/ARE5-6JHBC:
MHK16U=Y=*(JB-4M:JD8:L04AK=;>%$71FC53(V+'#E743)L@]AZ)&43R\_F^
MZY_W^(WW.-[W.-[K>:Z_[F=<YWW=SWV>Y_'0_M)F !P&NOJZ +IS  #=V0&@
MX0&/ /3GSOWG/ N&L_/\A?/G&1C.7V1B8KQPZ>*E2RP765A8V2YSL+)QLK&P
M</!P<')=X>;FOL3.>Y7GRM7+5[BO_.<A=/1G]S"<9SY_GOD**POKE?_EH+4!
M."_0=3.HT-/=!)SCI*/GI*-U 83/ZCQ/]U\!^-^#[MQ9C8Q,%Y@OLIQ=@.0
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M5M"01:V ]*&;!W/X4U5V"N' YS2 0F[?M0IT!PW :HM!8$XSJ[LK?[T=$\G
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M6^.9Q2QLW^H1ZN[J 7+0!@=W;@<[E,(F<:MD=407A$4'DXHQ@G,[DUT\)F@
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MDDW;6AT]!F&PDFHV>[)1REE=S+HGWQS5>7W'WDA[C0\N6&%DE!QT@F0!!J%
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MT=S..^]'QRI7SK67G45:M/?R93K<]DL#4B %$"*H0QX1?!7O^A&RR.VB/8$
M1;$>LXUS\_<D/[7UJ"I]H)"OWB;L=A6S94Y;]*#P>(5DGPSSE$AVTID7(ZHC
M6@^"<L0NEF7[$C\^,UMHW+@KH6.CT'TU>2,!Y/R7 (N3% .L)VWQW)\$(X*>
MW*>:MU'NHCY@(12%-ZMX8R LSL&,J.!KSK:B!'54Y(\)</-S$U6'9418JEF+
MT<MKH<?BPP''*C/5UE,'8K2.1AMD>F7Q\6]&<=ZRX(.)B0IP[@Q:\;$RE;1;
M@](EJ10*P)=#9![)!3UHR2GZ[019T%%BH0#HR3Z-"HZM"E#E;YW2"_<,V)S
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M[B!!/Z9.5# [*J<]8[A=3[<K6XR,#B22S.]'"D\))GO\@9B+I/#N#=]98HF
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MSQB,#8D#/0&:'Z!*WN4NYBY.=JX-PL'[V?WY33P=2+E669+W)/F)RS!_V5&
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MW>.0[; A)/@>T0.KGSB2AQ;7;Y "R[$[4,LH6II^XP6*+\\ 48?F@<Z\EBO
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M3K-TUXQ:@!G?[9JEZ;PU)01IR*V9[]KS\>@N& -16SU5<TS&R4GET9MGOP#
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MC&B&$0!5FJ*T/ZX<6#139:Z8TQ-D,]N7+?MO_%1N841K5*W6><?%Z"E-FO+
MZ\17/M>:2H^D-RL0F";5A>R4Y$,] Q48\&?K4=<2>VB^KUE7ZL)=I.>67IOI
MI+V.<XHA1 Q%SSKWB&/<F_&C;P V-5S9)-=Z2]&FR<FCT-(>QT'S[0:TE?.B
MFB18]]M20 4'^<&2969YDEF0XK%BJ7@BWJ<GYPKY2>*J&M-6/2HVA3P0S<6E
M7<EY4;L1V[J+'<')YQ+MGTS0A7O%2;\F,&9U&ZKD;VXWVE^;[K#NONC/8L+-
M)B*KKSD_2Z!<S;[]3:PY7G> $A!<U#AJU1?7JN^%&8DD93=]3%"9KTMK?/;M
M9GA5)O,5!;)3=\:208\!@R](FP#[4KM[S<K7AH#9OSV>[MER]=9O026V/R,O
MH16*GB*FFW+S4ADS+&8WKND\%JWQ]S9M(1L4W*T4,"(B%]MXS*G]".3;VDEI
M3CD8;_C>TCT%*]ZU.LDV OPWE1,Y_FQ261L,+FFB7Y9;JLW.^'ZQC)CPJN2U
M=ZU-NU8V*K'%W1)2V0?1=%^0(N9A0!>ZG"3;*F;!&UXP46\K1..UJWT(74P[
M/]F_'NEY!N!V)!W.QQ6&_D17M'+45S4QLKB63]_7$8X/"1+KC5W-3!R%IH."
MI@LL,X5_+,#)&:?E:=NO347ZXF2 ^B#]L97VUXB)O$>HIX8U]^+S>=\$*Y3+
M$6<6/Q">XS$$D9RC?JC4-EI.?HW'9\G%HU<Z/?FE^^@=8-F5LB8I1-/LJ(U2
M/G54T;2.(-2MRAH=8,[?>5M"Y.OSA<#21R>=>(XSP(33?]+E\CS$=P[VV-R=
MDOG^+LDW<>^W;OU?C5\7:$+]%/@>3O":*$K'^J7CB OHA$RG\22W&-36SMP!
MMWC"/]7[1.T>;L:=F@*GE.-TK_34QN1+EYCY=(SD@Y/U-(EKBVHWG$R;7V9A
M@7H53S=HOG;F]N*#!I94N]=0J=4EWDTVV9H!CJ9&JZ;!]CZ:KCG<9$A)H#(Q
M %JQ\1"H'T1_NS<U>HAK;GI9C.X0K@S#(KH1E[>"N53EQLG2JG&5<R+E^C^5
M.WWG?]_K?OY<""F04S&>>Z^4L LQU;1Z=K=%]Q0TRD_1='M%ML=;]T71?N)O
MN^1$NXBB?-6^<P:0/T7X", ,_./:Y8EL@8;G<+Y!D/@^>7P"M1^T]=%O(30\
M7N(J?EVJ\I.*G7?4/4X<UR=E#;']\1W$HL-4!>8Z(%A&[]F7V<%&\@S;VB77
MKM,UE9 U"6J=[2S_*NJRS*SJ:L<E0QY8N4B*"&R'T^3\?EVLDS\V5V1TM7:Y
MLBXXTE#3O0B;$]87-A*%:'!6^]4''.IS"7H8NS;+E8^']X"N^L[JM4QX6GNC
MCH;_L;@)#OAI< W2 CYUK+'./\Z?-= G?S(I1.GJ6=>A_VVN5TIU@LX!;*G"
M5%_^*>%R?6X0I_#OW-%XQ257'@0#$JS[ZAM??KG"L+19:*.A)MOE_V/L%UOH
M$IS+(E 5GYV'97S*$[6]_4JIQZ%TK-[\[C7.3YD)$]'+GNCX% _'9I5L. ;*
M3+26C6*GYVFS$7=C&/LU4/@N^^E5OD> XUS'[4_KE6> ,A?_#VS#F@2A3N,^
M#^%@L='W\3,:PQO%3Y_I^K,KM;\*TK<&<3@8Y-97-T]EHA3C^EYQ&&:XJ@3^
MQ5$<]IF$+*,QK;*$G,YL\<FZ%G&^EWSIKPE '3_AT1CPPK/KG\4N,9\PJ#P>
M\H)4@JM&O"YMLI?(EK\#?D%]8+S&B\FT7^'E-\C-^^"Z]>Z0+<IY"7;=QF'?
M\9\3R8KT6CA**J\M[H?&G'0$2HW%2#3F0$Q&H[RPKD@N/D_T%8=;AJO:5J$W
MM?8C;1N;MC929I=Y1F0UN=ARTQO2.6?QM[HW.#8_^K,:NT/BEG/>G9JB]LJR
MQHTMSXA%)I"44A71<*ICU7'4?,I&!D\M"/"R!U=NI)IYAV3$^$H)^=VZ5'E(
M)P[S+T;<;+V]^J;]WBAG%T>6('>LZ'N_WJ.31JOLHFC QMUR'A@_\1W2H &1
MT^W_0D[^F@U/FM1/\P+#B3+VCDNH&B^UZ&;:K$JB@9X.BD+6O_]KVFKZ6\I%
MVZB"=\,\A1,*0LKC-=/*PYW1O;6$HLC=W<KMBKKY1ZM[YTL)PK;L+"SHM?!C
MQ6W75(AP)TGLU]52B\>(_EIZUTB< I<J2$V53MGN*[>,J6D=MHVER_GB)JDG
M(F4\\YF42R++K0/K;GM\I;M ;#9[1N]2YU:QEF1VKQ(1SE!%27GO]T(WZLYN
MVN"EWZP2UE]56""D*73:G.'K':\LU6'P[6P2ZJIMS(AGX@=3<Q)$,)L#7?"J
M@8"(E#SPJ_.5I4@ZWV.IUUO?M75@)OW7W#SA\31]2,B)[(VB5'O-RX %#IA/
MWT/MSP"(M%G21#HT^D#?&I?29_ZKS2D?_ 88D/_U;_03NQ<LC1>?"'O^R?O#
M:"F>D(%-">> X0+Y:V10Y4=C<[MA>9HW>UT'UKQ-VJJ,A@C:G0]1CAX]6/T[
MNZ=R'-F;XD[K65B3K4;:I<+'?3(9.AXJB#_>/@W&)3\;X8R![_"I7\@<A;XY
MIQX&XP=#3X(W=B&W8VFI&)&JEEE91"FQ0>-?><6NK(2]P3C.Y0KSB)=G0GY^
M;$AY-ZTHJE0O9>- 1&DSSE$\A>A'X'E.3,-X$6B3UNYDC^DP.R6;/-;X[/ON
MX6YZ2Z'O5I?EY$;-.%FC #0?MO^"'5FE(VBPZVPJRG]0_\]NA6U8^S\;2]M+
M./CN.=";H)4J<Z\R5[JE*K4;9J]6M;XEU'3:,([7BF_%V0ROCENV 7ET<)4_
M'6:^"-?CIE$//VNY/N=;WT94:)!.&Y0&Q/DAG YRI%I%J^:%+/8B!4:VI/G>
M.U_YPXT?JX647B7P/(VWUI':Q=6&5S?+Q8E0YJY4*\19)7='<EY7<*[H=8N]
M>6%\U#QN"7J]\HML"O*@*I_E4S'/'^JP <5SON&PK!YUE.97P&B$-JS->7'W
M_>E'CS*-6B_GQ27^DQ_T$R:<AT-R3M\EEB8D;/RPTIHW_Q;DQWIY<?6#W'I<
M%^2)Q^>.%K4PM\GQ_&BJ=SZ06%DQH#OVQ_:"=EK+RKV>ZA]O>%E"0RM"/4;7
MX6ICJHI$>5,";4E>?97S6Z\W^%Z;(^S=O,9'8A_V=* YGS:LB8(AZG]4-J;-
MV*/OYC_X[Q&F\ 2$<Y!5/U;BT@LZ<;::E]JY=D(G=^&53A@X"FTH#^78J3@Y
M VC61Z@&_9.G#EF;?_"/A*4/IC(@O6'L/Z/%IU3O_O=8!?&#/$P..0E]_0R
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MY"5M3[ =]/0BCAF=Q=V!WL\^Q$BM?)SYG^L^-0-AFMO,(YCU(\V3B^N9Y:>
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MK:D.&#X%W"E?21>?J74.[KAP>\7;C"7HH%&1]+:,Q-*J?*;H];IS<A1#9YS
MB?+SNAUGXPM:@[_G5?_H6,:U'J#$+BWV;%/?)M+B0'Y$>?!PI,TI8#BF/N]W
M>.^O_W6(0+2F,],-/&59OY%AV];JH@QMN(QE,?Q8N/'#2?GNW4\$9PY3XU.
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MB5^N,SNOK$ZO.+VJ67;0DLK04EL9G$MY]*1\6-'6MW;\7IA-)*O.UJ=1.OM
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M .Z1\XZHM;J%3R0*BLCA/&"1FX;=72S/V*]$'TX*V^UM=9T$6*_R 1([WI(
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M@?OW\48FMAA3-D7N7D-N R].@?H$;\@#FIJ#M_5DWL/1_D8%XP8*JAJ+&B2
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MH_:7'=FS4H/45<@9DY3..2Z1!%"6DO"*LJ\7ZN?SD4Z]T, O[76\Q;>NH;I
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MJRZ0)\SE%6Z;.D>R.YQ[%H1#6G#VC(K+%MEZ1IWGIKLW+ST6E /\_H0S#9,
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MSISF3+U0V38=B; NGK=OY:Z/>]MI\CS-VA>N 7?UZ?%]*Y>@*N5QUD@"9)
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M_=SWS>WB>:V/MI;%+7>V,,,O__PPB]UH5^T7^.0[G-6-8-^S9 OK;M3YO-*
M:>X3??A%2S7%((VL+UZD2U5"[9;>@T]>HPR6)  N%D03$\2">9/)F<8A8U*M
MF3QUP".NX<2]KGZ_8_"[YGN_$^[(3=B[U6(EMIT@VD8,.JI<0:_0)$K>GP2@
MMNQWLA6.3&<T2I:Q2MF@ )%%SP*+ SBPK<5E%J,0\M.T:>BW?RZDB[G/(L]_
M/<T?KSCJE__N;J9DH'=1C$BK17 PC2R%:J9VUJ9=9*RV[EL-$(L<KD(L4N=N
M@/5T (T3:K2NO<A!8I?.4<?%6D]"K=KWH=>]("/S7]C,)/L %VQL&,J"K#N3
M!U,701'J>?76=A,PWPK1;";JW]'6_CY3GT<:.A.CUZ0VSZ$=:.;=658^N'OV
MGPPCO7&8?X8&_76G ]'K/U?XI]7N09HL"S"3.,CX_A6ARTJ=SDI1+MP2V2*.
M3)^ HM+M16F5R5\<O&5P_LEN'>D:)VRDM#M[L0%I%PKXN7YPN9BQ?RH$R2*(
M[P;Q8K635BZIUXQGQ.AZM>%O)[3XM)^. 61Y<  Z4%S=93:!PCW;8G?-U">[
M-D.D %9?71^)>4T"N(D[]O%]!*.NW7:>KY!?T^D890:U,B2_"E#W7/T*^KVP
M2VM_9&K6(:VV_L,PADR\?<U543 NYD!!8RU#LZ-5H!;#5^3@@(IY+\93U61@
MUC2'O,WM]:KE;3TW_R_7R!$Y]&) <AI1[*!!1ZL)F#ZKTX?FO\P-( /EB):[
MEFN G7#M_XSKO'?E&#(BMU'GN2G^2/POBYK/20EMT!2$:D,86.>\)OY'I+PM
M_55S]'Q?UXV+Y_9AWYDKKQ4@::PMU5?!8:T"6$0< O4DJN,TF9$I\^'DNIE0
M>,>?6^^C2W4$[3:V]GH$EV-;F?$I;S&]^Q14A2'N4B,M4DT.D>$R%B'19#6S
M-].0Z',\9/ARZ8V([^.B!2O$8;6BM^YE7A#7CM*#EO$*S^)D7(\GO-EF\L"2
MS>B3T]%'XR'7XK[.I]?0)H8(KM4&K%=5GB(L*5_:=#$SGFH(3B>#;,8/AKZ-
M?T+5>RU<;S'$9RG&N]32(L &DQ3V#>VIN:CSSLRV)?3)^X@A\:];XA<Y?J?%
MDN"OK6)CL*UH!R89 ?!J#"M*U/50@YZQ@"=%]B*GDF8F_#+Y_) H*G.1"('$
M_TK?2(*;+W_QNEA>]Q_BJN4/%O5<<!*0 @5+30V#P1[GG@/SHP]VX__\)*2
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MZ+).^UU&LY^,;FO@!@[!E!C"[36:R$Q>?'"YJ8_9VXG]@^-%CK)_IJ;43K5
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M)#WR-;5CUI-*/DCSRINRM1+MXT6OU(69@$7,)[G?'GT(;(]E4CZ.O_LZ_J%
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MWC82X*F_4?/40K.BQ63F-[<K/;RR7CF')O@2#P<D4,$GDD_38U1\YT);A'!
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M40M0?1)&(G*W<4!9W$$EMA;J"=LRPH)M8^.N0AUS80Z4[!<;=8-(DF^G1C@
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M#>-P?GO^#387@5\ %2H ^#S 8B85>Z& T?TO-,!LY(COJ=H/4W89B#HL?LP
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M S5/85:O39TFTM H5.K@AL)N1JZ;MP*#<%D+WS1F6HO_15U-7:S1]L!CRR=
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M'9/UE,/J#E.&4AO8'K6=J0%^A;[O?%Q19[#J/:(3B=R^2MTK@1!_R/_,46-
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M8[^YNZZ J/@HV5''=A6KEM21>!1AU(]BNDTX].G!O4'8I]+JO0!O@P0=^]P
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M^+//'XZ8N%3R2#%7&SRZ0 <^]G0 =RN"3'ABT#1\=4\[_KLW(?X(7M-@&PW
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M6%]OE'5:PU:+QP"RNK(Z9'I]74W>@ 9DY#:OV924JJRO3K=3&='.&D&Q!HA
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MU=22K0.H* Z(#*("40%!$ $!F8D3PH6K" (!0:*"0D!$99#)'!4193#*+%.
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M>Y;%SP((NUKGV !!3J;NTNDL(Y.8YP>S=)<VS&>C(/+I3,\JE7QR(327068
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MCY([#I]T6K(2(#\%<J+&#VV/7GFUZ6=R 05!@]9V__R51U%@Z:'R_U)R(M1
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MT;W%]^(7&^9U=V.WJ[6_7K(ZTACXB1J0?TI1OW*;KS.2%B2#@0<=-;UIT!%
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MW'>6^'/'_#76-AO^6W[\$Q6O"&\M#HKZCT%$(Q1J!;G=?P%02P,$%     @
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MC-D5"/UB=L W'I4=' F+70,B?+3^/EQ[1"127MO;=Z&(/A& 7C-3X BZ-A@
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ME/&B*X9G^+JE=O\@\!4LDR4 0EB[ D0/V 4YNG6G7Y89W!BG+ /?DZ).,2=
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MVAJ'X[6HZDFMLKN##"U 96YJ-T,SC>6U18$-QKV,8I=/+70 ,EM!W%FVK9-
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M,C0P,S,Q+GAS9%!+ 0(4 Q0    ( )8ZJE@V\"L>L@L  .63   4
M      "  0T.  !P;'@M,C R-# S,S%?8V%L+GAM;%!+ 0(4 Q0    ( )8Z
MJE@:O$P;V1X  .G! 0 4              "  ?$9  !P;'@M,C R-# S,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( )8ZJEC%?S*S>3\  *(\ P 4
M  "  ?PX  !P;'@M,C R-# S,S%?;&%B+GAM;%!+ 0(4 Q0    ( )8ZJE@D
M"/'F5BX  )/E @ 4              "  :=X  !P;'@M,C R-# S,S%?<')E
M+GAM;%!+ 0(4 Q0    ( )8ZJE@3BXA+:64! $*:#0 4              "
M 2^G  !P;'@M,C R-# S,S%X,3!Q+FAT;5!+ 0(4 Q0    ( )8ZJEBOM>@S
MZX,! *.[ 0 7              "  <H, @!P;'@M,C R-# S,S%X,3!Q,# U
M+FIP9U!+ 0(4 Q0    ( )8ZJECP=JSR:'D! 'J) 0 7              "
M >J0 P!P;'@M,C R-# S,S%X,3!Q,# V+FIP9U!+ 0(4 Q0    ( )8ZJECZ
M2KASD9@  ,W2   7              "  8<*!0!P;'@M,C R-# S,S%X,3!Q
M,# W+FIP9U!+ 0(4 Q0    ( )8ZJEA9 /R_N @  )TP   7
M  "  4VC!0!P;'@M,C R-# S,S%X97@S,60Q+FAT;5!+ 0(4 Q0    ( )8Z
MJECB['2>W @  $8Q   7              "  3JL!0!P;'@M,C R-# S,S%X
M97@S,60R+FAT;5!+ 0(4 Q0    ( )8ZJEB+?(/EZ 4  !H:   7
M      "  4NU!0!P;'@M,C R-# S,S%X97@S,F0Q+FAT;5!+ 0(4 Q0    (
M )8ZJE@7_%T [P4  #0:   7              "  6B[!0!P;'@M,C R-# S
C,S%X97@S,F0R+FAT;5!+!08     #0 - &L#  ",P04    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>plx-20240331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20240331.xsd" xlink:type="simple"/>
    <context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AoDmf9T7-EW8NibIGw8Drg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EVbVs5tNjUeS5vUf2w1OtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9j4H_qwYkSWRSCNd8Y63Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cabxw3GtuEGEzA6sOUlY4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R-M5bPoxwEejTI9jPZq0pA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UkNAV_nnI06H0twkkPSRjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_It9cBFHKPk6qc9vr0qHvLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1cdccZU09U-bigfo9gAdWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0ewi0kFMXU-CRUeaAv6HHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TnKkjPS4E0-jVZHJUJNLNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kzn5qEII7EOEguLWbvYS3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OfiAuwsd7ECIG9JmRKBQ6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dSj5Bua1QkaM-W1iMSZ6WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DqFs6ZdUS0WsAvycUW3EDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kD3z0qQXkGKOLbaYW_hYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_plWIvGvIFUyhx5jpML44MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_d371MQCH-UCwEc1UyItlwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_LIKQPrFmCUCnBtrg04Oumw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z99VySZvSUmmlbiiGP0ySQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Jd_SJ9gglEK0yT37LHcRGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_AB2WjkfrfEufyvdgXghKJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_WviQItZk-02YK8HpME_Dbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_pV_QgLXkMUeQZyfrpN-Feg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TI5qIQ-W5ECjpmDAaBfbkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_9_2024_To_5_9_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nWYpdchKYEGKP3xBFvtHig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <context id="Duration_5_8_2024_To_5_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_0fFQQ6KG80qYA735CyQAfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-08</startDate>
            <endDate>2024-05-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_HNYzKmZW0EGFk6AugmfHqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_MRoG3U83PUmyx0DXg4n4TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_6VgdHCEey0ChwG_Brnl3sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">plx:BalancesWithoutAdoptionOfAsu202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_A9tFbldDhUqAI-mwDvGBqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IMPE8wN7rEeMrPPPiQiN9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_DSkPUZ0Ock24wWZtXiDMDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0aoQ1IPKS0aCMthAjitzGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ZYB0fx44FEWMgVZL0Q2ZBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_IPYo9S6V0EqfSWhkVFWAYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C3_bHbEzuEi8F1H8pW2V5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_8a1FzJd1ik67d1aQt1PHIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VN0lXe7Da0uVnHnA1AZ-Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_xjgcoWRmyUq3QXN8beg6JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_N5rxkP1HDUKEqAztKtnJ2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_5ll4IzhZsUOjqRDIs4jcmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_o-lkPPcrrEeuOZNhLH7JRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">plx:BalancesWithoutAdoptionOfAsu202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_7SgXk48cW0uKG7aq9Ekk7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_e5XT7TC3JUOFCdJknj2Kxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_h9WLivGpgEyD1m0aAK4kOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_SyXMreozU0aUnXbYdjaAlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8VAgdb4ALkmKPOJ7uu_neA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6gG79eVy60GCAQmdhRp9TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XauTFxetDUimxtIcJ0CjJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D5tn2C8Vak231ybX4CNmDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_JDUfTJTYi0qDFhD9HD0akA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="As_Of_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_-uvexI6zj06OIfXhkzqtLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-15</instant>
        </period>
    </context>
    <context id="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-15</startDate>
            <endDate>2024-01-15</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_FTJ8oLhaw0eNY5HLHGDojQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZmijeMu1t0aGYXoOgDHBMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xX-MG2XLX0m9iz8FCKqqug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_mrSsBTSz6UuGt_rjv0O4wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_xVfX9yUYmU-4xeITZl_dtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_uKLBpQRGtUeyn34LZ3eWsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_mGOqXZx_bkyqGouEHLnUAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YaHpHVxvLEmVk7w9ELKIkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_dtTtAUZdsU-OMRlXaEJPuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_qjzJkxA5JEGDK6mwmBPwHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_sLr8N63ht0eaToO41XlL1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E_QTB-Qpi0GslgevMAMiVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_sTcnk7rZXkKGiMsDqP-mkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_gp6Tqjm6QkeG7ShEqzvLHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lwVtQlooKUmWHx0HxMj1WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_1_2024_3BAEb2yYok6aZSbSwaULdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_9OeDCEh91kqDTYHwfDEKIg">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_item__RvHgY9WKUuWNqJlDLZ_pg">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_2rgTiQvabkK-OvDBIrW98g">
        <measure>plx:Y</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      id="Hidden_VNZ6Et4Ick6Ne6-sIK5IJQ"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      id="Hidden_LhT2Lt5jMkmZz61In1sp6Q"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_Vav-0d4wWku23PA1jmVxsQ_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_t9nyX3azxk6O-xhXID5apw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_3UHQ-xC0AEm85UcRdfMp8w_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_eNbw5zSKbEOcIHjNlcmUlg_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_u8Z-mEs3QUu3xJwnpwd4fg_6_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_u1zmjt72NkOFSWFXC0lABA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_pkqMYV4LvUiMK2ywruW2Vg">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_Wm7Qppjtc0iAwPD8W4z2HQ">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_61yhpWZDt0-xQFFu7UGQGA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_HvUuYcXlo0e0_Xnxl8votw">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_oJ43oTELXEGu9DK95o28Yg">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_mcYiAIHwmU2f0CtlnZehVA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_D-jkB-mJU067DvqeU6fq8Q">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_W3gB5ik7EEKr08AsLsHwWg">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_medoSeZ2N0mJoIhJD0sLkw">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_RC3VKjTaNEe50T5kOrZiFQ">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_cX1VeAtRskCznOKMuQyCRQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_7KRsW_AfkE6FOHq6UrkWew_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_tZNlLA0sTkys7c4Y2JHDOA">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_IU9Isl2k3UmHGWTvkpaxcQ">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_4ZHTruih_Ue0PGeStPZXwg_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_hJCipwmbukC4CImqUggW1w_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_84LUMUzci0uuffsVypFufg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_8Xi1mwPvL0KwvvF-CjwwOw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_TSMOfj2jckmB5u_gmWXJsQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_aYk76m4iqUm4c3W5NyoT8A_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_KtJ-2FgwBUC9F1e1Cwwkvw_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tc_ZMjoDU3B-0KFtaZfd8RUIA_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_MKzF4Pu-uECDaaCPU8dmVA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_1_2024_3BAEb2yYok6aZSbSwaULdQ"
      decimals="INF"
      id="Narr_y7N6XqdkV0-gEj4LwAK8XQ"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">73316084</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_IM1wlSKII0e_GthT9GZI8Q_6_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">27209000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_TNSTyHXgMkmVPp_PoYxOkw_6_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">23634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_NuvP-OZGDkqIl0HZL-FExQ_7_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">21278000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_PSHR_Isk1Uuc-ZkIZ4Eq5A_7_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20926000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_c6rAoTWIxE2JYWJh_NjqcA_8_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3759000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_BUhu9VC0TkCTzlHZqk7_jA_8_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5272000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_uBstFpR9Z0uzjMxrhAo5hg_9_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">812000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_83OtTmURTkmdDxNXg-cbtA_9_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1055000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_Dv_7qtpoqU-0_Dv6IMdYFQ_10_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">22346000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_AScX3XLhf0anJ89nEFJCkQ_10_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">19045000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_WFd2RQz7LEK-_YuBWqk2yQ_11_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">75404000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_tNe6Xz2rkUicpFwmoFjgeA_11_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">69932000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_FYVM4CTtJEiAzbyMfH-hAw_14_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">531000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_T_rhDo0qBEGRXPkeW3Woug_14_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">528000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_y1RhrLOyTEWhlZZ4I_YoFA_15_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4781000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_ZjzqRYw_gUSH3vP9E0P0Cw_15_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4973000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_bbn2OSHLgkyoFdpwoIyNUA_16_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3230000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_L9k4VpAnCECSgQwO0S6X2g_16_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3092000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_mh13VWDpdUij2lBRJjRMwA_17_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5879000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_G7ytFD1ENUqSNn74H1GhMg_17_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5909000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_mmX1sMlR1kCK4Ds7ALXcwA_18_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">89825000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_95jddbE5E0qVowujV6lwGg_18_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">84434000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_JwZSbhwlPkegv9MZSx5VQA_24_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3146000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_BWTKGccTiEmawYYa_BNyew_24_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4320000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_Xc_aop2Am0SqlDQQbyHgfw_25_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">18770000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_ZAR0ej6E4kasIJqRWTcxWQ_25_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">19550000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_lwb-XKeQdEGzShagPcOa2Q_26_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1453000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_2qxN6YcMCUy63Pm4Gc4tUw_26_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_v0M7---9Ikq5U23o_WHz0w_27_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">11039000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_6EAYJN0PsEaoiOmU93GdnA_28_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20420000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_-jLhO4snTEuKsdRCc1-1FA_28_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20251000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_VxgjSRwKTke1xtD9fgQ4QA_29_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">54828000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_PAhSb0VbZ0W9aazZeRh6sA_29_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">45530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_y3Pd0-IcX0i3RwIsm-FYJQ_32_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">712000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_hcnkpjcJCUqi8h70Uk6QBw_32_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">714000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_Y8n6jnxA8UmVwYa4QlyI8g_33_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4499000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_JqTexTffp0mf_I_HjRw-QA_33_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4621000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_HSwK_lyk9Ue-KnCKASUfww_34_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5211000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_zsk0IKNEn0aXXPleFOiOWQ_34_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5335000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_hRrgdZkftkyQpbbILp0q7g_35_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">60039000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_tbWo6qCRWUOp1T35OLaK9Q_35_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">50865000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_Zh6S-GWk_EKA9gg4yivAHg_39_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">29786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_Tj3ADcLYXE2KIl4GSjMs5w_39_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">33569000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_A2dJ-a-OREqxJ1thL21xAw_40_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">89825000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_Mz3THUngLkSHeMTEXxNLYQ_40_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">84434000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_LIKQPrFmCUCnBtrg04Oumw"
      decimals="-3"
      id="Tc_Zgu-IDlF2kG-Y0m9-16Pig_3_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3677000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_WviQItZk-02YK8HpME_Dbg"
      decimals="-3"
      id="Tc_3UZIDFQ8w0uBBmKContwBw_3_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5066000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z99VySZvSUmmlbiiGP0ySQ"
      decimals="-3"
      id="Tc_n2TSy7-S4kWvMvjScpJNRw_4_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">71000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_pV_QgLXkMUeQZyfrpN-Feg"
      decimals="-3"
      id="Tc_AH0qJdhG60qUWEgkh2iqcw_4_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4522000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_8C82ueHaTkiLnC0keARKgA_5_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3748000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_bXoy5tZx5EKnV1COCqCVmw_5_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">9588000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_PhKXsFBd00inXpNg-XWf2A_6_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2602000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_Zix_6bej3kWNxBynuPIFFA_6_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3085000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_xDvm3MVhdkyJBkrAARDWlw_7_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2887000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_DPuc-Jsj4UWVu3ERCCKG2A_7_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5847000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_db8emrSrZEyzEpW5-2uZjw_8_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3115000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_dgJDU4y2U0G0DN1yJgvpHA_8_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3115000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_J2pfgH8FQUGlur68quqcKw_9_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-4856000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_259lhwI9WEOuuP16rryJog_9_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-2459000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_0mCVidCqGk2DomEcm35wMA_10_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">390000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_n3JIqXVBWUa9kL8MiumudQ_10_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">649000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_UpE__mwaIE-H1iQBavklFA_11_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">513000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_dg5VmIVFAUuIfI0p655oXA_11_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">172000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_qQ1DRImzdEWNQQYmofqqow_12_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">123000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_f5eaL5T4kUKW_RT3EIQrFw_12_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-477000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_aQlLwIKVQE6WCW1gdyO1oQ_13_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-4733000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_uwQZlzTdckaJwNrq3woOPg_13_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-2936000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_iAA7BDgQ_kKrCUMwf8ugiw_14_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-138000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_svW8kAzh3E6LVfmiQiPicQ_14_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">195000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_t81SvSsSVkC7WFXqoGvB3g_15_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-4595000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_tUzfg4yF4EOL5IVqzkDKOg_15_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-3131000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="2"
      id="Tc_3Cgodxnfu0eyhVrHxnihUg_16_3"
      unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="2"
      id="Tc_3Cgodxnfu0eyhVrHxnihUg_16_3_2"
      unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="2"
      id="Tc_cddVFEa1akSavlKaJoKiTw_16_6"
      unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="2"
      id="Tc_cddVFEa1akSavlKaJoKiTw_16_6_2"
      unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="0"
      id="Tc_cxsuRF854E6Ln2ZGP6l0Qg_18_3"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">73036569</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="0"
      id="Tc_cxsuRF854E6Ln2ZGP6l0Qg_18_3_2"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">73036569</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="0"
      id="Tc_xuXHGvTkQ0CnQ0nLOifbhg_18_6"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">57480009</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="0"
      id="Tc_xuXHGvTkQ0CnQ0nLOifbhg_18_6_2"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">57480009</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DqFs6ZdUS0WsAvycUW3EDw"
      decimals="INF"
      id="Tc_5jJVSBrasUWgBK3js2CxoQ_6_2"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">53790167</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DqFs6ZdUS0WsAvycUW3EDw"
      decimals="-3"
      id="Tc_mbn-mSQPHkaRi3y9jC7Q4Q_6_5"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TnKkjPS4E0-jVZHJUJNLNw"
      decimals="-3"
      id="Tc_zl_M8p2f1UW3sBosxSltTg_6_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">379167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0ewi0kFMXU-CRUeaAv6HHQ"
      decimals="-3"
      id="Tc_pWUjYWbjNUazUJZY6NOxbQ_6_11"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-389861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_N5rxkP1HDUKEqAztKtnJ2A"
      decimals="-3"
      id="Tc_hCbzzHkS-EGkwl94PGxh_Q_6_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-10640000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8VAgdb4ALkmKPOJ7uu_neA"
      decimals="INF"
      id="Tc_gosVfC_JMUCxqvplCA6nxA_8_2"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">8212482</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8VAgdb4ALkmKPOJ7uu_neA"
      decimals="-3"
      id="Tc_hlt6b7p3L0WovorEHYZJdQ_8_5"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">8000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D5tn2C8Vak231ybX4CNmDA"
      decimals="-3"
      id="Tc_ILGG0MszgkqueMDC21Xxmg_8_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">14225000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_-aHdXdZ4-E6HQ_EwgR6Z6A_8_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">14233000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D5tn2C8Vak231ybX4CNmDA"
      decimals="-3"
      id="Tc_XJvBBppZHk6-ldZzhOSaow_9_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">453000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_jIDprBljmEybhdnWZpvWew_9_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">453000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_D5tn2C8Vak231ybX4CNmDA"
      decimals="-3"
      id="Tc_Elct3sUldUKwJHktGkvL_A_10_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">93000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_OYcYSr6ng0qvSHvb8yj0VA_10_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">93000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IMPE8wN7rEeMrPPPiQiN9A"
      decimals="-3"
      id="Tc_sh96ksNAMUqSF_XVs6Gxxg_11_11"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-3131000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_JqFZJJQ3V0OAVBtupKcNSA_11_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-3131000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dSj5Bua1QkaM-W1iMSZ6WQ"
      decimals="INF"
      id="Tc_sndmI7N3c0yKdEk-SeoiAw_12_2"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">62002649</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dSj5Bua1QkaM-W1iMSZ6WQ"
      decimals="-3"
      id="Tc_3BEKlRZvtU24C-qSoaJOeQ_12_5"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1cdccZU09U-bigfo9gAdWw"
      decimals="-3"
      id="Tc_eHXZoORImU2_8-RwCEB8DA_12_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">393938000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_It9cBFHKPk6qc9vr0qHvLQ"
      decimals="-3"
      id="Tc_q5EmVcWEmkaz_Au0IL77fw_12_11"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-392992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_xjgcoWRmyUq3QXN8beg6JA"
      decimals="-3"
      id="Tc_sJWjeqhHoUy-PbTScqIyYw_12_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1008000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OfiAuwsd7ECIG9JmRKBQ6w"
      decimals="INF"
      id="Tc_FGp2-PEvW0uYn-0F3PL6TQ_13_2"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">72952124</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OfiAuwsd7ECIG9JmRKBQ6w"
      decimals="-3"
      id="Tc_kWtNcjywLkKtlit7W4-Ugw_13_5"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UkNAV_nnI06H0twkkPSRjg"
      decimals="-3"
      id="Tc_zLEuaa_wNEukyaj5mRScAg_13_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">415045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_R-M5bPoxwEejTI9jPZq0pA"
      decimals="-3"
      id="Tc__meieoDTgEqUtFyASW_GvA_13_11"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-381549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_f-ASgM-E60iVfUv35VWCkQ_13_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">33569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EVbVs5tNjUeS5vUf2w1OtA"
      decimals="-3"
      id="Tc_Dsy9Q92ack2IM6dWv35Xhg_15_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AoDmf9T7-EW8NibIGw8Drg"
      decimals="-3"
      id="Tc_oodz1Dz44kCSLvgyhPFooQ_15_11"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg"
      decimals="-3"
      id="Tc_v8PL0h3_wUiwfI-glHZlUA_15_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-169000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XauTFxetDUimxtIcJ0CjJQ"
      decimals="-3"
      id="Tc_TWo9GOd3zEupPau1MYg5UQ_16_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_RAKUf5NY00K8g5P2rFf9kg_16_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6gG79eVy60GCAQmdhRp9TQ"
      decimals="INF"
      id="Tc_33t8Gr9f0UeEkwYS_dtQJQ_17_2"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">100000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XauTFxetDUimxtIcJ0CjJQ"
      decimals="-3"
      id="Tc__UFD_oEU7U-RdfbTAf0yKw_17_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">481000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_Zzfnr6ydnkKdzs4ye8nGXQ_17_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">481000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_A9tFbldDhUqAI-mwDvGBqg"
      decimals="-3"
      id="Tc_E92oGXZbzESoGLtRmB1Zbg_18_11"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-4595000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_Oi1Jkwda706wtO5o7SgRqA_18_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-4595000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kzn5qEII7EOEguLWbvYS3g"
      decimals="INF"
      id="Tc_KgyFIzvufEafEs9RBm3e2w_19_2"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">73052124</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kzn5qEII7EOEguLWbvYS3g"
      decimals="-3"
      id="Tc_1vnPygbu-kCAzsKWsXnstA_19_5"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cabxw3GtuEGEzA6sOUlY4g"
      decimals="-3"
      id="Tc_6qcwGXz1Y0aMz9Lr1441FQ_19_8"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">415633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E9j4H_qwYkSWRSCNd8Y63Q"
      decimals="-3"
      id="Tc_ZO6gmVxdoky-h-byrpDMNQ_19_11"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-385920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_vON1sz0vKkW-QkUvL5Yr2g_19_14"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">29786000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="INF"
      id="Narr_ZE2uJGzu80SDHqd1F1g45g"
      unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="INF"
      id="Narr_iypOOTgJ3UGzktNVrs79iA"
      unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="INF"
      id="Narr_il5Qb-4RMEmpOFawdz8cFw"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="INF"
      id="Narr_7mn90FOaWk2cBFuU515ZEQ"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_Kbt3dD9DjUWEm6hNzOe3rg_4_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-4595000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_0JBkKYm1ukmiXN1YUeRZfQ_4_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-3131000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_qpGTXJUqrUmKqEx-_nXpQA_6_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">981000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_b5WLcgC0hUquS8Hb9j3O-Q_6_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">546000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_4UWkhxHN6k2vYiW4cnVFuQ_7_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">322000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc__8rSuYmTa0W0Te0ezAFaZQ_7_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">280000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_431mKaB_x0q1aa8WqJzqIA_8_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">471000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_g4FNklnsI0CGPCHX_bMe3g_8_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">91000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_FKL0XpItiUmMrBC7FOHlmQ_9_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">8000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_FezpEiTGWk2a4GEYvCx5Zg_9_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">19000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_cvxHyWE1RUOFUh_1-RoSvQ_10_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-138000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_AQTz4KXuL0e9QDq2HP42KQ_11_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_MchgnGjbTEGtLI5JBRXXag_11_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-1000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_RyGL-8MZcUmwLmtxxEewxg_12_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">80000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_dIRaoiEek06yobvGeGK_7A_14_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">11039000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_RXzIRfmRtUqd5iHBHlX_Mg_14_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-1388000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_uCrfEUVG4U-mB1yTi3MHug_15_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-1746000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_Qb8KCYqm-UGGr1bTClG5-w_15_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-3823000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc__BS79PN88k2VCmg7e2H9xw_16_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-14000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_0q4i_DnWi0i8K3P_ZRAARg_16_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-9000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_kWi4o2N7uka0mJ-3AK9DuA_17_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3301000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_r5DNX_YNVEOIIJrCD8dLfg_17_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3499000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_Glv_IyOK6UGxPkdtOUo-Cg_18_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-1414000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_6XLYoODgtEiBIkmPq-Ldag_18_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">353000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_dwfJ6FUOWkubLV0pmtC0xg_19_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4188000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_O37a9E7ozkuRL71XuaYSKg_19_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-2998000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_ec_OMziUl0O0ly4-eiFyDw_22_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_4bLz4du9akmUv1EInvYs2Q_23_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">598000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_8l84yOS5902XAhJYw991Zg_23_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">248000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_8cxYlPrevkGFdTfmWpvRJQ_24_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">8000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_Vg_HD1NjYU6GFoXV1azrjg_24_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_djtqz1pc3k-JQjZyYnasgQ_25_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-606000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_yKoubttZUk6gkcbNMBfWRg_25_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4732000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_GZIbB1QUvESg-C78pXfUdA_28_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">14233000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_MzZt28tC40yyYQP3Vfc2wA_29_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">14233000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_1wtumY9MRUio1kLzsJyfaw_30_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-7000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_qgGNenJrVE6kfSfF7aQAog_30_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-42000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_8hWygluGiEWNNaA1-7WtRA_31_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3575000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_r0ttSuMRdkamt5Zvdq7rvw_31_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">15925000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_CxrN7swxyUC-6ZJG8XK5FQ_32_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">23634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_N5rxkP1HDUKEqAztKtnJ2A"
      decimals="-3"
      id="Tc_D4lGaHopD0yKBB2rdV4RVQ_32_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">17111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_81U_VbGTVkm1Dkj8-B5AGA_33_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">27209000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2023_xjgcoWRmyUq3QXN8beg6JA"
      decimals="-3"
      id="Tc_wisunZ8ZrEWhKquVeNvAsA_33_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">33036000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_vePAnrDEKU6qe5kJxTYSKA_4_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">146000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_wcf61Na1-0OZDdeGA4Kf2w_4_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">326000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_iF1ZbODmK0OB4LwStDZAPg_5_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">186000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_JI6ePkBBGEmOOwIQvygARw_5_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">312000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_MKSNtcZOeEGeSHVTnHKHcg_7_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">766000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_jSNdCW1-fEKMqVWGAyhmew_7_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1078000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_jAWZ7fKOm0i8pnLvbW8hcg_8_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">33000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_fEn-qxWHAkacDmnkhkLoWg_8_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">78000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_KcMrpTkVOkK29Gx7NWunbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (also referred to as Study PB-102-F20). The FDA review team also concluded that the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/div&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;21, 2023, the first patient was dosed in the Company&#x2019;s phase&#160;I First-in-Human clinical trial of PRX-115. This study was designed to be conducted in approximately 56 adult male and female subjects in the dose escalation phase with seven sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of March&#160;31, 2024, 56 patients have been dosed in this study. The Company has decided to expand the study by adding an eighth cohort with eight new subjects and to commence preparations for a phase&#160;II clinical trial of PRX-115.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of March&#160;31, 2024, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due September 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, &lt;/span&gt;the Company is required to comply with certain&lt;span style="color:#222222;background:#ffffff;"&gt; &lt;/span&gt;financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of March&#160;31, 2024, the Company is in&lt;span style="background:#ffffff;"&gt; compliance with all such covenants. &lt;/span&gt;The Company believes that its cash, cash equivalents and short-term bank deposits as of March&#160;31, 2024 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company calculates loss per share by dividing the net loss by the weighted average number of shares of Common Stock outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted earnings per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted loss per share does not include 36,292,208 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2023 because the effect would be anti-dilutive. Diluted loss per share does not include 31,839,345 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2024 because the effect would be anti-dilutive.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate. &lt;span style="background:#ffffff;"&gt;The Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued &lt;/span&gt;ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&#x201d; (&#x201c;&lt;span style="background:#ffffff;"&gt;ASU 2020-06&#x201d;). &lt;/span&gt;ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#x2014;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. &lt;span style="background:#ffffff;"&gt;The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. &lt;/span&gt;Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Updated January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 415,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 414,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 381,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 381,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The impact of adoption of ASU 2020-06 on the condensed consolidated balance sheet as of March&#160;31, 2024 and on the Company&#x2019;s condensed consolidated statement of operations for the three months ended March&#160;31, 2024 was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances without Adoption of ASU 2020-06&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Financial expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (62)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (107)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 415,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 416,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 393&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 385,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 386,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (286)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;e.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;New accounting &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;pronouncements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently adopted accounting pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures&lt;/span&gt;&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_HHXnuzRg_kmiAHqf_xK3lQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland and Israel. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylization capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Elfabrio was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in the Company&#x2019;s phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open label extension studies was transferred to Chiesi, which is now administering the extension studies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;From time to time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open label extension studies. Some of the withdrawals transfer to a commercial setting, others withdraw for other reasons.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting the Company held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (also referred to as Study PB-102-F20). The FDA review team also concluded that the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development drug candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/div&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;21, 2023, the first patient was dosed in the Company&#x2019;s phase&#160;I First-in-Human clinical trial of PRX-115. This study was designed to be conducted in approximately 56 adult male and female subjects in the dose escalation phase with seven sequential dosing cohorts, each composed of eight subjects (six active and two placebo). As of March&#160;31, 2024, 56 patients have been dosed in this study. The Company has decided to expand the study by adding an eighth cohort with eight new subjects and to commence preparations for a phase&#160;II clinical trial of PRX-115.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of March&#160;31, 2024, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to the Company for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa in connection with the commercial fill/finish services. Under the F/F Agreement, and, following relevant technology and technical information transfer activities, Chiesi agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due September 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, &lt;/span&gt;the Company is required to comply with certain&lt;span style="color:#222222;background:#ffffff;"&gt; &lt;/span&gt;financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of March&#160;31, 2024, the Company is in&lt;span style="background:#ffffff;"&gt; compliance with all such covenants. &lt;/span&gt;The Company believes that its cash, cash equivalents and short-term bank deposits as of March&#160;31, 2024 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:NumberOfGlobalLicensingAndSupplyAgreements
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="INF"
      id="Narr_KWvfgS48HU2Is0_6GnpeBw"
      unitRef="Unit_Standard_agreement_9OeDCEh91kqDTYHwfDEKIg">2</plx:NumberOfGlobalLicensingAndSupplyAgreements>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xX-MG2XLX0m9iz8FCKqqug"
      decimals="INF"
      id="Narr_KZfqxbP3mUuBlE8y_fa21A"
      unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_xX-MG2XLX0m9iz8FCKqqug"
      decimals="-5"
      id="Narr_5sn1yOMaAEaXvEWFrta8Aw"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TI5qIQ-W5ECjpmDAaBfbkg"
      decimals="INF"
      id="Narr_qWjJoBpzA0WcXpE1tpLn5g"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">13980060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_TI5qIQ-W5ECjpmDAaBfbkg"
      decimals="-5"
      id="Narr_TsBv-2H6lE6lA9iXcPmVAQ"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ZmijeMu1t0aGYXoOgDHBMA"
      decimals="-5"
      id="Narr_4KQAlw7bfEG80h_XWkFT5Q"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_3_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_FTJ8oLhaw0eNY5HLHGDojQ"
      decimals="-5"
      id="Narr_ruSRHG2P7UO85HNunkrCGw"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">6400000</plx:SaleOfStockMaximumOfferingPrice>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_SyXMreozU0aUnXbYdjaAlg"
      decimals="-5"
      id="Narr_j6l5WwADkkiJIBQ9V3cLAg"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_h9WLivGpgEyD1m0aAK4kOw"
      decimals="-5"
      id="Narr_zUSxP6Kqx0qd1k9ab9hyiQ"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lwVtQlooKUmWHx0HxMj1WQ"
      decimals="-5"
      id="Narr_sdszIpU1RkKgv1I3p_iYXQ"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lwVtQlooKUmWHx0HxMj1WQ"
      decimals="-5"
      id="Narr_-LqULqHejkyrdikuOiJrfg"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_gp6Tqjm6QkeG7ShEqzvLHQ"
      decimals="-5"
      id="Narr_5F65NZmTekWeK3EYN9s8jg"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_gp6Tqjm6QkeG7ShEqzvLHQ"
      decimals="-5"
      id="Narr_WSndhCQCO0SDnV4XlK0-vw"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:MilestonePaymentReceived
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_YaHpHVxvLEmVk7w9ELKIkg"
      decimals="-5"
      id="Narr_SRLZAPi8xEa5omwZw9JF2Q"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20000000.0</plx:MilestonePaymentReceived>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_sTcnk7rZXkKGiMsDqP-mkA"
      decimals="-5"
      id="Narr_5M_aZz-IAUqk-FbtFdEBRw"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_E_QTB-Qpi0GslgevMAMiVw"
      decimals="-5"
      id="Narr__QGA6XI6Jky__6PjUzEJsA"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_uKLBpQRGtUeyn34LZ3eWsA"
      decimals="INF"
      id="Narr_Ki3S3XKkHkCs6YkRd3WGwg"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_mGOqXZx_bkyqGouEHLnUAg"
      decimals="INF"
      id="Narr_IPdLQck7kk-7p_kc4RQOaw"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_mrSsBTSz6UuGt_rjv0O4wg"
      decimals="INF"
      id="Narr_Z2VIA5eUakyHt9y9v0DUQw"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_xVfX9yUYmU-4xeITZl_dtw"
      decimals="INF"
      id="Narr_y-T-4n_31Eik_3hu00C_Bg"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:ExtendedTermOfAgreement
      contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_qjzJkxA5JEGDK6mwmBPwHQ"
      id="Narr_Ud8HhkjSP0CO6Mq67dz3-Q">P7Y</plx:ExtendedTermOfAgreement>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_sLr8N63ht0eaToO41XlL1A"
      decimals="2"
      id="Narr_A9XfHn2xu0CfeMkouAV3tg"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_dtTtAUZdsU-OMRlXaEJPuw"
      decimals="4"
      id="Narr_7vTc54V6uUqFp2TJxgLRIg"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_dtTtAUZdsU-OMRlXaEJPuw"
      decimals="-5"
      id="Narr_GUwVNVOz-Uyd99pBva4lKA"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_Td19wJRaGkumCTaDxY8FmQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2023 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2023.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_yxA46jLb9UCRoGAJLFRkTQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company calculates loss per share by dividing the net loss by the weighted average number of shares of Common Stock outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted earnings per share is calculated by dividing the net loss by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted loss per share does not include 36,292,208 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2023 because the effect would be anti-dilutive. Diluted loss per share does not include 31,839,345 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three months ended March&#160;31, 2024 because the effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="INF"
      id="Narr_WjpBWRASqUS_j95EpoYkTQ"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">36292208</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="INF"
      id="Narr_RUaPiE1zgUu6n4z2Dq9b9A"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">31839345</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_t26Hvol2E0K7LSOZvJe-rg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate. &lt;span style="background:#ffffff;"&gt;The Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued &lt;/span&gt;ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&#x201d; (&#x201c;&lt;span style="background:#ffffff;"&gt;ASU 2020-06&#x201d;). &lt;/span&gt;ASU&#160;2020-06 simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#x2014;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital. &lt;span style="background:#ffffff;"&gt;The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods. &lt;/span&gt;Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability. The impact to the Company's consolidated balance sheet as of December&#160;31, 2023 resulting from its adoption of ASU 2020-06 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Updated January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 415,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 414,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 381,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 381,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The impact of adoption of ASU 2020-06 on the condensed consolidated balance sheet as of March&#160;31, 2024 and on the Company&#x2019;s condensed consolidated statement of operations for the three months ended March&#160;31, 2024 was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances without Adoption of ASU 2020-06&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Financial expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (62)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (107)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 415,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 416,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 393&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 385,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 386,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (286)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Group_dmykjd-SY0OHCgwwZFdy5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Updated January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 415,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 414,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 381,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 381,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balances without Adoption of ASU 2020-06&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Financial expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (62)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20,313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (107)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 415,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 416,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 393&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 385,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 386,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (286)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_BNU8qhR3gEml-KeKGKnI9A_2_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20251000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_e5XT7TC3JUOFCdJknj2Kxg"
      decimals="-3"
      id="Tc_KA5K7vSrjUWCGirCEM_WPA_2_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20420000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_7SgXk48cW0uKG7aq9Ekk7Q"
      decimals="-3"
      id="Tc_0gWql53pnkOFaTQKL_Tx9A_2_9"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">169000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_vy736Q6xxEiJAQ7Gto3aGQ_3_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">415045000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_e5XT7TC3JUOFCdJknj2Kxg"
      decimals="-3"
      id="Tc_Hefx7tYXdU6SzZBR5ZoBbQ_3_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">414652000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_7SgXk48cW0uKG7aq9Ekk7Q"
      decimals="-3"
      id="Tc_BnrrBYiuYE-wWfDMP7cPXQ_3_9"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-393000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_89ysCFMOIkCV0e5N0q2QwQ_4_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">381549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_e5XT7TC3JUOFCdJknj2Kxg"
      decimals="-3"
      id="Tc_9Rlml1syo02MPRSahR7_hA_4_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">381325000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_7SgXk48cW0uKG7aq9Ekk7Q"
      decimals="-3"
      id="Tc_S4xNJ5A7Fk2097MaKFbIDw_4_9"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">224000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_MRoG3U83PUmyx0DXg4n4TQ"
      decimals="-3"
      id="Tc_0qHyZde-R0uxbxOpWLDnDQ_2_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">382000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_6VgdHCEey0ChwG_Brnl3sg"
      decimals="-3"
      id="Tc_iwxPMKTIBECcSoR4UClhow_2_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">444000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_HNYzKmZW0EGFk6AugmfHqA"
      decimals="-3"
      id="Tc_O5bEABjpbkCN0K6qpSJBAA_2_9"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-62000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_5ll4IzhZsUOjqRDIs4jcmw"
      decimals="-3"
      id="Tc_Mr6BCJApm0-ubZ8Qp9kbDw_3_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20420000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_o-lkPPcrrEeuOZNhLH7JRA"
      decimals="-3"
      id="Tc_1JqH_vbA6UCUn2NgI7m3uw_3_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20313000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg"
      decimals="-3"
      id="Tc_Dvkpx9naREauxXPcKow_Wg_3_9"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-107000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_5ll4IzhZsUOjqRDIs4jcmw"
      decimals="-3"
      id="Tc_kYAH-7WwfUiRZ7q5ZdYcIA_4_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">415633000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_o-lkPPcrrEeuOZNhLH7JRA"
      decimals="-3"
      id="Tc_hLlto2EyNEu-dJqbW84KVg_4_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">416026000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg"
      decimals="-3"
      id="Tc_C6RVQExmn0WG8U8E2QjdFA_4_9"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">393000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_5ll4IzhZsUOjqRDIs4jcmw"
      decimals="-3"
      id="Tc_L17Fw_G-LUKhv6sbukxmEg_5_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">385920000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_plx_BalancesWithoutAdoptionOfAsu202006Member_o-lkPPcrrEeuOZNhLH7JRA"
      decimals="-3"
      id="Tc_62mR3VHLMESHE21CSAta8w_5_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">386206000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2024_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_UUbPNngJ5E-PS-ZsC5qPhg"
      decimals="-3"
      id="Tc_g6j0up9VfUWgSdEWz8tU8g_5_9"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-286000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_MHYGD-XzKU-NSmqHfvyy2w">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;e.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;New accounting &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;pronouncements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently adopted accounting pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;ASU 2020-06, which was issued by the FASB in August 2020 and adopted by the Company in January 2024, simplifies the accounting for certain financial instruments with characteristics of both liability and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective for fiscal years beginning after December&#160;15, 2023, and interim periods within those fiscal years. See Note&#160;1(d).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the United States and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis. Early adoption is permitted, with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all of the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements and related disclosures&lt;/span&gt;&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_KFRjVSJX30W0KuNKrDF2Yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at March&#160;31, 2024 and December&#160;31, 2023 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,153&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb__axIGmRC3U27lmySgT4qNg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,153&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_S1fe5tnTckCWuUwWC9_pkQ_3_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4024000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_Iqc93tVZVEWbfN6fvS4hGQ_3_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4176000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_TE03mlPn40aaej4J14JYDg_4_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">9169000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_FlQUXVwI_EKsx3AO-T55cA_4_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">9055000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_x05m5d0yaEWED4z2Ux7i5g_5_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">9153000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_YVQYNTbbJk-Pm_hTWeKU2g_5_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5814000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_vwlhcVoR6keBrF0SH7mfQQ_6_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">22346000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_Py35xvmW_kKboA2UVhzAuw_6_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">19045000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_iSPh-HUPD0Kt30MGSEgjQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Based on a Level&#160;3 measurement, as of March&#160;31, 2024, the fair value of the $20.4&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2024 Notes is approximately $21.2&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VN0lXe7Da0uVnHnA1AZ-Ug"
      decimals="-5"
      id="Narr_JeYUDgRuDEOHWQlGT-oVyw"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">20400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_VN0lXe7Da0uVnHnA1AZ-Ug"
      decimals="-5"
      id="Narr_TVsMLf4GMkqJ7bAGQAFK_A"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">21200000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_DSkPUZ0Ock24wWZtXiDMDw"
      id="Tb_cw5_mRCfbUqPtDbiaivazw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.06&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0aoQ1IPKS0aCMthAjitzGQ"
      decimals="2"
      id="Tc_Sn7cb6wNgkmdk7bIE_2LSg_2_5"
      unitRef="Unit_Divide_USD_shares_1m_KFHh0L06HWPVaN55Tqg">1.26</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_C3_bHbEzuEi8F1H8pW2V5A"
      decimals="2"
      id="Tc_Gdtp8_-9eEqJlWzPoVd57Q_3_5"
      unitRef="Unit_Standard_Y_2rgTiQvabkK-OvDBIrW98g">0.42</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_ZYB0fx44FEWMgVZL0Q2ZBg"
      decimals="4"
      id="Tc_KOi7rrYeEU2c8X4tlgR1Rg_4_5"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.0516</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_IPYo9S6V0EqfSWhkVFWAYw"
      decimals="4"
      id="Tc_ZObkU_po3EeRK3SvzJZGxg_5_5"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.6706</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_3_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_8a1FzJd1ik67d1aQt1PHIw"
      decimals="4"
      id="Tc_bLdZyA5PC0KCcJ_lHCDEgA_6_5"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.1206</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_lSrcmqQrq0GiRUA-_MUA2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,066&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_sakxcqdf70aeqAak7aK4-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,266&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,800&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,066&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_plWIvGvIFUyhx5jpML44MA"
      decimals="-3"
      id="Tc__Gq1zolc7k-nJ52F8xMAjA_3_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1127000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Jd_SJ9gglEK0yT37LHcRGA"
      decimals="-3"
      id="Tc_mOtx4nVL_kmuvNTBzia28Q_3_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2266000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_d371MQCH-UCwEc1UyItlwA"
      decimals="-3"
      id="Tc_6k21pnh4vkSBq4ohQKbsMg_4_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2550000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_AB2WjkfrfEufyvdgXghKJA"
      decimals="-3"
      id="Tc_qUxzyFCH1kapeIdi9iBxOA_4_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_LIKQPrFmCUCnBtrg04Oumw"
      decimals="-3"
      id="Tc_wZwcfDYKYkamvjjWxj5H7Q_5_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">3677000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_WviQItZk-02YK8HpME_Dbg"
      decimals="-3"
      id="Tc_x4iU2_1b1ECRtSsslwPQbA_5_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">5066000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z99VySZvSUmmlbiiGP0ySQ"
      decimals="-3"
      id="Tc_XFL3vFQDTE6iPof8JB-CCg_6_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">71000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_pV_QgLXkMUeQZyfrpN-Feg"
      decimals="-3"
      id="Tc_wzW-Zk-8jU2WReG6sslejQ_6_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">4522000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_NvAm1pAhu06Il_jVJr_Ayw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On January&#160;15, 2024, the Company granted, with the approval of the Company&#x2019;s compensation committee, 100,000 shares of restricted Common Stock, in the aggregate, to certain of the Company&#x2019;s employees under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). All such shares of restricted Common Stock vest over a three-year period in 12&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.2&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA"
      decimals="INF"
      id="Narr_pRKa2jpEhU-PRc1xg4XVew"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA"
      id="Narr_M1dunx2DMEmEDWm0QoHxrw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements
      contextRef="Duration_1_15_2024_To_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_BIGnYxI8MUKpmNDlo9EAAA"
      decimals="INF"
      id="Narr_tKLs2HnYXUmlXsZjzyB0qg"
      unitRef="Unit_Standard_item__RvHgY9WKUuWNqJlDLZ_pg">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_1_15_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_-uvexI6zj06OIfXhkzqtLQ"
      decimals="-5"
      id="Narr_lO4lYHaYkkGZRW9fQCppGA"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">200000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_oqXjh-s2IUGim0cm9_OfKg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; TAXES ON INCOME&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company had an effective tax rate of (3)% for the three months ended March&#160;31, 2024, compared to an effective tax rate of 7% for the three months ended March&#160;31, 2023. For the three months ended March&#160;31, 2024, the difference between the Company&#x2019;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S. taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#x201c;TCJA&#x201d;).&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_FTvazY-hhkWPmZWlCYRI_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_TQsM44O-L02cRWJLTIwZFw_3_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">195000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_P506Z-QuG0CcsTusUpUcDw_4_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-138000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="-3"
      id="Tc_m7c7tFmAO0-34pGb3dEegg_5_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">-138000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="-3"
      id="Tc_WNIczZhgrkKjv-7jmGea6g_5_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">195000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="2"
      id="Narr_jMe2Rts2_kGO0rw3_Jwy2A"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">-0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_W9sGo43Zy0OUO2MoGtwP5A"
      decimals="2"
      id="Narr_ZNWiBeEujEqCXnsFa0N4fw"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.07</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      decimals="2"
      id="Narr_1w9edxyUTkCdzaXHq1paaA"
      unitRef="Unit_Standard_pure_gTZTGPHcmEqbNIMm6oJu5g">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_ETdnjbAoJ0iR1BOSTccp6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance sheets:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,451&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_u9A8Y1ssRkqU60eOYK3mgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,451&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_CqocsvfE50es8RMkg7rjCA_4_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2502000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_KlN8fkAI7EC_gQM6NSLktQ_4_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1437000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_S8Yb-_acEUChshsRXfkSug_5_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">128000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_idN-hmz9h0akqY6SwLorZA_5_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">511000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_S7h8gcMmcESCGZQHqVX2wg_6_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1696000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_SmJ8ibfZFEOZcXLOtQ36HQ_6_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1605000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_j4MrUQZnMUySyuNZfAYydA_7_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">8451000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_8PuNOYIRu0CpeKFbp1i7GQ_7_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">9009000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_Vv-qEBVebkWrewHO4XXnKQ_8_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">110000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_vwPCtf7_9UCAqv3s2D-nsA_8_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">637000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_StgzUWuViEOmpd9Lr1OZ2A_9_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2876000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_SavOv2jmpEyvWpRqpC0diw_9_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2876000</us-gaap:TaxesPayableCurrent>
    <plx:ReserveForDeductionsFromRevenueCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_agV9AwGlX0utifWldWmOBw_10_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2861000</plx:ReserveForDeductionsFromRevenueCurrent>
    <plx:ReserveForDeductionsFromRevenueCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_87nOBkEpuEmM-BfwQkyXlg_10_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2861000</plx:ReserveForDeductionsFromRevenueCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_p8b0fGRrWkWxTuA1v-jb2Q_11_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">146000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_J2-ZXypGh0WpMTp7qgr26w_11_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">614000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2024_Wk7JGJbXxUSZTcuzhJZxVw"
      decimals="-3"
      id="Tc_5qhWmFCbdUGuvIEVBP5Kew_12_3"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">18770000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_57E6-Q4TZ0qTu7sA1Vhq2w"
      decimals="-3"
      id="Tc_evzUwC3I70S_hIliPOvpQA_12_6"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">19550000</us-gaap:AccountsPayableCurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Tb_8Vu9TIMpFUWJHfNeNxseAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 8 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;1)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On May&#160;9, 2024 the Company collected approximately $1.1&#160;million from sales to Pfizer and on May&#160;8, 2024 the Company collected approximately $2.6&#160;million from sales to Brazil&lt;span style="background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;2)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On April&#160;1, 2024, the Company granted, with the approval of the Company&#x2019;s compensation committee, 263,960 shares of fully-vested restricted Common Stock, in the aggregate, to its President and Chief Executive Officer under the Plan. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $0.3&#160;million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_5_9_2024_To_5_9_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_nWYpdchKYEGKP3xBFvtHig"
      decimals="-5"
      id="Narr_cm3S0VYolkieeKzQTr4hZQ"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">1100000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_5_8_2024_To_5_8_2024_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_0fFQQ6KG80qYA735CyQAfw"
      decimals="-5"
      id="Narr_51R9TnRl8EiyV6anIjfUmw"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">2600000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_4_1_2024_To_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kD3z0qQXkGKOLbaYW_hYg"
      decimals="INF"
      id="Narr_H7yx1ePM4EKRcLnAsBbsuA"
      unitRef="Unit_Standard_shares_YIf6bweGB0qycnRBcu4pZQ">263960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_4_1_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_JDUfTJTYi0qDFhD9HD0akA"
      decimals="-5"
      id="Narr_8OG9BkLbDkaG8tGMh5CW1A"
      unitRef="Unit_Standard_USD_R6VggIVPrEKlnwuuUY6voA">300000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_7y972FXv90uovwiyV1ULdg">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_8ELvMOL1tEqSAZAuugyiFQ">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_YTtbR1awbEO8Dbp6JrZ28w">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2024_To_3_31_2024_C0O7Nlf-0ESzV5Qq_VekIg"
      id="Narr_Q5UWPHaxukOXd9Tqsif2jw">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_33t8Gr9f0UeEkwYS_dtQJQ_17_2"
          xlink:label="Tc_33t8Gr9f0UeEkwYS_dtQJQ_17_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of March&#160;31, 2024 and December&#160;31, 2023 &#x2013; 185,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_33t8Gr9f0UeEkwYS_dtQJQ_17_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gosVfC_JMUCxqvplCA6nxA_8_2"
          xlink:label="Tc_gosVfC_JMUCxqvplCA6nxA_8_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gosVfC_JMUCxqvplCA6nxA_8_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_5jJVSBrasUWgBK3js2CxoQ_6_2"
          xlink:label="Tc_5jJVSBrasUWgBK3js2CxoQ_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_5jJVSBrasUWgBK3js2CxoQ_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_sndmI7N3c0yKdEk-SeoiAw_12_2"
          xlink:label="Tc_sndmI7N3c0yKdEk-SeoiAw_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_sndmI7N3c0yKdEk-SeoiAw_12_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_FGp2-PEvW0uYn-0F3PL6TQ_13_2"
          xlink:label="Tc_FGp2-PEvW0uYn-0F3PL6TQ_13_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_FGp2-PEvW0uYn-0F3PL6TQ_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_KgyFIzvufEafEs9RBm3e2w_19_2"
          xlink:label="Tc_KgyFIzvufEafEs9RBm3e2w_19_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_KgyFIzvufEafEs9RBm3e2w_19_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
